Methods for Shortening and Extending the Carbon Chain in Carbohydrates by Monrad, Rune Nygaard
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 17, 2017
Methods for Shortening and Extending the Carbon Chain in Carbohydrates
Monrad, Rune Nygaard; Madsen, Robert
Publication date:
2008
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Monrad, R. N., & Madsen, R. (2008). Methods for Shortening and Extending the Carbon Chain in
Carbohydrates.
 Methods for  
Shortening and Extending 
the Carbon Chain in 
Carbohydrates 
 
 
Ph.D. Thesis 
 
By 
 
Rune Nygaard Monrad 
December 2008 
 
 
 
Department of Chemistry 
Technical University of Denmark
  
  
 
Methods for  
Shortening and Extending  
the Carbon Chain in 
Carbohydrates 
 
 
 
 
Rune Nygaard Monrad 
Ph.D. Thesis 
December 2008 
 
 
 
 
 
Department of Chemistry 
Technical University of Denmark 
Kemitorvet 
Building 201 
DK-2800 Kgs. Lyngby 
Denmark 
  
  Preface 
i 
Preface 
This thesis describes the work carried out during my three years as a Ph.D. student in Center for 
Sustainable and Green Chemistry at the Technical University of Denmark. In addition to research 
within the fields of organometallic and carbohydrate chemistry at the Technical University of 
Denmark, I had the opportunity to become acquainted with chemical biology during a six months 
research stay at University of Oxford. My period as a Ph.D. student has been very fruitful for me 
not only by means of education and achieving academic and technical qualifications, but also with 
respect to personal development as an individual and as a scientist. Many people have contributed 
to the present work, and most of all, I would like to express my gratitude to professor Robert 
Madsen. During the last three years of Ph.D. study, my theoretical and experimental skills have 
improved considerably. In particular, Robert Madsen’s support and guidance through critical 
decisions and his ability to suggest improvements of both overall strategies and specific reaction 
conditions have had a huge impact on the success of the projects I have been involved in. The 
decarbonylation team: Mike Kreis and Esben Taarning are thanked for good discussions, and 
Charlotte B. Pipper and Mette Fanefjord are acknowledged for collaborations on the calystegine and 
gabosine projects. A special thanks goes to Lars Linderoth for lots of fun and great company in the 
lab. The Department of Chemistry building 201, in particular the Madsen group, are gratefully 
acknowledged for invaluable help and for always maintaining an enthusiastic and positive spirit. I 
would like to thank professor Benjamin G. Davis for giving me the opportunity to work within such 
an interesting field of research in an interdisciplinary and highly dynamic group. The entire Davis 
group, in particular James, Conor, Justin and Nicola are thanked for invaluable help and good times 
in the lab. I am grateful to professor Andrew V. Stachulski for providing acyl glucuronide samples. 
Furthermore, Katja Rohr-Gaubert and Thomas Jensen are thanked for proofreading parts of this 
thesis. Last but not least, the Technical University of Denmark, Center for Sustainable and Green 
Chemistry, Danish Chemical Society, Civilingeniør Frants Allings Legat, Vera & Carl Johan 
Michaelsens Legat, Ulla & Mogens Folmer Andersens Fond, Krista & Viggo Petersens Fond, 
Fabrikant P. A. Fiskers Fond, Knud Højgaards Fond, Otto Mønsteds Fond and Oticon Fonden are 
gratefully acknowledged for financial support. 
 
 
  _____________________ 
Rune Nygaard Monrad 
Lyngby, December 2008 
Rune Nygaard Monrad – Ph.D. Thesis 
ii 
Abstract 
Carbohydrates play a central role in a variety of physiological and pathological processes such as 
HIV, cancer and diabetes. The understanding of these processes and the development of specific 
therapeutic agents is relying on the ability to chemically synthesize unnatural sugars, 
glycoconjugates and carbohydrate mimetics. Such polyhydroxylated compounds are conveniently 
synthesized from carbohydrates, however, due to the scarcity of many sugars from nature, efficient 
methods for transformation of readily available carbohydrates into valuable chiral building blocks 
are required. The work presented in this thesis focuses on the development and application of 
transition metal mediated methods for shortening and extending the carbon chain in carbohydrates 
thereby providing access to lower and higher sugars. 
 
A new catalytic procedure for shortening unprotected sugars by one carbon atom has been 
developed. By means of a rhodium-catalyzed decarbonylation of the aldehyde functionality, aldoses 
are converted into their corresponding lower alditols in yields around 70%. The reaction is 
performed with 8% of the catalyst Rh(dppp)2Cl in the presence of small amounts of pyridine to 
facilitate mutarotation. The procedure has been employed as the key step in a short five-step 
synthesis of the unnatural sugar L-threose in 74% overall yield from D-glucose. 
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A zinc-mediated one-pot fragmentation-allylation reaction has been used to elongate D-glucose and 
D-ribose by three carbon atoms thereby producing carbohydrate-derived α,ω-dienes, which have 
been converted into the natural products calystegine A3 and gabosine A. The glycosidase inhibitor 
calystegine A3 was produced by two similar routes from commercially available methyl 
α-D-glucopyranoside in 13 and 14 steps with 8.3 and 5.3% overall yield, respectively. The present 
work thereby constitutes the shortest synthesis of enantiomerically pure calystegine A3, and 
furthermore, it enables the absolute configuration of the natural product to be determined. Gabosine 
A has been prepared in nine steps and 13.9% overall yield from D-ribose, and this synthesis 
provides the first route to gabosine A from an abundant carbohydrate precursor. 
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During an external stay at University of Oxford, the metabolism of nonsteroidal anti-inflammatory 
drugs (NSAIDs) has been investigated. It was found that known acyl glucuronide metabolites of 
ibuprofen and several analogues modify human plasma protein under conditions encountered in 
therapy. Two different kinds of protein modification occur depending on the structure of the parent 
drug. The obtained results strongly suggest that irreversible modification of human proteins takes 
place during treatment with carboxylic acid containing drugs such as NSAIDs. Furthermore, the 
observed reactivity of these metabolites with respect to protein modification may provide an 
explanation for the severe toxicity that has led to the withdrawal of certain carboxylate drugs. 
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Resumé 
Kulhydrater spiller en central rolle i mange forskellige fysiologiske og patologiske processer såsom 
HIV, cancer og diabetes. Forståelsen af disse processer samt udviklingen af specifikke lægemidler 
afhænger i høj grad af kemisk at kunne syntetisere unaturlige sukkerstoffer samt stoffer, der 
imiterer kulhydrater. Ideelt set fremstilles sådanne polyhydroxylerede forbindelser fra kulhydrater, 
men på grund af meget lav tilgængelighed af mange sukkerstoffer fra naturens side, er der behov for 
effektive metoder til at omdanne tilgængelige kulhydrater til værdifulde kemiske byggeblokke. Det 
arbejde, der præsenteres i denne afhandling, fokuserer på udvikling og anvendelse af metoder, hvor 
overgangsmetaller benyttes til at forkorte og forlænge sukkerstoffers kulstofkæde og dermed giver 
adgang til ellers utilgængelige kulhydrater. 
 
En ny katalytisk metode til at forkorte ubeskyttede kulhydrater med ét kulstofatom er blevet 
udviklet. Ved hjælp af en rhodium-katalyseret decarbonylering af aldehyd-gruppen kan 
monosakkarider omdannes til de tilsvarende forkortede polyoler i udbytter omkring 70%. 
Reaktionen udføres med rhodium-katalysatoren Rh(dppp)2Cl i tilstedeværelse af en lille smule 
pyridin, der katalyserer mutarotation mellem kulhydratets hemiacetal- og aldehydform. Den 
udviklede metode er blevet anvendt som nøgletrin i en kort syntese af det unaturlige sukkerstof 
L-threose i 74% samlet udbytte i fem trin fra D-glukose. 
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Som en del af fremstillingen af naturstofferne calystegin A3 og gabosin A er D-glukose og D-ribose 
blevet forlænget med tre kulstofatomer ved hjælp af en zink-medieret fragmentering-
allyleringsreaktion. Calystegin A3 blev fremstillet på to lidt forskellige måder i 13 og 14 trin med 
henholdsvis 8,3 og 5,3% overordnet udbytte fra D-glukose. Herved er det lykkedes at udvikle den 
hidtil korteste syntese af naturligt forekommende calystegin A3 i enantiomerisk ren form, hvilket 
blandt andet har muliggjort, at den absolutte konfiguration af naturstoffet er blevet bestemt. 
Fremstillingen af gabosin A blev gennemført i ni trin med 13,9% samlet udbytte fra D-ribose og 
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udgør den første synteserute til gabosin A, der gør brug af et let tilgængeligt kulhydrat som 
startmateriale. 
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I løbet af et eksternt ophold ved Oxford Universitet er metabolismen af nonsteroidale anti-
inflammatoriske lægemidler (NSAID’er) blevet undersøgt. Under forsøgsbetingelser, som forventes 
at kunne forekomme ved behandling med ibuprofen, blev det observeret, at kendte acylglukuronid-
metabolitter af ibuprofen og flere analoger reagerer med et humant plasmaprotein. Afhængig af 
strukturen af lægemidlet blev der observeret to forskellige former for protein-modifikation, og de 
her opnåede resultater indikerer kraftigt, at der foregår irreversibel modifikation af proteiner i 
mennesker, når der indtages lægemidler, der indeholder en carboxylsyre-gruppe (f.eks. NSAID’er). 
Endvidere kan disse metabolitters reaktivitet med hensyn til modifikation af proteiner give en mulig 
forklaring på den toxicitet, der har været skyld i, at visse lægemidler indeholdende en carboxylsyre-
gruppe er blevet trukket tilbage fra markedet. 
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1 The diverse nature of carbohydrates 
 
Carbohydrates are the most abundant biomolecules in nature, and they are responsible for two thirds 
of the carbon found in the biosphere.1,2 In the form of mono-, di-, oligo- and polysaccharides, 
carbohydrates constitute our primary nutrient. In addition, various processed sugars, primarily 
polyols, are used in the food industry as reduced-calorie sweeteners and sugar substitutes.3  
 
Biochemically, carbohydrates are some of the most crucial molecules for life.1,4 Every cell is coated 
with carbohydrates in the form of glycoproteins and glycolipids.5 These glycoconjugates take part 
in a number of different processes including cell adhesion, cell growth and intercellular 
communication.6,7 The most frequent post-translational modification of proteins is glycosylation, 
and around 50% of all proteins found in nature are glycosylated.2,8 On proteins, carbohydrates 
ensure a correct folding, they increase the stability against proteolytic degradation and provide 
epitopes for recognition.2,5,7,9 In particular oligosaccharides are important in signal recognition 
events, where they act as information carriers. In such processes, lectins (sugar binding proteins) are 
capable of recognizing complex oligosaccharides thereby triggering a variety of cellular 
responses.1,2,6,10 
 
Glycosidases are enzymes, which are responsible for the cleavage of glycosidic bonds in 
saccharides and glycoconjugates.1,11 Carbohydrate-dependant processes are relying on the activity 
of specific glycosidases, and by interfering with such glycosidases, it is possible to inhibit resulting 
physiological or pathological effects induced by the enzymes. By chemical synthesis of glycosidase 
inhibitors, this concept has been used therapeutically in the treatment of influenza, viral infections 
(e.g. HIV), cancer and diabetes.1,2,10,11  
 
Contrary to inhibiting biological processes, certain desirable therapeutic effects may be gained by 
inducing such processes. This has been used in the development of carbohydrate-based cancer and 
HIV vaccines, where oligosaccharides conjugated to proteins and peptides have been used to induce 
an immune response leading to the production of specific antibodies.4,12 
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Carbohydrates also play a central role in the metabolism of xenobiotics, where D-glucuronic acid is 
coupled to hydrophobic drugs thereby increasing the water solubility of the drug and enabling its 
excretion.13,14 In analogy, enhanced anti-cancer activity has recently been achieved by coupling of a 
monosaccharide to an anti-cancer agent to increase its water solubility thereby improving the anti-
cancer activity of the drug.15 
 
In chemistry, carbohydrates represent cheap and readily available densely functionalized, chiral 
starting materials.16 Since many biologically active natural products are glycosylated or contain 
polyhydroxylated carbohydrate motifs as part of their structure, carbohydrates are well-suited 
enantiomerically pure precursors.10,17,18  
 
With the great potential of sugars, glycoconjugates and carbohydrate mimetics in biochemistry and 
medicine, the development of new methodologies for controlled formation of glycosidic bonds,19 
synthesis of homogeneous glycoproteins20 and preparation of glycosidase inhibitors10,18 is important 
to understand biological processes, and to be able to modulate or alter biosynthetic pathways e.g. to 
obtain desired therapeutic effects.2,4,7 
 
From another perspective, concerns about the depletion of the fossil fuel reserves demand new 
technologies for producing energy from renewable resources.21 In this respect carbohydrates, most 
efficiently as polyols, are promising substrates for the production of hydrogen by steam 
reforming.22,23 Also the generation of liquid fuels from biomass is increasingly important. Bio-
ethanol and liquid hydrocarbons can be produced from carbohydrates by fermentation of glucose24 
and by various reforming, dehydration and hydrogenation processes, respectively.25 
 
All together, carbohydrates are highly important biomolecules, and from a synthetic point of view, 
it is important to develop new synthetic methodologies to convert these inexpensive compounds 
into valuable synthetic building blocks and biologically relevant targets. 
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2 Methods for shortening and extending the carbon chain in carbohydrates  
 
As mentioned in chapter 1, lower sugars like pentose and tetrose derivatives are important for 
example as sweeteners in food ingredients and as building blocks in organic synthesis. Higher 
sugars are often employed as intermediates for the synthesis of biologically active, 
polyhydroxylated compounds, and due to the scarcity of many lower and higher sugars from nature, 
the development of efficient protocols for shortening and extending readily available carbohydrates 
is important. Shortening and extending the carbon chain in carbohydrates has been a subject in 
carbohydrate chemistry for more than a century, and the literature up to 1997 is covered in the book 
’Monosaccharide Sugars: Chemical Synthesis by Chain Elongation, Degradation, and 
Epimerization’ by Györgydeák and Pelyvás.26 The scope of the present chapter is to give an 
overview of the advances within the field since then.  
 
C-Glycosides are an important class of carbohydrates, which are potential inhibitors of 
carbohydrate processing enzymes due to their increased stability as compared to O- and N-
glycosides. The formation of C-glycosides from monosaccharides can be considered a chain 
elongating process, which affords higher carbon anhydro sugars, and the purpose of the present 
review is only to include the recent advances in C-glycoside formation, which have particular 
relevance to chain elongation. 
 
2.1 Methods for shortening the carbon chain in carbohydrates 
2.1.1 Ruff degradation 
The available methods for shortening the chain in unprotected sugars are sparse. The Ruff 
degradation, which has been known since 1898,27 converts salts of aldonic acids into aldoses with 
loss of one carbon atom. The reaction is performed with hydrogen peroxide in alkaline solution in 
the presence of Fe(III) or Cu(II)-salts, the latter being the most efficient.28 Due to its importance in 
the preparation of pentose sugars e.g. industrial production of xylitol,3 the Ruff degradation has 
received considerable interest in recent years.  
 
The reaction generally occurs in moderate yields,26 and since one of the major disadvantages in the 
Ruff degradation is the separation of the product from large quantities of metal salts, work has been 
done to cleave carbon dioxide from the aldonate electrochemically or by the use of catalytic 
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amounts of metal. Jiricny and Stanek recently used a fluidized bed electrode cell for the production 
of D-arabinose in approximately 70% yield from sodium D-gluconate without addition of any 
chemical oxidants.29 The production of D-arabinose from calcium D-gluconate has been achieved 
catalytically by Germain and co-workers using Cu(II)-exchanged zeolites.30 During the reaction, 
copper was found to leach from the zeolite, and once the aldonic acid was consumed, copper 
precipitated on the zeolite again. The catalyst could be recycled twice thereby achieving the 
advantages of heterogeneous catalysis, although copper was in solution during the reaction.30 
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Scheme 1. Proposed mechanisms for the Ruff degradation suggested by a) Isbell and Salam31 and b) Stapley and 
BeMiller.28 
 
Several different mechanisms for the Ruff degradation have been proposed over the years, and these 
have recently been critically reviewed.28 The generally accepted mechanism suggested by Isbell and 
Salam31 (Scheme 1a) starting with H-abstraction to generate an α-alkoxy radical (2) followed by 
oxidation by Fe(III) to produce the lower aldose 3 with loss of carbon dioxide has been questioned 
by Stapley and BeMiller.28 Instead, a Hofer-Moest-type reaction mechanism with two successive 
one-electron oxidations has been proposed (Scheme 1b). The aldonic acid 1 is oxidized to an 
acyloxy radical (4), which upon loss of carbon dioxide and subsequent oxidation produces a 
carbocation (5) that is captured by the solvent. This mechanism is believed to be valid both in the 
electrochemical Ruff degradation and in the classical versions, where the anode is replaced by a 
transition metal, which is regenerated by oxidation with hydrogen peroxide.28 
 
In transition metal mediated Ruff degradations the carboxylate and the α-hydroxy group of the 
aldonate 1 are believed to coordinate to the transition metal during the initial oxidation.28 As a 
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result, uronic acids are not decarboxylated efficiently by iron or copper due to the α-hydroxy group 
being part of a hemiacetal group thereby disabling coordination to the metal, when the uronic acid 
is on the pyranose form.32 However, recently sodium D-glucuronate and methyl 
D-glucuronopyranoside have been found to undergo electrochemical degradation yielding the 
corresponding xylo-configured pentodialdose,32 thus enabling degradation of uronic acids by 
electrochemical methods. 
 
2.1.2 Periodate cleavage 
Cleavage of 1,2-diols and α-hydroxy carbonyl compounds with periodates or lead tetraacetate to 
yield the corresponding aldehydes is a well-known and widely applied method for shortening the 
carbohydrate chain.33-36 Oxidative cleavage with sodium periodate is usually performed on partly 
protected sugars because the oxidation of unprotected sugars cannot be controlled and over-
oxidation otherwise occurs.  
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Scheme 2. Periodate cleavage of monoprotected D-glucopyranose.37 
 
Recently, Storz and Vasella applied the periodate oxidation on mono-protected 3-O-allyl-
D-glucopyranose (6) easily available in three steps from diacetone D-glucose (Scheme 2).37 
D-Glucose and D-galactose are known to react with sodium periodate primarily in their pyranose 
form,38 and by careful control of the pH only the C1-C2 bond was cleaved by sodium periodate 
leaving the formyl group as a ’protective group’ on the C4 alcohol in the resulting 
D-arabinopyranose 7 thereby preventing further periodate cleavage. Adjustment of the pH after 
quenching with ethylene glycol and removal of inorganic salts by filtration effected hydrolysis of 
the intermediate formyl ester. Loss of the formyl group during the reaction with periodate or 
isomerization to the furanose would lead to failure producing a mixture of pentose, tetrose and 
trioses, but under mild conditions this was elegantly avoided producing the interesting chiral 
pentose building block 8 in 95% yield.37 
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2.1.3 Alkoxy radical fragmentation 
The alkoxy radical fragmentation of anomeric alcohols was first reported in 1992,39,40 and has since 
then been further developed by Suárez and co-workers to become a useful tool for the synthesis of a 
variety of one carbon atom shortened sugar-derived chiral building blocks. 
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Scheme 3. Alkoxy radical fragmentation.39,41 
 
Under oxidative conditions employing the hypervalent iodine reagents (diacetoxyiodo)benzene 
(DIB) or iodosylbenzene in the presence of iodine, carbohydrate anomeric alcohols (9) undergo 
alkoxy radical fragmentation cleaving the C1-C2 bond to produce a C2 radical 10, which can react 
in two different ways depending on the nature of the substituents at C2 (Scheme 3). The presence of 
an ether functionality at C2 leads to oxidation of 10 to an oxonium ion (11) which can be inter- or 
intramolecularly trapped by nucleophiles (path a). Electron-withdrawing groups decrease the 
electron density at C2 thereby preventing oxidation of 10, which is then trapped by iodine leading 
to 1-iodoalditols (12) with one less carbon atom (path b). 2-Deoxy- and 2-deoxy-2-haloaldoses also 
lead to iodine incorporation following path b, and mono-, di- and trihalo-1-deoxyalditols can be 
achieved from the corresponding 2-deoxy-,39 2-deoxy-2-halo-41-43 and 2-deoxy-2,2-dihalosugars.44-
46
 Instead of trapping the intermediate radical 10 by nucleophiles (Scheme 3a and b), one carbon 
atom shortened alditols possessing a terminal alkene (ald-1-enitols) can be formed by radical 
fragmentation of 2,3-dideoxy-3-(phenylsulfonyl)-aldoses, which leads to the corresponding 
1,2-dideoxy-2-(phenylsulfonyl)-ald-1-enitol derivatives with loss of a carbon atom.47 
 
Fragmentation of 2,3,5,6-tetra-O-methyl-D-galactofuranoside (Table 1, entry 1) and subsequent 
nucleophilic attack of acetate from DIB leads to the corresponding D-arabinose derivative in 85% 
yield as the mixed acetal. The presence of a benzoate at C2 results in incorporation of iodine 
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producing the corresponding 1-iodo-D-arabinitol instead (entry 2). Such iodoalditols can be reduced 
to the corresponding alditols by treatment with Bu3SnH and AIBN, or they can be elongated for 
example by radical allylation using allyltri-n-butyltin and AIBN (see also section 2.2.7).48 
 
Table 1. Oxidative alkoxy radical fragmentation using DIB or PhIO and I2. 
Entry Substrate Substituents Product Yield (%) 
     
1  R = Me, R1 = OAc  85 (1:1)48  
2  R = Bz, R1 = I  63 (1:1)48 
     
     
3  X = O, R = H, H  3649 
4  X = R = O  4350,51 
5   X = NBoc, R = H, H  7352 
     
     
     
6  R = Ac  8853,54 
7  R = β-D-Gal  9754 
     
     
     
     
8    70a,55 
     
     
     
     
9  R = Bn, R1 = OAc  28 (1:0)56 
10  R = Piv, R1 = NHAcb  81 (15:66)56 
     
     
a
 DIB was replaced by (CF3CO2)2IPh and H2O (1 eq.) b The reaction was performed in MeCN. 
  
Intramolecular capture of oxonium ions (11) by attack of alcohols, carboxylic acids or amines occur 
in moderate yield leading to the corresponding cyclized aldoses, alduronic acid lactones and 
azasugars (Table 1, entries 3-5). The presence of an azide at C2 leads to aldononitriles with loss of 
one carbon in excellent yield, and the methodology can even be applied on disaccharides (entries 
6-7). When 2-ketoses are subjected to alkoxy radical fragmentation using the (CF3CO2)2IPh/I2 
system, the sugar chain is shortened by two carbon atoms, and in the presence of water, free 
aldehydo sugars can be obtained.55 Alkoxy radical fragmentation of benzyl protected L-tagatose 
(entry 8), which is readily available by Meerwein-Ponndorf-Verley/Oppenauer oxidation of 
2,3,4,6-tetra-O-benzyl-D-glucopyranose,57 gave a L-threose derivative with conveniently 
differentiated protective groups at C2/C3 and C4 enabling further synthetic manipulations.  
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In contrast to anomeric alcohols, fragmentation of primary alcohols by alkoxy radical fragmentation 
is not completely reliable due to competing intramolecular hydrogen atom transfer leading to 
various side-products.56 When intramolecular hydrogen atom transfer from the anomeric protective 
group is possible, the alkoxy radical fragmentation is disfavored as illustrated with the benzyl and 
pivaloyl anomeric protective groups (Table 1, entries 9-10). Performing the reaction in acetonitrile 
led to fragmentation in 81% yield producing the shortened 4-acetamido derivative by a Ritter 
reaction between the intermediate oxonium ion and the solvent (entry 10).  
 
Under reductive conditions, the alkoxy radical fragmentation can be achieved by treatment of 
anomeric nitrates or N-phthalimido glycosides with Bu3SnH and AIBN to produce alditols 
shortened by one carbon atom (Table 2).  
 
Table 2. Reductive alkoxy radical fragmentation using Bu3SnH and AIBN. 
Yield (%) Entry Substrate Substituents Product R = CHO R = H 
      
      
1  R1 = NO2, R2 = TBDMSO  79 1658,59 
2  R1 = NPht, R2 = TBDMSO  42 3959,60 
3  R1 = NO2, R2 = CN  - 8359 
      
      
      
4    - 4759,60 
      
      
      
5    78a,59,60 - 
      
      
      
6  R1 = NO2  33 1859 
7  R1 = NPht  64 3159,60 
      
      
      
8  R1 = H  8961 
      
      
9  R1 = Me  9561 
      
      
a
 After hydrolysis of the formate and silyl protection. 
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To avoid the formation of toxic tin byproducts during the fragmentation, (Me3Si)3SiH can replace 
Bu3SnH, however in slightly lower yields.61 Introduction of the N-phthalimido group and the nitrate 
ester can easily be accomplished from the corresponding alcohol under Mitsunobu conditions or by 
employing LiNO3/(CF3CO)2O,62 respectively.  
 
Partial hydrolysis of the resulting formate is often observed, and under reductive conditions, the 
degree of hydrolysis depends on the substrate and the reaction time (Table 2, entry 1 and 2). The 
methodology requires fully protected carbohydrates, but tolerates functional groups like nitriles and 
acetamido groups, the latter however in moderate yield (entry 3 and 4). 2-Deoxy substrates are 
easily fragmented giving 1-deoxyalditols (entry 5). In general, N-phthalimido derivatives react 
faster than the corresponding nitrate esters, and due to instability of the latter compounds in some 
cases (compare entries 6 and 7), the two different approaches complement each other well.  
 
Recently, the reductive alkoxy radical fragmentation was used to prepare 1,2-O-isopropylidene-
β-L-threose in 55% overall yield in three steps from readily available 1,2:5,6-di-O-isopropylidene-
D-glucofuranose thereby providing a very efficient approach to an otherwise inaccessible sugar.59 
 
In the case of primary N-phthalimido glycosides, the alkoxy radical fragmentation competes with 
intramolecular hydrogen atom transfer, and unexpectedly, Sartillo-Piscil and co-workers61 found 
that formation of internal hydrogen bonds may have a drastic effect on the fragmentation of primary 
alkoxy radicals. The primary alkoxy radical derived from the N-phthalimido derivative in Table 2, 
entry 8 can achieve a stabilizing internal six-membered hydrogen bond interaction with the free C3 
alcohol leading to fragmentation, whereas in the C3 methoxy substrate (entry 9) no such six-
membered interaction is possible resulting in intramolecular hydrogen atom transfer followed by 
reduction regenerating the parent alcohol. In good hydrogen bond accepting solvents like THF, 
increased amounts of the hydrogen atom transfer products were observed at the expense of the 
fragmentation products.61 
 
2.1.4 PCC-induced shortening of β-azido alcohols 
In addition to the alkoxy radical fragmentation (Table 1, entry 6 and 7), aldononitriles can also be 
produced by a recently developed PCC-induced oxidative degradation of primary β-azido alcohols 
(Table 3).63 The oxidation is performed under very mild conditions using two equivalents of PCC in 
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DCM at room temperature. Good yields are obtained for protected 2-azido-2-deoxyalditols, and in 
contrast to alkoxy radical fragmentation, the acetamido functionality is tolerated without reducing 
the yield (Table 3, entries 1-2). Also furanose derivatives with terminal β-azido alcohol side-chains 
can be oxidized to their corresponding nitriles (entry 3), whereas secondary β-azido alcohols are 
inert, and β-azido hemiacetals are oxidized to their 2-azidolactones instead of being shortened.63 
The incompatibility of the PCC-induced degradation of β-azido alcohols with anomeric substrates 
renders the oxidative alkoxy radical fragmentation (section 2.1.3) a more widely applicable 
approach to aldononitriles. 
 
Table 3. Oxidative degradation of β-azido alcohols using PCC.63 
O
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The mechanism for the PCC-mediated degradation of β-azido alcohols is believed to proceed via a 
2-azidoaldehyde generated by PCC-oxidation followed by intramolecular attack of the azide on the 
carbonyl group giving a hydroxy-triazole derivative, which is subsequently oxidized by PCC 
affording the aldononitrile with loss of carbon monoxide and nitrogen.63 
 
2.2 Methods for extending the carbon chain in carbohydrates 
2.2.1 The Kiliani ascension 
The Kiliani ascension is one of the longest known tools to elongate carbohydrates,26 but it has 
primarily been used on aldoses due to low accessibility of ketoses and difficulties separating the 
formed epimers. The Fleet group has recently applied the Kiliani ascension on different ketoses 
thereby accessing a range of different branched carbohydrate building blocks (Table 4).64-66 After 
Chapter 2 Methods for shortening and extending the carbon chain in carbohydrates 
11 
subjecting ketoses to aqueous sodium cyanide at room temperature, hydrolysis of the nitrile 
functionality by heating to reflux afforded epimeric pairs of chain elongated lactones. Treatment of 
the crude product with sulfuric acid and acetone gave the corresponding diisopropylidene 
derivatives, which could easily be separated by crystallization. Although the yields are moderate, 
the procedure constitutes a very easy and convenient approach to 2-C-branched sugars in high 
purity. Further manipulation of these via reduction to the corresponding alditols gives access to 
several 5-C-branched carbohydrate scaffolds by microbial oxidation and isomerization.67  
 
Table 4. One-pot Kiliani ascension and diisopropylidene protection of unprotected ketoses. 
i) NaCN, H2O
ii) Me2CO, H+
gketose
2-C-branched 
aldonolactone
 
 
Entry Ketose 2-C-Branched 
aldonolactone 
Yield 
(%) 
    
    
1 D-fructose  5164 
    
    
    
    
    
2 L-sorbose  1764 
    
    
    
    
3 D-tagatose  4466 
    
    
    
    
4 D-psicose  3866 
    
    
    
 
The one-pot Kiliani ascension and diisopropylidene protection of D-fructose gave 51% yield of 
2-C-hydroxymethyl-2,3:5,6-di-O-isopropylidene-D-mannono-1,4-lactone (Table 4, entry 1), which 
could be converted into the formal Kiliani product of the inaccessible sugar L-psicose in 42% 
overall yield in only three steps by inversion of two stereocenters.64 With this Kiliani ascension of 
D-fructose, a range of different 2-C-branched derivatives of D-mannose has become available after 
only a few synthetic transformations.68  
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The diacetonide of 2-C-hydroxymethyl L-gulonolactone (Table 4, entry 2) could be obtained from 
L-sorbose in 17% yield without chromatography, which despite the low yield illustrates the 
simplicity of the procedure even on a moderate scale. D-Tagatose and D-psicose can similarly be 
converted into the corresponding 2-C-branched acetonides and crystallized in 44 and 38% yield, 
respectively (entry 3 and 4). The one-step Kiliani ascension and isopropylidene protection of 
aldoses69 and ketoses followed by isolation of the major products by simple crystallization is a 
convenient improvement of the classic procedure.26  
 
The problems associated with separation of epimers have recently been addressed by Herbert and 
co-workers by applying Sm3+-ion exchange column chromatography. Separation of the epimeric 
mixture of D-ribose and D-arabinose produced from the Kiliani ascension of D-erythrose could 
readily be achieved on a preparative scale by this methodology, and the column could be used 
repeatedly without recharging or cleaning.70  
 
(R)-PaHNL
HCN, iPr2O
13: L-glycero
15: D-glycero
14: L-threo  
16: D-erythro
O
O
O
O
O
OH
CN
99% (82% de)
85% (60% de)
 
Scheme 4. Enzymatic Kiliani ascension of isopropylidene protected glyceraldehydes 13 and 15.71 
 
Recently, the first stereoselective, enzymatic Kiliani ascension of a sugar aldehyde was reported.71 
2,3-O-Isopropylidene-glyceraldehydes 13 and 15 were converted into tetrononitriles 14 and 16 in 
excellent yield and moderate to good stereoselectivity by treatment with (R)-hydroxynitrile lyase 
from  Prunus amygdalus ((R)-PaHNL) (Scheme 4). (R)-PaHNL afforded 99% yield of 
3,4-O-isopropylidene-L-threononitrile (14) in 82% de from 2,3-O-isopropylidene-L-glyceraldehyde 
(13), whereas 3,4-O-isopropylidene-D-erythrononitrile (16) was produced in 85% yield and 60% de 
from the corresponding D-glyceraldehyde derivative 15. The enzymatic Kiliani ascension is a new 
possibility for enantioselective synthesis of desired cyanohydrins in high yield thereby 
circumventing tedious separation of epimers. 
 
2.2.2 The Sowden homologation 
Together with the Kiliani ascension, the Sowden homologation72 is one of the classical ways to 
obtain one-carbon elongated sugars. Both methodologies suffer from moderate selectivities and 
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difficulties separating the formed epimers. The Kiliani ascension is usually preferred, but the 
Sowden protocol is often used when the latter procedure is impeded by tedious separation or fails to 
give the desired epimer.26 Recently, Dromowicz and Köll reported an improved synthesis of 
D-idose from D-xylose by means of the Sowden homologation (Scheme 5).73 The separation of the 
epimeric 1-deoxy-1-nitro-alditols produced by the nitroaldol condensation (Henry reaction) was 
improved by multiple fractional crystallizations, and the desired isomer 17 could be isolated in 75% 
yield. By performing the subsequent Nef reaction74 under an argon atmosphere, an increased yield 
compared to the literature procedure was obtained,75 and D-idose could thereby be isolated in 51% 
overall yield over two steps.73  
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Scheme 5. Improved Sowden homologation of D-xylose by Dromowicz and Köll.73 
 
2.2.3 Chain elongation by means of the Baylis-Hillman reaction 
Over the last five years, the application of the Baylis-Hillman reaction in carbohydrate chemistry 
has received considerable interest in particularly from the group of Krishna, who has recently 
reviewed the field.76 The chirality of carbohydrates enables stereoselective transformations, and 
sugars have lately been applied in the Baylis-Hillman reaction as electrophilic aldehydes,77-87 
activated alkenes88,89 and chiral auxiliaries.80,90 Different applications of the Baylis-Hillman 
reaction as a tool to elongate carbohydrates are shown in Table 5. The reaction of ethyl acrylate, 
methyl vinyl ketone or acrylonitrile with protected and partially protected sugar-derived aldehydes 
occurs in good yield with low to moderate de (entries 1-4).77,78 Double asymmetric induction using 
both a sugar-based acrylate and a sugar aldehyde can lead to excellent stereoselectivities, however 
often in moderate yields (entry 5). The existence of matched and unmatched pairs of chiral 
aldehydes and acrylates leads to observed de’s ranging from excellent to poor as illustrated in 
entries 6 and 7. Proper selection of the sugar acrylate can improve the stereoselectivity significantly, 
but finding suitably matched pairs may be time consuming. As observed for 1-aldehydo-
2,3:4,6-di-O-isopropylidene-L-sorbose (entries 8 and 9), very good yields and de’s can be achieved 
with non-chiral activated alkenes in some cases. Of the available activated alkenes, ketones and 
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nitriles generally give higher yields than the corresponding esters, whereas the best 
stereoselectivities are achieved with nitriles followed in turn by ketones and esters.77,78  
 
Table 5. Chain elongation of carbohydrates by the Baylis-Hillman reaction. 
 
R H
O EWG DABCO
R
OH
EWG+
 
 
 
Entry Aldehyde Substituents EWG Product Yield (%) 
de 
(%) 
       
       
1  R1 = OMe, R2 = H CO2Et  7377-79 36 
2  R1 = OMe, R2 = H COMe  8277,78 53 
3  R1 = OMe, R2 = H CN  7677,78 60 
4  R1 = H, R2 = OH CN  8078 76 
5  R1 = OMe, R2 = H CO-Sug  4380 >95 
       
       
       
6 2R,3S  CO-Sug  7380 >95 
7 2S,3R  CO-Sug  7880 33 
       
       
       
       
8   CN  8578 90 
9   CO2Et  8078 >95 
       
       
       
10   COMe  55a,81,82  
       
       
       
11   COMe  70b,81,82  
       
       
a
 DABCO was replaced by Me2S–TiCl4 at 0 ºC for 15 min. b DABCO was replaced by Me2S–TiCl4 at 0 ºC 
for 6-9 h. 
 
α,β-Unsaturated aldehydes derived from sugars cannot easily be used in the Baylis-Hillman 
reaction, however, in the presence of Me2S–TiCl4 at 0 ºC, moderate yields can be obtained (Table 5, 
entry 10). Side-reactions leading to chloro-substituted byproducts is a major problem (entry 11), 
and the reaction has to be stopped before full conversion to afford the initial Baylis-Hillman 
product.81,82  
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Even stereoselective, intramolecular Baylis-Hillman reactions giving rise to the corresponding 
chain elongated lactones have been reported (Scheme 6). The intramolecular Baylis-Hillman 
reaction of 18 occured with >95% de giving the desired lactone 19 as a single isomer in 71% yield 
together with small amounts of 3-O-alkyl derivatives as byproducts (8% of 20), when alcohols were 
present as co-solvents.91 
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Scheme 6. Intramolecular Baylis-Hillman reaction.91 
 
Recently, sugar-derived activated alkenes have also been used in the Baylis-Hillman reaction as a 
synthetic route to 2- or 3-C-branched carbohydrates (Table 6). Of a range of aromatic and aliphatic 
aldehydes, the best results were achieved with electron poor aldehydes, however, excellent 
stereoselectivities were achieved in most cases independently of the nature of the aldehyde (entries 
1-4).  
 
Table 6. Baylis-Hillman reaction of sugar acrylates. 
Entry Acrylate Aldehyde R-CHO Product 
Yield 
(%) 
de 
(%) 
      
      
      
1  R = p-NO2-Ph  7589 82 
      
      
      
      
2  R = Ph  2688 >98 
3  R = p-NO2-Ph  8288 >98 
4  R = CH3(CH2)2  8588 >98 
      
      
      
 
If the Baylis-Hillman reaction is combined with ozonolysis, fully hydroxylated higher carbon 
sugars can be obtained in relatively few steps. The D-glycero-D-altro-heptose derivative 24 was 
isolated in 13% overall yield as the major isomer in six steps from D-ribose as illustrated in Scheme 
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R
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7. A few synthetic manipulations of 2,3-O-isopropylidene-D-ribose (21) afforded the suitably 
protected aldehyde 22, which was reacted with ethyl acrylate in the Baylis-Hillman reaction giving 
23 in 30% de. The diastereomers could easily be separated and subsequent ozonolysis and reduction 
afforded the fully hydroxylated heptose derivative 24 in 60% de. Similarly, diacetone D-mannose 
could be converted into four diastereomeric octose derivatives in nine steps in a 7:3:2:1 ratio.83 
 
O OH
O O
HO
O O
OO
O
O O
OO OH
CO2Et
O O
OO OH
CO2Et
OH
1) LiAlH4
2) 2,2-dimethoxy-
propane, p-TsOH
3) (COCl)2, DMSO, Et3N ethyl acrylate, DABCO
38% (4 steps)
(30% de)
1) O3
2) NaBH4
65% (60% de)
21 22
23 24
 
Scheme 7. Synthesis of higher sugars by the Baylis-Hillman reaction.83 
 
2.2.4 Chain extension based on the aldol reaction 
The aldol reaction is one of the most frequently employed methods for C-C bond formation in 
carbohydrate chemistry.92 Aldol reactions can be performed on protected as well as unprotected 
sugars, and the reaction is particularly well-suited for the synthesis of ketoses, aldonic acid esters 
and ulosonic acid derivatives.26,93 Diastereoselective aldol reactions have been extensively studied, 
and under non-chelating conditions, several models for asymmetric induction have been 
proposed.94,95 Under chelating conditions, thermodynamic control leads to threo products 
exclusively, whereas under kinetic control, E and Z enolates predominantly give threo and erythro 
products, respectively.92,93 
 
During the last 10 years, stereoselective, organocatalytic aldol reactions of 1,3-dihydroxyacetone 
derivatives have appeared as a powerful tool to construct polyhydroxylated compounds.96,97 The 
methodology has recently been used in the synthesis of a range of ketopentoses and -hexoses from 
C2 and C3 building blocks.98-102 Very recently, the organocatalyzed aldol reaction was applied on 
protected D-ribose102 and D-arabinose101 to give fully hydroxylated 2-octuloses (Scheme 8). By the 
use of (S)-proline and 2-tert-butyl-2-methyl-1,3-dioxan-5-one (25), the protected D-ribose 26 could 
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be elongated by three carbon atoms to give the corresponding D-glycero-D-manno-2-octulose 27 in 
good yield and excellent de together with small amounts of the dehydrated product 28. 
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Scheme 8. Organocatalytic aldol reaction on protected D-ribose.102 
 
More importantly, MacMillan and co-workers have developed a procedure for enantioselective 
assembly of aldohexoses in only two steps from α-hydroxy acetaldehydes by employing two 
subsequent aldol reactions.103,104 Organocatalyzed dimerization of protected α-hydroxy 
acetaldehydes affords fully hydroxylated aldehydo tetroses, which after Lewis acid catalyzed 
Mukaiyama aldol reaction with a second protected α-hydroxy acetaldehyde afford hexoses in good 
yields and excellent stereoselectivities. Furthermore, the preparation of hexoses from two different 
C2 building blocks conveniently enables orthogonal protection of the hydroxy groups, which is 
particularly useful for further synthetic manipulations. 
 
Enzymatic aldol reactions have also been extensively studied and are emerging as attractive 
reactions even on a preparative scale.105 By the reaction of pyruvate with various aldoses, aldolases 
have been utilized to produce a range of 3-deoxy-2-ulosonic acids without the requirement of 
protective groups.105-107 This has for example been achieved by chain elongation of L-threose to 
give 3-deoxy-L-lyxo-hept-2-ulosonate (29) in 70% yield and >98% de (Scheme 9).108 
 
O OH
HO OH
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CO2-
CO2-
O
HH
OH
OH
HO
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KDG-aldolase
50 °C
70% (>98% de)
pyruvateL-threose 29
 
Scheme 9. Enzymatic aldol reaction on unprotected L-threose.108 
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2.2.5 Organometallic addition to sugar aldehydes and hemiacetals 
The addition of organometallic reagents to various protected carbohydrates in their hemiacetal or 
aldehydo form is one of the most studied methods for extending the carbohydrate chain.92 The 
organometallic addition to C1 or C6 aldehydo sugars generally follows the known models for 
asymmetric induction during nucleophilic attack on carbonyl groups e.g. the Felkin-Anh and the 
Cram chelate models,109-111 whereas organometallic addition to free hemiacetals is more complex 
and dependant on the substrate and the reaction conditions.26,112 Addition of vinylic reagents to 
sugar hemiacetals or aldehydes followed by either ozonolysis113,114 or dihydroxylation115,116 is a 
widely applied methodology to obtain higher carbon sugars possessing a fully hydroxylated carbon 
skeleton.  
 
Most organometallic additions require fully protected carbohydrate substrates, but in the early 
1990’s tin117 and, more efficiently, indium118 were found to mediate allylation of unprotected sugars 
in aqueous media. With unprotected carbohydrates, the reaction most often occurs with chelation 
favoring the threo configuration between the α-hydroxy group and the newly formed 
stereocenter.119 Indium-mediated allylation of unprotected sugars has received considerable interest 
in particular in combination with ozonolysis and dihydroxylation to produce chain elongated 
carbohydrates like the 3-deoxy-2-ulosonic acids KDN, KDO and N-acetyl neuraminic acid.116,120-122  
 
The methodology has been extended to carbohydrate-derived allylic bromides by Lubineau and co-
workers.123,124 As shown in Table 7, 2-C- and 4-C-branched sugars can be formed this way, and by 
subsequent dihydroxylation, the saturated sugars can be accessed in good yield. Unprotected 
hydroxy groups in the allylic bromides are tolerated, but so far only protected sugar aldehydes have 
been employed in the reaction.  
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Table 7. Indium-mediated allylation of aldehydes in aqueous solution using sugar-derived allylic bromides. 
Entry Allylic bromide 
Aldehyde 
R-CHO Product 
Yield 
(%) R/S 
      
      
1  R = Ph  95124 0:1 
      
2  R =   94124 1:0 
      
      
3  R =  55124 1:1 
      
      
      
4  R = Ph  45123 1:0 
      
      
      
5  R = Ph  57a,123 0:1 
      
      
a
 Together with 13% of the 2-C-branched product. 
 
Excellent yields and diastereoselctivities can be obtained (Table 7, entries 1-2), but with slower 
reacting aldehydes (entry 3), indium-promoted elimination of the ethoxy group by Vasella-type 
fragmentation125-128 of the allylic bromide becomes an increasing problem reducing the yield of the 
desired product.124 With the β-anomer of the allylic bromide (entry 4), the yield is considerably 
lower, and the stereoselectivity is reversed due to steric repulsion between indium and the anomeric 
ethoxy group. With the bromide in a pseudo-equatorial position, the α-anomer led to the 
4-C-branched product in 57% yield together with small amounts of the 2-C-branched product (13%) 
(entry 5), whereas the β-anomer primarily gave the 2-C-branched product, however in low yield 
(not shown).123 
 
Recently, Palmelund and Madsen employed 3-bromopropenyl acetate and benzoate in indium-
mediated allylation of unprotected sugars to obtain fully hydroxylated carbohydrates elongated with 
two carbon atoms (Table 8).129 Following allylation, deesterification of the crude reaction mixture 
gave two diastereomers, which were separated and subjected to ozonolysis to afford heptoses and 
octoses in good overall yield.  
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Table 8. Sequential indium-mediated allylation and ozonolysis of unprotected sugars.129 
O
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R
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HO OH OH
1) In
2) NaOMe/MeOH
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    diastereomers
Br OBz
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Entry Substrate Substituents Major diastereomer 
Yield 
(%) Selectivity 
      
      
      
      
1 D-galactose   90a 3.5:1 
      
      
      
      
      
      
      
2 D-xylose R = H  75a 4.5:1 
3 D-glucose R = CH2OH  71a 3.5:1 
      
      
      
      
      
      
4 D-lyxose R = H  60 8.5:1 
5 D-mannose R = CH2OH  71a 3:1 
      
      
      
a Isolated as the peracetate after treatment with Ac2O/pyridine. 
 
The allylation developed by Palmelund and Madsen occurs with moderate to good 
diastereoselectivity favoring the lyxo configuration at the reducing end, and the procedure is a 
convenient improvement of previously reported multistep preparations of heptoses based on the 
indium-mediated allylation.130 Kosma and co-workers recently allylated unprotected L-lyxose in 
aqueous ethanol in the presence of indium and allylbromide to give an 8:1 threo/erythro mixture.131 
This result is in accordance with the stereselectivity observed by Palmelund and Madsen when 
using D-lyxose and 3-bromopropenyl benzoate (Table 8, entry 4). Following allylation of L-lyxose, 
the corresponding 1,2,3-trideoxy-L-galacto-oct-1-enitol could be isolated in 75% yield after 
peracetylation, and it was subsequently converted into 3,4,5,6,7-penta-O-acetyl-2-deoxy-L-galacto-
heptose in 47% overall yield from L-lyxose after dihydroxylation of the double bond and oxidative 
cleavage of the diol with sodium periodate.131 
HO
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Reductive fragmentation of ω-haloglycosides developed by Bernet and Vasella125-128 produces 
aldehydo sugars containing a terminal alkene, which can be elongated by organometallic addition to 
the carbonyl group. Since the development of efficient ring-closing olefin metathesis catalysts,132-134 
the Vasella-fragmentation has been extensively studied in combination with elongation by 
organometallic addition to produce carbohydrate-derived α,ω-dienes. This has elegantly been 
accomplished by Madsen and co-workers in a zinc-mediated tandem reaction where 
ω-iodoglycosides (30) are converted into α,ω-dienes (32) in one pot (Scheme 10).135,136 Zinc-
mediated reductive fragmentation of a protected ω-iodoglycoside 30 generates an aldehyde 31, 
which can be alkylated immediately by an in situ formed organozinc species thereby extending the 
carbohydrate chain by one, two or three carbon atoms. One carbon atom elongations can be 
achieved with diiodomethane in the presence of a Lewis acid and catalytic PbCl2. Introduction of 
two carbon atoms can be effected by vinylation, however, divinyl zinc cannot be formed in situ and 
has to be preformed, whereas the addition of allylbromides facilitates three-carbon homologations. 
The resulting dienes 32 (α,ω-dienitols) can be subjected to ring-closing olefin metathesis, and by 
choosing either a pentose or a hexose in combination with the above mentioned homologations, 
carbocycles 33 with different ring sizes can easily be accessed. The methodology has recently been 
reviewed18 and has successfully been applied in the synthesis of a number of natural products from 
readily available carbohydrate precursors. 
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Scheme 10. Zinc-mediated tandem fragmentation-alkylation of ω-iodoglycosides 30 and subsequent ring-closing 
metathesis to produce carbocycles 33.135,136 
 
2.2.6 Chain elongation by olefination 
Both phosphorane (Wittig olefination) and phosphonate ylides (i.e. the Horner-Emmons olefination) 
have found numerous applications in the chain extension of carbohydrate substrates.26 Although the 
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Wittig chain extension has been known on unprotected carbohydrates for more than 40 years,137 the 
formation of complex product mixtures results in moderate yields of the desired chain elongated 
products. With stabilized ylides (34), both open chain (35) and different cyclized products are 
produced due to spontaneous intramolecular Michael addition giving C-glycosides (36 and 37), or 
addition to the carbonyl group giving lactones (38) (Scheme 11).26  
O
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Scheme 11. Wittig reactions on unprotected sugars usually give complex product mixtures.26 
 
As a result, the Wittig and the Horner-Emmons approaches to higher carbon sugars are primarily 
performed on protected sugars possessing a free aldehyde or hemiacetal functionality. 
Dihydroxylation of the resulting double bond is a common way to produce fully hydroxylated 
sugars, and this methodology has recently been employed by Ohira and co-workers to synthesize 
the naturally occurring 2-ulosonic acid KDO from D-glucose.138  
 
With unprotected sugars, the formation of the Michael adducts 36 and 37 can be partially 
suppressed by addition of cupric acetate.139 Furthermore, Railton and Clive recently found that by 
using bulky ester-stabilized phosphoranes, the Michael addition can be completely suppressed 
giving open chain α,β-unsaturated esters 35 with high E selectivities.140 
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Table 9. Sequential Wittig reaction and dihydroxylation to produce elongated sugars. 
 
aldose PPh3=CHCO2
tBu
unsaturated ester higher sugarOsO4, NMO
 
 
Entry Aldose Unsaturated 
ester Substituents 
Yield 
(%) 
E/Z 
selectivity 
Higher 
sugar 
Yield 
(%) Selectivity 
         
         
1 D-glucose  R = CH2OH 66140 1:0  76141 5:1 
         
2 D-glucose  R = CH2OH    68b,141  
         
3 D-xylose  R = H 94141 1:0  53141 6:1 
         
4 D-xylose  R = H    63b,141  
         
         
         
5 D-arabinose   92140 1:0  69141 7:1 
         
6 D-arabinose      73b,141  
         
         
         
         
7 D-galactose  R = H 76140 1:0  85141 8:1 
         
8 D-galactose  R = H    77b,141  
         
9 
D-glycero- 
D-galacto-
heptose 
 R = CH2OH 52141 1:0  54a,141 5:1 
         
a
 Isolated as the 1,4-lactone, b Isolated yield of the major isomer after one-pot Wittig-dihydroxylation reaction. 
 
As depicted in Table 9, Wittig reactions of unprotected sugars using stabilized tert-butyl ester 
phosphoranes are more efficient for pentoses (entry 3 and 5) than for hexoses (entry 1 and 7) and 
heptoses (entry 9). However, in all cases the E unsaturated ester is formed exclusively. Subsequent 
dihydroxylation gives fully hydroxylated sugars elongated with two carbon atoms in good yield. 
The dihydroxylation follows Kishi’s rule142 giving good diastereoselectivities for 2,3-threo 
configured sugars, and the Wittig-dihydroxylation sequence is therefore most efficient for formation 
of higher sugars containing the galacto configuration at the reducing end. The Wittig-
dihydroxylation sequence can even be carried out as a one-pot procedure (entries 2, 4, 6 and 8), 
which is more convenient and give higher yields than the corresponding two-step procedure.141 
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Railton and Clive’s E-selective procedure has recently been used by Chang and Paquette in an 
approach towards the highly hydroxylated polyketide amphidinol 3. In this case, the Wittig reaction 
between the tert-butyl-stabilized phosphonium ylide PPh3=CHCO2tBu and the partially protected 
3,4-O-isopropylidene-β-D-ribopyranose afforded the E isomer exclusively in 90% yield.143 
 
Recently, Sasaki and co-workers synthesized all eight L-hexoses by elongation of each of the two 
protected L-tetroses 39, which are available in six and seven steps from L-ascorbic acid (Scheme 
12).144,145 Wittig reactions on tetroses 39 using the stabilized phosphorane ylide PPh3=CHCO2Et 
gave somewhat poor E/Z selectivities ranging from 2:1 to 10:1, and instead the Horner-Emmons 
approach using the corresponding stabilized phosphonate ylide afforded (E)-α,β-unsaturated esters 
40 in excellent stereoselectivity. By applying the Still modification146 of the Horner-Emmons 
reaction, the two (Z)-configured unsaturated esters 42 were obtained exclusively. Subsequent 
asymmetric dihydroxylation of each of the four unsaturated esters 40 and 42 afforded the eight 
L-hexose ester derivatives 41 and 43, which were further manipulated to produce the corresponding 
L-aldoses.145 
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Scheme 12. Schematic representation of Sasaki and co-workers’ route to all eight L-hexoses from L-ascorbic acid.145 
 
One-carbon homologation of sugars by formation of ketene dithioacetals via Peterson and Horner-
Emmons olefination has been achieved by Mlynarski and Banaszek (Table 10). Transformation of 
sugar lactones (44) into ketene dithioacetals (45) using the Peterson olefination only works for lyxo 
configured aldonolactones (Table 10, entry 1). Due to the basicity of the reagent, there is a great 
tendency to β-eliminate an alkoxy substituent,147 and application of the Peterson olefination on 
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arabino and ribo configured aldonolactones either resulted in decomposition, or led to formation of 
unsaturated lactones, which upon exposure to excess reagent gave the corresponding 
α,β-unsaturated ketene dithioacetals in low yield.148 On the other hand, the Horner-Emmons 
approach is more generally applicable (entries 2-6), however, due to the competing β-elimination, 
the yields of the desired ketene dithioacetals 45 are strongly dependant on the configuration of the 
aldonolactone (44).  
 
Table 10. One-carbon homologation of sugar lactones via  ketene dithioacetals. 
O
R
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CO2Me
O
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1) LiBH4, TMSCl
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Entry Sugar lactone 44 Substituents 
Yield of ketene 
dithioacetal 45 
(%) 
    
1  R2 = TBS, R3 = H  78a,148 
2  R2 = TBS, R3 = H  80b,148 
3  R2 = Bn, R3 = H  72-82b,148,149 
4  R2 = Bn, R3 = CH2OBn  51b,150 
    
    
5  R2 = OBn, R3 = H 62b,148,149 
    
6  R2 = H, R3 = OBn 37b,148 
    
    
a
 Peterson olefination was carried out with BuLi and R1 = TMS, b Horner-
Emmons olefination was carried out with KHMDS and R1 = P(O)(OCH2CF3)2. 
 
As with the Peterson olefination, the Horner-Emmons reaction gave best results for lyxo and manno 
configured aldonolactones (Table 10, entries 2-4). Conversion of the ketene dithioacetals into 
2-ulosonic acid derivatives has been accomplished by oxidation and hydrolysis of 45 in methanolic 
solution giving 3-deoxy-2-ulosonic acids 46 (Table 10, path a), or by reduction of the double bond 
followed by hydrolysis of the dithiane affording the C-glycosidic 2,3-dideoxy ulosonic acids 47 
(Table 10, path b).148,149 By this procedure KDO and several 2-S-, 2-N- and 2-O-glycosides of KDO 
O
O
R2O
R2O
R2O
R3
O
OBnO
BnO
R3
R2
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have been prepared by hydrolysis of ketene dithioacetals 45 in the presence of thiols, azides and 
sugar-derived primary alcohols, respectively.147,150,151 
 
In an efficient two-step sequence, protected D-manno and D-arabino hemiacetals 48 and 51 have 
been converted into one carbon atom elongated 2-deoxy-aldonolactones 50 and 53 via ketene 
dithioacetals by Peterson olefination (Scheme 13). The key step in the protocol is the cyclization of 
the ketene dithioacetal functionality of 49 and 52 with the free hydroxy group, and by subsequent 
deprotection of the resulting thioacetal, chain elongated lactones are produced. This procedure 
constitutes an improved route to the 2-ulosonic acids KDO and DAH since the produced D-manno 
and D-arabino configured lactones 50 and 53 are known intermediates in their synthesis.152 
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Scheme 13. One carbon atom homologation via ketene dithioacetals using the Peterson olefination.152 
 
2.2.7 Radical based approaches to chain elongated sugars 
The alkoxy radical fragmentation, which is usually a chain shortening process (see section 2.1.3), 
can be coupled to a three carbon atom extension by a tandem radical fragmentation-allylation 
reaction. Alkoxy radical fragmentation of N-phthalimido glycosides 54 and 57 in the presence of 
allyltri-n-butyltin and AIBN generates an intermediate radical (55 or 58), which is intermolecularly 
trapped by allyltri-n-butyltin to produce the corresponding hept-1-enitols 56 and 59 (Scheme 14). 
The presence of a carbamate at C2 (54) decreases the electron density at this position and enables a 
faster and higher yielding reaction with the electron-rich allyltri-n-butyltin species (2 h, 81% yield) 
compared to the diisopropylidene ether 57 (3.5 h, 65%).153 By this one-pot reaction, aldoses are first 
shortened by one carbon atom followed by a three carbon atom extension thereby producing two-
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carbon elongated ald-1-enitols, which may be useful intermediates in the synthesis of 
polyhydroxylated compounds. 
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Scheme 14. One-pot alkoxy radical fragmentation and allylation of N-phthalimido glycosides. a Partial hydrolysis of the 
formate occurs during the reaction (~10%).153 
 
Synthesis of γ-butyrolactones by SmI2-mediated radical coupling of aldehydes and acrylates is well-
known in organic chemistry.154,155 Recently, this reaction was successfully applied on a sugar 
aldehyde for the first time. The samarium(II)-induced reductive coupling of diisopropylidene 
D-arabinose 60 and ethyl acrylate was achieved in THF in the presence of small amount of tBuOH 
to give a 68:32 epimeric mixture of gluco and manno configured 2,3-dideoxy-octono-1,4-lactones 
61 in 74% yield (Scheme 15). Only moderate stereoselectivity was obtained, but the octose 
derivatives 61, which are intermediates in previously reported syntheses of gluco- and manno-KDO, 
could easily be separated by chromatography.156 
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Scheme 15. Samarium(II)-mediated coupling of protected D-arabinose (60) and ethyl acrylate.156 
 
The formation of 2-C-branched sugars by transition metal mediated radical addition of malonates to 
glycals has been achieved by Linker and co-workers (Table 11).157 By treatment of malonates 63 
with either Mn(OAc)3 or CAN, malonyl radicals are formed. These can react with glycals (62) in a 
highly regioselective process to give an anomeric radical that is oxidized to a glycosyl cation, which 
is finally trapped by the solvent to produce 2-C-branched sugars (64). The reaction is sensitive to 
sterics, and the malonyl radicals predominantly attack trans to the 3-O-acetyl substituent. Similarly, 
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steric effects, and probably also neighboring group participation of the malonyl substituent, leads to 
a stereoselective attack of the solvent trans to the newly incorporated malonyl substituent. Attack of 
the malonyl radical cis to the 3-O-acetyl group leads to small amounts of the 2-epimeric byproducts 
(0-14% yield), and in the CAN-mediated reactions, capture of the glycosyl cation by nitrate from 
the oxidizing agent instead of by the solvent is a competing side-reaction.157,158 
 
Table 11. Transition metal mediated radical addition of malonates to glycals. 
O
O
AcO
CO2R1
CO2R1
Mn(OAc)3/AcOHa 
or CAN/MeOHb AcO OR2
CO2R1
CO2R1
+
62 63 64
 
Products 
Entry Starting 
material Substituents A: glycoside 
B:  
ortho ester 
A 
Yield 
(%) 
 B 
Yield 
(%) 
α/β 
ratio 
        
        
1  .  R1 = iPr, R2 = Ac, R3 = OAc   57a,158  8:92 
2  .  R1 = iPr, R2 = Me, R3 = OAc   68b,158  0:1 
3  .  R1 = iPr, R2 = Me, R3 = H   75b,158  3:97 
4  .  R1 = Me, R2 = Me, R3 = H   81b,158  5:95 
        
        
        
5  .  R1 = Me   89b,158  92:8 
        
        
        
6  .  R1 = Me, R3 = H   78-86b,158,159 0 0:1 
7  .  R1 = Me, R3 = CONH2   70b,159 0  
8  .  R1 = Me, R3 = CO2Me   7 70b,159  
9  .  R1 = Me, R3 = CN   0 80b,159  
        
        
a
 Mn(OAc)3 (2-4 eq.), AcOH, KOAc, 95 °C, b CAN (2-6 eq.), MeOH, 0 °C. 
  
With Mn(III), 95 ºC are required for the reaction to proceed (Table 11, entry 1), and the 
2-C-branched gluco derivative can be obtained in good yield and diastereoselectivity. CAN, on the 
other hand, is capable of mediating the reaction under mild conditions (0 ºC), which leads to higher 
yields and increased diastereoselectivities as compared to Mn(OAc)3 (entry 2). Pentals give higher 
yields than the corresponding hexals (entries 2 and 3), and by using the more sterically demanding 
isopropyl malonate (as compared to the methyl malonate), slightly higher diastereoselectivities can 
be obtained at the expense of the yield (compare entries 3 and 4). Arabinal and galactal (entry 5 and 
6), which only have substituents on one side of the pyranoid ring, react with malonyl radicals 
exclusively from the β- and α-face of the ring, respectively, and no cis byproducts with respect to 
O
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the 3-O-acetyl group are observed.158 With electron-withdrawing substituents at the anomeric center 
(entries 7-9), the oxidation potential of the produced anomeric radicals change,159 and with esters 
and nitriles this leads to cyclic ortho esters as the main products due to intramolecular capture of the 
anomeric radical by the malonyl carbonyl oxygen atom.  
 
This transition metal mediated radical reaction is a highly efficient way to obtain 2-C-branched 
sugars 64 from easily available glycals 62, and the methodology has recently been used in the 
synthesis of C-glycosylated glycine derivatives in few synthetic steps.160 
 
Also ald-1-enitols react with malonyl radicals in the presence of Mn(OAc)3. In this case the malonyl 
group is attached to C1 of the ald-1-enitol 65, however in low yield (<25%).156,161 Instead, it has 
been found that in the absence of dimethyl malonate, acetate can be added to the double bond to 
produce γ-butyrolactones in excellent yield (Scheme 16). After heating to 90 ºC for 60 h, the 
epimeric two-carbon extended 2,3-dideoxy-gluco- and manno-octono-1,4-lactones 66 were formed 
with moderate stereoselectivity in favor of the manno isomer.161  
 
AcO
OAc
OAc
OAc Mn(OAc)3 (4 eq.)
AcOH, KOAc
90 °C, 60 h
90% (∼2:1)
AcO
OAc
OAc
OAc
O O
65 66
 
Scheme 16. Manganese-mediated radical addition of acetate to a protected D-gluc-1-enitol (65).161 
 
2.2.8 Formation of C-glycosides by the Knoevenagel condensation 
Chain elongation of protected or unprotected sugars with malonester derivatives by a non-radical 
mechanism, i.e. the so-called Knoevenagel condensation of aldehydes and ketones has been used to 
elongate carbohydrates during the last 40 years.26 Recently, Lubineau and co-workers found that 
condensation of unprotected carbohydrates with penta-2,4-dione in alkaline aqueous solution 
resulted in formation of β-glycosidic ketones in excellent yield (Table 12).162 As a result of 
thermodynamic control, the β-C-glycosides are formed exclusively in most cases.  
 
D-Glucose, D-mannose and the disaccharide D-cellobiose are cleanly converted into their 
corresponding β-C-glycosides (Table 12, entries 1, 2 and 5) using penta-2,4-dione. Lipophilic 
β-diketones result in lower yields due to decreased solubility (entry 3), whereas unsymmetrical 
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β-diketones give 1:1 mixtures of the corresponding β-C-glycosidic ketones with no selectivity in the 
elimination step (not shown).163 In the case of N-acetyl-D-glucosamine (entry 4), equilibration at C2 
occurs to produce a 2:3 epimeric mixture of the corresponding 1-β-C-D-glucose and 
1-β-C-D-mannose derivatives in 83% combined yield. Epimerization is also observed in the case of 
N-acetyl-D-mannosamine, whereas N-acetyl-D-galactosamine gives a single isomer.164 D-Glycero-
D-manno-heptose gives a majority of the α-glycosidic ketone (entry 6), but after equilibration of the 
2:1 α/β-mixture, 65% of the desired β-isomer could be isolated as its peracetylated derivative.165 
D-Xylose gives a 2:5 α/β-mixture in 97% yield (entry 7), whereas D-ribose predominantly gives the 
furanoid product as a 1:2 anomeric mixture (not shown).166 Surprisingly, a bicyclic branched 
2-octulose was isolated in 27% yield when the reaction conditions were applied to D-fructose 
(entry 8).  
 
Table 12. One-step Knoevenagel condensation of unprotected sugars with β-diketones in aqueous NaHCO3. 
Entry Substrate Diketone Substituents Product Yield (%) 
β/α 
ratio 
       
       
1 D-glucose  R1 = H, R2 = OH, R3 = CH3  96-99162,166 10:1-1:0 
2 D-cellobiose  R1 = β-D-glc, R2 = OH, R3 = CH3  93162 1:0 
3 D-glucose  R1 = H, R2 = OH, R3 = (CH2)5CH3  75163 1:0 
       
4 N-acetyl- D-glucosamine  R1 = H, R2 = NHAc, R3 = CH3  83
a,164
 1:0 
       
       
5 D-mannose  R1 = H  95-97162,166 20:1-1:0 
       
6 
D-glycero- 
D-manno-
heptose 
 R1 = CH2OH  (65% β)b,165 1:2 
       
       
7 D-xylose    97166 5:2 
       
       
       
       
8 D-fructose    27167  
       
       
a Formed as a 2:3 mixture with the C2 epimer, b 65% of the β-isomer was isolated as the pentaacetate after equilibration 
of the initially formed α/β-mixture with NaOMe/MeOH and subsequent treatment with Ac2O/pyridine. 
 
The applicability of this one-step procedure on unprotected carbohydrates in water with excellent 
stereocontrol is a major improvement of previous chain elongation procedures based on the 
Knoevenagel condensation, and the formed β-C-glycosidic ketones can easily be transformed into 
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other functionalities e.g. conversion into the corresponding 1-β-C-formyl-glycosides in few steps 
(Scheme 17). By this procedure acetyl protected 2,6-anhydro-D-glycero-D-gulo-heptose 68 has been 
prepared in five steps in 59% overall yield from D-glucose.168,169 Both the β-C-glycosidic ketone 67 
and the 2,6-anhydroheptose 68 are conveniently set up for further chain elongation reactions e.g. the 
aldol condensation.170 
 
O
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Scheme 17. Transformation of 1-β-C-glycosidic ketone 67 into 2,6-anhydro-D-glycero-D-gulo-heptose 68.168 
 
The condensation of unprotected sugars with β-dicarbonyl compounds to produce polyhydroxylated 
furans is known as the Garcia-González reaction, and it is usually performed under relatively harsch 
reaction conditions.171 As a result of increased attention on the preparation of β-C-glycosidic 
ketones from sugars via the Knoevenagel cndensation, the Garcia-González reaction has also been 
improved. As shown in Scheme 18, D-glucose and penta-2,4-dione can be converted into a 
polyhydroxylated furan derivative 69 in 95% yield under solvent free conditions using catalytic 
amounts of CeCl3 and NaI.171,172 
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Scheme 18. Improved protocol for the Garcia-González reaction between D-glucose and penta-2,4-dione.172 
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2.2.9 Synthesis of exo glycals  
C-Glycosides having an exo double bond at the anomeric center (exo glycals) are interesting 
synthetic intermediates towards various C-glycosides. The presence of the ring oxygen next to the 
double bond enables transformation of these enol ethers into a variety of useful functionalities. The 
synthesis of exo glycals has recently been described in two reviews, to which the reader is referred 
for a more thorough discussion.93,173 
 
Exo glycals are most frequently accessed from sugar lactones, although efficient transformation of 
sugar lactones into exo glycals mainly has been limited to the Tebbe reagent.26 By this procedure 
only disubstituted exo glycals can be produced, and tri- and tetrasubstituted exo glycals are harder to 
access. Olefination reactions based on the Wittig reaction suffer from poor reactivity of sugar 
lactones, and quite harsh reaction conditions (110-140 ºC) are required giving almost no E/Z 
selectivity.173 Recently, Xie and co-workers found that perbenzylated 1,5-lactones 70 and 72 react 
with stabilized phosphonium ylides to give exclusively the Z isomers 71 and 73 in good yield 
(Scheme 19).174,175 
 
O
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Scheme 19. Perbenzoylated six-membered sugar lactones give exclusively the Z exo glycals by Wittig reaction with 
stabilized ylides.174 
 
Alternatively, carbohydrates carrying a phosphonium ylide at the anomeric carbon can be employed 
to produce tri- and tetrasubstituted exo glycals.173 An improved protocol for the formation of 
anomeric phosphonium ylides has recently been reported by Lieberknecht and co-workers, and by 
refluxing methyl glycosides with PPh3 and HBF4 in acetonitrile, the corresponding anomeric 
phosphonium salts are formed in excellent yield in a single step.176  
 
Also the Ramberg-Bäcklund rearrangement of anomeric sulfoxides can be employed to produce exo 
glycals.177-179 Base-mediated rearrangement of anomeric sulfoxides (75), which are easily available 
from thioglycosides (74) by oxidation, predominantly gives Z exo glycals (76) (Scheme 20). This 
Chapter 2 Methods for shortening and extending the carbon chain in carbohydrates 
33 
procedure has recently been employed in the synthesis of C-disaccharides180,181 and a C-glycoside 
of an amino acid.182 
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Scheme 20. The Ramberg-Bäcklund approach to exo glycals.177 
 
Very recently, Gueyrard and co-workers applied the Julia olefination on sugar lactones producing a 
number of di-, tri- and tetrasubstituted exo glycals (Scheme 21).183,184 For trisubstituted exo glycals, 
the E/Z selectivity is good for arabino configured lactones (e.g. 77, which favors the E exo glycal 
78), whereas gluco configured lactones are less selective giving 1:1 mixtures. 
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Scheme 21. Formation of exo glycals by the Julia olefination.184 
 
2.2.10 Chain extension by coupling of two sugars 
Several strategies for extending the carbohydrate chain by coupling of two suitably derivatized 
sugars have recently been exploited. A detailed discussion of such approaches is outside the scope 
of the present chapter, but the available methods include nitrile oxide cycloaddition,185 Baylis-
Hillman type condensation,186,187 cross metathesis,188 aldol condensation,189-191 hetero Diels-Alder 
reaction,192 Wittig and Horner-Emmons reactions,193-195 and tin-mediated allylation of 
aldehydes.196,197 
 
2.3 Concluding remarks 
Several different methods for shortening and extending the carbon chain in sugars exist, each with 
its own specific advantages and drawbacks. The most noteworthy advantage is the ability to 
modulate sugars without protective groups e.g. the recent advances within indium-mediated 
allylation, the Wittig reaction and the Knoevenagel condensation. In addition, the fact that the 
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stereochemical outcome can be predicted and controlled makes such processes extremely attractive 
routes for elongation of carbohydrates. Together, all the available methods constitute a diverse tool 
box for construction of carbohydrate-based polyhydroxylated compounds, which is particularly 
useful in synthetic chemistry given the importance of sugars in chemistry and biology as discussed 
in chapter 1. 
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3 Chain shortening of aldoses by rhodium-catalyzed decarbonylation 
 
3.1 Introduction 
As mentioned in chapter 2, a number of different methods for shortening protected carbohydrates 
are available,26 although not many of these are applicable to unprotected sugars. The most notable 
methods for shortening unprotected carbohydrates are the Ruff degradation (section 2.1.1), which 
converts salts of aldonic acids into aldoses with one less carbon,27,31 and the Humphlett degradation, 
which produces aldonic acids from the corresponding higher aldoses.198,199 Recently, homogeneous 
transition metal mediated transformations have grown to become an extremely powerful tool in 
synthetic organic chemistry,200 and transition metals have also found numerous applications in 
carbohydrate chemistry.16 In 1988, Andrews and Klaeren201 used Wilkinson’s reagent202 
(RhCl(PPh3)3) to shorten unprotected aldoses by one carbon atom by means of a decarbonylation of 
the aldehyde functionality to produce the corresponding lower alditol (Scheme 22). 
 
1 eq. RhCl(PPh3)3
NMP, 130 °C R
OH
OH
R
OH
OH
O
 
Scheme 22. Decarbonylation of aldoses using stoichiometric amounts of Wilkinson’s reagent.201 
 
However, the decarbonylation reaction developed by Andrews and Klaeren requires stoichiometric 
amounts of rhodium, and as a result, the procedure is not convenient except for small scale 
synthesis. As we shall see in section 3.2.2 below, the rhodium-mediated decarbonylation of simple 
alkyl and aryl aldehydes has improved considerably during the last few years, and it can now be 
performed with catalytic amounts of rhodium. Based on these recent developments, the objective of 
this project is to improve the decarbonylation of unprotected carbohydrates to become catalytic with 
regards to rhodium thereby providing a procedure to shorten unprotected sugars, which is 
complementary to other existing methods.  
 
3.2 Literature background 
3.2.1 Rhodium-mediated decarbonylation 
The rhodium-mediated decarbonylation of aldehydes was initially discovered by Tsuji and Ohno203 
in an attempt to find a more efficient decarbonylation catalyst than metallic palladium. At that time 
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palladium on carbon was known to decarbonylate both aldehydes and acyl halides catalytically at 
temperatures exceeding 200 ºC (Scheme 23).204  
 
R X
O M
R X
X = H, halide
R = alkyl, aryl
M = transition metal species
+ CO
 
Scheme 23. Transition metal mediated decarbonylation of aldehydes and acyl halides. 
 
It was found that square-planar RhCl(PPh3)3 could mediate the decarbonylation of a range of 
aliphatic, α,β-unsaturated, and aromatic aldehydes under mild conditions at room temperature or in 
refluxing solvents like benzene and toluene.203 The decarbonylation was stoichiometric in rhodium 
due to formation of RhCl(CO)(PPh3)2, which is very stable205 and cannot lose carbon monoxide to 
regenerate the active decarbonylation species.206 A couple of years later, Tsuji and Ohno reported 
that catalytic decarbonylations with RhCl(CO)(PPh3)2207,208 or RhCl(PPh3)3206 could be achieved at 
higher temperatures. In fact, temperatures above 200 ºC were required in order for catalytic 
decarbonylation to occur.208 Due to increasing decomposition and unwanted side-reactions of 
aliphatic aldehydes (aldol condensations) at elevated temperatures, the catalytic version was only 
applicable to aromatic aldehydes possessing no other functional groups.206,208,209  
 
Tsuji and Ohno also discovered that acyl halides could be catalytically decarbonylated using 
Wilkinson’s reagent.205,206,208 With acyl halides, the corresponding shortened olefins are formed as a 
result of facile β-hydrogen elimination, whereas in the absence of β-hydrogens, alkyl or aryl halides 
are formed instead.208,210 Later it was found that also ketones could be decarbonylated in specialized 
cases. There are only a few examples in the literature, but α- or β-diketones211 as well as 
biarylketones212 can be decarbonylated catalytically employing Wilkinson’s reagent, however in 
low to moderate yields with relatively high catalyst loadings. For example acetylacetone is 
converted into methyl ethyl ketone,211 and 4,4’-dimethylbenzophenone is converted into 
4,4’-dimethylbiphenyl212 by this procedure. Also various carboxylic acid derivatives like acid 
anhydrides213,214 and acyl nitriles215 can be decarbonylated by Rh(I)-species. 
 
Other transition metals than rhodium have also been found to facilitate the decarbonylation of 
aldehydes. In addition to Wilkinson’s reagent, stoichiometric amounts of [RuCl2(PPhEt2)3]2 can be 
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applied in homogeneous decarbonylation at 80-90 ºC,206,209 whereas catalytic decarbonylation can 
be achieved homogeneously with [IrCl(COD)]2 in the presence of phosphine ligands at 
101-120 ºC,♦,216,217 or heterogeneously with metallic Pd, Pt, Rh and Ni at temperatures above 
200 ºC.209 In contrast to Wilkinson’s reagent, the above mentioned metals generally produce the 
corresponding decarbonylated olefins as the major products, and alkene-alkane mixtures are often 
observed. Furthermore, Ir gives rise to alkene isomerization even at low temperature.217 In any case, 
until recently, RhCl(PPh3)3 was the most efficient reagent for decarbonylation of aldehydes.206,209 
 
The rhodium-mediated decarbonylation of aldehydes is sensitive to steric hindrance, and for 
aliphatic aldehydes the order of reactivity is primary > secondary > tertiary.207,208,218 Primary 
aldehydes are readily decarbonylated at room temperature, whereas secondary aldehydes generally 
require heating.208 Sterically hindered secondary and tertiary aldehydes are not easily 
decarbonylated, but when excess of Wilkinson’s reagent is used more sterically demanding 
substrates can be decarbonylated in good yields (Scheme 24).219,220  
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Scheme 24. The decarbonylation reaction is sensitive to steric hindrance, and bulky tertiary aldehydes require an excess 
of Wilkinson’s reagent.219 
 
Rhodium-mediated decarbonylation is stereospecific and both alkene geometry and the 
configuration of a stereocenter next to the aldehyde moiety are rigorously retained.207-209,218 
However, under catalytic decarbonylation at forcing conditions (160-260 ºC), alkene isomerization 
can be observed. Walborsky and Allen found that during decarbonylation of 2-substituted 
cinnamaldehydes, up to 26% double bond isomerization to the more stable (E)-isomers occurred.218 
The alkene isomerization is rather thermal than rhodium-mediated,218 but as a result, substituted 
α,β-unsaturated aldehydes cannot conveniently be decarbonylated catalytically, and instead 
stoichiometric amounts of Wilkinson’s reagent at lower temperatures are required.  
                                                 
♦
 During the preparation of this thesis, an efficient procedure for decarbonylation of various aldehydes in good yield 
(63-94%) using commercially available [IrCl(COD)]2 (5%) and PPh3 (5%) for 24-48 h in refluxing dioxane (101 ºC) 
was reported (Iwai, T.; Fujihara, T.; Tsuji, Y. Chem. Commun. 2008, 6215). Compare with the catalytic decarbonylation 
mediated by rhodium(I), which will be described in section 3.2.2. 
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3.2.2 Catalytic decarbonylation 
Due to the inconvenience of using stoichiometric amounts of costly rhodium complexes, 
considerable effort has been put into making the decarbonylation catalytic with regards to rhodium. 
In 1978, Doughty and Pignolet speculated that cationic rhodium(I) complexes containing chelating 
phosphine ligands should bind carbon monoxide less strongly. This would enable decarbonylation 
and subsequent loss of carbon monoxide at lower temperatures than required with Wilkinson’s 
reagent.221 Cationic metal carbonyl complexes are less electron rich than their corresponding neutral 
metal complexes, and this results in a decreased Rh-CO π back-donation making carbon monoxide 
more weakly bound to the metal.222 Doughty and Pignolet rationalized that the lower electron 
density on the metal complex combined with a trans rhodium-phosphorous stereochemistry would 
bind carbon monoxide less strongly and place carbon monoxide in an equatorial position in a 
distorted trigonal bipyramidal structure as depicted in Figure 1.221 This structural composition had 
earlier been firmly determined by X-ray crystallography of the analogues iridium complex 
[Ir(CO)(dppe)2]+Cl-,223 which is known to reversibly bind carbon monoxide in solution.221 
 
Rh
PPh2
CO
PPh2
Ph2P
Ph2P
 
Figure 1. Proposed distorted trigonal bipyramidal structure of cationic Rh(I)-complexes containing two bidentate 
phosphine ligands and carbon monoxide.221,223 
 
Doughty and Pignolet screened the rhodium(I)-complexes of four different bidentate phosphine 
ligands: dppm, dppe, dppp and dppb (Figure 2). Catalytic decarbonylation was achieved at 
115-178 ºC for all four rhodium(I) complexes, but the reaction rate was very dependant on the 
chelate ring size and the bite angle.224 The reaction rate increases when going from four- to six-
membered chelate rings obtaining the best results with Rh(dppp)2Cl. Further increase to the seven-
membered chelate ring of Rh(dppb)2Cl  results in much lower catalytic activity.225  
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Figure 2. Structures and bite angles224 of bidentate phosphine ligands tested by Doughty and Pignolet.225 
 
The catalytic activity was found to be independant of the identity of the counterion, and identical 
results could be obtained using Cl- and BF4- metal complexes. Several different aliphatic, 
α,β-unsaturated and aromatic aldehydes could be decarbonylated catalytically with Rh(dppp)2Cl at 
more useful temperatures.221,225 However, Rh(dppp)2Cl is not commercially available thereby 
limiting the utility of the procedure compared to Wilkinson’s reagent. In an attempt to address this 
problem, Meyer and Kruse formed Rh(dppp)2Cl in situ by heating Wilkinson’s reagent together 
with 2.2 equivalents of dppp in xylene at 80 ºC for 15 min. Subsequent addition of different 
aromatic aldehydes followed by heating to reflux for 18-24 h gave the decarbonylated products in 
82-95% yields with 1-4% in situ formed Rh(dppp)2Cl.226 Boeckman and co-workers later 
successfully formed the catalyst in situ from dppp and another rhodium(I)-complex, 
[RhCl(COD)]2.227 However, since the introduction of Rh(dppp)2Cl by Doughty and Pignolet, its use 
in the decarbonylation reaction has remained somewhat limited. In fact, it may not be completely 
reliable as experienced by McCague and co-workers, who failed decarbonylating a dialdehyde with 
catalytic Rh(dppe)2Cl and Rh(dppp)2Cl, and had to turn to stoichiometric amounts of Wilkinson’s 
reagent instead.228 Also Hansson and Wickberg unsuccessfully applied catalytic Rh(dppp)2Cl to the 
decarbonylation of a vinylic aldehyde, and just like McCague and co-workers, they had to use 
Wilkinson’s reagent instead.229 As a result of these unsuccessful attempts to use Rh(dppp)2Cl, most 
applications of rhodium-mediated decarbonylation in synthesis have employed the more reliable 
Wilkinson’s reagent in stoichiometric amounts.219,220,230,231  
 
In a search for a more widely applicable mild catalytic decarbonylation procedure, O’Connor and 
Ma realized that additives capable of abstracting carbon monoxide from rhodium would enable 
catalysis at low temperature.232 They found that stoichiometric amounts of diphenylphosphoryl 
azide (DPPA) together with catalytic RhCl(PPh3)3 in THF decarbonylated a range of different 
primary aldehydes in excellent yield at room temperature. By addition of DPPA, carbon monoxide 
is abstracted from the initially formed RhCl(CO)(PPh3)2 by formation of diphenylphosphoryl 
isocyanate with loss of nitrogen gas. However, the application of DPPA to abstract carbon 
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monoxide is limited to primary aldehydes,232 and attempts to apply the procedure to aromatic 
aldehydes failed.233  
 
At the same time, it was found that catalytic decarbonylation could be achieved using the dimeric 
rhodium(I)-species [RhCl(CO)(PMe3)]2 during continuous purging with argon.234 The rate of 
decarbonylation with [RhCl(CO)(PMe3)]2 at 100 ºC was comparable to the rate of Rh(dppp)2+ 
developed by Doughty and Pignolet.221,234 Crabtree and co-workers later used a tridentate phosphine 
ligand in the metal complex [Rh(CO)(triphos)]SbF6, which reversibly binds a second molecule of 
carbon monoxide.235 In this way, they successfully decarbonylated 4-biphenylcarboxaldehyde in 
refluxing dioxane at 100 ºC, but the reaction was very slow. After 94 h, only 34% yield was 
achieved with 5% catalyst loading. However, increasing the temperature to 162 ºC in refluxing 
diglyme enabled simple primary and aromatic aldehydes to be decarbonylated in 43-100% yield 
after 45-48 h, whereas more sterically demanding aliphatic aldehydes gave low conversion. In 
addition to reasonably slow conversion, the catalyst requires several steps to prepare, and as a 
result, it has only found very little practical use. 
 
A major improvement was provided by our group when Anders Palmelund found that Rh(dppp)2Cl 
could be prepared in situ form commercially available RhCl3 • 3H2O and dppp.236 Testing a number 
of different solvents showed that the polyether solvent diglyme with a boiling point of 162 ºC was 
very suitable for the decarbonylation. A screening of numerous bi- and tridentate phosphine ligands 
revealed that metal complexes containing ligands with bite angles224 between 91 and 96º were very 
reactive giving quantitive conversion of 2-naphthaldehyde into naphthalene within 3 h.236 
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Figure 3. The four most reactive metal complexes employed bidentate phosphine ligands with bite angles between 91 
and 96º.224,236 
 
Metal complexes of BINAP and dppp were found to be the most reactive (Figure 3), and due to 
lower cost, dppp was chosen for further optimization. Best results were obtained with two 
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equivalents of dppp compared to RhCl3 • 3H2O, and a range of aromatic aldehydes were smoothly 
decarbonylated with 0.4-10% catalyst in 74-94% isolated yield. Also primary and secondary 
aliphatic aldehydes were easily decarbonylated, however, with sterically demanding tertiary 
substrates, no decarbonylation was achieved. The procedure tolerates many functional groups such 
as ethers, esters, nitriles, chlorides, substituted amines and amides as well as alkenes, and it 
constitutes a very general and convenient procedure for catalytic decarbonylation of aldehydes.236 
 
3.2.3 Mechanism 
In 1982, Doughty and Pignolet suggested a mechanism for the rhodium-catalyzed decarbonylation 
of aldehydes using bidentate phosphine ligands based on deuterium labeling, kinetic isotope effect, 
reaction kinetics and analysis of reaction intermediates (Scheme 25a).225 They believed that the 
square-planar Rh(dppp)2+ (79) was the catalytically active species and their proposed mechanism 
consisted of five elementary steps: coordination of the aldehyde to 79, oxidative addition to give 81, 
migratory extrusion of carbon monoxide giving 82, liberation of the product by reductive 
elimination and finally loss of carbon monoxide to regenerate 79.  
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Scheme 25. Proposed catalytic cycles for the rhodium(I)-catalyzed decarbonylation of aldehydes. a) Doughty and 
Pignolet’s mechanism consists of five elementary steps: coordination of the aldehyde, oxidative addition, migratory 
extrusion, reductive elimination and loss of carbon monoxide.225 b) The mechanism proposed by Fristrup et al. consists 
of four elementary steps: coordination of the aldehyde, oxidative addition, migratory extrusion and reductive 
elimination.237 
 
However, mechanistic studies in our group by Fristrup et al. by means of experimental Hammett 
studies and kinetic isotope effect as well as computational DFT (density functional theory) 
calculations suggest a catalytic cycle based on the catalytically active species Rh(dppp)(CO)L+ (83), 
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where L is a spectator ligand (Scheme 25b).237 The identity of the ligand L may be either a second 
molecule of carbon monoxide or another dppp coordinating as a monodentate ligand as suggested 
by Doughty and Pignolet,225 but calculations showed that coordination of an aldehyde to the square-
planar Rh(dppp)2+ (79) is highly unfavorable.237 As a result, the square-planar Rh(dppp)(CO)L+ 
(83) is more likely to be the catalytically active species. 
 
The mechanism proposed by Fristrup et al. is based on experimental and computational studies with 
benzaldehyde and phenylacetaldehyde, and it consists of four elementary steps: coordination of the 
aldehyde to 83 with loss of the carbon monoxide ligand, oxidative addition producing 84, migratory 
extrusion of carbon monoxide to give 85 and finally reductive elimination. The experimentally 
determined kinetic isotope effects were in excellent agreement with computational values 
suggesting that the reaction mechanism is the same for both substrates, and that migratory extrusion 
(84 → 85) is the rate-determining step.237 This is in contrast to Doughty and Pignolet’s proposed 
mechanism where oxidative addition (80 → 81) was believed to be rate-determining,225 but the 
comprehensive experimental study supported by computational calculations performed by Fristrup 
and co-workers strongly suggests a mechanism according to Scheme 25b. 
 
3.2.4 Recent synthetic applications 
The impact of the decarbonylation of aldehydes in synthetic organic chemistry can be illustrated by 
the following recent applications. In these examples the rhodium-mediated decarbonylation of an 
aldehyde has been used in combination with a number of other reactions to achieve more than one 
transformation in a single pot.  
 
Intramolecular trapping of aryl-rhodium species produced from their corresponding aldehydes have 
been achieved by Kampmeier and co-workers to perform carbocyclizations (Scheme 26).238 
Insertion of rhodium into the aldehydic C-H bond of 2-allylbenzaldehyde (86) followed by 
decarbonylation and intramolecular capture by the alkene led to indane (87) in a 4:1 ratio with the 
decarbonylation product. 
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Scheme 26. Intramolecular capture of rhodium-aryl species to produce carbocycles.238 
 
Tandem Oppenauer-decarbonylation reactions can be achieved using in situ generated Rh(dppp)2Cl 
at 170 ºC thereby removing a hydroxymethyl group from a primary alcohol (Scheme 27).236 
Applying 2% of the hydrogen transfer catalyst [Cp*IrCl2]2 in the presence of K2CO3 together with 
4% of the in situ generated decarbonylation catalyst afforded 73% yield of p-xylene from 
2-(4-methylphenyl)ethanol (88). 
 
OH 2% [Cp*IrCl2]2, K2CO3
4% RhCl3 • 3H2O, 8% dppp
benzophenone, 170 °C
73%
88
 
Scheme 27. Tandem Oppenauer-decarbonylation reaction.236 
 
Aldehydes can be used as alkene equivalents in the Diels-Alder reaction.239 Performing a 
BF3 • Et2O catalyzed Diels-Alder reaction followed by quenching of the Lewis acid, addition of 
Rh(dppp)2Cl and heating to 162 ºC lead to good yields of cyclohexene products, which are not 
available by a direct Diels-Alder reaction between the diene and ethylene (Scheme 28). In this way, 
the carbonyl group can be used as a removable handle controlling both reactivity and 
regioselectivity. 
 
O
H1) 6% BF3 • OEt2, rt
2) 0.3% Rh(dppp)2Cl
diglyme, 162 °C
81%
+
 
Scheme 28. Tandem Diels-Alder – decarbonylation sequence.239 
 
This concept of using the carbonyl group as a removable steering group to enable specific chemical 
reactivity has also been achieved very recently by a one-pot 1,4-addition of a boronic acid to the 
α,β-unsaturated aldehyde 89 followed by decarbonylation to produce enantiomerically pure 
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1,1-diarylethane 90 (Scheme 29).240 The one-pot reaction could be achieved with dimeric 
[Rh(epi-(–)-dolefin)Cl]2 complexes in low yield, but addition of an additional rhodium(I)-catalyst 
(1.5% each) to facilitate the decarbonylation was necessary to achieve a reasonable yield. 
 
O
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Scheme 29. Sequential conjugate addition – decarbonylation sequence.240 
 
Application of aldehydes as a source of carbon monoxide in different carbonylation reactions was 
first envisioned by Morimoto and co-workers.241 The fact that carbonylation reactions are usually 
carried out by the same kind of transition metal catalysts as the decarbonylation reaction has been 
utilized in a number of rhodium-catalyzed Phauson-Khand reactions employing aldehydes as the 
source of carbon monoxide (Scheme 30).241-243 Catalytic Phauson-Khand reactions using aldehydes 
as the source of carbon monoxide has also recently been achieved with 5% of [IrCl(COD)]2 and 
10% of BINAP by using a five-fold excess of the aldehyde.216 
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Scheme 30. Phauson-Khand reaction employing 2-naphthaldehyde as carbon monoxide donor.241 
 
The Pauson-Khand reaction of enyne 91 can even be performed with formaldehyde as the carbon 
monoxide donor.244 In this case, the reaction is performed in aqueous formaldehyde in the presence 
of the surfactant SDS together with dppp and the water soluble analogue TPPTS producing the 
desired product 92 in 97% yield with 5% catalyst loading.  
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3.2.5 Application on carbohydrate substrates 
In carbohydrate chemistry, decarbonylation has not received much attention, and only a few 
decarbonylations of fully protected sugars using stoichiometric amounts of Wilkinson’s reagent 
have been reported.245,246 Transition metal mediated decarbonylation of unprotected sugars was first 
addressed by Kruse and Wright247 in 1978 and Kuriacose and co-workers248 in 1983. In two studies 
investigating the hydrogenation of D-glucose catalyzed by RuCl2(PPh3)3 in DMA, it was found that 
the desired reaction was inhibited by a decarbonylation reaction. No carbohydrate products were 
isolated, but three metal complexes were characterized as RuHCl(CO)(PPh3)2,247 
RuCl2(CO)(PPh3)2(DMA) and cis-RuCl2(CO)2(PPh3)2,248 and it was realized that D-glucose had 
underwent a decarbonylation reaction.248 However, in 1988 Andrews and Klaeren reported the first 
useful transition metal mediated decarbonylation of unprotected sugars.201 The reactions were 
performed on a small scale (150 µmol) with stoichiometric amounts of Wilkinson’s reagent in NMP 
at 130 ºC producing the corresponding lower alditols. The following year the procedure was 
extended to a range of different aldoses including deoxyaldoses, N-acetylaldoses and disaccharides, 
which were synthesized in 37-87% isolated yields.249 As with simple aldehydes, the 
decarbonylation occurred with complete retention of stereochemistry. All attempts to make the 
reaction catalytic in rhodium employing Rh(dppe)2+ or Rh(dppp)2+ were unsuccessful.249 
 
Andrews also applied the procedure to ketoses and found that in the case of D-fructose a complex 
dehydration-isomerization mechanism occurred leading to intermediate 5-hydroxymethyl furfural 
(93), which was decarbonylated to give furfuryl alcohol (94) (Scheme 31).201,250 As with the 
aldoses, the reaction was stoichiometric in rhodium and 94 was formed in 80% GC-yield. 
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Scheme 31. Dehydration and decarbonylation of D-fructose gives furfuryl alcohol (94).201,250 
 
Similar to O’Connor and Ma’s observations, Beck and co-workers found that the decarbonylation of 
D-glucose could be achieved catalytically in the presence of additives.251 Performing the reaction 
with DPPA, sodium azide, urea or the bidentate phosphine ligands dppe, dppb or dpph together 
with 5-10% of RhCl(PPh3)3 in NMP gave 30-52% HPLC-yield of D-arabinitol after 24 h at 
Rune Nygaard Monrad – Ph.D. Thesis 
46 
50-130 ºC. The decarbonylations were rather slow, and in all cases full conversion was not achieved 
resulting in considerable amounts of residual D-glucose,251 which may be difficult to remove from 
D-arabinitol. Based on these results, the decarbonylation of aldoses is not feasible on a preparative 
scale emphasizing the need for a convenient catalytic procedure. 
 
3.3 Previous work on the decarbonylation project in the group 
As a part of the studies on the decarbonylation of aldehydes in our group,236,237,239 Anders 
Palmelund discovered that unprotected D-arabinose could be decarbonylated catalytically with 
preformed Rh(dppp)2Cl in a closed vial in a microwave oven (Scheme 32). Attempts to generate 
Rh(dppp)2Cl in situ from RhCl3 • 3H2O or perform the reaction in an open system failed.252 
 
2% Rh(dppp)2Cl
dioxane/H2O
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76%
OH
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O
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Scheme 32. Rhodium(I)-catalyzed decarbonylation of D-arabinose by Anders Palmelund employing microwave 
heating.252 
 
3.4 Results and discussion 
Because the evolution of a molecule of carbon monoxide has been found to inhibit decarbonylation 
in a closed system,239 and the application of microwave heating is less convenient for general 
synthetic use, it is desirable to be able to decarbonylate aldoses in an open system. As a result of 
this, the initial decarbonylation experiments were carried out in an open system. Due to Anders’ 
failed attempts to use the in situ generated catalyst on unprotected sugars, preformed Rh(dppp)2Cl 
was used for the initial experiments on D-glucose. (For experiments with in situ generated catalysts, 
see section 3.4.3). 
 
Rh(dppp)2Cl was synthesized in two steps in excellent yield using a slightly modified literature 
procedure (Scheme 33).253,254 Reduction of Rh(III) to Rh(I) with 2-propanol followed by exchange 
of the dummy ligand COE with dppp gave Rh(dppp)2Cl in 91% yield over two steps. The metal 
complex is not sensitive to air when stored at room temperature, but in solution at elevated 
temperatures, a strict inert atmosphere is necessary to obtain constant catalytic activity.236 
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RhCl3 • 3H2O                               Rh(COE)2Cl                                    Rh(dppp)2Cl
COE, H2O
2-propanol
rt, 15 d
92%
dppp, toluene
reflux, 1.5 h
99%
 
Scheme 33. Synthesis of Rh(dppp)2Cl from RhCl3 • 3H2O. 
 
3.4.1 Solvent system 
Not many solvents can be used in the decarbonylation reaction due to the hydrophobic nature of 
Rh(dppp)2Cl in contrast to the hydrophilic carbohydrate substrates. In addition, a sufficiently high 
boiling solvent system is required in order for the reaction to proceed at a reasonable rate. Andrews 
and co-workers employed NMP as the solvent for stoichiometric decarbonylation of sugars,201,249 
and such amide solvents are uniquely capable of dissolving both metal complexes and unprotected 
carbohydrates. However, the disadvantage of using NMP is the difficulties associated with its 
removal in the purification step. From the results on simple aryl and alkyl aldehydes,236 diglyme, 
which might have a stabilizing effect on the positively charged metal complex, was found to be a 
suitable solvent, but since carbohydrates are not soluble in pure diglyme, a number of different 
solvent systems were screened (Table 13).  
 
Table 13. Decarbonylation of D-glucose into D-arabinitol using different solvent systems. 
10% Rh(dppp)2Cl
solvent, reflux
9-16 h
HO
OH
OH
OH
OH
+       CO
O
OH
HO
HO
OH
OH
D-glucose                                                    D-arabinitol
 
Entry Solvent Reflux temperature ( ºC) 
Conversiona 
(%) 
1 diglyme 162 decomposition 
2 H2O 100 0b 
3 diglyme/H2O (40:1) 152 100 
4 diethyleneglycolmonoethylether 202 100 
5 diglyme/NMP 162 100 
6 diglyme/DMA 162 100 
a
 Conversions are based on TLC analysis. b No conversion was observed within 64 h. 
 
The use of pure diglyme led to decomposition of D-glucose due to poor solubility (Table 13, 
entry 1). Performing the reaction in water at 100 ºC gave no conversion within 64 h (entry 2), 
whereas diglyme/water mixtures were found to produce a homogeneous reaction mixture. However, 
diglyme and water forms an azeotrope (bp 99 ºC) resulting in no conversion. With low amounts of 
water (diglyme/water = 40:1 – 20:1), a high reaction temperature (152 ºC) could be maintained 
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leading to full conversion in 18 h producing D-arabinitol as the main product (entry 3). However, by 
reducing the amount of water, decomposition became an increasing problem. A diglyme/water ratio 
of 40:1 was found to be optimal on a small scale (100 mg D-glucose), but on a larger scale this led 
to poor conversion due to the decreased reaction temperature. Diethyleneglycolmonoethylether 
dissolves both the metal complex and the carbohydrate, but the solvent is very difficult to remove 
after the reaction (entry 4). Extraction of the product into an aqueous phase is not possible, and due 
to a high boiling point (bp 202 ºC), the solvent cannot be removed by evaporation. Additionally, 
glycosylation with the solvent thereby deactivating the substrate towards decarbonylation might 
take place during the harsh reaction conditions. Using NMP (bp 202 ºC) or DMA (bp 165 ºC) as 
co-solvents enabled full conversion without substantial decomposition (entries 5 and 6). The 
reaction can easily be performed in pure DMA, but although it is easier to remove than NMP, the 
amount of DMA should be minimized. Using a 7:1 diglyme/DMA ratio gave consistently good 
results. Initially, the purification was performed by reverse phase column chromatography eluting 
with water, but residual DMA was not efficiently removed due to co-elution with D-arabinitol. 
Other workup procedures were therefore attempted. Bulb-to-bulb distillation at 50-90 ºC neither 
removed DMA nor diglyme, but the latter could be completely removed as an azeotrope with water 
by steam distillation. However, only traces of DMA could be removed by steam distillation for 2 h. 
Instead, it was found that residual DMA could be removed effectively by normal column 
chromatography eluting with DCM/MeOH/H2O = 65:25:4. A control experiment revealed that no 
silica gel was dissolved by the polar eluent during the column chromatography. 
 
3.4.2 Formation of 1,4-anhydro-D-arabinitol 
Decarbonylation of D-glucose in refluxing diglyme/DMA with 10% of Rh(dppp)2Cl gave the 
desired product D-arabinitol in 71% yield in 9 h. To our surprise, 20% of 1,4-anhydro-D-arabinitol 
(95) was isolated as a byproduct in addition to the desired product (Scheme 34).  
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Scheme 34. Rhodium(I)-catalyzed decarbonylation of D-glucose produces D-arabinitol together with the byproduct 
1,4-anhydro-D-arabinitol (95). 
 
1,4-Anhydro-D-arabinitol 95 is formed to a much larger extent than 2,5-anhydro-D-arabinitol 96 
(1,4-anhydro-D-lyxitol) (Scheme 35). Although 95 was isolated in 20% yield,♦ 96 could only be 
detected in trace amounts by NMR spectroscopy. As we will see later in section 3.4.5 (Table 17), 
the exclusive formation of 1,4-anhydroalditols is general for the decarbonylation of aldoses. In 
addition, only 1,4-anhydroalditols with retention of stereochemistry at C4 are observed, which 
suggests an activation of the C1 hydroxy group followed by displacement by the secondary alcohol 
at C4 (Scheme 35, green). The formation of 2,5-anhydroalditols would require displacement of the 
C5 hydroxy group by the secondary alcohol at C2 (Scheme 35, red).  
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Scheme 35. 1,4-Anhydro-D-arabinitol (95) is formed exclusively (green), whereas only a trace of 2,5-anhydro-
D-arabinitol (96) can be observed (red). The formation of 95 requires activation of the C1 hydroxy group followed by 
nucleophilic displacement by the C4 hydroxy group. 
 
 
                                                 
♦
 The identity of 95 was rigorously established by conversion into the corresponding triacetate (see section 8.2 for 
experimental details). 
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To test if rhodium is responsible for the formation of 1,4-anhydroalditols, D-glucose was heated in 
refluxing diglyme and DMA for 24 h without any rhodium present, and, as expected, no 
anhydroarabinitols were formed. In addition, D-arabinitol was heated to reflux in diglyme/DMA 
together with 5% of Rh(dppp)2Cl for 32 h, and neither 1,4- nor 2,5-anhydro-D-arabinitol were 
formed. This clearly indicates that the formation of 1,4-anhydroalditols is rather mediated by 
rhodium than a result of a thermal dehydration. In addition, since no 2,5-anhydroalditols are 
formed, the formation of 1,4-anhydroproducts most likely occurs while rhodium is still bound to the 
C1 of the alditol. We tried to avoid the formation of 95 by reducing the reaction temperature and by 
adding a small amount of water to the reaction mixture, but it was still formed in 20% yield. Since it 
was formed in quite large amounts, it was attempted to direct the decarbonylation process towards 
this product, because it might be an interesting chiral building block for organic synthesis. 
However, treatment of D-glucose with 1% of the catalyst at 162 ºC for 74 h failed to produce the 
anhydroproduct in a reasonable yield. Instead, D-arabinitol and 95 were isolated in less than 30% 
combined yield indicating that the degree of decomposition is more pronounced for prolonged 
reaction times. 
 
3.4.3 Catalyst system 
After the successful decarbonylation of D-glucose in diglyme/DMA with preformed Rh(dppp)2Cl 
(Table 14, entry 1), other catalysts were screened as well. As mentioned in section 3.2.2, 
rhodium(I)-complexes of BINAP and dppp were found to be equally reactive in the decarbonylation 
of simple aryl and alkyl aldehydes (Figure 3),236 and it was decided to test Rh(BINAP)2Cl in the 
decarbonylation of sugars. Rh(BINAP)2Cl was synthesized by ligand exchange of Rh(COE)2Cl in 
82% yield, but in the decarbonylation of D-glucose, it reacted considerably slower than 
Rh(dppp)2Cl (entry 2).  
 
Rh(COE)2Cl is known to decarbonylate 2-naphthalene catalytically, but it reacts much slower than 
Rh(dppp)2Cl.252 Therefore, it was attempted to generate Rh(dppp)2Cl in situ from Rh(COE)2Cl and 
dppp (Table 14, entry 3). However, the decarbonylation occurred slowly and full conversion was 
observed only after more than 17 h using 7.5% catalyst loading.  
 
After testing these stable Rh(I)-complexes (Table 14, entries 1-3), it was attempted to develop a 
simple procedure to generate the catalytic species directly from Rh(III). Preparation of Rh(dppp)2Cl 
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in two steps from RhCl3 • 3H2O and dppp (Scheme 33) is not difficult, but due to the time-
consuming precipitation of the intermediate Rh(COE)2Cl, it would be more convenient to be able to 
prepare the catalyst in situ from commercially available precursors. 
 
Table 14. Decarbonylation of D-glucose using different rhodium catalysts. 
10% catalyst
diglyme/DMA
additive
reflux
HO
OH
OH
OH
OH
O
OH
HO
HO
OH
OH
D-glucose                                                    D-arabinitol
 
Entry Catalyst Additive Time (h) Yield 
1 Rh(dppp)2Cl – 9 71% 
2 Rh(BINAP)2Cl – 6 <10% conversion 
3 Rh(COE)2Cl + 2 dppp – 17 >90% conversiona 
4 RhCl3 • 3H2O + 2 dppp – 16 decompositionb 
5 RhCl3 • 3H2O + 2 dppp 20% PhCH2CHO 16 trace b 
6 crude Rh(dppp)2Cl – 2 decomposition b 
7 crude Rh(dppp)2Cl 20% PhCH2CHO 3 9 %b 
a 7.5% catalyst loading was used. b D-Glucose dissolved in DMA was added after 20 min. 
 
It was attempted to generate the catalyst in situ by heating RhCl3 • 3H2O, dppp and D-glucose in 
diglyme,236 however, the reaction mixture turned black and a rhodium mirror could be observed. 
The same result was achieved in diglyme/DMA. Although dppp is usually responsible for reduction 
of Rh(III) to Rh(I), it was realized that D-glucose also acts as a reducing agent resulting in 
formation of Rh(0). This means that D-glucose has to be added after formation of the catalytically 
active species. However, addition of D-glucose in crystalline form or dissolved in H2O or DMA to a 
preheated solution of RhCl3 • 3H2O, dppp and diglyme only resulted in decomposition (Table 14, 
entry 4).  
 
In another approach, the catalyst was formed in situ using 20% of phenylacetaldehyde as an 
additive together with RhCl3 • 3H2O and dppp followed by addition of D-glucose dissolved in 
DMA. In this case, traces of D-arabinitol were observed (Table 14, entry 5). Most likely not all the 
Rh(III) is reduced to Rh(I) when the catalyst is generated in situ, and the presence of Rh(III) 
together with D-glucose in the reaction mixture probably leads to further reduction to Rh(0) and 
decomposition.  
 
Rune Nygaard Monrad – Ph.D. Thesis 
52 
Since Wilkinson’s reagent can be formed in one step from RhCl3 • 3H2O in the presence of PPh3 by 
reduction in ethanolic solution,202 it was anticipated that Rh(dppp)2Cl could be prepared in the same 
way. When refluxing RhCl3 • 3H2O and dppp in a solution of 96% EtOH for 30 min, a color change 
from dark red to orange could be observed indicating reduction of Rh(III) to Rh(I). Removal of 
EtOH in vacuo to prevent possible sugar glycosylation gave crude Rh(dppp)2Cl. The crude 
Rh(dppp)2Cl has been successfully used in a one-pot Diels-Alder – decarbonylation reaction in our 
group by Esben Taarning.239 Crude Rh(dppp)2Cl readily dissolves in cold diglyme whereas 
preformed Rh(dppp)2Cl is completely non-soluble in cold diglyme. In addition, subjecting 
D-glucose to the crude catalyst at 162 ºC leads to complete decomposition within 2 h (Table 14, 
entry 6). These observations suggest that crude Rh(dppp)2Cl might not have the same composition 
as preformed Rh(dppp)2Cl. Analysis of the crude catalyst by IR spectroscopy revealed a weak band 
at 2168 cm-1, which might indicate the presence of a carbonyl ligand222 arising from the 
decarbonylation of acetaldehyde produced by oxidation of EtOH during formation of crude 
Rh(dppp)2Cl. Benzaldehyde, on the other hand, could readily be decarbonylated using crude 
Rh(dppp)2Cl,239 and after the reaction, the catalyst was precipitated and analyzed by IR 
spectroscopy. In this case, strong bands were observed at 2101, 1971 and 1718 cm-1, indicating that 
carbon monoxide and benzaldehyde are present as ligands. Based on these data, the crude 
Rh(dppp)2Cl most likely only contains very small amounts of carbonyl ligands, and the difference 
in reactivity between the crude and the preformed catalysts is probably a matter of purity rather than 
identity. 
 
Using the crude Rh(dppp)2Cl together with 20% of phenylacetaldehyde as an additive followed by 
addition of D-glucose dissolved in DMA leads to full conversion within 3 h giving 9% of 
D-arabinitol  (Table 14, entry 7). This result can probably be improved, but it would require a lot of 
work with no foreseeable success in the near future. The preformed catalyst was therefore selected 
for further optimizations. 
 
3.4.4 Optimization of the decarbonylation procedure 
A series of experiments were performed to optimize the conditions as shown in Table 15. Reducing 
the catalyst loading from 10 to 1% (entries 1-3) resulted in considerably longer reaction times and 
lower yields. With 5% catalyst, 40% of D-arabinitol could be isolated (entry 2), whereas with 1% 
catalyst full conversion could not be achieved within 16 h (entry 3). 
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Table 15. Optimization of the decarbonylation procedure. 
Rh(dppp)2Cl
diglyme/DMA
additive
reflux
HO
OH
OH
OH
OH
O
OH
HO
HO
OH
OH
D-glucose                                                    D-arabinitol
 
Entry Catalyst loading Additive 
Time 
(h) 
Isolated 
Yield 
Reflux temperature 
(ºC) 
1 10% – 9 71%a 162  
2 5% – 14 40%b 162 
3 1% – 16 <20% conversion 162 
4 10% 20% dppp 16 16% 162 
5 5% 10 eq. H2O 18 50% 152 
6 5% Ar-bubblingc 13 52% 155 
7 5% 15% AcOH 9 51% 162 
8 5% 13% pyridine 9.5 58% 162 
a
 20% of 1,4-anhydro-D-arabinitol (95) is formed as well. The amount of 95 has not been determined 
for the other entries. b A slightly higher yield (44%) could be achieved by stopping the reaction 
before full conversion (11 h), however, this was inconvenient due to the tedious separation of 
D-glucose and D-arabinitol. c The reaction was performed by bubbling a continous stream of argon 
through the reaction mixture. 
 
With longer reaction times decomposition becomes an increasing problem, and in order to reduce 
the degree of decomposition, the evolution of carbon monoxide during the course of the reaction 
was measured (Figure 4). In this way, the progress of the decarbonylation can be monitored, and the 
reaction can be stopped when no more carbon monoxide is produced. From Figure 4 it is clear that 
the decarbonylation of D-glucose proceeds faster with 10% catalyst (green) than with 5% catalyst 
(black). 
 
During decarbonylation of D-glucose, Beck and co-workers found that the addition of dppp together 
with Wilkinson’s reagent had a favorable effect possibly forming Rh(dppp)2Cl in situ.251 When 
D-glucose was decarbonylated in the presence of dppp and Rh(dppp)2Cl, only 16% of D-arabinitol 
was formed (Table 15, entry 4) showing that the presence of phosphines is not desirable when the 
preformed catalyst is used. Addition of small amounts of water (diglyme/H2O = 40:1) (entry 5) 
improved the yield of D-arabinitol, but required 18 h to reach full conversion due to a lower reflux 
temperature. When argon was bubbled through the reaction mixture in an attempt to remove carbon 
monoxide,234 52% yield could be obtained (entry 6).  
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Figure 4. Carbon monoxide evolution during the course of the decarbonylation. The figure shows carbon monoxide 
evolution curves for decarbonylation of 2.78 mmol aldose in a diglyme/DMA solution with different Rh(dppp)2Cl 
loading and additives. At room temperature (25 ºC), full conversion corresponds to formation of 68 mL CO. See section 
8.2 for further experimental details. 
 
The reaction rate for the decarbonylation of carbohydrates is much lower than for simple aldehydes. 
D-Glucose requires 9 h to reach full conversion using 10% preformed Rh(dppp)2Cl, whereas only 
3 h are needed to decarbonylate 2-naphthaldehyde using 5% in situ generated catalyst. The reaction 
of sugars is limited by an unfavorable hemiacetal-aldehyde equilibrium (Scheme 36), and in the 
case of D-glucose, less than 0.02%♦ of the sugar is present as the free aldehyde in aqueous 
solution.255,256 Both acids and bases are known to catalyze the mutarotion via the open-chain 
aldehydo form,257 and small amounts of acetic acid and pyridine were therefore added to the 
reaction mixture (Table 15, entries 7 and 8). Both additives were found to decrease the reaction 
time, and as a result, increased yields were obtained.  
 
                                                 
♦
 In aqueous solution at 82 ºC and pH 4.8, D-glucose exists as a mixture of the free aldehyde (0.019%), the hydrated 
aldehyde (0.022%), two furanose forms (1.29%) and two pyranose forms (98.6%) (Maple, S. R.; Allerhand, A. J. Am. 
Chem. Soc. 1987, 109, 3168). 
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Scheme 36. Hemiacetal – aldehyde equilibrium for D-glucose. 
 
A series of experiments with acetic acid and pyridine were performed, and it was found that 
pyridine gave slightly better results than acetic acid (Table 16, compare entries 1-3 with 4-6). The 
effect of added pyridine can be visualized in the carbon monoxide evolution curve (Figure 4, red). 
Using an excess of pyridine resulted in a considerably lower yield (Table 16, entry 7). A catalyst 
loading of  8 or 10% together with pyridine (6%) led to full conversion in 8 and 7.5 h, respectively 
(entries 8 and 9), and it was decided to reduce the catalyst loading to 8% using 6% of pyridine as an 
additive. 
 
Table 16. Optimization of the decarbonylation procedure with acid and base. 
Rh(dppp)2Cl
diglyme/DMA
additive
reflux
HO
OH
OH
OH
OH
O
OH
HO
HO
OH
OH
D-glucose                                                    D-arabinitol
 
 
Entry Catalyst loading Additive 
Time 
(h) 
Isolated 
yield 
1 5% 15% AcOH 9 39% 
2 5% 7% AcOH 9.5 51% 
3 5% 3% AcOH 9.5 39% 
4 5% 13% pyridine 9.5 58% 
5 5% 6% pyridine 9.5 55% 
6 5% 1% pyridine 10.5 40% 
7 5% 4 eq. pyridine 18 18% 
8 8% 6% pyridine 8 71% 
9 10% 6% pyridine 7.5 67% 
 
3.4.5 Extension of the procedure to other aldoses 
Having successfully developed a catalytic decarbonylation procedure, it was applied on a range of 
aldoses (Table 17). Of the hexoses, D-glucose and D-mannose gave similar results (entries 1-4), 
whereas D-galactose was decarbonylated in lower yield (entries 5-6). In addition to the desired 
D-arabinitol, D-galactono-1,4-lactone (97) and 1,4-anhydro-D-lyxitol 96 (2,5-anhydro-D-arabinitol) 
were formed as an inseparable mixture in 34% yield during decarbonylation of D-galactose 
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(entry 5). The reason for oxidation of D-galactose to produce 97 in approximately 19% yield cannot 
be rationalized. D-Galactose is less soluble in DMA than D-glucose and D-mannose, and 
decarbonylation of D-galactose in pure DMA gave 27% of D-arabinitol accompanied by significant 
decomposition.  
 
The pentoses (Table 17, entries 7-12) react slightly faster than the hexoses, and the evolution of 
carbon monoxide from the decarbonylation of D-xylose can be seen in Figure 4 (Figure 4, blue). 
Although it is more soluble in DMA, the 6-deoxy sugar, L-rhamnose, (Table 17, entries 13-14) 
requires slightly longer reaction times than the other hexoses. However, the desired product, 5-
deoxy-L-arabinitol, is isolated in comparable yields. As mentioned earlier in section 3.4.2, 
1,4-anhydroalditols are formed as the only byproducts in the decarbonylation reaction, and the 
amount of 1,4-anhydroalditols produced from each carbohydrate is shown in Table 17. 
1,4-Anhydroalditols are formed both in the absence and in the presence of pyridine. 
 
Table 17. Application of the procedure on different aldoses. 
Rh(dppp)2Cl
diglyme/DMA
reflux
Cn aldose                                         Cn-1 alditol     +     Cn-1 1,4-anhydroalditol
 
 
Entry Aldose Methoda Time (h) Alditol 
Yield 
(%) 1,4-Anhydroalditol 
Yield 
(%) 
1 D-glucose A 9 D-arabinitol 71 1,4-anhydro- D-arabinitol (95) 20 
2 D-glucose B 8 D-arabinitol 71 n.d.  
3 D-mannose A 9 D-arabinitol 69 n.d.  
4 D-mannose B 8 D-arabinitol 72 1,4-anhydro- D-arabinitol (95) 20 
5 D-galactose A 9 D-arabinitol 39 1,4-anhydro- D-lyxitol (96) 15
b
 
6 D-galactose B 8 D-arabinitol 56 n.d.  
7 D-arabinose A 9 erythritol 68 n.d.  
8 D-arabinose B 6.5 erythritol 70 n.d.  
9 D-ribose A 8 erythritol 71 n.d.  
10 D-ribose B 6.5 erythritol 76 n.d.  
11 D-xylose A 8 D-threitol 70 1,4-anhydro- D-threitol (98) 13 
12 D-xylose B 7.5 D-threitol 74 n.d.  
        
13 L-rhamnose A 11 5-deoxy- L-arabinitol 66 n.d.  
        
14 L-rhamnose B 10 5-deoxy- L-arabinitol 71 
1,4-anhydro-5-deoxy- 
L-arabinitol (99) 17 
a
 The experiments were performed according to the general decarbonylation procedure A (10% Rh(dppp)2Cl) 
or B (8% Rh(dppp)2Cl and 6% pyridine), see section 8.2. b Formed as an inseparable 3:4 mixture with 
D-galactono-1,4-lactone (97) (19%). 
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Decarbonylation of N-acetyl-D-glucosamine required reaction times of around 16 h leading to 28 
and 34% yield of 1-acetylamino-1-deoxy-D-arabinitol (100) in the absence and in the presence of 
pyridine, respectively (Table 18, entries 1 and 2). The slow decarbonylation of N-acetyl-
D-glucosamine was also observed by Andrews and co-workers,249 and can be explained by 
coordination to rhodium with the N-acetyl group. In addition to the desired product 100, a complex 
mixture of unidentified byproducts was formed. Both the addition of small amounts of water and 
increasing the amount of pyridine were found to be favorable, however, the decarbonylation still 
occurred in low yield (entries 3-4).  
 
Table 18. Decarbonylation of N-acetyl-D-glucosamine to produce 1-acetylamino-1-deoxy-D-arabinitol (100). 
Rh(dppp)2Cl
diglyme/DMA
reflux
HO
OH
OH
NHAc
OH
O
OH
HO
HO
OH
NHAc
N-acetyl-D-glucosamine 100
 
Entry Methoda Additive Time (h) 
Yield 
(%) 
1 A – 16 28 
2 B – 15.5 34 
3 A 10 eq. H2O 16 42 
4 B – 14.5 40b 
a
 The experiments were performed according to the general 
decarbonylation procedure A (10% Rh(dppp)2Cl) or B (8% 
Rh(dppp)2Cl and 6% pyridine), see section 8.2. b The amount 
of pyridine was increased to 15%. 
 
3.4.6 Decarbonylation of other substrates 
Attempts to decarbonylate D-glucurono-6,3-lactone (101) which would produce the rare and 
expensive sugar D-lyxose by subsequent reduction were unsuccessful (Scheme 37). The lactone 101 
was consumed very rapidly, and only 14% of the desired D-lyxono-1,4-lactone 102 was produced. 
In addition, 5% of L-gulono-1,4-lactone 103 (formed by reduction of 101) was isolated as a 
byproduct. The reaction mixture turns completely black upon heating and the development of gas 
occurs very quickly (Figure 4, orange). Performing the reaction at 125 ºC resulted in recovery of 
72% of the starting material after 7 h, and neither addition of small amounts of water or pyridine 
nor changing the substrate to free D-glucuronic acid improved the yield. 
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Scheme 37. Decarbonylation of D-glucurono-6,3-lactone (101). 
 
Although D-fructose and L-ascorbic acid do not possess an aldehyde functionality, they were 
subjected to the decarbonylation conditions to see if interesting products could be formed from 
these cheap and readily available carbohydrates. As mentioned in section 3.2.5, Andrews and co-
workers reported that furfuryl alcohol (10) was formed as the main product following treatment of 
D-fructose with Wilkinson’s reagent (Scheme 31).201,249 However, treatment of D-fructose with 10% 
of Rh(dppp)2Cl surprisingly afforded 21% of 1,4-anhydro-D-arabinitol (95) after 5.5 h. When 
L-ascorbic acid was subjected to the decarbonylation conditions at 162 ºC, decomposition was a 
major problem, and it was not possible to detect any carbohydrate products. At lower temperatures 
L-ascorbic acid was not consumed as rapidly, and 29% of the starting material could be recovered 
after 23 h at 125 ºC. No other products could be isolated. 
 
3.4.7 Decarbonylation of unprotected cyclodextrins 
To test the scope of the rhodium-catalyzed decarbonylation reaction, it was attempted to 
decarbonylate aldehydes derived from cyclodextrins. Cyclodextrins are composed of 
D-glucopyranose residues connected in a ring structure with α(1,4)-glycosidic linkages.258 The 
α-, β- and γ-cyclodextrins contain six, seven and eight glucose residues, respectively,258 and their 
structure can be represented by a ‘bucket’ with the hydroxy groups positioned on the outside 
(Figure 5). As a result, cyclodextrins have a hydrophilic surface and a hydrophobic cavity.259 The 
latter is known to form complexes with small organic and inorganic compounds thereby resembling 
the pocket of an enzyme.258 
 
In fact, Bols and co-workers have recently used modified α- and β-cyclodextrins260 as artificial 
enzymes catalyzing the oxidation of anilines to nitrobenzenes261 and benzylic alcohols to 
aldehydes262 in the presence of hydrogen peroxide. The inner diameter varies from 5.7 to 9.5 Å 
when going from α- to γ-cyclodextrin,259 and by choosing different cyclodextrins as template, one 
can design artificial enzymes with different properties. The ability to bind organic molecules in the 
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hydrophobic cavity combined with a high solubility in water make cyclodextrins well suited for 
biologically important applications like drug delivery or artificial enzymes.259 Due to an increasing 
interest in cyclodextrins, it is important to be able to perform selective modifications on 
cyclodextrins without protective group manipulations. However, despite their well-defined 
structure, the selective modification of cyclodextrins is not an easy task due to the presence of a 
large number of hydroxy groups.259  
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Figure 5. Two representations of β-cyclodextrin (104). The primary hydroxy groups are positioned on the upper part of 
the ‘bucket’ (right), whereas the secondary hydroxy groups are on the bottom.259 
 
In the following it was attempted to remove a hydroxymethyl group from unprotected 
β-cyclodextrin (104) using an oxidation – decarbonylation sequence (Scheme 38). Following the 
procedure of Bieniarz and co-workers,263 104 was oxidized to the monoaldehyde 105 using two 
equivalents of Dess-Martin Periodinane (DMP) in d6-DMSO. As described by Bieniarz,263 the 
reaction can be followed by 1H NMR spectroscopy by comparing the developing signal of a new 
anomeric proton at 4.93 ppm with the remaining anomeric protons at 4.82 ppm. A 1:6 ratio between 
these signals indicates full conversion to the monoaldehyde 105, and depending on the quality of 
the DMP reagent, the reaction requires 2-4 h at room temperature. However, analysis of the product 
by MALDI TOF MS revealed the presence of unreacted 104 as well as trace of the di- and tri-
aldehydes. If the reaction was performed with longer reaction times or with a larger excess of DMP, 
considerable amounts of the di- and tri-aldehydes were formed. Using IBX264 for the oxidation 
instead of DMP also led to 105 contaminated by the di- and tri-aldehydes as well as unreacted 104. 
The problems of obtaining a pure product in this simple oxidation illustrates the difficulties 
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associated with selective reactions on cyclodextrins,259 and as a result, slightly impure samples of 
105 were subjected to the decarbonylation conditions.  
 
O
(OH)20 (OH)20
10% Rh(dppp)2Cl
DMA, reflux
OH
OAc
O
HOHO
OH
O
HO
(OH)21
DMP or IBX
DMSO, rt
104 105
106
 
Scheme 38. Attempted decarbonylation of β-cyclodextrin monoaldehyde (105). The desired product was not formed, 
but instead a complex mixture presumably consisting of glycosylated and acetylated β-cyclodextrins 106 was observed. 
 
Using 10% of Rh(dppp)2Cl in pure DMA♦ led to significant decomposition. Only approximately 
20% of the material could be isolated presumably as a mixture of glycosylated and acetylated 
β-cyclodextrins 106. The reaction mixture turned black within 5 min, and almost no gas was 
developed during the reaction. It was impossible to follow the reation by TLC or 1H NMR 
spectroscopy due to formation of product mixtures with very similar structure and polarity. Analysis 
of the crude product by MALDI TOF MS showed a mixture of four major compounds separated by 
162 Da, which is indicative of a glycosylation of β-cyclodextrin with up to three glucose residues. 
In addition, minor compounds corresponding to the masses of the before-mentioned glucosylated 
products plus 42 and 2 x 42 Da were observed. The observation of (M + 42 Da) and 
(M + 2 x 42 Da) indicates that acetyl groups are incorporated on the glycosylated β-cyclodextrins 
(see Table 34 in Appendix I for further details).  
 
The crude product was peracetylated265 using acetic anhydride, DMAP and pyridine, and a complex 
mixture of glucosylated β-cyclodextrins were obtained after flash column chromatography. 
Analysis of these peracetylated products by MALDI TOF MS revealed a mixture of 13 compounds 
separated by 288 Da indicating peracetylated β-cyclodextrins containing up to 12 peracetylated 
glucose residues (see Table 35 in Appendix I for further details). Surprisingly, in both cases the MS 
data fits very well with derivatives of β-cyclodextrin (104) rather than β-cyclodextrin 
                                                 
♦
 β-Cyclodextrin is completely insoluble in diglyme, but dissolves readily in DMA. 
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monoaldehyde (105). This suggests that 105 may not be stable to the reaction conditions, and upon 
decomposition of 105, glucose residues or smaller fragments might be formed, which glycosylate 
the more stable 104. The observation of acetyl groups in the crude product can only be rationalized 
by decomposition of the solvent DMA during the reaction leading to acetylation. Based on these 
results, it was decided not to attempt further decarbonylations on cyclodextrins. 
 
3.4.8 Hydroacylation of alkenes 
Intramolecular hydroacylation of 4-alkenals 107 to produce cyclopentanones 108 can be catalyzed 
by rhodium(I)-complexes (Scheme 39).266 The procedure has been limited to the synthesis of five-
membered rings due to competing decarbonylation, which reduces the yield of the hydroacylation 
product.267 This was experienced by Gable and Benz268 obtaining a moderate yield of the desired 
cyclohexanone in a rhodium-catalyzed intramolecular hydroacylation of a carbohydrate-derived 
5-alkenal. On the other hand, Kampmeier and co-workers238 utilized the competing decarbonylation 
to convert the 5-alkenal 2-allylbenzaldehyde (86) into indane (87) rather than the corresponding 
cyclohexanone produced by hydroacylation (see Scheme 26).  
 
O
cat. Rh(I)Ln
R
O
R
107 108
 
Scheme 39. Rhodium(I)-catalyzed intramolecular hydroacylation.266,267 
 
Recently, several research groups have attempted to extend the method to intermolecular 
hydroacylation of alkenes. However, this has proven difficult, and it can only be achieved by 
addition of amines to generate an imine with the aldehyde in situ,269 or when either the aldehyde270 
or the alkene271 possess a functional group capable of chelating to rhodium thereby preventing 
decarbonylation. Although several examples of hydroacylation of alkenes have been reported 
recently, there is no precedence for direct hydroacylation with carbohydrates in the literature. The 
presence of several hydroxy groups might enable carbohydrates to react as chelating aldehydes, and 
it was therefore attempted to hydroacylate styrene with D-glucose using Rh(dppp)2Cl. The 
formation of a carbon-carbon bond at the anomeric center by direct hydroacylation would thereby 
constitute a new route to chain elongated carbohydrates. 
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When D-glucose was subjected to Rh(dppp)2Cl in the presence of five equivalents of styrene, no 
coupling product 109 could be isolated within 23 h. Instead of hydroacylation, decarbonylation 
occurred to give 45% of D-arabinitol and 28% of 1,4-anhydro-D-arabinitol (95) (Scheme 40). The 
development of carbon monoxide during decarbonylation of D-glucose in the presence of styrene 
can be seen in Figure 4 (purple). The formation of the usual decarbonylation products indicated that 
direct hydroacylation of alkenes with carbohydrates would require considerable experimentation 
with the reaction conditions, and as a result, the hydroacylation was not pursued further. 
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Scheme 40. Attempted intermolecular hydroacylation of styrene with D-glucose. 
 
3.4.9 Synthesis of L-threose by chain shortening of D-glucose 
L-Threose is often employed as a chiral C4 building block in synthesis,95,272-276 but it is not available 
from nature. By using two consecutive chain shortening reactions, it is possible to synthesize 
L-threose in a few steps from D-glucose by employing the rhodium-catalyzed decarbonylation 
reaction as the key step (Scheme 41). L-Threose can be formed by decarbonylation of a protected 
D-xylo-dialdose 110, which is readily available from diactoneglucose 111 by periodate cleavage. 
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Scheme 41. Retrosynthetic analysis of L-threose. 
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Diisopropylidene protected D-glucose 111, which is readily available from D-glucose in 96% 
yield,277 was selectively deprotected and oxidatively cleaved using H5IO6 following the one-pot 
procedure developed by Wu and Wu34 (Scheme 42). Unfortunately, only 42-50% yield of 110 could 
be achieved using 1.5-3 equivalents of H5IO6 in dry ether at 25-40 ºC. Instead, the terminal 
isopropylidene protective group of 111 was removed to produce 112 in quantitative yield using 
aqueous acetic acid.33 Subsequent sodium periodate cleavage33 gave the one carbon atom shortened 
aldehyde 110 in 91% yield. The aldehyde 110 crystallizes as the dimer 114 (Scheme 43), but slowly 
equilibrates to the monomer 110 in aqueous solution.  
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Scheme 42. Synthesis of L-threose from D-glucose by employing the rhodium(I)-catalyzed decarbonylation reaction as 
the key step. 
 
The decarbonylation of 110 with Rh(dppp)2Cl proceeded smoothly in 86% yield using only 2% 
catalyst loading (Scheme 42). Attempts to use the in situ generated catalyst were unsuccessful and 
led to decomposition of the carbohydrate and precipitation of the catalyst. In contrast to unprotected 
monosaccharides, the xylo-pentodialdose 110 is not in equilibrium with cyclic hemiacetals, and the 
addition of pyridine is unnecessary.  In addition, the partially protected 110 is readily soluble in 
organic solvents and the reaction can be performed in pure diglyme.  
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Scheme 43. The aldehyde 110 crystallizes as the dimer 114, but slowly equilibrates to the monomer 110 in solution. 
 
Final deprotection of 113 using aqueous acetic acid278 afforded L-threose in an overall yield of 74% 
for the five-step sequence from D-glucose. The current synthesis of L-threose employing rhodium-
catalyzed decarbonylation is the shortest and most high-yielding route to L-threose from D-glucose 
to date. Synthesis of L-threose from D-glucose can also be accomplished by employing the alkoxy 
radical fragmentation of a nitrate ester developed by Suaréz and co-workers as the key step (see 
section 2.1.3), however in this case, L-threose is produced in lower yield than in the present 
synthesis.59 
 
3.5 Concluding remarks 
A catalytic procedure for decarbonylation of unprotected carbohydrates using Rh(dppp)2Cl has been 
developed (Scheme 44). In contrast to simple aryl and alkyl aldehydes, the aldehyde functionality of 
unprotected carbohydrates is masked as a hemiacetal making it less available. Prolonged heating at 
162 ºC is therefore required for the reaction to occur, and decomposition of the carbohydrate 
substrate becomes an increasing problem. However, the addition of small amounts of pyridine 
facilitates mutarotation making the aldehyde functionality more available. As a result, slightly 
shorter reaction times and lower catalyst loadings are possible in the presence of pyridine. The 
procedure has successfully been used to convert a range of different aldoses into their 
corresponding shortened alditols in 70-75% yield. In addition to the desired alditols, 
1,4-anhydroalditols are also formed as byproducts in 10-20% yield.  
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Scheme 44. Rhodium-catalyzed decarbonylation of aldoses. 
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Requiring only catalytic amounts of expensive rhodium complexes, the developed decarbonylation 
procedure is a major improvement compared to the previously reported stoichiometric 
decarbonylation using Wilkinson’s reagent.249,251 Application of the rhodium-catalyzed 
decarbonylation as the key step in a short and efficient synthesis of L-threose from D-glucose 
illustrates that the catalytic decarbonylation constitutes a general procedure for shortening 
unprotected and protected carbohydrates by one carbon atom.  
 
3.6 Outlook 
In an industrial view, carbohydrates are a renewable source of energy, and as a result, considerable 
effort has recently been invested in the conversion of biomass into hydrogen.22,23,25,279,280 Production 
of hydrogen can be performed by steam reforming of sugars like glucose, sorbitol and 
glycerol,22,23,280 and since alditols are more easily converted into hydrogen than aldoses,22 the 
decarbonylation might become useful in combination with steam reforming. Furthermore, 
ruthenium-mediated dehydrogenation of secondary alcohols to produce ketones and hydrogen has 
recently been reported,281,282 and based on these results, further development of the decarbonylation 
reaction in combination with such dehydrogenation catalysts might enable direct degradation of 
sugars into hydrogen and carbon monoxide. In that case carbohydrates might even be used for 
asymmetric hydrogenation of double bonds, since rhodium(I)-species are well-known 
hydrogenation catalysts.200 At present the efficiency of the rhodium-catalyzed decarbonylation of 
carbohydrates is not sufficient to enable such applications, but it might become relevant once more 
potent decarbonylation catalysts are developed. 
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4 Synthesis of calystegine A3 by chain elongation of D-glucose 
 
4.1 The calystegine alkaloids 
The calystegine alkaloids are a family of naturally occurring iminosugar mimetics.283 They were 
isolated from Calystegia sepium in 1988,284 and the first structure elucidations were reported in 
1990.285,286 Since then a total of 14 different calystegines have been isolated from various plants 
(Scheme 45).287  
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Scheme 45. Naturally occurring calystegine alkaloids.287 
 
The calystegines all share a polyhydroxylated, bicyclic nortropane ring system possessing a tertiary 
hydroxy group as part of an interesting bridgehead aminoketal functionality. They are divided into 
four groups according to the number of hydroxy groups. The A calystegines contain three hydroxy 
groups, whereas four and five hydroxy groups are present in the B and C calystegines, respectively. 
The bridgehead hydroxy group has been exchanged with an amino group in calystegine N1, which is 
the only discovered calystegine with an aminal functionality.287 
 
Many of the calystegine alkaloids have been found to be potent glycosidase inhibitors288-294 making 
them interesting pharmaceutical lead compounds especially in relation to cancer, viral infection and 
diabetes.283 Calystegine A3 is a moderately potent inhibitor of various glycosidases.  Calystegine A3 
inhibits pig kidney trehalase, Caldocellum saccharolyticum β-glucosidase, almond β-glucosidase 
and green coffee bean α-galactosidase with Ki values of 5.3, 12, 20 and 20 µM, respectively.289,294 
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Due to scarcity of calystegines from natural sources, efficient chemical syntheses are necessary in 
order to establish their full potential as drug candidates.287 
 
The synthetic efforts towards the calystegine alkaloids were pioneered by Lallemand and co-
workers in the early 1990’s,295-298 but since then several syntheses have been reported. Of the 
naturally occurring calystegines only A3,296,299 A7,300 B2,297,298,301-306 B3304,306 and B4304,306 have been 
made by chemical synthesis, but also a number of analogues have been synthesized and tested for 
glycosidase activity.293,307-313  
 
OH
NH3+Cl-
8 steps HO
HO NHCbz
O
NHHO
OH
HO
rac-117
H2, Pd/C
MeOH
115 rac-116
 
Scheme 46. The synthesis of racemic calystegine A3 (117) by Lallemand and co-workers.296 
 
The first synthesis of calystegine A3 (117) was reported in 1992 by Lallemand and co-workers and 
gave racemic 117 in nine steps from the hydrochloride of 4-aminocyclohexanol (115) (Scheme 
46).296 In 1995 Johnson and Bis synthesized both enantiomers of calystegine A3 (117) in 18 and 20 
steps respectively from cycloheptatriene (118) (Scheme 47).299 However, the identity of each 
enantiomer was not established, and as a result, the absolute configuration of naturally occurring 
calystegine A3 is still not known, although it is believed to exhibit the same configuration as 
naturally occurring calystegine B2 (see Scheme 45 above).287  
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NH • HClHO
OH
HO
+
NH
HO
NH • HCl
HO OH
HO HO
OH
NaOH, D2O
pH > 11
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Scheme 47. Synthesis of both enantiomers of calystegine A3 (117) by Johnson and Bis.299 Due to decomposition of the 
product in the final step, the absolute configuration of each enantiomer was not determined. 
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In addition, the synthesis by Johnson and Bis was performed via the hydrochloride of calystegine 
A3 (119 and 120), and upon conversion into the natural product using strong base (pH > 11), the 
compound could not be recovered, and only NMR data were reported (Scheme 47).299 As a result, it 
is still necessary to establish a short and reliable synthesis of calystegine A3 for further biological 
evaluation.  
 
The objective of this project is therefore to apply the fragmentation-allylation-metathesis 
methodology developed by our group to the synthesis of calystegine A3. This methodology might 
provide the shortest synthetic route to enantiomerically pure calystegine A3, which would enable the 
absolute configuration of calystegine A3 to be determined. In addition to this, the aim of the project 
is also to determine the stability of calystegine A3 in basic solution.  
 
4.2 Synthesis of natural products by chain elongation of ω-iodoglycosides 
As mentioned earlier (section 2.2.5), a variation of the chain elongation of carbohydrates is the 
reductive elimination (fragmentation) of a methyl ω-iodoglycoside followed by a one-, two- or 
three-carbon elongation of the carbohydrate chain by either olefination (CH2I2), vinylation or 
allylation, respectively.136 This sequence gives an α,ω-diene, which is conveniently set up for ring-
closing olefin metathesis18 to produce carbocycles. The strategy has successfully been used by our 
group to synthesize a number of natural products: cyclophellitol,314 7-deoxy pancratistatin,315 
conduritols,136,316,317 inositols317 and quercitols136 as well as the calystegines B2, B3 and B4.304,306 
Other research groups have also used this methodology to synthesize natural products,18 e.g. the 
recent synthesis of calystegine A7 by Csuk’s laboratory.300 
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Scheme 48. Formation of carbocycles from ω-iodoglycosides. 
 
The synthetic methodology is well described in the literature,18,135,136 and the overall strategy will 
only be discussed briefly (Scheme 48). The key steps include the conversion of a protected or 
unprotected methyl ω-iodoglycoside (30) into an unsaturated aldehyde 31 by Vasella 
fragmentation125-128 employing zinc as the metal of choice. Other metals like indium and manganese 
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have also been found to facilitate the reductive elimination, however, the use of indium is 
limited,136,314,318,319 and manganese requires a co-catalyst/oxidant.320 The subsequent Barbier type321 
allylation of the aldehyde 31 or the corresponding imine can either be conducted as a one-pot 
fragmentation-allylation with zinc, or by allylation of the aldehyde or imine with other metals like 
indium or magnesium.136,306,314,316 The resulting diene 121 can subsequently be subjected to ring-
closing olefin metathesis18,136 to produce a carbocycle 122 which can be used for further 
manipulations. 
 
4.3 Retrosynthetic analysis of calystegine A3 
Retrosynthetically (Scheme 49), the bicyclic aminoketal of calystegine A3 is expected to be formed 
by cyclization of aminoketone 123 during hydrogenolysis similar to the racemic synthesis of 
calystegine A3 by Lallemand and co-workers (see the conversion of 116 to 117 in Scheme 46). The 
aminoketone 123 may be formed by hydroboration and oxidation of a suitably protected 
cycloheptene 124, which is available from the corresponding diene 125 by ring-closing metathesis. 
The required diene 125 can be produced from the protected ω-iodoglucopyranoside 126 by zinc-
mediated fragmentation and allylation. Removal of the secondary alcohol in the 2-position of the 
D-glucopyranoside can either be performed before or after the fragmentation-allylation sequence.  
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Scheme 49. Retrosynthetic analysis of calystegine A3. 
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4.4 Previous work on the calystegine project in the group 
The current project is based on previous work on the calystegine alkaloids in our group. Philip R. 
Skaanderup’s synthesis of calystegine B2 is shown in Scheme 50,304,306 whereas the previous 
synthetic efforts towards calystegine A3 by Charlotte B. Pipper are summarized in Scheme 51.322 
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Scheme 50. Synthesis of calystegine B2 (131) by Philip R. Skaanderup.306,323 
 
In Philip’s synthesis of calystegine B2, iodination and benzyl protection of methyl 
α-D-glucopyranoside 127 furnished the protected methyl 5-deoxy-5-iodo-α-D-glucopyranoside 128 
for the key tandem sequence involving zinc-mediated fragmentation, imine formation and 
allylation. The diene 129 was isolated in good diastereoselectivity (5:1) in favor of the desired 
(6R)-isomer. Noteworthy, the stereochemistry could be further improved if the imine allylation was 
carried out as a separate step replacing zinc with magnesium (16:1) or indium (1:0). After 
protection of the amine, ring-closing metathesis and oxidation, the final deprotection-cyclization 
step was performed by hydrogenolysis of 130 using Pearlman’s catalyst in acidic THF/water to give 
the natural product 131 in excellent yield.306 
 
In Charlotte’s synthetic efforts towards calystegine A3, she was following the same strategy as 
Philip, but using different protecting groups in order to selectively deoxygenate D-glucose in the 
2-position after performing the fragmentation-allylation reaction (Scheme 51, pathway A). Methyl 
α-D-glucopyranoside (127) was therefore selectively trityl- and PMB-protected in the 6- and 
2-positions, respectively, which after benzylation enabled selective transformations at these 
postitions. The removal of the trityl group and iodination to give 133 was followed by the zinc-
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mediated fragmentation and subsequent imine allylation affording 134 in excellent yield and good 
diastereoselectivity (5.3:1) in accordance with Philip’s observations during the calystegine B2 
synthesis. 
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Scheme 51. Synthetic efforts towards calystegine A3 (117) by Charlotte B. Pipper.322 Reagents: a) TrCl, pyridine, b) 
Bu2SnO, Bu4NI, PMBCl, c) NaH, Bu4NI, BnBr then H2SO4, d) I2, PPh3, imidazole, e) CbzCl, KHCO3, f) Grubbs’ 2nd 
gen. cat., g) DDQ, h) NaH, Bu4NI, BnBr, i) H2SO4. 
 
However, after Cbz-protection, ring-closing metathesis and removal of the PMB-group, Charlotte 
encountered unexpected problems regarding the subsequent removal of the C5 secondary alcohol of 
135. After numerous attempts to deoxygenate 135 including hydride displacement of a triflate and 
several variations of the Barton-McCombie radical deoxygenation,324-326 the desired cycloheptene 
136 could be isolated in only 23% yield over the two steps. Charlotte therefore decided to try the 
deoxygenation of D-glucopyranoside 137 in the 2-position before the fragmentation-allylation 
sequence (Scheme 51, pathway B). The standard Barton-McCombie radical deoxygenation worked 
well on this substrate producing the desired 2-deoxy D-glucose derivative 138, which was 
transformed into the ω-iodoglucopyranoside 139 for fragmentation and allylation.322 At this point, 
the project was handed over to the author of this thesis. 
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4.5 Results and discussion 
4.5.1 Initial strategy towards calystegine A3 
Initially, the work was directed towards removal of the C2 hydroxy group of D-glucose before 
fragmentation and allylation (Scheme 51, pathway B). Starting from the trityl- and PMB-protected 
methyl α-D-glucopyranoside 132, the C3 and C4 hydroxy groups were benzyl protected327 in good 
yield followed by removal of the 2-O-PMB-group with DDQ to give 137 in excellent yield applying 
standard conditions328 (Scheme 52). 
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Scheme 52. Synthesis of the protected 2-deoxy-6-iodoglucopyranoside 139 for zinc-mediated fragmentation. 
 
The Barton-McCombie radical deoxygenation324 using NaH, imidazole and CS2 produced the 
intermediate methyl xanthate 141 in 89% yield, and the following AIBN-initiated Bu3SnH 
reduction of 141 to 138 occurred in 86% yield. The removal of the trityl group using sulfuric acid in 
methanol and the introduction of iodine occurred in excellent yield producing the protected methyl 
2,6-dideoxy-6-iodo-α-D-glucopyranoside 139 for the fragmentation-allylation sequence. Notably, 
the more sensitive glycosidic linkage in the 2-deoxy glucoside 138 was not affected by the reaction 
conditions used for removal of the trityl group. 
 
4.5.2 Fragmentation-imine formation-allylation 
Subjecting 139 and freshly activated zinc136 to sonication at 40 ºC in THF resulted in fragmentation 
to produce the desired aldehyde 143 (Table 19). Addition of benzylamine to trap 143 as the imine 
144 followed by drowise addition of allylbromide gave a diastereomeric mixture of the two dienes  
145 and 146 in 94% yield (Table 19, entry 1). In contrast to Philip and Charlotte’s results 
employing the 2-O-Bn and the 2-O-PMB substituted imines 147 and 148 (Table 19, entries 2 
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and 3), almost no stereoselectivity was observed, and 145 and 146 were formed in a 4,6-syn/4,6-anti 
(6R/6S) ratio of 1:1.13 favoring the undesired 4,6-anti product 146 (Table 19, entry 1). The identity 
of each diastereomer was later established by Cbz-protection and ring-closing metathesis followed 
by comparison with material synthesized via strategy A (see section 4.5.7 below).  
 
Table 19. Zinc-mediated tandem fragmentation-allylation sequence. 
O
BnO
BnO
OMe
I
OBn
OBn
OBn
OBn
Zn, )))
TMSCl
THF
BnNH2
Zn, )))
allylbromide
R R R
OBn
OBn R
NHBn
1 4
5
6 4,6-anti
5,6-anti
(6S)
OBn
OBn R
NHBn
1 4
5
6 4,6-syn
5,6-syn
(6R)
+
NBnO
139: R = H
128: R = OBn
133: R = OPMB
143: R = H 144: R = H
147: R = OBn
148: R = OPMB
145: R = H
129: R = OBn
134: R = OPMB
146: R = H
 
Entry R Yield (%) 
Selectivity 
(6R/6S) 
1 H 94 1 : 1.13 
2306 OBn 85 5 : 1 
3329 OPMB 90 5.3 : 1 
Diastereomer ratios were determined by 13C NMR 
spectroscopy. 
 
 
It was attempted to improve the selectivity of the allylation by varying the metal and the reaction 
conditions (Table 20). The fragmentation of 139 was performed with zinc metal in THF under 
sonication followed by addition of benzylamine to trap aldehyde 143 as imine 144. Zinc salts were 
removed by filtration followed by evaporation of the solvent, and the crude imine 144 was 
subsequently redissolved in different solvents and allylated with allylbromide and the metals zinc, 
indium and magnesium.  
 
Both indium and magnesium are known to allylate by chelation to α-alkoxy substituents,119,306,330 
and in such cases a non-polar solvent might improve the degree of chelation of the metal in the 
transition state thereby enhancing the stereoselectivity. Like-wise addition of excess metal salts in a 
polar solvent can be used to inhibit the organometallic species from coordinating to α- or β-alkoxy 
substituents thereby reversing the stereochemistry by favoring non-coordinating pathways.317 Both 
a polar (THF) and a non-polar solvent (toluene/DCM = 4:1) were therefore used, however, no 
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significant improvement of the diastereoselectivity was observed, although indium and magnesium 
seem to be slightly more selective towards the undesired 4,6-anti isomer 146 than zinc (Table 20).  
 
Table 20. Imine allylation with different metals. 
O
BnO
BnO
OMe
I
OBn
OBn
OBn
OBn
Zn, )))
TMSCl
THF
OBn
OBn
NHBn
1 4
5
6 4,6-anti
(6S)
OBn
OBn
NHBn
1 4
5
6 4,6-syn
(6R)
+
NBnO BnNH2
4 Å MS
1) Celite filtration
removal of solvent
2) M, ))), allylbromide
solvent
M = Zn, In, Mg
139 143 144
145
146
 
Metal Yield (%) 
Selectivity (6R/6S) 
THF 
Selectivity (6R/6S) 
Tol/DCM = 4:1 
Zinc 85 1 : 1.13 1 : 1.27 
Indium 73 1 : 1.38 1 : 1.44 
Magnesium 71 1 : 1.33 1 : 1.38 
Diastereomer ratios were determined by 13C NMR spectroscopy. 
 
Initial 1:1 diastereoselectivities for organometallic addition to aldehydes have previously 
successfully been improved in our group by variation of solvent polarity, additives such as metal 
salts as well as the identity of the metal counterion.314,317 But with no indication of success after 
these initial variations of metal and solvent (Table 20), it was decided to abandon this strategy.  
 
4.5.3 Stereochemical considerations 
Usually the Felkin-Anh model109,110 and Cram’s chelate model111 are used to predict the π-facial 
selectivity of nucleophilic addition to α-alkoxy aldehydes. By analogy these models can also be 
used for α-substituted imines,330 and by applying these models to the allylation of the 2-O-Bn and 
the 2-O-PMB protected imines 147 and 148 (Table 19, entries 2 and 3), the 5,6-anti product would 
be expected under non-chelating conditions (the Felkin-Anh model, Scheme 53a), whereas the 
5,6-syn isomer would be produced under chelation control (Cram’s chelate model, Scheme 53b). 
Good diastereoselectivities (5,6-syn/5,6-anti = 5:1), which may be explained by chelation, were 
observed by Philip and Charlotte with the 2-alkoxy substrates 147 and 148 (Table 19 , entries 2 and 
3).  
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Scheme 53. Predominant transition states during allylation of α-alkoxy imines 147 and 148 according to a) the Felkin-
Anh model109,110 and b) Cram’s chelate model.111 
 
With β-alkoxy aldehydes and imines lacking an α-alkoxy substituent, the Felkin-Anh and Cram 
chelate models can no longer be used. Such β-alkoxy aldehydes are known to preferentially afford 
the anti products regardless of chelating or non-chelating conditions (Scheme 54a and b), however, 
product mixtures with low selectivity are most often observed.94,119,331 The anti relationship between 
the β-alkoxy substituent and the newly formed stereocenter can either be rationalized by 
chelation119,331 (Scheme 54a) or by minimizing steric and electrostatic interactions with the β-alkyl 
and -alkoxy substituents as depicted for the 2-deoxy imine 144 in Scheme 54b in a transition state 
model proposed by Evans and co-workers.94 
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Scheme 54. Predominant transition states during allylation of β-alkoxy imine 144 a) under chelation control119,331 and 
b) as recently suggested by Evans and co-workers.94 
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As shown in Table 19 (entry 1), the 2-deoxy substrate 139, gave a 4,6-syn/4,6-anti ratio of 1:1.13 
when zinc was used for the allylation. With indium and magnesium, which are known to react by 
chelation,119,306,330 the 4,6-anti isomer 146 was obtained as the major product in slightly higher 
diastereoselectivity than with zinc (Table 20). Although the general trend in reactivity from Table 
20 is consistent with the reported models for asymmetric induction in β-alkoxy aldehydes (Scheme 
54),94,119,331 the stereoselectivity is poor, and the 4,6-syn and the 4,6-anti isomers 145 and 146 are 
formed in almost equal amounts. 
 
Evans and co-workers recently reported that nucleophilic attack on α,β-bisalkoxy aldehydes under 
non-chelating conditions is more complex than what can be explained by the Felkin-Anh model.95 
α,β-Anti bisalkoxy aldehydes seem to give good diastereoselectivities favoring an anti relationship 
between the α-alkoxy substituent and the newly formed stereocenter, whereas for α,β-syn bisalkoxy 
aldehydes, which are less selective, it is difficult to predict whether the anti or the syn product will 
dominate.95 These trends suggested by Evans are in accordance with previous results from our 
group in the synthesis of calystegine B2, B3 and B4, where D-glucose and D-galactose derived 
imines (α,β-syn configuration) gave lower stereoselectivities than the corresponding D-mannose 
derived imine (α,β-anti configuration).306 As a consequence of these recent observations, it is not 
completely clear, whether the observed 5:1 5,6-syn/5,6-anti ratio for allylation of the 2-alkoxy 
substituted imines 147 and 148 (Table 19, entries 2 and 3) is a result of chelation or a complex 
relationship between the nature of the alkoxy substituents and the organometallic reagent. 
 
4.5.4 Formation of diastereomeric carbocycles 
The completion of pathway B with both isomers 145 and 146 required Cbz-protection of the amine 
followed by ring-closing metathesis using Grubbs’ 2nd generation catalyst133 (Scheme 55). 
Protection of the amine is necessary because unprotected amines are known to coordinate to 
ruthenium thereby hampering the ring-closing metathesis reaction.18,332 The Cbz-protective group 
was chosen since it is readily removed by hydrogenation in the final step.333 With the introduction 
of the Cbz-group, a broadening of the peaks in both 1H and 13C NMR spectroscopy could be 
observed due to the presence of rotamers thereby complicating analysis by NMR spectroscopy. 
Protection of the diastereomeric amines 145 and 146 with CbzCl to produce 149 and 150 occurred 
in 91 and 93% yield, respectively, and the subsequent ring-closing metatheses both gave 97% yield 
of 136 and 151, respectively. 
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Scheme 55. Formation of seven-membered carbocycles 136 and 151 from the diastereomeric nonadienes 145 and 146. 
 
The conversion of the diastereomeric nonadienes 149 and 150 into the corresponding cycloheptenes  
136 and 151 enabled direct comparison with the cycloheptene 136 synthesized by pathway A (see 
section 4.5.7 below), thereby determining the identity of each diastereomer. The lack of 
stereocontrol in the fragmentation-allylation sequence produced the desired nonadiene 145 as the 
minor isomer in less than 50% yield in the key step, and this disfavors pathway B as a synthetic 
route to calystegine A3. As a result, the synthetic efforts towards calystegine A3 were focused on 
optimization of the low-yielding Barton-McCombie deoxygenation of the 5-hydroxy-cycloheptene 
135 (Scheme 51, pathway A). 
 
4.5.5 Revised strategy towards calystegine A3 
Since the difficult deoxygenation of 135 is late in the synthesis, it was necessary to carry out the 
first steps on a large scale (20-30 grams). The fully protected intermediate 140 was deprotected at 
the 6-position using sulfuric acid in MeOH/toluene followed by iodination with iodine, PPh3 and 
imidazole in THF in 98 and 93% yield, respectively (Scheme 56). This gave access to the 
2,3,4-O-protected methyl 6-deoxy-6-iodo-α-D-glucopyranoside 133 for the fragmentation-allylation 
sequence.  
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Scheme 56. Synthesis of cycloheptene 135 via pathway A. 
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Applying the conditions previously used on this 2-O-PMB protected substrate 133 gave two 
diastereomeric dienes in 85% yield in a 5.3:1 ratio favoring the desired (6R)-isomer 134♦ (Scheme 
56). This result was in accordance with Philip and Charlotte’s observations (Table 19, entries 2 
and 3), and the stereochemical outcome was later confirmed by completing the synthesis of 
calystegine A3 (see section 4.5.7). 
 
The major (6R)-isomer 134 was subsequently Cbz-protected affording the desired diene 153 for 
ring-closing metathesis. The diene 153 was successfully cyclized with 5% of Grubbs’ 2nd generation 
catalyst133 in DCM to produce the seven-membered carbocyclic skeleton of calystegine A3 in 
almost quantitative yield. Subsequent deprotection of the PMB-protected secondary alcohol 154 to 
give 135 occurred in 88% yield. 
 
4.5.6 Deoxygenation 
Due to the previous difficulties with the deoxygenation, a number of different deoxygenation 
strategies were considered. Barton-McCombie deoxygenations324,325 are usually performed by 
reduction with Bu3SnH, but also other hydrogen sources like H3PO2334 and a range of different silyl 
hydrides including (Me3Si)3SiH335 and Ph2SiH2336 have been developed primarily due to lower 
toxicity. Displacement of leaving groups like sulfonates with hydrides was also considered. 
Mesylates and tosylates of primary alcohols can readily be displaced by various hydride reagents, 
but with secondary substrates, the reaction often fail due to competing attack on sulfur thereby 
regenerating the starting alcohol.337,338 This problem can be avoided using Bu4NBH4, which is a 
useful reagent for the reduction of triflates of secondary alcohols.339 However, since Charlotte had 
no success with such triflate displacements, the two classical Barton-McCombie deoxygenation 
variations using 1,1’-thiocarbodiimidazole325 or CS2324 together with Bu3SnH and AIBN were 
attempted (Scheme 57). 
 
                                                 
♦
 The desired (6R)-isomer 134 is the 5,6-syn product according to the nomenclature of Table 19. 
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Scheme 57. Initial Barton-McCombie radical deoxygenation. The thiocarbonyl derivative (155 or 156) (40 mg) was 
degassed and heated to reflux in toluene. To the solution was added a mixture of AIBN and Bu3SnH in toluene over a 
period of 30 min. 
 
Of the available thiocarbonyl derivatives, methyl xanthates are known to be the most reactive 
species with respect to the deoxygenation step,340 and indeed the methyl xanthate 156 gave an 
encouraging yield of 43% in the initial deoxygenation experiments. Based on this result, it was 
decided to optimize the deoxygenation using the methyl xanthate approach. However, having 
decided to use the CS2-protocol, the formation of methyl xanthate 156 proved difficult, because a 
bicyclic side-product 157 was formed as the major product in 62% yield using 20 equivalents of 
CS2 as depicted in Table 21 (entry 1). The side-product 157 results from intramolecular attack of 
the alkoxy anion on the carbonyl functionality of the Cbz-group instead of intermolecular attack on 
CS2. 
 
Table 21. Formation of methyl xanthate 156. 
 
BnO
BnO NBn
OH Cbz
BnO
BnO NBn
O Cbz
S SMe
CS2, NaH
imidazole
THF, rt
then MeI
BnO
BnO NBn
O
O
+
135 156 157
 
Entry NaH (eq.) 
CS2 
(eq.) 
Yield of 156 
(%) 
Yield of 157 
(%) 
1 3 20 22 62 
2 3 200 64 26 
3 3 500 66 19 
4 3 1000a 39 34 
5 5 500 72 16 
6 4 1000 78 13 
The reactions were performed by dropwise addition of the alcohol 135 dissolved 
in THF/CS2 to a suspension of NaH and imidazole in CS2. a No THF was used. 
 
Increasing the amount of CS2 to 200 equivalents gave the desired methyl xanthate 156 as the major 
product in 64% yield (Table 21, entry 2). Only a slight improvement was observed using 
500 equivalents of CS2, and performing the reaction neat resulted in a considerably lower yield 
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(entries 3 and 4). Changing the amount of NaH from three to five equivalents was found to have a 
favorable effect (entry 5), and combining this finding with an even larger excess of CS2 (1000 eq.), 
gave 156 in 78% yield (entry 6). 
 
Thorough degassing of both the reaction mixture and the reagents to exclude oxygen is of vital 
importance in order to prevent side reactions in highly functionalized substrates during the 
deoxygenation step.341 The thiocarbonyl derivative is usually added to a refluxing solution of 
Bu3SnH in toluene to ensure an excess of Bu3SnH compared to the thiocarbonyl derivative,324,325 
and in contrast to the earliest reported radical deoxygenations,324,325 a catalytic amount of AIBN is 
often used to increase the reaction rate and reproducibility.341,342 In addition, it seems advantageous 
to add the thiocarbonyl derivative together with AIBN to a refluxing solution of Bu3SnH to 
maintain a constant amount of radicals throughout the reaction. Taking the above parameters into 
consideration, an initial screening of the reaction conditions was performed according to Table 22.  
 
Table 22. Deoxygenation of methyl xanthate 156 – screening of conditions.  
BnO
BnO NBn
O Cbz
S SMe
AIBN, Bu3SnH
toluene, reflux
BnO
BnO NBn
Cbz
156 136
 
Entry AIBN (eq.) 
Bu3SnH 
(eq.) Conditions 
Conversiona 
after 90 min 
(%) 
1 0 3  ~ 40 
2 0.2 3 156 was added to Bu3SnH and AIBN ~ 75 
3 0.2 3 AIBN and 156 were added to Bu3SnH >95 
4 0.2 1.5 AIBN and 156 were added to Bu3SnH ~ 90 
The deoxygenations were performed by dropwise addition of 156 (100 mg) in toluene to freshly 
distilled Bu3SnH in refluxing toluene. a Conversions are based on TLC analysis. 
 
As can be seen from Table 22, the highest conversion within 90 min was achieved by adding 156 
together with AIBN (0.2 eq.) to a refluxing solution of Bu3SnH (3 eq.) in toluene (entry 3). Notably, 
when no AIBN is used (entry 1), the conversion is much lower than in the presence of AIBN. This 
illustrates that AIBN efficiently generates radicals, and in order for the deoxygenation to occur 
without AIBN, a much longer reaction time is required.  
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Choosing the conditions described in Table 22, entry 3, the reaction was scaled up and optimized 
with respect to reaction time as can be seen in Table 23 below. 
 
Table 23. Deoxygenation of methyl xanthate 156 – optimization of conditions. 
Entry AIBN (eq.) 
Bu3SnH 
(eq.) 
Scale 
(mg) 
Time 
(min) 
Yield of 136 
(%) 
1a 0.4 4 40 180 43 
2 0.2 3 100 90 56 
3 0.2 3 200 60 74 
4 0.2 3 500 50 72 
The deoxygenations were performed by dropwise addition of 156 and AIBN 
in toluene to Bu3SnH in refluxing toluene. a Bu3SnH and AIBN in toluene 
were added dropwise to a refluxing solution of 156 in toluene. 
 
Increasing the scale and at the same time reducing the reaction time gave a gratifying 74% yield 
(Table 23, entry 3) in the light of previous failed attempts to optimize this reaction. From Table 23 
it is also obvious that radical reactions are sensitive to the scale. On a small scale it is more difficult 
to produce a sufficient amount of radicals for the reaction to proceed, and small scale reactions 
therefore constitute a higher risk of failure.  
 
4.5.7 Calystegine A3 end game 
The completion of the deoxygenation sequence produced material to establish the identity of the 
two cycloheptenes 136 and 151 synthesized via strategy B, and as mentioned previously, the minor 
isomer 136 from strategy B was identical in all respects to the cycloheptene 136 produced by 
strategy A. 
 
Having successfully optimized the Barton-McCombie radical deoxygenation of 135, we looked 
forward towards the end game of the calystegine A3 synthesis. The next step was the hydroboration-
oxidation sequence306 (Scheme 58), which was performed with borane-THF complex followed by 
oxidation with alkaline hydrogen peroxide to produce an isomeric mixture of four alcohols. The 
crude alcohols were directly oxidized using DMP to produce a 2:1 mixture of the isomeric ketones 
158 and 159 in 76% yield. The selectivity in the hydroboration was a bit lower than the 3:1 ratio 
observed by Philip in the similar calystegine B2 system,306 but the desired isomer was still favored. 
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Scheme 58. Synthesis of calystegine A3 (117). 
 
The final deprotection and cyclization to the bicyclic aminoketal was performed by hydrogenation 
using Pearlman’s catalyst followed by acidification with hydrochloric acid to facilitate the ring 
closure as developed by Philip.306 Initially, THF/H2O was used as the solvent, but after leaving the 
reaction mixture for a prolonged time (36 h) under acidic conditions, small amounts of 
1,4-butanediol resulting from unexpected ring opening of THF could be observed. The diol was 
difficult to remove from the natural product by Sephadex LH-20 column chromatography,343 and it 
was found that by performing the reaction in dioxane/H2O, the side-reaction could be avoided. In 
addition, dioxane/H2O gave a slight improvement of the yield from 81 to 84% as compared to 
THF/H2O. However, these differences are subtle on such a small scale and are probably within 
experimental error. 
 
NHMe
O
oligomers
161160
N
OH Me
 
Scheme 59. Aminoketal – aminoketone equilibrium of physoperuvine (160).344 
 
Physoperuvine (160), which represents the general nortropane skeleton, exists as an equilibrium 
mixture between its bicyclic aminoketal 160 and the corresponding aminocycloheptanone 161 
(Scheme 59).344 Even though the naturally occurring calystegines are found exclusively in their 
bicyclic form in nature, it is reasonable to assume that the calystegine alkaloids also exist in 
equilibria between their aminoketal and aminoketone forms in which the number and position of 
oxygenated substituents are decisive for the position of the equilibrium.295,296 The formation of 
Rune Nygaard Monrad – Ph.D. Thesis 
84 
oligomers of certain unnatural calystegines via the monocyclic aminoketone as experienced by 
Lallemand and co-workers under acidic conditions296,298 was therefore a concern prior to the final 
deprotection-cyclization step producing calystegine A3. This concern was amplified by difficulties 
producing calystegine A3 from its hydrochloric salts as experienced by Johnson and Bis299 (Scheme 
47) and by Philip’s observation that epimers of B2, B3 and B4 were not well-defined compounds.306 
However, despite those concerns, calystegine A3 was formed in good yield in accordance with the 
data reported for the natural product.289 Our work-up procedure306 utilized ion exchange resin IRA 
400 OH- thereby avoiding the problems associated with the hydrochloric salt of the natural product, 
and it is therefore a major improvement to the procedure by Johnson and Bis.299 
 
NHCbz
OHAcO
NHCbz
OHHO or
NHCbz
OAcHO
Amano P-30 lipase
isopropenyl acetate
50 °C, 91%
?
steps
both enantiomers of 
calystegine A3163:
162
 
Scheme 60. The desymmetrization step in the synthesis of calystegine A3 by Johnson and Bis was performed 
enzymatically, but the absolute configuration of the produced acetate 163 was not established.287,299 
 
The structure of calystegine A3 was reported in 1990,285,286 however, no specific rotation was given 
in the literature until 1995. At that time Asano and co-workers reported [α]D –17.3.289 Even though 
calystegine A3 had already been synthesized twice; racemic by Lallemand and co-workers in 
1992296 (Scheme 46) and both enantiomers by Johnson and Bis in 1995299 (Scheme 47), the 
absolute configuration has remained unknown until now. Since both enantiomers of calystegine A3 
synthesized by Johnson and Bis were produced by enzymatic acetylation of a single hydroxy group 
in the prochiral diol 162, the absolute configuration of the resulting acetate 163 could not be 
determined  (Scheme 60). As a result of this, the identity of each enantiomer of calystegine A3 was 
not established leaving the absolute configuration of calystegine A3 unknown.287,299 
 
With the current synthesis of calystegine A3 from D-glucose, the absolute configuration can finally 
be determined. The specific rotation was measured to [α]25D –13.6, which is in accordance with the 
value reported by Asano and co-workers,289 and as expected, the absolute configuration of naturally 
occurring calystegine A3 resembles that of calystegine B2. 
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4.5.8 Isomerization of calystegine A3 to A6 
Dräger has previously suggested that calystegine A3 (117) might be involved in the biosynthesis of 
calystegine A6 (166) by a base-mediated isomerization via 164 and 165 as depicted in Scheme 
61.287 Calystegine A6 has been isolated from Hyoscyamus niger290 and Lycium chinense,294 and in 
both cases together with calystegine A3.287 It is therefore reasonable to suspect that calystegine A6 
might be derived from calystegine A3 by simple isomerization. Based on the instability of 
calystegine A3 observed by Johnson and Bis,299 it was therefore decided to investigate the stability 
of calystegine A3 in basic solution with focus on possible isomerization to calystegine A6.. 
 
HO
HO NH2
O
O
HO NH2
HO
117 166
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oligomers
NHHO
OH
HO
HN OH
HO
HO
164 165
 
Scheme 61. Proposed base-mediated isomerization of calystegine A3 (117) to A6 (166).287 
 
Base-mediated isomerization of sugars is most often performed with bases like KOH, Ca(OH)2, 
Et3N or pyridine.26 Usually, isomerization and anomerization of carbohydrates is achieved under 
slightly basic conditions,26 and refluxing pyridine is frequently used.345,346 However, also stronger 
alkaline media like aqueous KOH at pH > 11 has been studied in detail and facilitates a range of 
isomerizations.346 Since the isomerization of carbohydrates is dependant on pH,26 both a weak 
(pyridine-d5) and a strong (Ca(OH)2) base were chosen for the attempted isomerization of 
calystegine A3 to calystegine A6 (Table 24).  
 
Initially, calystegine A3 was dissolved in pyridine-d5 and left at room temperature for 14 days to 
investigate its stability in weak base (Table 24, entry 1). Surprisingly, no conversion could be 
observed neither by TLC nor 1H NMR, and calystegine A3 could be recovered in >80% yield. 
Calystegine A3 was even stable in pyridine-d5 at 100 ºC for up to 24 h, after which slow degradation 
was indicated by TLC analysis (entries 2-4). 
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Table 24. Attempted base-mediated isomerization of calystegine A3 (117) to A6 (166). 
Entry Base Temperature (ºC) Time Observations 
1 pyridine-d5 25 14 days No conversion. Recovery of 117 
2 pyridine-d5 100 1 h No conversion. Recovery of 117 
3 pyridine-d5 100 4 h No conversion. Recovery of 117 
4 pyridine-d5 100 24 h No conversion. Recovery of 117a 
5b 1 M aq. Ca(OH)2 25 14 days Slow degradation.c More than one spotd 
6b 1 M aq. Ca(OH)2 100 1 h Residue of 117 
7b 1 M aq. Ca(OH)2 100 4 h Trace of 117. More than one spotd 
8b 1 M aq. Ca(OH)2 100 24 h More than one spotd 
a
 Slow degradation. b The reaction mixtures were inhomogeneous and stirring was applied. c Slow 
broadening of the peaks in 1H NMR when the reaction was performed in D2O. d After workup TLC 
analysis revealed more than one spot (Rf 0.13 for the most intense new spot), a complex product 
mixture was observed by 1H NMR, and no calystegine A3 could be isolated. TLCs were eluted with 
1-propanol/AcOH/H2O = 4:1:1 (Rf 0.42 for calystegine A3). 
 
In stronger base however, calystegine A3 proved to be less stable. When calystegine A3 was 
dissolved in 1 M aqueous Ca(OH)2 (pH >12) at room temperature, slow degradation was observed 
accompanied by development of a weak spot with a smaller Rf than calystegine A3 (Table 24, entry 
5). Performing the same reaction in 1 M Ca(OH)2 in D2O resulted in broadening followed by slow 
disappearance of the signals in 1H NMR spectroscopy. The broadening of the signals in 1H NMR 
spectroscopy can either be explained by a beginning epimerization of the stereocenters or by 
deuterium exchange with the solvent due to the highly basic conditions. In addition, it may also be a 
result of partial oligomerization,296,298 which would give a less well-defined spectrum. After stirring 
for 14 days at room temperature (entry 5), no calystegine A3 could be recovered just as experienced 
by Johnson and Bis treating calystegine A3 with 2 M NaOH in D2O.299 Heating calystegine A3 to 
100 ºC in the presence of 1 M aqueous Ca(OH)2 revealed almost complete degradation of 
calystegine A3 within 4 h (entries 6-8). However, a new spot could be seen by TLC analysis, but 
after workup and Sephadex LH-20 column chromatography, a complex product mixture was 
observed by 1H NMR spectroscopy. 
 
In summary, calystegine A3 is stable to weak base even at elevated temperatures, but it is quickly 
degraded under strong alkaline conditions. Furthermore, on the basis of the failed attempts to 
isomerize calystegine A3 to A6 under several different conditions, it is reasonable to conclude that 
calystegine A6 is in fact an individual natural product and not just a base-mediated isomerization 
product of calystegine A3 as speculated by Dräger.287 
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4.6 Concluding remarks 
Enantiomerically pure calystegine A3 has been synthesized by elongation of the carbon chain of 
commercially available methyl α-D-glucopyranoside (127) by two different routes. By 
deoxygenating D-glucose in the 2-position before the key zinc-mediated tandem fragmentation-
allylation, almost no diastereoselectivity was obtained in the allylation reaction, and calystegine A3 
was produced in 14 steps and 5.3% overall yield. Removal of the secondary C2-hydroxy group of 
D-glucose after the fragmentation-allylation sequence gave rise to 6.4% yield of calystegine A3 in 
14 steps. However, combined with the work performed by Charlotte B. Pipper,322 we have 
developed a 13 step synthesis of calystegine A3 in 8.3% overall yield. To close this project, the two 
parallel routes to calystegine A3 (117) developed in the group are shown in their entirety in Scheme 
62. 
 
The current work constitutes the shortest synthesis of enantiomerically pure calystegine A3 to date 
and proves the absolute configuration of naturally occurring calystegine A3. Calystegine A3 is stable 
in weak base, but is quickly degraded in strong base. It was not possible to isomerize calystegine A3 
to A6, which indicates that calystegine A6 is a natural product itself in contrast to an isomerization 
product of calystegine A3. 
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Scheme 62. Overview of the two routes to calystegine A3 (117) developed by our group. Reagents and conditions: a) 
TrCl, pyridine, 90 ºC, b) Bu2SnO, Bu4NI, PMBCl, MeCN, reflux, c) NaH, Bu4NI, BnBr, DMF, 0 ºC → rt, d) DDQ, 
DCM, H2O, rt, e) NaH, CS2, imidazole, THF, rt, then MeI, f) Bu3SnH, AIBN, toluene, reflux, g) H2SO4, MeOH, H2O, 
rt, h) I2, PPh3, imidazole, THF, 40 ºC, i) Zn, TMSCl, ))), THF, 40 ºC, then BnNH2, then allylbromide, j) CbzCl, 
KHCO3, DCM, H2O, 0 ºC → rt, k) 5% Grubbs’ 2nd gen. cat., DCM, rt, l) BH3, THF, -40 ºC → rt, then NaOH, H2O2, 
H2O, rt, m) DMP, DCM, rt, n) H2, Pd(OH)2/C, dioxane, H2O, rt, then HCl, o) NaH, Bu4NI, BnBr, DMF, 0 ºC → rt, then 
H2SO4, MeOH, H2O, rt. 
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5 Synthesis of gabosine A by chain elongation of D-ribose 
 
5.1 The gabosines 
The gabosines are a family of polyhydroxylated carbocycles possessing a 
cyclohexanone/cyclohexenone skeleton (Figure 6). They were first isolated in 1974347 as secondary 
metabolites from Streptomyces strains. Since then a total of 14 different gabosines have been 
isolated.348-350 The gabosines do not possess any significant biological activity, but Thiericke and 
co-workers found that many of the gabosines exhibit weak DNA binding properties.349  
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Figure 6. Naturally occurring gabosines. The structure of gabosine K is at present unknown since the initially proposed 
structure348 turned out to be wrong.351 
 
The biosynthesis of the gabosines occurs via a pentose phosphate pathway by cyclization of 
sedoheptulose 7-phosphate by an aldol condensation.352 Chemical syntheses have been reported for 
gabosines A,353,354 B,351,354 C,355-360 D,354 E,354,356 G,361 I,361,362 N363 and O.363,364 Gabosine A has 
been synthesized by Banwell and co-workers in 2001353 and Shinada and co-workers in 2002.354,365 
The shortest synthesis was provided by Banwell accessing gabosine A in six steps from 
cis-1,2-dihydroxycatechol 168 (Scheme 63), which is available in a single step by enzymatic 
dihydroxylation of iodobenzene.353  
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Scheme 63. Synthesis of gabosine A (171) by Banwell and co-workers.353 
 
Selective silyl protection of a single hydroxy group of 168 followed by dihydroxylation and 
isopropylidene protection afforded 169, which was subsequently oxidized to cyclohexenone 170. 
Displacement of the iodide by a methyl group and deprotection gave gabosine A (171) in 58% 
overall yield from 168. The synthesis by Shinada and co-workers, on the other hand, required 
12 steps from (-)-quinic acid (172) affording gabosine A in approximately 8% overall yield 
(Scheme 64).354,365 
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Scheme 64. Synthesis of gabosine A (171) by Shinada and co-workers.354,365 
 
None of the above mentioned syntheses take advantage of the convenient stereochemical 
configuration of abundant carbohydrates, and the aim of the current project is to apply the well-
established fragmentation-allylation-metathesis methodology (section 4.2) to the synthesis of 
gabosine A from D-ribose. 
 
5.2 Retrosynthetic analysis of gabosine A 
The synthetic strategy towards gabosine A is very similar to the synthesis of calystegine A3, and the 
retrosynthesis of gabosine A is shown in Scheme 65. The cyclohexenone skeleton can be accessed 
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by ring-closing metathesis of diene 174. The required diene 174 could be provided by chain 
elongation of a suitably protected ω-iodoribofuranoside 175 by zinc-mediated fragmentation and 
allylation.135,136 By employing D-ribose as the starting material, two of the stereocenters in gabosine 
A are conveniently set from chiral pool, and the strategy enables preparation of both gabosine A 
and its epimer, gabosine N. 
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Scheme 65. Retrosynthetic analysis of gabosines A (171) and N (173). 
 
5.3 Previous work on the gabosine project in the group 
Several people from the group have been working on the synthesis of the gabosines. Mette 
Fanefjord successfully completed the synthesis of gabosine N,366 whereas Flemming Gundorph 
Hansen prepared small amounts of gabosine A.367 The work towards gabosine A and N performed 
by Mette and Flemming is summarized in Scheme 66.366-368 
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Scheme 66. Synthesis of gabosine N (173) by Mette Fanefjord366,368 and synthetic efforts towards gabosine A (171) by 
Flemming Gundorph Hansen and Mette Fanefjord.367,368 
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The initial strategy was to use the known methyl 2,3-O-isopropylidene-5-deoxy-5-iodo-
β-D-ribofuranoside 176369 as a common intermediate. The iodide 176 is available from D-ribose in 
two steps in 77% yield,370 and metal-mediated fragmentation-allylation would produce the 
diastereomeric (4S)- and (4R)-dienes (177-180) conveniently set up for the synthesis of both 
gabosines A and N. However, zinc-mediated fragmentation-allylation only produced the 
diastereomeric (4S)-dienes 177 and 178, and after several failed attempts to synthesize the 
(4R)-dienes 179 and 180 for gabosine A by zinc and indium mediated allylation,367 it was decided 
to invert the C4 secondary alcohol of 181 instead. However, this proved difficult and in addition to 
this, the following steps occurred in very low yield leaving the synthesis of gabosine A unfinished. 
 
5.4 Results and discussion 
5.4.1 Stereochemical considerations 
The synthesis of gabosine N by Mette Fanefjord was performed with the major (3S,4S)-isomer 177 
from the allylation as shown in Scheme 67. The stereochemistry at C4 was rigorously established 
by completing the synthesis, but the configuration at C3 has not been unambiguously established.  
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Scheme 67. Mette’s synthesis of gabosine N employed only the major (3S,4S)-isomer 177.366 
 
In order to determine the absolute configuration of the allylation product 177 at C3 (Scheme 67), 
the diol 183 derived from the major isomer 177 was subjected to 2,2-dimethoxypropane and 
catalytic amounts of CSA at room temperature (Scheme 68).  
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Scheme 68. 
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The diol 183 reacted smoothly to produce the diisopropylidene derivative 184 in 73% yield within 
40 min, and this indicates a cis relationship between the hydroxy groups in question. However, 
since a trans fused bicyclic system is not impossible (especially not when the six-membered ring is 
slightly flattened by the double bond), the reactivity of the minor isomer 178 was also investigated 
(Scheme 69). 
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Scheme 69. 
 
After ring-closing metathesis of 178 (which will be discussed in section 5.4.2 below) and 
deprotection, the trans diol 186 was subjected to 2,2-dimethoxypropane and CSA. Under identical 
conditions as with the cis isomer 183, no conversion was observed, and only after 3 h using a larger 
excess of 2,2-dimethoxypropane, any conversion was achieved. The diisopropylidene protected 
compound 187 could be isolated in 29% yield together with 35% of unreacted starting material. 
Although these data strongly support the proposed stereochemical configurations, 13C NMR data for 
the acetal carbons were compared for the two diisopropylidene compounds. According to Buchanan 
and co-workers371 cis fused isopropylidene acetals have a slightly lower chemical shift than trans 
fused isopropylidene acetals.♦ The cis fused substrate 184 showed acetal 13C chemical shifts of 
110.4 and 110.3, whereas the trans fused derivative 187 showed acetal 13C chemical shifts of 111.2 
and 109.9 for the two isopropylidene groups. Together, the reactivities of the two isomeric diols 183 
and 186 with 2,2-dimethoxypropane and the 13C NMR data of the corresponding diisopropylidene 
                                                 
♦
 Isopropylidene acetals which are cis fused to a pyranoid or cyclohexane rings are reported to have a 13C chemical shift 
of 108.1-111.4 ppm for the acetal carbon, whereas trans fused isopropylidene acetals have 13C chemical shifts of 111.8-
112.3 ppm for the acetal carbon. (Buchanan, J. G.; Edgar, A. R.; Rawson, D. I.; Shahidi, P.; Wightman, R. H. 
Carbohydr. Res. 1982, 100, 75). 
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derivatives 184 and 187 provide evidence for the proposed stereochemistry in the allylation reaction 
(Scheme 66). 
 
The obtained (S)-configuration at C4 can be rationalized by the Felkin-Anh model109,110 (Scheme 
70), and it is in accordance with previous observations in a similar allylation in the synthesis of 
conduritol D.316 In contrast to allylation of α,β-syn bisalkoxy imines 147 and 148 in the synthesis of 
calystegine A3 (see section 4.5.2 and 4.5.3), the stereochemical outcome from allylation of the 
α,β-anti bisalkoxy aldehyde 188 (generated by zinc-mediated fragmentation of 176) can be 
explained by the Felkin-Anh model although the reactions were performed under identical 
conditions.  
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Scheme 70. The observed stereochemical outcome in the allylation of aldehyde 188 can be rationalized by the Felkin-
Anh model.109,110  
 
The observation that the α,β-anti bisalkoxy acetonide 188 reacts according to the Felkin-Anh model 
and produces the 4,5-anti (4S) product (177 and 178) is in accordance with recent results from the 
Evans group, which suggest that acetonide protected α,β-bisalkoxy aldehydes predominantly afford 
anti relationships between the α-alkoxy substituent and the newly formed stereocenter irrespective 
of the configuration of the β-alkoxy substituent.95 The decreased conformational flexibility of the 
isopropylidene protected aldehyde 188 decreases steric and electrostatic interactions between the 
β-substituent and the incoming nucleophile, and the π-facial stereoselectivity can thus be predicted 
by the Felkin-Anh model. 
 
5.4.2 Ring-closing metathesis 
As shown in Scheme 69, ring-closing metathesis of 178 using Grubbs’ 2nd generation catalyst133 
occurred in 74% yield. Earlier, Mette only obtained a maximum of 47% yield for ring-closing 
metathesis of 178 using P(CH2OH)3 at 40 ºC for 24 h to quench the catalyst.366 Although 
P(CH2OH)3 has been reported to remove ruthenium byproducts efficiently,372 the product may not 
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be stable to these conditions. Instead, it was found that by purifying the product directly by flash 
column chromatography, a considerably higher yield of 185 could be achieved. The 74% yield for 
the ring-closing metathesis of 178 is in contrast to Mette’s nearly quantitative yield of 97%♦ for the 
diastereomeric diene 177.368 Generally, ring-closing metathesis of 2,2-disubstituted alkenes occur in 
slightly lower yield than monosubstituted alkenes,373 but since both substrates 177 and 178 contain 
a disubstituted double bond, an explanation for their different reactivity could not be rationalized. 
However, significant differences in the reactivity of diastereomeric dienes in ring-closing 
metathesis reactions have previously been observed in the literature,305,374,375 and it can therefore be 
concluded that the reactivity of dienes in ring-closing metathesis is highly dependant on the nature 
and the configuration of the substituents. 
 
5.4.3 Synthesis of gabosine A 
In order to synthesize gabosine A, the unprotected hydroxy group of 181 needs to be inverted. 
Usually the Mitsunobu reaction376 would be employed to invert secondary alcohols, but in this case 
the substrate is probably too sterically hindered, and instead triflic anhydride in pyridine followed 
by treatment with sodium nitrite377 in DMF was used (Table 25, entry 1). Triflates can be formed in 
almost quantitative yield, whereas the displacement by nitrite may often be accompanied by 
significant decomposition or byproduct formation leading to moderate overall yields.315 In this case, 
182 was isolated in 52% yield from 181, and competing E2 elimination of the triflate 189 might be 
responsible for the moderate yield. No single byproduct could be identified, since a complex 
mixture of byproducts was observed by 1H NMR spectroscopy. 
 
In Table 25, the observed 52% yield of 182 is compared with Mette and Flemming’s previous 
attempts to invert the secondary alcohol of 181 (entries 2-5).367,368 From these results it seems 
important to keep the reaction time of the nitrate-mediated triflate displacement low to prevent 
decomposition and side reactions. 
 
 
                                                 
♦
 In this case the catalyst was removed by treatment with activated carbon. (Cho, J. H.; Kim, B. M. Org. Lett. 2003, 5, 
531). 
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Table 25. Inversion of the secondary alcohol of 181. 
O
O
OBz
OH
O
O
OBz
OH
Tf2O
pyridine, DCM
0 °C, 1.5 h
NaNO2, DMF
25 °C
O
O
OBz
OTf
181 189 182
 
Entry Base Tf2O (eq.) 
NaNO2 
(eq.) 
Time 
(h) 
Yield of 182 
(%) 
1 pyridine 1.5 4 5.5 52 
2 pyridine 1.4 4 16 33 
3 pyridine 5 10 16 41 
4 Et3N 2 5 16 13 
5 pyridine 1.4 7 a 16 40 
Entries 2-5 were performed by Mette and Flemming.367,368 
a
 NaNO2/DMF was replaced by Bu4NNO2/toluene. 
 
Completion of the synthesis of gabosine A was achieved by protective group manipulations and 
allylic oxidation as shown in Scheme 71. Direct allylic oxidation with DDQ, PDC or MnO2 in the 
presence of an unprotected homoallylic alcohol has previously been found to occur in low 
yield,366,367 and a protective group for the homoallylic alcohol of 182 is therefore necessary. The 
tetrahydropyranyl (THP) group378 was chosen since it can be removed together with the acetonide 
under acidic conditions. However, analysis by NMR spectroscopy was complicated by the 
introduction of the THP group, since the additional stereocenter affords two diastereomers.  
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Scheme 71. Synthesis of gabosine A (171). 
 
The THP group was introduced in 85% yield, and subsequent deprotection of 190 under Zémplen 
conditions129 afforded 191 in 90% yield. Oxidation of the allylic alcohol 191 with PDC and final 
deprotection of 192 with acetic acid afforded gabosine A with analytical data in accordance with the 
natural product.348,353 
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5.5 Concluding remarks 
To conclude the gabosine project, gabosine N (173) and A (171) have been synthesized from 
D-ribose in eight and nine steps, respectively together with Mette Fanefjord and Flemming 
Gundorph Hansen (Scheme 72). The key steps in the syntheses are the chain elongation of 
2,3-O-isopropylidene-5-deoxy-5-iodo-β-D-ribofuranoside 176 by zinc-mediated fragmentation-
allylation and subsequent ring-closing olefin metathesis to produce 181. Due to unsuccessful 
attempts to control the stereochemical outcome of the allylation reaction, an additional step was 
required to invert the homoallylic alcohol of 181 to obtain 182 for the synthesis of gabosine A. 
Gabosine N was prepared in 16.5% yield, whereas gabosine A was synthesized in 13.9% overall 
yield from D-ribose. The work has very recently been published in European Journal of Organic 
Chemistry. 
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Scheme 72. Overview of the syntheses of gabosine N (173) and A (171) from our group. Reagents and conditions: a) 
Zn, ))), THF, H2O, 40 ºC, then (E)-BrCH2C(CH3)=CHOBz, b) 10% Grubbs’ 2nd gen. cat., DCM, 40 ºC, c) DHP, PPTS, 
DCM, rt, d) NaOMe, MeOH, rt, e) PDC, DCM, rt, f) AcOH, H2O, 40 ºC, g) Tf2O, pyridine, DCM, -20 ºC → rt, then 
NaNO2, DMF, rt. 
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The present synthesis of gabosine A cannot compete with the synthesis developed by Banwell and 
co-workers,353 but together with the synthesis of calystegine A3 (chapter 4) and previous reports 
from our group,136,304,306,314-317 it illustrates that carbocyclic natural products are easily available 
from carbohydrates by chain elongation and subsequent cyclization. 
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6 Interaction between plasma protein and acyl glucuronide drug metabolites 
 
This part of the thesis describes the work carried out during a six months stay at the Chemistry 
Research Laboratory at University of Oxford. The research was performed under the supervision of 
professor Benjamin G. Davis in collaboration with the group of professor Andrew V. Stachulski at 
University of Liverpool. The project involves the metabolism of nonsteroidal anti-inflammatory 
drugs (NSAIDs) with particular focus on their acyl glucuronide (AG) metabolites and the 
interaction of these with human plasma protein.  
 
6.1 Introduction 
The NSAIDs are among the most widely used drugs on the market, and include drugs like 
acetylsalicylic acid, ibuprofen and diclofenac. In humans, the NSAIDs function by inhibiting 
cyclooxygenase 1 and 2, which are enzymes responsible for the production of prostaglandins from 
arachidonic acid. Whenever the body is ‘threatened’ by a trauma, an infection or introduction of a 
foreign object, the synthesis of prostaglandins is stimulated. The liberation of prostaglandins induce 
pain, inflammation and fever, and the inhibition of cyclooxygenase 1 and 2 by NSAIDs lead to 
analgesic, anti-inflammatory and fever reducing effects.13,14  
 
The metabolism of relatively non-polar drugs like NSAIDs primarily takes place in the liver, 
whereas polar drugs, on the other hand, are excreted in the kidney. Non-polar drugs are metabolized 
by phase I and II reactions in the liver to increase their water solubility and enable subsequent 
urinary excretion via the kidney (Figure 7).13,14 The phase I reactions include oxidation, 
hydroxylation, dealkylation, deamination and hydrolysis to make the drug more polar. Some drugs 
can be excreted after phase I metabolism, but many drugs including the NSAIDs require further 
conjugation in phase II metabolism to be excreted. One of the most important phase II reactions is 
glucuronidation, in which UDP-glucuronosyltransferases couple D-glucuronic acid to the drug.13 
Other phase II reactions include sulfonation and coupling of the drug to glutathione. As a result of 
increased water solubility, the metabolites are transported to the kidney or the gallbladder and 
excreted in urine or faeces, respectively.13,14 
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Figure 7. Phase I and II drug metabolism in the liver.13,14 
 
Phase I metabolites are often more reactive and may be more toxic than their parent drugs, whereas 
the phase II metabolites are generally inactive.13 The NSAIDs are extensively metabolized to their 
1-β-O-acyl glucuronides (AGs),379 but in contrast to the unreactive glucuronides of alcohol and 
phenolic drugs (196), the glucuronides of carboxylate drugs (197) are highly reactive metabolites 
(Scheme 73).380 The increased reactivity of the AGs 197 as compared to their parent drugs enables 
reaction with nucleophiles, and such processes have the potential to covalently modify endogenous 
macromolecules like proteins or DNA (Scheme 73b). Hydrolysis to reform the parent drug and 
transacylation to produce 198 occur by direct displacement of glucuronic acid by attack of 
nucleophiles. Acyl migration producing 2-, 3- or 4-O-AGs (e.g. 199), on the other hand, leads to 
various N-glycosylation adducts such as 200.381 1-β-O-Acyl glucuronides are stable to acid, but 
under basic or neutral conditions, migration occurs to produce 2-, 3- or 4-O-AGs.382,383 After 
migration, the acyl group is less prone to hydrolysis or transacylation, and stable 2-, 3- or 4-O-AGs 
can be isolated.384 Both the transacylation and the glycosylation pathways are capable of covalently 
modifying hepatic and plasma proteins in vivo, however, the resulting modified proteins (198 and 
200) have not been fully characterized.381 
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Scheme 73. Reactivity of glucuronides. a) Glucuronides of alcohol and phenolic drugs (196) are stable, whereas 
b) glucuronides of carboxylate drugs (197) may react directly with proteins via transacylation, or by initial acyl 
migration to produce 2-, 3- or 4-O-acyl glucuronides such as 199 (only shown for the 3 position), which can 
subsequently modifiy proteins by N-glycosylation. Evidence for the glycosylation pathway has been made by trapping 
experiments with a reducing agent like sodium cyanoborohydride.381 
 
Around 25% of all drugs withdrawn due to severe toxicity are carboxylic acid containing drugs,385-
387
 and one of the mechanisms underlying the observed toxicity of NSAIDs is believed to be the 
AG-derived covalent modification of endogenous proteins (Scheme 73b).388 Such protein 
modification might be associated with immune responses and cellular dysfunction, and acyl 
glucuronides constitute a major concern in drug discovery and development.381,388,389 Evidence for 
AG-induced toxicity is still lacking,379,381,389,390 but it has been shown that reversible binding of 
other compounds (like diazepam or warfarin) to plasma protein is severely altered, when plasma 
protein is modified by AGs.391  
 
AGs can be synthesized chemically in a number of ways. Classical approaches mainly rely on the 
coupling of fully protected glucuronic acids, which are typically produced in several steps from 
glucose392,393 or levoglucosan,394,395 to carboxylic acids under Mitsunobu conditions.396-398 In 1997 
Juteau and co-workers found that 6-O-allyl-D-glucuronate (201) could be conveniently coupled to 
carboxylic acids under Mitsunobu conditions without any other protective groups (Scheme 74),399 
however this strategy suffers from poor α/β-selectivity.383,400  
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Scheme 74. Synthesis of AGs under Mitsunobu conditions.399 
 
Very recently Stachulski and co-workers reported a selective acylation strategy, which exclusively 
produces acyl glucuronides as their β-anomers. In a three-step procedure HATU and NMM are used 
to couple partially protected glucuronic acids 202 to carboxylic acids to produce the desired AGs 
203 in good yield (Scheme 75).401,402  
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Scheme 75. Synthesis of 1-β-O-acyl glucuronides by selective acylation of allyl, benzyl or p-methoxybenzyl protected 
glucuronic acid 202.401,402
 
 
1-β-O-Acyl glucuronides 211-216 derived from p-bromobenzoic acid 205, ponalrestat 206 and four 
ibuprofen analogues 207-210 (Figure 8) were available in small quantities from the Stachulski 
group in Liverpool via the above mentioned acylation strategy (Scheme 75). p-Bromobenzoic acid 
(205) resembles a model NSAID, whereas ponalrestat (206) is a known aldose reductase inhibitor, 
which has been used in the treatment of diabetes.403-405 In contrast to (R)- and (S)-ibuprofen 
(208 and 209), which are used as an NSAID worldwide, ibufenac (207) was withdrawn from the 
U.K. market in 1968 due to hepatotoxicity.406 
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Figure 8. Available AGs (211-216) of carboxylate drugs and analogues (205-210) from the Stachulski group. 
 
As a result of the potential toxicity of acyl glucuronides, the assessment of the degree of protein 
modification by NSAID-derived acyl glucuronides is important in both drug monitoring and 
development. The objective of the present project is to investigate, if such drug-derived acyl 
glucuronide metabolites modify plasma protein under conditions encountered in therapy.  
 
6.2 Results and discussion 
6.2.1 Purification of HSA 
With plasma concentrations in the range of 30-50 g/L, human serum albumin (HSA) is the most 
abundant protein in blood plasma.407,408 It is monomeric and consists of 585 amino acids of which 
59 are lysines.409-411  HSA has a molecular mass of 66438 Da and the protein is held together by 
17 disulfides.409,412 The protein is produced in the liver, and it has several different roles such as 
buffering of pH and transport of various compounds in blood plasma.13,14  In addition to transport of 
drugs and other compounds in serum, HSA has been reported to participate in drug transport into 
the brain across the blood-brain barrier.413,414 It has also shown esterase activity and has been found 
to convert acetyl salicylic acid into salicylic acid, thereby increasing the activity of the drug.415  
 
The first objective of the project was to obtain HSA as a single protein species. Albumin isolated 
from humans contains several post-translational modifications of which glycosylation (lysines 199, 
281, 439 and 525),416-418 oxidation of Cys34 by binding to NO or a free cysteine, as well as loss of 
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Asp-Ala from the N-terminus and loss of Leu from the C-terminus are the most common.412 MS 
analysis of commercial HSA isolated from humans revealed an approximately 1:1 mixture of 
unmodified HSA and Cys34-cysteine modified HSA.♦ Separation of these by preparative HPLC 
proved very difficult. Some purification could be achieved, but it was very dependant on the 
amount of protein injected, and in most cases no purification was obtained. Instead, purification of 
the protein was achieved by reduction of the Cys34-cysteine disulfide bond with 1,4-dithiothreitol 
(DTT).419,420 The disulfides were reduced by treatment of commercial HSA with 13 mM DTT at 
pH 8. Excess reducing agent and free cysteine were removed by size-exclusion chromatography, 
and the protein was refolded420 in atmospheric air in the presence of 0.02 mM DTT. Refolding to a 
different secondary structure than the native HSA structure is not believed to occur.420 This 
purification process gave a single protein species contaminated with trace amounts of glycosylated 
and acetylated HSA. Attempts to perform the disulfide reduction on a large scale (500 mg) resulted 
in denaturation and precipitation of the protein, and only 5% of the reduced protein could be 
recovered. As a result, the DTT reduction was performed batch-wise on a smaller scale (50-100 mg) 
to minimize denaturation of the disulfide-reduced protein. Concentration of the protein solution was 
either achieved using Vivaspin or Amicon filtration. The latter method gave the best results, since 
protein material was lost by adhesion to the Vivaspin filter. When Amicon filtration was employed, 
more than 95% of the protein material could be recovered. 
 
6.2.2 Methods for modification of lysines 
The reactivity of acyl glucuronides is expected to be between an activated ester and an anhydride, 
and they are expected to react with amino groups of lysine residues by transacylation. Because of 
low availability of the acyl glucuronides 211-216, model studies with other lysine modifying 
reagents were performed.  
 
Several different techniques for modification of lysine residues exist. Some of the most widely used 
protein glycosylation methods are the direct reductive amination of an aldehyde and a lysine amino 
group with sodium cyanoborohydride,421 and the reaction of 2-imino-2-methoxyethyl 
thioglycosides (IME reagents, 217) with lysine amino groups.422 The sequential attack of a primary 
amine and a lysine residue on diethyl squarate423,424 as well as the reaction between a lysine amino 
group and acyl azides,425 mixed anhydrides426 or activated esters like N-hydroxysuccinimide esters 
                                                 
♦
 Protein solutions were analyzed by LC/MS and/or MALDI TOF MS (see section 9.2 for experimental details). 
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(NHS esters, 218),427 are all well-established methods for protein modification. Most of the above 
mentioned methods are applicable to protein glycosylation as well as modification with non-
carbohydrate substrates, but they are all unselective and the lysine residues are more or less 
randomly modified. To be able to obtain uniformly modified protein species, the development of 
site-selective protein modification techniques (mainly relying on the presence of a single cysteine 
residue) has received increasing interest in recent years.9,428-430  
 
Acyl glucuronides (204) are expected to react with lysine residues in a non-controlled manner, and 
the non-selective IME reagents 217 and NHS esters 218 were therefore chosen as model 
compounds to get a feel for the biochemical techniques before incubating the acyl glucuronides 
with HSA (Figure 9). 
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Figure 9. General structures of acyl glucuronides (204) and model compounds (217 and 218). 
 
6.2.3 Modification of HSA with IME reagents 
The IME reagents (217) were developed by Lee and co-workers422,431 more than 20 years ago. Since 
then IME reagents have been widely used to couple sugars to proteins,432,433 and the Davis group 
have shown their selectivity for lysine side chains on smaller peptides434 and used them for virus 
modification435 and drug delivery.436  
 
It was chosen to synthesize the D-galactose (Gal-) and N-acetyl-D-glucosamine (GlcNAc-) IME 
reagents 223 and 229, since Gal- and GlcNAc-modified proteins (the latter when converted into 
LacNAc) are suitable starting materials for enzymatic sialylation. Following the route developed by 
Stowell and Lee,431 Gal- and GlcNAc-IME reagents 223 and 229 were synthesized in five steps 
according to Scheme 76 and Scheme 77, respectively. 
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Scheme 76. Synthesis of Gal-IME (223) following the procedure developed by Stowell and Lee.431 
 
Peracetylation of D-galactose, introduction of bromine at the anomeric position and subsequent 
displacement of bromine by thiourea proceeded in excellent yield to give 221. Attachment of the 
cyanomethyl group occurred in 87% yield, and the final deprotection of 222 and nucleophilic attack 
by methoxide on the nitrile gave a 4:3 mixture of Gal-IME (223) and the corresponding 
deacetylated cyano-compound 224. Gal-IME 223 was thereby synthesized in 48% overall yield, and 
the mixture of 223 and 224 was used directly for the coupling reactions with HSA.  
 
Similarly, GlcNAc-IME 229 was synthesized in 19% overall yield (Scheme 77). The bromination 
of peracetylated N-acetyl-D-glucosamine (225) only occurred in 47% yield, which is probably due 
to loss of material during the workup, and a direct one-step acetylation and chlorination using 
acetylchloride might therefore be a more convenient approach. Displacement of bromine and 
introduction of the cyanomethyl group proceeded in good yield, and GlcNAc-IME 229 was formed 
as a 5:3 mixture with the corresponding deacetylated cyano-compound 230.  
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Scheme 77. Synthesis of GlcNAc-IME (229) following the procedure developed by Stowell and Lee.431 
 
When IME reagents are used for protein modification, hydrolysis by water is a competing side 
reaction, and the choice of pH is important to avoid hydrolysis of the coupling reagent. With 
smaller peptides, it was found that IME reagents are most reactive at pH > 9,434 and in order to 
remain close to physiological pH, HSA was incubated with the Gal- and GlcNAc-IME reagents 
223 and 229 at pH 9 (Table 26). 
 
Table 26. Modification of HSA with Gal- and GlcNAc-IME reagents 223 and 229. 
O
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pH 9, 16 h, 25 °C
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Average number of modifications Eq. per 
lysine 
clysine 
(mM)
 
Gal-IME GlcNAc-IME 
1 4 26.0 15.9 
2.5 4 37.4 26.4 
5 4 43.0 35.1 
16 4 48.9 44.9 
25 4 49.4 46.7 
16 29 50.3 47.5 
 
As can be seen in Figure 10, the degree of modification increases rapidly with the number of 
equivalents of IME reagent per lysine residue, and 45-50 lysines can easily be glycosylated by using 
a 16-25 fold excess of the IME reagent. However, with more than 45-50 modified lysines, the 
Rune Nygaard Monrad – Ph.D. Thesis 
108 
conversion cannot be further improved by increasing the number of equivalents or the lysine 
concentration. The protein is probably very crowded, and the remaining lysine side chains are 
therefore less reactive due to decreased surface availability. 
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Figure 10. Degree of HSA-modification with Gal- and GlcNAc-IME reagents 223 and 229 at pH 9 by varying the 
number of equivalents (see Table 26 for further details). 
 
After modification of HSA with the Gal-IME reagent 223, it was attempted to sialylate the modified 
protein by the use of various enzymes. Glycoproteins containing a terminal sialic acid residue as 
well as polysialylated cell surfaces are found in several mammals including humans.437,438 The 
protein bound, linear α(2,8)-polysialic acid polymer has been found to be up-regulated in leukemia 
and breast cancer cells,439 and polysialylated cells are receiving increased attention as potential 
markers in cancer diagnostics.440,441 As a result of this, the synthesis and structural investigation of 
polysialylated surfaces is an important research area.  
 
Gal-modified HSA 231 (76.4 kDa, 42.5 galactose units on average) was incubated with CMP-sialic 
acid and α(2,3)-SiaT442 at 37 ºC, but even though additional reagents were added, almost no 
conversion to 232 (approximately 5%) was achieved within 48 h (Scheme 78). The same result 
(<10% conversion) was obtained with two other sialylating enzymes, CstII and Trypanosoma cruzi 
(T. cruzi) transsialidase.443,444 α(2,3)-SiaT and CstII employ CMP-sialic acid as the glycosyl donor, 
whereas T. cruzi transsialidase transfers sialic acid from one protein to another. Sialic acid is 
thereby transferred to the desired carbohydrate from fetuin, which is a protein covered with 
Chapter 6 Interaction between plasma protein and acyl glucuronide drug metabolites  
109 
tetrasaccharides in which sialic acid is the terminal residue.444 The activity of both α(2,3)-SiaT and 
T. cruzi transsialidase was confirmed by simple sialylations of di- and tetrasaccharides in solution.♦ 
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HO
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Scheme 78. Attempted enzymatic sialylation of Gal-modified HSA 231. The enzymes α(2,3)-SiaT and CstII were used 
together with CMP-sialic acid, whereas T. cruzi transsialidase employed the protein fetuin as the sialic acid donor. Less 
than 10% conversion was achieved in each case. 
 
α(2,3)-SiaT and other sialyl transferases are usually inhibited by the liberation of CMP, and alkaline 
phosphatase442 can therefore be added to the reaction mixture to cleave CMP to phosphate and 
cytidine thereby pushing the reaction forward. Although no alkaline phosphatase was used in these 
enzymatic reactions, this is not the reason for the failed sialylations since the enzymes are usually 
not inhibited until a reasonable concentration of CMP is achieved. Because all three enzymes 
usually transfer sialic acid to LacNAc (as opposed to D-galactose), the low conversion might 
instead be explained by a high degree of substrate specificity. It may also simply be a matter of 
steric effects since the glycosyl acceptor is more flexible and available when it is bound to HSA as 
the disaccharide LacNAc.  
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Scheme 79. Attempted enzymatic synthesis of LacNAc-modified HSA from GlcNAc-modified HSA. Only 16% 
conversion could be achieved. 
 
Instead of coupling sialic acid to D-galactose, it was attempted to synthesize LacNAc-modified 
HSA 234 by attaching D-galactose to GlcNAc-modified HSA 233 (79.5 kDa, 47.5 N-acetyl-D-
glucosamine units on average) by using β(1,4)-GalT445 as shown in Scheme 79. The reaction was 
very slow, and addition of more β(1,4)-GalT as well as alkaline phosphatase to prevent UDP 
                                                 
♦
 The activity assays of (2,3)-SiaT, T. cruzi transsialidase and β(1,4)-GalT (the latter will be discussed below) were 
performed by Wei-Chun Liu, Sarah Allman and Sung You Hong, respectively. 
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inhibiting the galactosyltransferase did not improve the conversion, and only 16% conversion could 
be achieved within 48 h. The enzymatic synthesis of LacNAc-modified HSA 234 and subsequent 
sialylation would have been attempted more thoroughly, but due to lack of time, the focus was 
concentrated on the acyl glucuronide incubations, which will be discussed in section 6.2.5. 
 
6.2.4 Modification of HSA with NHS esters  
N-Hydroxysuccinimide activated esters (NHS esters, 218) are well-known to react with primary 
amines to produce amides with liberation of N-hydroxysuccinimide.446 NHS esters react readily 
with lysine residues in peptides447,448 and proteins,427 and they constitute a simple and convenient 
way to form amides in aqueous solution at physiological pH. The reactivity of NHS esters is 
expected to be similar to acyl glucuronides (transacylation), and the NHS esters are therefore 
believed to be a better AG model system than the IME reagents (217). p-Bromobenzoic acid (205) 
was chosen as a model NSAID, and p-bromobenzoic acid NHS ester 236 was synthesized by a 
DCC coupling446,449 between N-hydroxysuccinimide (235) and 205 in both DCM (81%) and DMF 
(94%) (Scheme 80). In DCM, column chromatography was required to remove the byproduct, 
dicyclohexylurea, whereas in DMF it could readily be removed by filtration. 
 
N
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O
HO
O
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OH +
R R
DCC
DMF, 25 °C
236: R = H     
238: R = SO3Na
94%
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235: R = H
237: R = SO3Na 205
 
Scheme 80. Synthesis of NHS esters by DCC coupling. 
 
Initial incubation of HSA with 50 equivalents of 236 per lysine showed that only a few lysines 
could be modified (Table 27, entries 1-5). As opposed to the IME reagents, a slightly acidic pH is 
optimal for NHS esters (Figure 11a). Hydrolysis of NHS esters is more facile under neutral or basic 
conditions, and as a result, no protein modification could be obtained at pH 9. In order to mimic 
physiological conditions (pH 7.4) and still get a reasonable degree of protein modification, pH 6 
was chosen for the remaining experiments. 
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Table 27. Modification of HSA with 236 at 5.0 mM lysine concentration. 
HSAN
O
O
O
O
Br
O
Br
HSA Lys
n
PBS buffer
16 h
236
 
 
Entry Eq. per lysine pH 
Temperature 
 (ºC) 
Average number 
of modifications 
1 50 9 25 0 
2 50 7.4 25 2.6 
3 50 6 25 4.3 
4 50 5 25 6.5 
5 50 4 25 5.5 
6 0.02 6 25 0.6 
7 1 6 25 2.0 
8 16 6 25 3.3 
9 1 6 37 3.0 
10 16 6 37 4.3 
11 50 6 37 10.7 
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Figure 11. Degree of HSA-modification with 236 by varying a) the pH and b) the number of equivalents (see Table 27 
for further details). 
 
As depicted in Figure 11b, the conversion does not improve significantly by increasing the number 
of equivalents. The low conversion might be a result of low solubility of 236 in aqueous solution, 
and to improve the solubility, 10-20% of DMSO, MeCN and DMF were used as co-solvents. 
However, HSA only tolerates small amounts of organic solvents and precipitation of the protein 
was observed. Instead, it was decided to synthesize a more water soluble coupling reagent thereby 
mimicking the high polarity of the acyl glucuronides and at the same time avoiding the use of co-
solvents. The sulfonated NHS ester 238 was therefore synthesized by a DCC coupling448 in 92% 
yield (Scheme 80).  
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Due to a greater solubility in aqueous solution, the sulfonated NHS ester 238 is more reactive than 
236, and a high degree of modification can be achieved with relatively few equivalents (Table 28). 
The degree of modification increases almost linearly with increasing equivalents (Figure 12a),♦ 
whereas a much smaller effect can be seen when varying the lysine concentration (Figure 12b).  
 
Table 28. Modification of HSA with 238 at pH 6. 
N
O
O
O
O
Br
238
NaO3S
HSA
O
Br
HSA Lys
n
PBS buffer
16 h
 
 
Entry Eq. per lysine 
clysine 
(mM) 
Temperature 
 (ºC) 
Average number 
of modifications 
1 0.02 5 25 1.4 
2 0.17 5 25 7.7 
3 0.51 5 25 22.0 
4 1 5 25 33.4 
5 50 5 25 precipitation 
6 0.17 1 25 6.6 
7 0.17 4 25 7.1 
8 0.17 9 25 8.2 
9 0.17 27 25 9.3 
10 0.17 5 37 7.5 
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Figure 12. Degree of HSA-modification with 238 at pH 6 by varying  a) the number of equivalents and b) the lysine 
concentrations (see Table 28 for further details). 
 
With more than one equivalent of 238 per lysine (Table 28, entry 5), the modified protein 
precipitates out during the reaction presumably as a result of the increasing number of hydrophobic 
                                                 
♦
 Note, the X-axis in Figure 12a has a different unit than in Figure 11b. 
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aromatic groups on the surface. The degree of protein modification with 236 and 238 seems to 
increase slightly when the temperature is increased from 25 to 37 ºC, however, the results are not 
unambiguous (compare Table 27, entries 7 and 9, 8 and 10, 3 and 11 and Table 28, entries 2 and 
10). 
 
To map the sites of modification, the modified HSA was digested with trypsin and the resulting 
tryptic peptides were analyzed by LC-coupled MS/MS analysis. Two lysines (Lys137 and Lys212) 
could be identified as selective sites for modification with 236 (see Appendix III for further details). 
 
6.2.5 Incubation of HSA with acyl glucuronides  
After the successful reaction of HSA with the sulfonated NHS ester 238 using a relatively low 
number of equivalents, the six drug-derived acyl glucuronides 211-216 (Figure 8) were incubated 
with HSA. The incubations of AGs with HSA were performed at 37 ºC in phosphate buffered saline 
at pH 7.4, and the concentration of HSA was chosen to be within the level of albumin in human 
serum (33 g/L).407 AGs are generally thought to be rapidly excreted, but substantial plasma 
concentrations, sometimes exceeding their parent drug, are often found.450,451 In order to mimic 
conditions encountered in therapy, an AG concentration of 0.5 mM resembling the peak plasma 
concentration of drug achieved in chronic cystic fibrosis patients treated with ibuprofen was used.452 
In addition, high-concentration experiments using 5.0 mM of AG were also performed. The results 
of the incubations of acyl glucuronides 211-216 with HSA are shown in Table 29 (see Scheme 73b 
for a generalized reaction scheme).  
 
In the case of the acyl glucuronide of p-bromobenzoic acid (211), a N-glycosylation adduct was 
observed (together with unmodified HSA) at both 0.5 and 5.0 mM of AG in 58 and 59% conversion, 
respectively (Table 29, entries 1 and 2).♦ Incubation of D-glucuronic acid with HSA as a control 
experiment gave no conversion under identical conditions. Although HSA is not modified by 
D-glucuronic acid alone, acyl glucuronides are sufficiently activated to cause extensive protein 
modification as shown in Table 29.  
 
                                                 
♦
 The observed mass of the glycosylation adduct of 211 and HSA (found 66798, expected 66797) could in principle be 
a result of double transacylation (expected 66804). However, this is very unlikely since no adducts corresponding to 
single or triple transacylation could be observed. 
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Previously, evidence for the formation of such N-glycosylation adducts from proteins and AGs have 
only been achieved by trapping the adducts with a reducing agent like sodium cyanoborohydride 
(reduction of the formed imine),383,391,453 or at very high concentrations of the AG compared to the 
protein.383,453,454 As a result, this is the first time a stable glycosylation adduct has been isolated in 
vitro under conditions encountered in therapy. The formation of stable glycosylation adducts in the 
absence of a reducing agent was surprising, but the high conversion even at 0.5 mM clearly indicates 
that irreversible glycosylation of endogenous proteins can occur during treatment with AG 
metabolizing drugs. 
 
Table 29. Selectivity and conversion after incubation of HSA with AGs. 
Entry AG Concentration (mM) 
Selectivity 
(Transacylation/ 
Glycosylation) 
Conversion 
(%) 
1 211 0.5 <5:95 58 
2 211 5.0 <5:95 59 
3 212 0.5 55:45 4 
4 212 5.0 72:28 24 
5 213 0.5 60:40 16 
6 213 5.0 61:39 44 
7 214 0.5 64:36 5 
8 214 5.0 63:37 23 
9 215 0.5 44:56 9 
10 215 5.0 55:45 24 
11 216 0.5 - 0 
12 216 5.0 34:66 8 
Incubation of HSA (33 g/L) with  AGs 211-216 for 16 h at 37 °C 
and pH 7.4. Selectivities between the transacylation and glycosylation products 
and conversions (% modified HSA) are based on peak heights in respective 
deconvoluted mass spectra. 
 
As mentioned earlier, the acyl group of 2-, 3- or 4-O-acyl glucuronides is less prone to direct 
hydrolysis or displacement by nucleophiles as well as further migration due to the lack of a 
neighboring electron withdrawing ring oxygen.388 Since the migration is catalyzed more readily by 
base than acid, it was attempted to perform the incubation of 211 with HSA at pH 6 to observe 
whether the acyl migration pathway was suppressed or not. As expected, the glycosylation was in 
fact inhibited, and no glycosylation occurred, however, no transacylation occurred either 
(0% conversion).  
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Transacylation Glycosylation AG Found (Da) Expected (Da) Found (Da) Expected (Da) 
213 66610 66612 66787 66788 
214 66627 66626 66802 66802 
215 66625 66626 66801 66802 
216 66635 66640 66813 66816 
 
   
 
 
Figure 13. Mass spectra (LC/MS) of HSA (33 g/L) incubated with ibuprofen analoques 213-216 at 5.0 mM for 16 h at 
37 ºC and pH 7.4. Unmodified HSA is the major peak in all cases (found 66440, 66442, 66439 and 66439 Da; 
expected 66438 Da). 
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With the acyl glucuronide of ponalrestat (212), only 5.0 mM AG concentration (Table 29, entry 4) 
led to formation of adducts (24% conversion). In this case both transacylation and glycosylation 
could be observed in a 72:28 ratio. The ibuprofen analogues (entries 5-12) also gave mixtures of 
transacylation and glycosylation adducts,♦ and the degree of modification can be visualized in the 
combined mass spectrum of 213-216 (Figure 13).  
 
Ibufenac, (R)- and (S)-ibuprofen AGs (213-215) are reasonably reactive with conversions of 44, 23 
and 24% respectively, whereas the dimethyl analogue 216 (only 8% conversion) is much less 
reactive (Table 29, entries 6, 8, 10 and 12). In addition to the individual transacylation and 
glycosylation adducts, small amounts of dual adducts (produced by simultaneous transacylation and 
glycosylation) could be observed for 212-215. The type (transacylation or glycosylation) and site of 
modification was further analyzed by tryptic digest followed by MS/MS analysis (Table 30).  
 
In the case of incubation of HSA with ibufenac AG 213, seven different lysines were found to be 
modified (Table 30).♦♦ As expected from the data in Table 29, both transacylation (lysines 195, 
436, 525 and 534) and glycosylation (lysines 137, 199, 205, 525) were observed. (For a sequence 
map of HSA, see Figure 14 in Appendix II). Lys525 is the only residue, which exhibits both 
transacylation and glycosylation reactivity. The dual reactivity of this residue is in accordance with 
previously reported results, stating that Lys525 is one of the major non-enzymatic glycosylation 
sites of HSA responsible for approximately 33% of overall non-enzymatic glycosylation in 
vivo.416,417 In order to investigate the correlation between modification sites and accessibility, 
relative solvent accessibilities for each individual amino acid residue were calculated using the 
computer program Naccess.455 However, a direct correlation between AG-modification site and 
calculated accessibility could not be found. (For a thorough discussion of surface accessibilities and 
site of modification, see Appendix II). 
 
                                                 
♦
 The observed mass of the N-glycosylation adduct of ibufenac AG 213 (observed 66787, expected 66788) could in 
principle be a result of double transacylation (expected 66786). However, the observed dual reactivity of the 
structurally similar ponalrestat AG 212 (72:28 ratio) as well as the presence of both transacylation and N-glycosylation 
adducts in the MS/MS analysis of tryptic peptides from ibufenac-modified HSA (see Table 30) renders double 
transacylation in place of glycosylation extremely unlikely. 
♦♦
 Data for tryptic peptides of HSA modified with 211 and 212 can be found in Appendix III. 
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Table 30. Tryptic peptides of HSA modified with ibufenac AG 213. 
Retention 
time (min) 
m/z 
predicted 
m/z 
observed Residues Sequence 
Modified 
lysine Modification 
33.49 704.1 704.1 137 – 144 K(+)YLYEIAR K-137 Glycosylation 
24.36 921.8 921.4 191 – 197 ASSAK(+)QR K-195 Transacylation 
27.80 621.6 621.6 198 – 205 LK(+)CASLQK K-199 Glycosylation 
27.80 621.6 621.6 198 – 205 LKCASLQK(+) K-205 Glycosylation 
24.16 450.5 451.2 433 – 439 VGSK(+)CCK K-436 Transacylation 
22.07 652.7 651.4 525 – 534 K(+)QTALVELVK K-525 Transacylation 
18.86 740.7 741.1 525 – 534 K(+)QTALVELVK K-525 Glycosylation 
22.07 652.7 651.4 525 – 534 KQTALVELVK(+) K-534 Transacylation 
Modified protein was hydrolyzed with trypsin followed by LC-coupled MS/MS analysis. The amino acid 
sequence of HSA was derived from the RCSB protein data bank:  DOI 10.2210/pdb1bm0/pdb.411 Residues are 
numbered for this sequence of 585 amino acids. 
 
Based on the results in Table 29, it can be concluded that in all cases except p-bromobenzoic acid 
AG 211, the amount of adduct formed is considerably lower than unmodified HSA indicating a 
much lower reactivity of alkyl as compared to aryl AGs. Furthermore, both the nature and extent of 
protein modification with alkyl AGs are highly dependant on the degree of α-substitution. When the 
α-substitution is varied from unsubstituted (212 and 213) through monosubstituted (214 and 215) to 
disubstituted AGs (216), the preference for formation of transacylation adducts slowly changes to a 
preference for glycosylation. This is in fact a logical observation, because a higher degree of 
α-substitution constitutes an increased steric hindrance disfavoring direct displacement following 
the transacylation pathway. Acyl migration, on the other hand, is not affected by increased 
α-substitution to the same extent, and glycosylation adducts are therefore predominantly formed for 
highly α-substituted AGs like the dimethyl analogue 216 (Table 29, entry 12). In addition to the 
different type of reactivity (transacylation or glycosylation), alkyl AGs with no α-substitution are 
more reactive than mono- and disubstituted alkyl AGs, and AGs of drugs without α-substitution are 
therefore more likely to modify endogenous proteins in vivo than AGs of α-substituted drugs. The 
observed reactivity of alkyl AGs with respect to α-substitution is also reflected in their half-lives. 
Half-lives of less than 1 h for unsubstituted (zomepirac 0.45 h, diclofenac 0.51 h), 1-4 h for 
monosubstituted ((S)-naproxen 1.8 h, (S)-ibuprofen 3.3 h) and from 7 to more than 40 h for 
disubstituted (clofibric acid 7.3 h, gemfibril 44 h) alkyl AGs have previously been found.381 As 
indicated by short half-lives (probenecid 0.40 h, diflunisal 0.67 h)381 and supported by the reactivity 
of 211, aryl AGs are very reactive with respect to protein modification, but they seem to be too 
hindered for transacylation to occur, and glycosylation adducts are therefore formed exclusively. 
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6.3 Concluding remarks 
In the present study, HSA has initially been modified by the well-known IME reagents (223 and 
229) and NHS esters (236 and 238). The dependency of pH, the number of equivalents of the 
coupling reagent, the lysine concentration and the temperature has been determined for the NHS 
esters. The techniques have been used to incubate 1-β-O-acyl glucuronides 211-216 with HSA to 
investigate the reactivity of phase II metabolites of NSAIDs with respect to potential modification 
of plasma protein in humans. For the first time, it has been found that aryl 1-β-O-acyl glucuronides 
form stable glycosylation adducts with HSA at conditions encountered in therapy. In contrast to aryl 
AGs, alkyl AGs, which are slightly less reactive, exhibit both transacylation and glycosylation 
reactivity. A rationalization of AG-reactivity based on structure has been established, and this may 
become a useful tool for development of new carboxylic acid containing drugs as well as in 
monitoring and assessment of potential toxicity of existing drugs. The increased reactivity of 
ibufenac AG 213 compared to (R)- and (S)-ibuprofen AGs 214 and 215 due to the lacking α-methyl 
substituent is striking, when keeping in mind that hepatotoxicity led to withdrawal of ibufenac (207) 
from the U.K. market 40 years ago and (R)- and (S)-ibuprofen (208 and 209) are still extensively 
used. The current work strongly supports that AG-induced modification of plasma protein during 
treatment with carboxylic acid containing drugs is likely to take place thereby potentially initiating 
adverse drug reactions. 
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7 General concluding remarks 
The importance of carbohydrates in glycobiology, as chiral building blocks in organic chemistry, 
and as renewable resources cannot be over-emphasized. The investigation of their roles in 
biological processes and the development of new synthetic methodologies, which can be applied to 
carbohydrates are therefore key research areas for understanding and utilizing nature’s most 
abundant biomolecules in chemistry, biology and medicine. The present research has dealt with 
different areas of carbohydrate chemistry mainly focusing on the development and application of 
transition metal mediated transformations for shortening and extending the carbohydrate chain. 
 
A new rhodium-catalyzed procedure for shortening unprotected aldoses by one carbon atom has 
been developed. Aldoses are decarbonylated to their corresponding shortened alditols by employing 
Rh(dppp)2Cl as the catalyst. The developed catalytic decarbonylation reaction is an improvement of 
a previously reported stoichiometric procedure, and it constitutes an interesting alternative to 
classical methods for shortening unprotected carbohydrates. The general applicability of the 
procedure has been illustrated by a concise synthesis of the unnatural sugar L-threose in 74% 
overall yield in five steps from D-glucose. At present, the method is limited to aldoses, and more 
challenging substrates like uronic acid lactones and unprotected cyclodextrins led to disappointing 
results. Initially, the rhodium-catalyzed decarbonylation of carbohydrates was envisioned to be 
potentially relevant to the production of hydrogen from renewable resources, but the catalyst is not 
yet efficient enough for such applications. 
 
Carbocyclic natural products often possess interesting biological activities, which make them 
potential pharmaceutical lead compounds. A zinc-mediated fragmentation-allylation sequence has 
been used to elongate D-glucose and D-ribose by three carbon atoms, and by subsequent ring-
closing metathesis, they have been converted into the carbocyclic natural products calystegine A3 
and gabosine A. The synthesis of the glycosidase inhibitor calystegine A3 constitutes the shortest 
enantioselective route to the natural product, and it firmly establishes the absolute configuration of 
naturally occurring calystegine A3. The synthetic route to gabosine A represents the first synthesis 
from a carbohydrate precursor. Together with previous syntheses of carbocyclic natural products 
developed in the group, the present syntheses of calystegine A3 and gabosine A illustrate that such 
compounds are conveniently synthesized from carbohydrates. 
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During an external stay at University of Oxford, the metabolism of NSAIDs has been investigated. 
Carboxylate drugs like NSAIDs are extensively metabolized to 1-β-O-acyl glucuronides, and it has 
been found that such metabolites are highly reactive and may lead to potentially toxic protein 
adducts in man. By incubation of human serum albumin with acyl glucuronides of several ibuprofen 
analogues, it has been found that transacylation and glycosylation adducts are formed. The product 
ratios and the degree of protein modification can be rationalized by the degree of α-substitution in 
the acyl group, and this information may provide a useful tool in the monitoring, interpretation and 
assessment of the potential toxicity of existing carboxylic acid containing drugs. 
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8 Experimental work performed at DTU 
 
8.1 General experimental methods 
Diglyme, DMA and pyridine were distilled before use. DCM was dried by distillation from CaH2 
while MeOH and DMF were dried over 4 Å molecular sieves. All reagents were obtained from 
commercial sources and used without further purification. All sonications were performed in a 
Branson 1210 sonic bath. For reproducibility, sonications were performed in flat-bottomed conical 
flasks using 2% liquid detergent in water as bath media.456 Reactions were monitored by TLC using 
aluminum plates precoated with 0.25 mm silica gel 60. Compounds were visualized by dipping in a 
solution of (NH4)6Mo7O24 • 4H2O (25 g/L) and Ce(SO4)2 (10 g/L) in 10% aqueous H2SO4 followed 
by heating. Flash column chromatography was performed on silica gel 60 (particle size 0.035 – 
0.070 mm). Machery-Nagel Silica gel 60 C18 (particle size 0.055 – 0.105 mm) was used for reverse 
phase column chromatography. NMR spectra were recorded on a Varian Mercury 300 instrument. 
Chemical shifts (δ) are given in ppm employing residual solvent peaks as internal references 
according to literature.457 High resolution mass spectra were recorded at the Department of Physics 
and Chemistry, University of Southern Denmark. Microanalyses were performed at the 
Mikroanalytisches Laboratorium at Universität Wien. Optical rotations were measured on a Perkin-
Elmer 241 polarimeter while IR spectra were recorded on a Bruker Alpha FT-IR spectrometer. IR 
absorptions are given in cm-1. Melting points are uncorrected. 
 
 
8.2 Compounds referred to in chapter 3 
 
Rhodium(I)bis(cyclooctene)chloride 
Following a literature procedure,254 degassed solutions of 2-propanol (50 mL), H2O (12 mL) and 
cyclooctene (8.6 mL, 67 mmol) were added to RhCl3 • 3H2O (2.52 g, 9.55 mmol) under an argon 
atmosphere. The suspension was stirred at room temperature for 20 min and then left without 
stirring for 15 days under an argon atmosphere. The reaction mixture was filtered, and the crystals 
were washed with EtOH (150 mL) and dried in vacuo to give orange-red crystals (2.95 g). 
Additional crystals (0.19 g) could be obtained by further crystallization of the remaining liquids 
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followed by filtration, washing with EtOH and drying in vacuo. This gave Rh(COE)2Cl (3.14 g, 
92%) as orange-red crystals. IR (KBr): 3448, 3000, 2977, 2920, 2845, 1465, 1448, 1355, 952, 899. 
 
Rhodium(I)bis(1,3-diphenylphosphinopropane)chloride 
Following a modified literature procedure,253 a suspension of Rh(COE)2Cl (2.95 g, 8.2 mmol) and 
dppp (7.80 g, 18.9 mmol) in freshly distilled toluene (150 mL) was thoroughly degassed under high 
vacuum and then stirred under an argon atmosphere at reflux for 1.5 h. The solution was cooled to 
room temperature, and the reaction mixture was filtered. The solids were washed with toluene (150 
mL) and dried in vacuo to give Rh(dppp)2Cl (7.83 g, 99%) as yellow crystals. IR (KBr): 3410, 
3047, 2909, 2848, 1477, 1433, 1095, 743, 700, 652. 
 
Rhodium(I)bis(BINAP)chloride 
A suspension of Rh(COE)2Cl (108 mg, 0.30 mmol) and rac-BINAP (467 mg, 0.75 mmol) in freshly 
distilled toluene (10 mL) was thoroughly degassed under high vacuum and then stirred under a 
nitrogen atmosphere at reflux for 1 h. The solution was cooled to room temperature, and the 
reaction mixture was filtered. The solids were washed with toluene (20 mL) and dried in vacuo to 
give Rh(BINAP)2Cl (343 mg, 82%) as pale, brown crystals. IR (KBr): 3447, 3050, 1481, 1434, 
1116, 818, 740, 695. 
 
General procedures for decarbonylation of unprotected aldoses 
General decarbonylation procedure A: To the aldose (400-650 mg, 2.78 mmol) were added 
Rh(dppp)2Cl (267 mg, 0.28 mmol), DMA (3 mL) and diglyme (20 mL). The mixture was 
thoroughly degassed under high vacuum and then stirred at reflux (162 ºC) under a nitrogen 
atmosphere until TLC showed full conversion to the corresponding alditol (8-16 h). The solution 
was cooled to room temperature followed by addition of H2O (50 mL). The mixture was washed 
with DCM (4 × 50 mL) and the combined organic phases were extracted with H2O (2 × 10 mL). 
The combined aqueous phases were concentrated and the residue co-concentrated with EtOH. The 
resulting residue was purified by either flash column chromatography (DCM/MeOH/H2O = 4:1:0 – 
65:25:4) or reverse phase column chromatography (H2O). 
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General decarbonylation procedure B: To the aldose (400-650 mg, 2.78 mmol) were added 
Rh(dppp)2Cl (214 mg, 0.22 mmol), DMA (3 mL), diglyme (20 mL) and freshly distilled pyridine 
(14.5 µL, 0.18 mmol). The mixture was thoroughly degassed under high vacuum and then stirred at 
reflux (162 ºC) under a nitrogen atmosphere until TLC showed full conversion to the corresponding 
alditol (6-15 h). The solution was cooled to room temperature and the product was isolated as 
described in general decarbonylation procedure A. 
 
General procedure for measurement of CO evolution: A flask containing aldose (2.78 mmol), 
Rh(dppp)2Cl (0.14 – 0.28 mmol), pyridine (0 – 0.14 mmol), diglyme (20 mL) and DMA (3 mL) 
was equipped with a condenser connected to a burette filled with water. The bottom of the burette 
was further connected to a water reservoir with a large surface area. A three-way valve was placed 
between the condenser and the burette enabling evacuation and purge with nitrogen. The reaction 
mixture was thoroughly degassed and then stirred at reflux (162 ºC) in a preheated oil bath. The 
measurement of developing carbon monoxide was started 15 min after the reaction flask was placed 
in the oil bath. The amount of carbon monoxide produced was measured as the amount of water 
depleted from the burette. At room temperature (25 ºC), full conversion of the aldose corresponds to 
formation of 68 mL of carbon monoxide. 
 
Attempted decarbonylation of D-glucose using in situ generated Rh(dppp)2Cl 
Following the literature procedure for decarbonylation of simple aldehydes,236 a mixture of RhCl3 • 
3H2O (15 mg, 0.06 mmol), dppp (47-59 mg, 0.12-0.15 mmol), diglyme (10 mL) and 
phenylacetaldehyde (14 µL, 0.12 mmol) was thoroughly degassed under high vacuum and heated to 
reflux (162 ºC). The solution quickly turned yellow and homogeneous. A degassed solution of D-
glucose (100 mg, 0.56 mmol) in DMA (1 mL) was added to the reaction mixture after 20 min at 
reflux. The color of the reaction mixture slowly changed from yellow-orange to black. The reaction 
was followed by TLC analysis but only traces of D-arabinitol were formed within 16 h. 
 
Decarbonylation of D-glucose using crude Rh(dppp)2Cl239  
RhCl3 • 3H2O (73 mg, 0.28 mmol), dppp (229 mg, 0.56 mmol) and EtOH (96 % aq., 12 mL) were 
mixed, and the solution was thoroughly degassed under high vacuum and then stirred at reflux 
under a nitrogen atmosphere for 30 min. The reaction mixture was cooled to room temperature and 
the solvent was removed under high vacuum to give fine yellow-orange crystals. IR (KBr): 3448, 
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3052, 2917, 2168 (weak), 1483, 1434, 1097, 742, 696, 647. The crude Rh(dppp)2Cl was used 
directly for decarbonylation of D-glucose. To the crude product were added phenylacetaldehyde (46 
µL, 0.42 mmol) and diglyme (20 mL), and the solution was thoroughly degassed under high 
vacuum. The solution was heated to reflux under a nitrogen atmosphere and after 20 min, a 
degassed solution of D-glucose (500 mg, 2.78 mmol) dissolved in DMA (3 mL) was added. After 3 
h at reflux, the reaction mixture was cooled to room temperature, diluted with H2O (20 mL), and 
washed with DCM (5 x 30 mL). The aqueous phase was co-concentrated with EtOH, and the 
residue was purified by flash column chromatography (DCM/MeOH/H2O = 65:25:4) to give D-
arabinitol (39 mg, 9%) as a colorless oil. Spectroscopic data are given below. 
 
When crude Rh(dppp)2Cl was used for decarbonylation of benzaldehyde according to the procedure 
developed by Esben Taarning,239 a crystalline metal complex could be isolated after the reaction 
and an IR-spectrum of the crystals was recorded. IR (KBr): 3421, 3043, 2938, 2101 (strong), 1971 
(strong), 1718 (strong), 1434, 1270, 1097, 752, 703. 
 
D-Arabinitol  
HO
OH
OH
OH
OH
 
White crystals. Rf 0.49 (acetone/BuOH/H2O = 5:4:1). [α]22D  –10.3 (c 0.2, MeOH) (lit.458 [α]19D  –12 
(c 1, MeOH)). mp 98 – 99 ºC (MeOH) (lit.459 mp 101 – 102 ºC (EtOH)). 1H NMR (300 MHz, D2O): 
δ 3.86 (ddd, J = 2.0, 5.3, 7.3 Hz, 1H), 3.77 (dd, J = 2.7, 11.5 Hz, 1H), 3.68 (ddd, J = 2.7, 6.2, 8.8 
Hz, 1H), 3.58 (m, 3H), 3.50 (dd, J = 2.0, 8.3 Hz, 1H). 13C NMR (75 MHz, D2O): δ 72.3, 71.8, 71.7, 
64.5, 64.4. NMR data are in accordance with literature values.460,461 Anal. calcd for C5H12O5: C, 
39.47; H, 7.95. Found: C, 39.55; H, 7.65. 
  
1,4-Anhydro-D-arabinitol (95) and 2,3,5-tri-O-acetyl-1,4-anhydro-D-arabinitol (239) 
O
OHHO
OH
O
OAcAcO
OAc
and
95 239
 
1,4-Anhydro-D-arabinitol (95) was isolated as a byproduct from decarbonylation of D-glucose or D-
mannose as a slightly yellow oil. Rf 0.68 (acetone/BuOH/H2O = 5:4:1). 13C NMR (75 MHz, D2O): δ 
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86.5, 78.9, 77.8, 73.8, 62.6. 13C NMR data are in accordance with literature values.461 The anhydro 
compound 95 was peracetylated462 by addition of freshly distilled pyridine, acetic anhydride and a 
catalytic amount of DMAP followed by stirring at room temperature under an argon atmosphere 
overnight. The solvent was removed in vacuo and the residue was purified by flash column 
chromatography (EtOAc/heptane = 1:9 – 1:4) to give 239 as a slightly yellow oil. Rf 0.14 
(EtOAc/heptane = 1:4). [α]25D  +13.7 (c 0.5, MeOH). 1H NMR (300 MHz, D2O): δ 5.27-5.24 (m, 
1H), 5.08 (d, J = 3.7 Hz, 1H), 4.40-4.06 (m, 5H), 2.12 (s, 3H), 2.11 (s, 6H). 13C NMR (75 MHz, 
D2O): δ 174.0, 173.1, 173.1, 81.5, 78.1, 77.9, 71.6, 63.6, 20.5, 20.3, 20.3. NMR data are in 
accordance with literature values.463 Anal. calcd for C11H16O7: C, 50.77; H, 6.20. Found: C, 50.59; 
H, 6.34. 
 
1,4-Anhydro-D-lyxitol (96) and D-galactono-1,4-lactone (97) 
O
OHHO
OH
O
OH
O
HO
HO
HOand
96 97
 
An inseparable 3:4 mixture of 96 and 97 was isolated in 34% combined yield as byproducts from 
decarbonylation of D-galactose. Rf 0.68 (acetone/BuOH/H2O = 5:4:1). 13C NMR (75 MHz, D2O): 
96: δ 81.6, 72.1, 72.1, 71.8, 61.3; 97: δ 172.7, 80.5, 74.9, 73.8, 69.6, 62.9. 13C NMR data are in 
accordance with literature values.461 
 
Erythritol 
OH
OH
OH
OH
 
White crystals. Rf 0.47 (acetone/BuOH/H2O = 5:4:1). mp 116 – 117 ºC (MeOH/heptane) (lit.464 mp 
120 – 121 ºC). 1H NMR (300 MHz, D2O): δ 3.74-3.65 (m, 2H), 3.62-3.49 (m, 4H). 13C NMR (75 
MHz, D2O): δ 73.3, 64.0. 13C NMR data are in accordance with literature values.461 Anal. calcd for 
C4H10O4: C, 39.34; H, 8.25. Found: C, 39.05; H, 8.00. 
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D-Threitol  
HO
OH
OH
OH
 
White crystals. Rf 0.52 (acetone/BuOH/H2O = 5:4:1). [α]22D  –7.5 (c 0.5, MeOH) (lit.465 [α]23D  –7.0 (c 
0.9, MeOH)). mp 89 – 91 ºC (MeOH) (lit.466 mp 90 – 91 ºC (BuOH)). 1H NMR (300 MHz, D2O): δ 
3.69-3.51 (m, 6H). 13C NMR (75 MHz, D2O): δ 72.9, 63.9. NMR data are in accordance with 
literature values.460,461 Anal. calcd for C4H10O4: C, 39.34; H, 8.25. Found: C, 39.19; H, 8.05. 
 
1,4-Anhydro-D-threitol (98) and 2,3-di-O-benzoyl-1,4-anhydro-D-threitol (240) 
O
OHHO
O
OBzBzO
and
98 240
 
1,4-Anhydro-D-threitol (98) was isolated as a byproduct from decarbonylation of D-xylose as a 
slightly yellow oil. Rf 0.76 (acetone/BuOH/H2O = 5:4:1), 1H NMR (300 MHz, D2O): δ 4.24 (d, J = 
3.5 Hz, 2H), 4.00 (dd, J = 3.5, 10.5 Hz, 2H), 3.74 (d, J = 10.4 Hz, 2H). 13C NMR (75 MHz, D2O): 
δ 77.2, 73.8. 13C NMR data are in accordance with literature values.461 The anhydro compound 98 
was cooled to 0 ºC and perbenzoylated by addition of freshly distilled pyridine and benzoylchloride 
followed by stirring at room temperature under an argon atmosphere overnight. The reaction was 
quenched by addition of EtOH, diluted with DCM and washed with sat. aq. NaHCO3 and brine. The 
organic phase was dried (MgSO4), filtered and concentrated in vacuo to give a residue, which was 
purified by flash column chromatography (EtOAc/heptane = 1:9 → 2:8) to afford 240 as a white 
crystalline material. Rf 0.31 (EtOAc/heptane = 1:4). 1H NMR (300 MHz, CD3OD): δ 8.06-7.98 (m, 
4H), 7.58-7.48 (m, 2H), 7.46-7.36 (m, 4H), 5.54 (d, J = 4.2 Hz, 2H), 4.27 (dd, J = 4.3, 10.6 Hz, 
2H), 3.97 (d, J = 10.7 Hz, 2H). 13C NMR (75 MHz, CD3OD): δ 166.9, 134.6, 131.7, 129.6, 79.2, 
72.8. m/z (ESI+)  C18H16O5 190 ([M – C6H5CO2H]). 
 
5-Deoxy-L-arabinitol 
OH
HO
HO
OH
 
Colorless syrup. Rf 0.68 (acetone/BuOH/H2O = 5:4:1). [α]22D  +11.7 (c 3.8, MeOH). [α]22D  +13.1 (c 
0.5, H2O) (reported for the enantiomer467 [α]23D  –10.6 (H2O)). 1H NMR (300 MHz, D2O): δ 3.85-
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3.74 (m, 2H), 3.64-3.53 (m, 2H), 3.38-3.28 (m, 1H), 1.17 (d, J = 6.4 Hz, 3H). 13C NMR (75 MHz, 
D2O): δ 74.6, 70.7, 67.1, 63.1, 18.3. NMR data are in accordance with literature values.249 Anal. 
calcd for C5H12O4: C, 44.11; H, 8.88. Found: C, 43.85; H, 8.59. 
 
1,4-Anhydro-5-deoxy-L-arabinitol (99)  
and 2,3-di-O-acetyl-1,4-anhydro-5-deoxy-L-arabinitol (241) 
O
OHHO
O
OAcAcO
and
99 241
 
1,4-Anhydro-5-deoxy-L-arabinitol (99) was formed as a byproduct from decarbonylation of L-
rhamnose. Rf 0.76 (acetone/BuOH/H2O = 5:4:1). 13C NMR (75 MHz, D2O): δ 82.6, 81.6, 77.6, 72.7, 
18.1. The anhydro compound 99 was peracetylated462 by addition of freshly distilled pyridine, 
acetic anhydride and a catalytic amount of DMAP followed by stirring at room temperature under 
an argon atmosphere overnight. The solvent was removed in vacuo and the residue was purified by 
flash column chromatography (EtOAc/heptane = 1:9 – 1:4) to afford 241 as a colorless oil. Rf 0.17 
(EtOAc/heptane = 1:4). 1H NMR (300 MHz, CDCl3): δ 5.13 (dt, J = 1.6, 4.4 Hz, 1H), 4.85 (d, J = 
3.4 Hz, 1H), 4.05-3.84 (s, 3H), 2.09 (s, 6H), 1.38 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 170.4, 
170.2, 82.4, 80.2, 78.7, 71.8, 21.1, 21.0, 18.6. HRMS calcd for C9H14O5Na [M + Na]+ m/z 
225.0739, found m/z 225.0733. 
 
1-Acetylamino-1-deoxy-D-arabinitol (100) 
HO
OH
OH
NHAc
OH
100
 
White crystals. Rf 0.49 (acetone/BuOH/H2O = 5:4:1). [α]22D  +23.5 (c 0.5, H2O) (lit.468 [α]23D  +23 
(H2O)). mp 142 – 143 ºC (MeOH) (lit.468 mp 146.5 – 147.5 ºC). 1H NMR (300 MHz, D2O): δ 3.81 
(t, J = 6.7 Hz, 1H), 3.67 (dd, J = 2.6, 11.4 Hz, 1H), 3.57 (ddd, J = 4.4, 7.8, 7.7 Hz, 1H), 3.48 (dd, J 
= 6.2, 11.5 Hz, 1H), 3.32 (d, J = 8.5 Hz, 1H), 3.25-3.11 (m, 2H), 1.85 (s, 3H). 13C NMR (75 MHz, 
D2O): δ 175.4, 71.7, 71.7, 69.1, 63.9, 43.3, 22.8. NMR data are in accordance with literature 
values.249 Anal. calcd for C7H15NO5: C, 43.52; H, 7.83; N, 7.25. Found: C, 43.67; H, 7.56; N, 7.18. 
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D-Lyxono-1,4-lactone (102) 
O
OH
O
HO
HO
102
 
Following general decarbonylation procedure A, D-glucurono-6,3-lactone (101) (489 mg, 2.78 
mmol) was decarbonylated. The solution turned black within 45 min. Based on TLC analysis and 
the amount of carbon monoxide developed, full conversion was achieved within 2.5 h. Workup and 
flash column chromatography (DCM/MeOH = 4:1) gave 102 (58 mg, 14%) as a colorless oil. Rf 
0.75 (acetone/BuOH/H2O = 5:4:1). 1H NMR (300 MHz, D2O): δ 4.72-4.68 (m, 1H), 4.62-4.56 (m, 
1H), 4.55-4.51 (m, 1H), 3.90-3.85 (m, 2H). 13C NMR (75 MHz, D2O): δ 179.0, 82.4, 71.3, 70.3, 
60.6. 13C NMR data are in accordance with literature values.461  
 
L-Gulono-1,4-lactone (103) 
O
OH
O
HO
HO
HO
103
 
L-Gulono-1,4-lactone (103) was isolated as a byproduct from decarbonylation of D-glucurono-6,3-
lactone (101) (25 mg, 5%) as a colorless oil. Rf 0.66 (acetone/BuOH/H2O = 5:4:1). 1H NMR (300 
MHz, D2O): δ 4.58-4.50 (m, 1H), 4.11-4.02 (m, 1H), 3.92-3.60 (m, 4H). 13C NMR (75 MHz, D2O): 
δ 178.8, 82.2, 71.7, 70.9, 70.4, 62.3.13C NMR data are in accordance with literature values.461 
 
β-Cyclodextrin monoaldehyde (105) 
Following a literature procedure,263 a solution of Dess Martin Periodinane (1.12 g, 2.6 mmol) in 
anhydrous d6-DMSO (9 mL) was added to a solution of β-cyclodextrin (104) (1.5 g, 1.3 mmol) in 
anhydrous d6-DMSO (15 mL) and stirred at room temperature. The reaction was monitored by 1H 
NMR spectroscopy and after 3.5 h, the reaction mixture was poured into a beaker and the product 
was precipitated by addition of acetone (400 mL) and cooling to -10 ºC. The solution was filtered, 
washed with cold acetone (100 mL) and dried in vacuo to give 105 (1.5 g, 100%) as an inseparable 
mixture with the di- and tri-aldehydes as well as unreacted 104. White crystals. Rf 0.76 (MeOH/H2O 
= 10:1). IR (KBr): 3331, 2926, 1734 (weak), 1617, 1420, 1339, 1136, 1020, 947. 1H NMR (300 
MHz, d6-DMSO): δ 9.69 (s, CHO), 4.93 (s, H1 of residue containing CHO), 4.83 (s, 6 x H1). 
MALDI TOF MS calcd for C42H68O35Na [M + Na]+ m/z: 1155.4, found m/z 1155.6. 
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β-Cyclodextrin monoaldehyde (105) 
Following a literature procedure,264 IBX (320 mg, 1.1 mmol) was added  to a solution of β-
cyclodextrin (104) (1.0 g, 0.88 mmol) in anhydrous DMSO (29 mL) and stirred at room 
temperature. After 3 h, the solution was poured into a beaker, and acetone (350 mL) was added to 
facilitate precipitation. The solids were washed with acetone (150 mL), redissolved in H2O (90 mL) 
and stirred at 50 ºC for 1 h to remove complexed DMSO. After cooling to room temperature, the 
product was precipitated by addition of acetone (300 mL) and cooling on ice. The solution was 
filtered, washed with acetone (100 mL) and dried in vacuo to give 105 (764 mg, 77%) as an 
inseparable mixture with the di- and tri-aldehydes as well as unreacted 104. Spectroscopic data are 
given above. 
 
Attempted decarbonylation of β-cyclodextrin monoaldehyde 
Following general decarbonylation procedure A, a solution of 105 (1.5 g, 1.3 mmol) and 
Rh(dppp)2Cl (128 mg, 0.13 mmol) in DMA (10 mL) was heated to reflux. The solution turned black 
within 5 min. After 11 h the reaction mixture was cooled to room temperature (neutral pH) and the 
solvents were evaporated at 70 ºC using high vacuum. The resulting black syrup was dissolved in 
DMSO, cooled to -10 ºC and precipitated by addition of acetone (350 mL). The black crystals were 
filtered, washed with acetone (100 mL) and dried in vacuo. The crude product (640 mg) was 
peracetylated265 by addition of freshly distilled pyridine (10 mL), Ac2O (10 mL) and a catalytic 
amount of DMAP followed by stirring at 60 ºC overnight. The reaction was quenched by addition 
of ice (40 g). The mixture was filtered, and the black crystals were washed with cold H2O and dried 
in vacuo. The residue was purified by flash column chromatography (acetone/heptane = 2:3 → 4:1) 
to give a mixture of glycosylated β-cyclodextrin products (approximately 540 mg) as white crystals. 
For MALDI TOF MS data of both crude and peracetylated products see Table 34 and Table 35 in 
Appendix I. 
 
Attempted hydroacylation of styrene with D-glucose 
Following general decarbonylation procedure B, D-glucose (500 mg, 2.78 mmol) was 
decarbonylated in the presence of styrene (1.6 mL, 13.9 mmol). Full conversion was achieved 
within 23 h, and workup and flash column chromatography (DCM/MeOH/H2O = 65:25:0 → 
65:25:2) gave D-arabinitol (188 mg, 45%) and 1,4-anhydro-D-arabinitol (95) (103 mg, 28%). 
Spectroscopic data are given above. 
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1,2-O-Isopropylidene-α-D-glucofuranose (112) 
O
OHO
OHO
HO
112
 
1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose (111) (10.0 g, 38.4 mmol) was dissolved in 60% 
aqueous AcOH (150 mL) and stirred at room temperature for 21 h.33 The liquids were evaporated in 
vacuo and remaining AcOH was removed by co-evaporation with H2O to give 112 (8.44 g, 100%) 
as white crystals. Rf 0.18 (EtOAc/heptane = 4:1). [α]22D –12.0 (c 1.0, H2O) (lit.469 [α]25D –12.2 (H2O)). 
mp 153 – 154 ºC (H2O) (lit.470 mp 159 – 160 ºC). 1H NMR (300 MHz, D2O): δ 5.90 (d, J = 3.7 Hz, 
1H), 4.58 (d, J = 3.7 Hz, 1H), 4.20 (d, J = 1.9 Hz, 1H), 3.98 (dd, J = 2.5, 9.0 Hz, 1H), 3.80 (t, J = 
6.1 Hz, 1H), 3.70 (ddd, J = 1.3, 2.7, 12.0 Hz, 1H), 3.53 (ddd, J = 1.3, 6.0, 12.1 Hz, 1H), 1.41 (s, 
3H), 1.26 (s, 3H). 13C NMR (75 MHz, D2O): δ 113.5, 105.6, 85.3, 80.6, 74.5, 69.3, 64.4, 26.4, 26.0. 
NMR data are in accordance with literature values.471,472 Anal. calcd for C9H16O6: C, 49.09; H, 7.32. 
Found: C, 48.87; H, 7.09. 
 
1,2-O-Isopropylidene-α-D-xylo-pentodialdo-1,4-furanose (110) 
O
OHO
O
O
110
 
To a solution of diol 112 (1.00 g, 4.54 mmol) in MeOH (30 mL) at 0 ºC was added a cooled 
solution of NaIO4 (0.97 g, 4.54 mmol) in H2O (10 mL) dropwise over 5 min.33 The solution was 
stirred at 0 ºC for 1 h and then filtered. The filtercake was washed with DCM (3 × 20 mL) and the 
combined liquids were evaporated in vacuo to give the crude aldehyde as a semi-crystalline residue. 
Further purification was achieved by dissolving the residue in H2O (20 mL) and extracting with 
DCM (8 × 30 mL). The combined organic phases were dried (MgSO4), filtered and concentrated in 
vacuo to give a residue, which was purified by flash column chromatography (EtOAc/heptane = 1:3 
– 3:1). This afforded 110 (780 mg, 91%) as a mixture of the free aldehyde (110) and its dimer 114 
as white crystals. Rf 0.35 (EtOAc/heptane = 4:1). [α]22D  +13.1 (immediately) → –22.3 (after 24h) (c 
4.0, H2O) (lit.473 [α]23D  –25.7 (monomer, c 0.5, H2O)). [α]22D  +17.5 (c 3.3, CHCl3) (lit.474 [α]25D  
+27.8 (dimer, c 0.3 CHCl3)). mp 78 – 86 ºC (EtOAc/heptane) (lit.473 mp 162 – 164 ºC (monomer, 
H2O)) (lit.474 mp 181 – 182 ºC (dimer, EtOAc/hexane)). IR (KBr): 3440, 2988, 2938, 1735 (weak), 
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1636 (weak), 1457, 1377, 1219, 1165, 1074, 1017, 858. 1H NMR (300 MHz, D2O): δ 6.00 (d, J = 
3.6 Hz, 1H), 5.09 (d, J = 7.5 Hz, 1H), 4.66 (d, J = 3.6 Hz, 1H), 4.25 (d, J = 2.6 Hz, 1H), 4.00 (dd, J 
= 2.7, 7.5 Hz, 1H), 1.49 (s, 3H), 1.32 (s, 3H). 13C NMR (75 MHz, D2O): δ 113.8, 105.6, 89.0, 85.6, 
83.7, 74.5, 26.6, 26.1. Anal. calcd for C8H12O5/C16H24O10: C, 51.06; H, 6.43. Found: C, 50.77; H, 
6.43. HRMS calcd for C16H24O10Na [M + Na]+ m/z 399.1267, found m/z 399.1284. 
 
1,2-O-Isopropylidene-α-D-xylo-pentodialdo-1,4-furanose (110) 
Following a modified literature procedure,34 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (111) 
(2.00 g, 7.68 mmol) was added to a solution of H5IO6 (2.63 g, 11.5 mmol) in freshly distilled ether 
(30 mL) under an argon atmosphere. The solution was stirred at room temperature for 20 h. The 
reaction mixture was filtered and the sticky precipitate was washed with dry ether (3 x 20 mL). The 
combined liquids were evaporated in vacuo and the residue was purified by flash column 
chromatography (EtOAc/heptane = 1:1) to give 110 (716 mg, 50%) as a mixture of the free 
aldehyde (110) and its dimer 114 as white crystals. Spectroscopic data are given above. 
 
1,2-O-Isopropylidene-β-L-threofuranose (113) 
O
OHO
O
113
 
To aldehyde 110 (500 mg, 2.66 mmol) were added Rh(dppp)2Cl (51 mg, 0.053 mmol) and a 
degassed solution of diglyme (10 mL). The mixture was thoroughly degassed and then stirred at 
reflux (162 ºC) in a preheated oil bath for 26 h. The solvent was removed under high vacuum at 70 
ºC to give a black residue, which was purified by flash column chromatography eluting with 
ether/pentane = 2:3 → 4:1 to afford 113 (366 mg, 86%) as white crystals. Rf 0.35 (EtOAc/heptane = 
3:2). [α]22D  +13.1 (c 0.8, acetone) (lit.278 [α]D +13 (c 1, acetone)). mp 80 – 81 ºC (ether) (lit.59,278 mp 
84 – 85 ºC (ether/hexane)). 1H NMR (300 MHz, CD3OD): δ 5.78 (d, J = 3.7 Hz, 1H), 4.35 (d, J = 
3.7 Hz, 1H), 4.04 (d, J = 2.8 Hz, 1H), 3.92 (dd, J = 2.9, 9.8 Hz, 1H), 3.68 (dd, J = 1.0, 9.8 Hz, 1H), 
1.32 (s, 3H), 1.19 (s, 3H). 13C NMR (50 MHz, CD3OD): δ 112.7, 106.7, 86.4, 75.9, 73.9, 27.1, 26.4. 
NMR data are in accordance with literature values.59 Anal. calcd for C7H12O4: C, 52.49; H, 7.55. 
Found: C, 52.79; H, 7.47. 
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L-Threose 
O
HO OH
OH
 
Compound 113 (100 mg, 0.62 mmol) was dissolved in 30% aqueous AcOH (10 mL) and heated to 
reflux for 4 h.278 The liquids were removed in vacuo and the residue was purified by reverse phase 
column chromatography eluting with H2O to give L-threose (74 mg, 99%) as a colorless oil 
consisting of a 14:11:5 mixture of the α- and β-furanose forms and the hydrate. Rf 0.57 
(acetone/BuOH/H2O = 5:4:1). [α]22D  +12.3 (c 2.0, H2O) (lit.278 [α]D +12 (c 1, H2O)). 1H NMR (300 
MHz, D2O): δ 5.33 (d, J = 4.2 Hz, H1 β-anomer), 5.17 (d, J = 1.1 Hz, H1 α-anomer), 4.94 (d, J = 
6.3 Hz, H1 hydrate), 4.50-3.36 (m, 4H). 13C NMR (75 MHz, D2O): α-anomer: δ 103.4, 81.9, 76.4, 
74.3; β-anomer: δ 97.9, 77.4, 76.1, 71.8; hydrate: δ 91.0, 74.5, 72.1, 64.2. NMR data are in 
accordance with literature values.461,475,476 Anal. calcd for C4H8O4: C, 40.00; H, 6.71. Found: C, 
40.74; H, 6.72. HRMS calcd for C4H8O4Na [M + Na]+ m/z 143.0320, found m/z 143.0327. 
 
 
8.3 Compounds referred to in chapter 4♦ 
 
Activation of Zn136  
Zn dust (<10 micron, 50 g) was suspended in H2O (100 mL) and 4 M aqueous HCl (100 mL) was 
added. After stirring under an argon atmosphere at room temperature for 15 min, the suspension 
was filtered and washed with H2O (2 x 20 mL), MeOH (20 mL) and Et2O (20 mL). The finely 
dispersed Zn powder was dried in vacuo by heating with a heat gun for 10 min. 
 
General procedure for imine allylation using different metals 
A suspension of activated Zn (140 mg, 2.14 mmol) and 139 (100 mg, 0.214 mmol) in freshly 
distilled THF (4 mL) was sonicated at 40 oC under an argon atmosphere in a flat-bottomed conical 
flask. TMSCl (13.5 µL, 0.107 mmol) was added in two portions, after 10 and 20 min of sonication. 
When NMR revealed full conversion to the aldehyde (1.5 h), flame-dried, powdered 4 Å molecular 
sieves (50 mg) were added followed by dropwise addition of BnNH2 (117 µL, 1.07 mmol). When 
NMR revealed full conversion of the aldehyde to the imine (1 h), the solution was cooled to room 
                                                 
♦
 A small part of the characterization of the intermediates towards calystegine A3 was performed by Charlotte B. 
Pipper. 
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temperature, filtered through a plug of Celite, washed with anhydrous Et2O (20 mL) and 
concentrated in vacuo.  
The crude imine (144) was redissolved in freshly distilled solvent (THF or toluene/DCM = 4:1), the 
metal (Zn, In or Mg, 0.64 mmol) was added and the solution was sonicated at 40 oC under an argon 
atmosphere. Allylbromide (59.1 µL, 0.68 mmol) was added dropwise to the solution, and after an 
additional 2-3 h of sonication, the solution was cooled to room temperature, diluted with Et2O (60 
mL) and H2O (20 mL) and filtered through a plug of Celite. The organic phase was washed with 
H2O (3 x 20 mL) and brine (20 mL), dried (K2CO3), filtered and concentrated in vacuo to give a 
colorless oil, which was purified by flash column chromatography (EtOAc/heptane 1:6 → 1:2) to 
afford a diastereomeric mixture of 145 and 146. 
 
Methyl 3,4-di-O-benzyl-2-O-p-methoxybenzyl-6-O-trityl-α-D-glucopyranoside (140) 
O
BnO
BnO
OMePMBO
OTr
140
 
To a solution of diol 132 (31.5 g, 56.6 mmol) and NaH (19 mg, 50%, 0.40 mmol, prewashed with 
heptane) in anhydrous DMF (600 mL) at 0 oC was added Bu4NI (2.1 g, 5.7 mmol) followed by 
dropwise addition of BnBr (21.7 mL, 183 mmol). The reaction mixture was left at ambient 
temperature overnight while it warmed to room temperature. The reaction mixture was quenched by 
addition of MeOH (60 mL), diluted with Et2O (600 mL) and washed with H2O (700 mL). The 
aqueous phase was extracted with Et2O (2 x 500 mL), and the combined organic phases were dried 
(MgSO4), filtered and evaporated on Celite. Dry column vacuum chromatography477 
(EtOAc/heptane = 1:5) afforded 140 (34.4 g, 82%) as a white foam. Rf 0.47 (EtOAc/heptane = 1:2). 
[α]25D +10.9 (c 1.0, CHCl3). IR (KBr): 3061, 3030, 2926, 1612, 1513, 1449, 1249, 1159, 1072, 1036, 
1028, 755, 703. 1H NMR (300 MHz, CDCl3): δ 7.41-7.35 (m, 6H), 7.30-7.06 (m, 19H), 6.83-6.74 
(m, 4H), 4.86 (d, J = 10.7 Hz, 1H), 4.71 (d, J = 10.7 Hz, 1H), 4.69 (d, J = 11.8 Hz, 1H), 4.62 (d, J = 
3.7 Hz, 1H), 4.57 (d, J = 11.1 Hz, 1H), 4.61 (d, J = 9.0 Hz, 1H), 4.20 (d, J = 10.4 Hz, 1H), 3.86 (t, J 
= 8.8 Hz, 1H), 3.76-3.68 (m, 1H), 3.73 (s, 3H), 3.57-3.49 (m, 2H), 3.41 (d, J = 10.0 Hz, 1H), 3.36 
(s, 3H), 3.10 (dd, J = 4.7, 9.9 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 159.5, 144.1, 138.8, 138.0, 
130.5, 129.8, 128.9, 128.6, 128.3, 128.3, 128.2, 127.9, 127.8, 127.7, 127.0, 114.0, 98.1, 86.4, 82.4, 
79.9, 78.2, 76.1, 75.1, 73.1, 70.3, 62.7, 55.4, 55.1. HRMS calcd for C48H48O7Na [M+Na]+ m/z 
759.3292, found m/z 759.3257. 
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Methyl 3,4-di-O-benzyl-6-O-trityl-α-D-glucopyranoside (137) 
O
BnO
BnO
OMeHO
OTr
137
 
To a solution of fully protected 140 (14.8 g, 20.1 mmol) in DCM/H2O (19:1, 350 mL) was added 
DDQ (6.84 g, 30.1 mmol). The atmosphere was exchanged with argon and the reaction mixture was 
stirred at room temperature for 2.5 h. The solution was diluted with DCM (700 mL) and quenched 
by stirring with sat. aqueous NaHCO3 (500 mL) for 1.5 h. The aqueous phase was extracted with 
DCM (2 x 500 mL) and the combined organic phases were washed with brine (200 mL), dried 
(Na2SO4), filtered and evaporated on Celite. Purification by dry column vacuum chromatography 
(EtOAc/heptane = 2:1) gave 137 (12.0 g, 97%) as a colorless oil. Rf 0.49 (EtOAc/heptane = 1:1). 
[α]25D +71.5 (c 1.0, CHCl3). IR (KBr): 3448, 3060, 3029, 2929, 1490, 1449, 1156, 1125, 1047, 745, 
698. 1H NMR (300 MHz, CDCl3): δ 7.51-7.45 (m, 6H), 7.41-7.15 (m, 17H), 6.87 (dd, J = 1.8, 7.7 
Hz, 2H), 4.91-4.81 (m, 3H), 4.67 (d, J = 10.4 Hz, 1H), 4.29 (d, J = 10.4 Hz, 1H), 3.84-3.62 (m, 4H), 
3.53 (dd, J = 1.8, 10.1 Hz, 1H), 3.47 (s, 3H), 3.22 (dd, J = 4.6, 10.0 Hz, 1H), 2.17 (d, J = 7.4 Hz, 
OH). 13C NMR (75 MHz, CDCl3): δ 144.1, 138.7, 137.9, 128.9, 128.6, 128.3, 128.2, 128.1, 127.9, 
127.7, 127.1, 99.3, 86.5, 83.6, 78.0, 75.7, 75.0, 73.2, 70.7, 62.6, 55.1. HRMS calcd for C40H40O6Na 
[M+Na]+ m/z 639.2717, found m/z 639.2734. 
 
Methyl 3,4-di-O-benzyl-2-O-(methylsulfanylthiocarbonyl)-6-O-trityl-α-D-glucopyranoside 
(141) 
O
BnO
BnO
OMeO
OTr
SMeS
141
 
To NaH (1.65 g, 50%, 34.4 mmol, prewashed with heptane) were added imidazole (374 mg, 5.5 
mmol) and a solution of alcohol 137 (7.06 g, 11.4 mmol) in CS2 (13.8 mL, 22.8 mmol) and freshly 
distilled THF (140 mL) under a nitrogen atmosphere. The reaction mixture was stirred at room 
temperature for 3.5 h after which MeI (3.6 mL, 57.8 mmol) was added. After an additional 1.5 h at 
room temperature, the reaction mixture was evaporated, redissolved in DCM (300 mL), and washed 
with H2O (2 x 100 mL). The aqueous phase was extracted with DCM (50 mL) and the combined 
organic phases were dried (Na2SO4), filtered, evaporated on Celite followed by dry column vacuum 
Chapter 8 Experimental work performed at DTU 
135 
chromatography (heptane → EtOAc/heptane = 1:19) to afford 141 (7.2 g, 89%) as a yellow solid. Rf 
0.71 (EtOAc/heptane = 1:1). [α]25D +52.9 (c 1.0, CHCl3). IR (KBr): 3058, 3030, 2926, 1491, 1449, 
1359, 1207, 1171, 1046, 740, 688, 630. 1H NMR (300 MHz, CDCl3): δ 7.51-7.46 (m, 6H), 7.32-
7.16 (m, 17H), 6.87 (dd, J = 1.7, 7.7 Hz, 2H), 5.80 (dd, J = 3.7, 9.9 Hz, 1H), 5.17 (d, J = 3.7 Hz, 
1H), 4.78 (d, J = 10.7 Hz, 1H), 4.72 (d, J = 10.7 Hz, 1H), 4.68 (d, J = 10.4 Hz, 1H), 4.30 (d, J = 
10.4 Hz, 1H), 4.16 (dd, J = 8.7, 9.9 Hz, 1H), 3.90-3.83 (m, 1H), 3.76 (dd, J = 8.7, 10.1 Hz, 1H), 
3.53 (dd, J = 1.5, 9.9 Hz, 1H), 3.43 (s, 3H), 3.24 (dd, J = 4.5, 10.1 Hz, 1H), 2.60 (s, 3H). 13C NMR 
(75 MHz, CDCl3): δ 216.1, 144.0, 138.2, 137.8, 128.9, 128.5, 128.3, 128.2, 128.1, 128.0, 127.9, 
127.8, 127.1, 96.2, 86.5, 81.6, 80.4, 78.2, 75.8, 75.2, 70.4, 62.5, 55.1, 19.6. HRMS calcd for 
C42H42O6S2Na [M+Na]+ m/z 729.2315, found m/z 729.2330. 
 
Methyl 3,4-di-O-benzyl-2-deoxy-6-O-trityl-α-D-glucopyranoside (138) 
O
BnO
BnO
OMe
OTr
138
 
The methyl xanthate 141 (10.3 g, 14.6 mmol) was dissolved in anhydrous toluene (190 mL) under a 
nitrogen atmosphere and heated to reflux. A solution of AIBN (239 mg, 1.46 mmol) and Bu3SnH 
(8.9 mL, 33.6 mmol) in anhydrous toluene (60 mL) was added dropwise to the reaction mixture 
over a period of 1 h. The solution was stirred at reflux for 6 h, cooled to room temperature and 
evaporated on Celite. The product was purified by dry column vacuum chromatography (heptane → 
EtOAc/heptane = 1:19) to afford 138 (7.53 g, 86%) as a white solid. Rf 0.55 (EtOAc/heptane = 1:2). 
1H NMR (300 MHz, CDCl3): δ 7.49-7.37 (m, 6H), 7.39-7.07 (m, 17H), 6.83 (dd, J = 2.0, 7.2 Hz, 
2H), 4.84 (d, J = 2.5 Hz, 1H), 4.67 (d, J = 10.5 Hz, 1H), 4.59-4.56 (m, 2H), 4.26 (d, J = 10.5 Hz, 
1H), 3.92-3.81 (m, 1H), 3.71 (dd, J = 3.3, 9.8 Hz, 1H), 3.57-3.48 (m, 1H), 3.47-3.41 (m, 1H), 3.30 
(s, 3H), 3.17 (dd, J = 4.8, 9.9 Hz, 1H), 2.25 (dd, J = 5.0, 12.9 Hz, 1H), 1.70 (ddd, J = 3.6, 11.7, 13.0 
Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 144.2, 138.8, 138.3, 129.0, 128.5, 128.3, 128.2, 127.9, 
127.8, 127.7, 127.6, 127.0, 98.4, 86.4, 78.8, 77.9, 75.0, 72.2, 70.9, 63.1, 54.5, 35.8. HRMS calcd for 
C40H40O5Na [M+Na]+ m/z 623.2768, found m/z 623.2764. 
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Methyl 3,4-di-O-benzyl-2-deoxy-α-D-glucopyranoside (142) 
O
BnO
BnO
OMe
OH
142
 
A suspension of 138 (7.5 g, 12.5 mmol) in 1% H2SO4 in MeOH (550 mL) was stirred at room 
temperature under an argon atmosphere for 2.5 h. The reaction mixture was neutralized by stirring 
with Na2CO3 (10 g), filtered and evaporated on Celite. Purification by dry column vacuum 
chromatography (EtOAc/heptane = 1:9 → 1:4) gave 142 (4.15 g, 93%) as a colorless oil. Rf 0.38 
(EtOAc/heptane = 1:1). 1H NMR (300 MHz, CDCl3): δ 7.39-7.24 (m, 10H), 4.95 (d, J = 11.1 Hz, 
1H), 4.80 (d, J = 3.2 Hz, 1H), 4.72-4.60 (m, 3H), 4.05-3.94 (m, 1H), 3.85-3.72 (m, 2H), 3.68-3.60 
(m, 1H), 3.55-3.47 (m, 1H), 3.30 (s, 3H), 2.29 (dd, J = 5.0, 13.1 Hz, 1H), 1.95 (s, OH), 1.66 (ddd, J 
= 3.6, 11.5, 13.0 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 138.7, 138.5, 128.5, 128.5, 128.1, 127.9, 
127.7, 127.7, 98.6, 78.2, 77.6, 75.0, 71.9, 71.2, 62.3, 54.7, 35.6. HRMS calcd for C21H26O5Na 
[M+Na]+ m/z 381.1672, found m/z 381.1693. 
 
Methyl 3,4-di-O-benzyl-2,6-dideoxy-6-iodo-α-D-glucopyranoside (139) 
139
O
BnO
BnO
OMe
I
 
Alcohol 142 (4.4 g, 12.2 mmol), PPh3 (5.1 g, 19.4 mmol) and imidazole (2.0 g, 29.4 mmol) were 
co-evaporated with toluene (2 x 125 mL) and then dissolved in freshly distilled THF (250 mL) 
under an argon atmosphere. The solution was heated to reflux and a solution of I2 in freshly distilled 
THF (0.17 mmol/mL) was added dropwise to the reaction mixture until a permanent color change 
was achieved (79.4 mL, 13.3 mmol). Full conversion was confirmed by TLC analysis, and the 
reaction mixture was cooled to room temperature, filtered, washed with a little THF and evaporated 
on Celite. The product was purified by dry column vacuum chromatography (EtOAc/heptane = 1:49 
→ 1:9) to afford 139 (5.33 g, 93%) as a colorless oil. Rf 0.53 (EtOAc/heptane = 1:2). IR (film): 
3030, 2933, 2901, 1496, 1453, 1366, 1213, 1130, 1100, 1047, 955, 741, 699. 1H NMR (300 MHz, 
CDCl3): δ 7.32-7.15 (m, 10H), 4.93 (d, J = 11.0 Hz, 1H), 4.75 (d, J = 3.0 Hz, 1H), 4.64 (d, J = 11.0 
Hz, 1H), 4.58 (d, J = 11.5 Hz, 1H), 4.51 (d, J = 11.5 Hz, 1H), 3.93 (ddd, J = 5.1, 8.3, 11.5 Hz, 1H), 
3.52-3.20 (m, 4H), 3.28 (s, 3H), 2.23 (dd, J = 5.1, 13.1 Hz, 1H), 1.62 (ddd, J = 3.6, 11.6, 13.1 Hz, 
1H). 13C NMR (75 MHz, CDCl3): δ 138.5, 138.4, 128.6, 128.5, 128.1, 127.9, 127.8, 98.6, 82.2, 
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77.3, 75.4, 71.8, 69.9, 55.1, 35.5, 8.7. HRMS calcd for C21H25IO4Na [M+Na]+ m/z 491.0690, found 
m/z 491.0698. 
 
(3R,4R,6R)- and (3R,4R,6S)-6-[(N-Benzyl)-amino]-3,4-bis(benzyloxy)-nona-1,8-diene 
(145 and 146) 
BnO
BnO NHBn
BnO
BnO NHBn
and
145 146
 
A suspension of activated Zn (140 mg, 2.14 mmol) and iodide 139 (100 mg, 0.214 mmol) in freshly 
distilled THF (4 mL) was sonicated at 40 oC under an argon atmosphere in a flat-bottomed conical 
flask. TMSCl (13.5 µL, 0.107 mmol) was added in two portions, after 15 and 25 min of sonication. 
When NMR revealed full conversion to the aldehyde (1 h 15 min), BnNH2 (117 µL, 1.07 mmol) 
was added dropwise to the solution. When NMR revealed full conversion of the aldehyde to the 
imine (45 min), allylbromide (55.4 µL, 0.64 mmol) was added dropwise to the solution. After an 
additional 2 h of sonication, the solution was cooled to room temperature, diluted with Et2O (60 
mL) and H2O (20 mL) and filtered through a plug of Celite. The organic phase was washed with 
H2O (3 x 20 mL) and brine (20 mL), dried (K2CO3), filtered and concentrated in vacuo to give a 
colorless oil, which was purified by flash column chromatography (EtOAc/heptane 1:4) to afford a 
separable 1:1.13 diastereomeric mixture of 145 and 146 (89 mg, 94%) as colorless oils. 
 
Data for the minor isomer 145: Rf 0.20 (EtOAc/heptane = 1:2). [α]23D +6.7 (c 2.0, CDCl3). IR (film): 
3064, 3029, 2925, 2861, 1496, 1454, 1353, 1206, 1092, 1069, 1027, 995, 918, 735, 697. 1H NMR 
(300 MHz, CDCl3): 7.28-7.09 (m, 15H), 5.74 (ddd, J = 7.5, 10.6, 17.1 Hz, 1H), 5.68-5.53 (m, 1H), 
5.27-5.17 (m, 2H), 5.01-4.92 (m, 2H), 4.66 (d, J = 11.5 Hz, 1H), 4.55 (d, J = 12.0 Hz, 1H), 4.41 (d, 
J = 11.5 Hz, 1H), 4.29 (d, J = 12.0 Hz, 1H), 3.83 (dd, J = 5.6 Hz, 7.4 Hz, 1H), 3.61 (s, 2H), 3.58-
3.50 (m, 1H), 2.62 (p, J = 6.3 Hz, 1H), 2.18-2.06 (m, 1H), 2.04-1.93 (m, 1H), 1.62-1.54 (m, 2H). 
13C NMR (75 MHz, CDCl3): δ 140.8, 138.7, 138.6, 135.5, 135.3, 128.4, 128.3, 128.1, 127.9, 127.6, 
127.6, 126.8, 119.0, 117.5, 82.2, 79.0, 72.9, 70.6, 53.8, 51.1, 38.3, 35.3. HRMS calcd for 
C30H36NO2 [M+H]+ m/z 442.2741, found m/z 442.2733. 
 
Data for the major isomer 146: Rf 0.27 (EtOAc/heptane = 1:2). [α]23D +32.5 (c 1.0, CDCl3). IR 
(film): 3064, 3028, 2918, 2859, 1495, 1453, 1355, 1261, 1207, 1089, 1065, 1027, 993, 913, 733, 
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696. 1H NMR (300 MHz, CDCl3): δ 7.44-7.27 (m, 15H), 5.94-5.75 (m, 2H), 5.41-5.31 (m, 2H), 
5.19-5.10 (m, 2H), 4.82-4.64 (m, 2H), 4.49 (d, J = 11.4, 1H), 4.46 (d, J = 12.0, 1H), 3.96 (t, J = 6.6 
Hz, 1H), 3.90-3.80 (m, 2H), 3.65 (d, J = 12.9 Hz, 1H), 2.96-2.86 (m, 1H), 2.32 (dd, J = 6.9, 14.5 
Hz, 2H), 2.04 (bs, NH), 1.70-1.62 (m, 2H). 13C NMR (75 MHz, CDCl3): δ 140.8, 138.8, 138.6, 
135.4, 135.3, 128.5, 128.4, 128.3, 128.2, 128.1, 127.8, 127.5, 127.4, 126.9, 118.9, 117.4, 82.6, 78.6, 
73.4, 70.6, 52.9, 50.5, 38.7, 35.6. HRMS calcd for C30H36NO2 [M+H]+ m/z 442.2741, found m/z 
442.2728. 
 
(3R,4R,6R)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)-nona-1,8-diene 
(149) 
BnO
BnO NBn
Cbz
149
 
KHCO3 (109 mg, 1.09 mmol) was added to a solution of amine 145 (80 mg, 0.18 mmol) in 
DCM/H2O (1:1, 10 mL) at 0 oC. Then CbzCl (28 µL, 0.20 mmol) was added under vigorous 
stirring, and the reaction mixture was slowly allowed to reach room temperature. After 1.5 h, the 
solution was diluted with DCM (20 mL) and washed with H2O (10 mL) and brine (10 mL). The 
combined aqueous phases were extracted with DCM (5 mL) and the combined organic phases were 
dried (K2CO3), filtered and concentrated in vacuo. Purification of the residue by flash column 
chromatography (EtOAc/heptane 1:9) gave 149 (95 mg, 91%) as a colorless oil. Rf 0.54 
(EtOAc/heptane = 1:2). [α]25D –16.5 (c 3.0, CDCl3). IR (film): 3086, 3064, 2926, 2864, 1692, 1496, 
1453, 1414, 1338, 1309, 1232, 1208, 1093, 1069, 1028, 993, 918, 734, 697. 1H NMR (300 MHz, 
CDCl3): δ 7.34-7.02 (m, 20H), 5.77-5.53 (m, 1H), 5.49-4.96 (m, 5H), 4.85-4.66 (m, 2H), 4.59-4.09 
(m, 6H), 4.01-3.67 (m, 2H), 3.38-3.20 (m, 1H), 2.26-1.55 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 
157.3, 139.1, 138.7, 138.5, 136.8, 135.3, 135.1, 128.6, 128.4, 128.4, 128.2, 128.0, 127.9, 127.7, 
127.2, 127.0, 118.9, 117.1, 81.4, 78.5, 72.7, 70.5, 67.0, 55.2, 48.7, 37.5, 33.9. Only the major 
rotamer reported. HRMS calcd for C38H41NO4Na [M+Na]+ m/z 598.2928, found m/z 598.2918. 
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(3R,4R,6R)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)-cycloheptene 
(136) 
BnO
BnO NBn
Cbz
136
 
A solution of diene 149 (53 mg, 0.092 mmol) and Grubbs’ 2nd generation catalyst (3.9 mg, 4.6 
µmol) in freshly distilled DCM (15 mL) was degassed by bubbling nitrogen through the solution for 
5 min. The solution was protected from sunlight and left stirring at room temperature for 48 h. The 
reaction mixture was concentrated in vacuo, and the residue was purified by flash column 
chromatography (heptane → EtOAc/heptane = 3:17) to give 136 (49 mg, 97%) as a colorless oil. Rf 
0.45 (EtOAc/heptane = 1:2). [α]25D –10.6 (c 2.0, CDCl3). IR (film): 3087, 3063, 3029, 2961, 2927, 
2857, 1693, 1496, 1453, 1413, 1357, 1305, 1259, 1233, 1090, 1070, 1027, 801, 733, 695. 1H NMR 
(300 MHz, CDCl3): δ 7.32-7.00 (m, 20H), 5.64-5.51 (m, 2H), 5.18-4.97 (m, 2H), 4.66-4.19 (m, 6H), 
4.00-3.80 (m, 2H), 3.43-3.18 (m, 1H), 2.35-1.83 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 155.7, 
138.9, 138.7, 136.6, 133.0, 128.5, 128.3, 127.9, 127.8, 127.6, 127.5, 127.4, 127.1, 81.9, 79.2, 73.0, 
72.6, 67.2, 53.9, 47.9, 39.6, 33.0. Only the major rotamer reported.  HRMS calcd for C36H37NO4Na 
[M+Na]+ m/z 570.2615, found m/z 570.2633. 
 
(3R,4R,6S)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)-nona-1,8-diene 
(150) 
BnO
BnO NBn
Cbz
150
 
KHCO3 (214 mg, 2.14 mmol) was added to a solution of amine 146 (157 mg, 0.36 mmol) in 
DCM/H2O (1:1, 10 mL) at 0 oC. Then CbzCl (55 µL, 0.39 mmol) was added under vigorous 
stirring, and the reaction mixture was slowly allowed to reach room temperature. After 1.5 h, full 
conversion was not yet achieved and additional CbzCl (25 µL, 0.18 mmol) was added. After stirring 
at room temperature for 40 min, the phases were separated and the organic phase was washed with 
H2O (20 mL) and brine (20 mL), dried (K2CO3), filtered and concentrated in vacuo. Purification of 
the residue by flash column chromatography (EtOAc/heptane 1:19 → 3:17) gave 150 (190 mg, 
93%) as a colorless oil. Rf 0.56 (EtOAc/heptane = 1:2). [α]25D +30.6 (c 3.0, CDCl3). IR (film): 3066, 
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3030, 2928, 2866, 1695, 1496, 1454, 1413, 1337, 1236, 1116, 1089, 1070, 1028, 994, 919, 735, 
698. 1H NMR (300 MHz, CDCl3): δ 7.32-7.03 (m, 20H), 5.67-5.28 (m, 2H), 5.23-4.71 (m, 6H), 
4.61-4.10 (m, 7H), 3.66-3.49 (m, 1H), 3.34-3.23 (m, 1H), 2.33-1.93 (m, 2H), 1.74 (t, J = 12.5 Hz, 
1H), 1.44 (t, J = 12.6 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 157.9, 139.2, 138.9, 138.6, 136.8, 
135.4, 135.0, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.2, 127.0, 
119.0, 117.2, 82.5, 78.2, 73.8, 70.5, 67.2, 54.2, 54.2, 47.5, 38.7, 34.3. Only the major rotamer 
reported. HRMS calcd for C38H41NO4Na [M+Na]+ m/z 598.2928, found m/z 598.2906. 
 
(3R,4R,6S)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)-cycloheptene 
(151) 
BnO
BnO NBn
Cbz
151
 
A solution of diene 150 (87 mg, 0.15 mmol) and Grubbs’ 2nd generation catalyst (7 mg, 8.2 µmol) 
in freshly distilled DCM (10 mL) was degassed by bubbling argon through the solution for 10 min. 
The solution was protected from sunlight and left stirring at room temperature for 36 h. The 
reaction mixture was concentrated in vacuo, and the residue was purified by flash column 
chromatography (heptane → EtOAc/heptane = 3:17) to give 151 (80 mg, 97%) as a colorless oil. Rf 
0.46 (EtOAc/heptane = 1:2). [α]25D –106.1 (c 2.0, CDCl3). IR (film): 3088, 3054, 3027, 2930, 2878, 
2857, 1687, 1495, 1451, 1413, 1361, 1304, 1229, 1090, 1070, 1027, 969, 735, 696. 1H NMR (300 
MHz, CDCl3): δ 7.32-7.06 (m, 20H), 5.77 (ddd, J = 4.5, 7.8, 11.6 Hz, 1H), 5.63 (ddd, J = 1.9, 5.5 
11.4 Hz, 1H), 5.17-5.03 (m, 2H), 4.59-3.88 (m, 8H), 3.68 (d, J = 16.3 Hz, 1H), 2.69-2.57 (m, 1H), 
2.36 (t, J = 12.5 Hz, 1H), 2.25-2.03 (m, 1H), 1.91 (t, J = 12.6 Hz, 1H). 13C NMR (75 MHz, CDCl3): 
δ 156.9, 139.1, 138.7, 136.8, 131.5, 130.7, 129.7, 128.5, 128.4, 128.3, 128.0, 127.6, 127.5, 127.1, 
76.6, 76.2, 70.9, 70.8, 67.1, 50.7, 49.0, 34.4, 34.0. Only the major rotamer reported. HRMS calcd 
for C36H37NO4Na [M+Na]+ m/z 570.2615, found m/z 570.2602. 
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Methyl 3,4-di-O-benzyl-2-O-p-methoxybenzyl-α-D-glucopyranoside (152) 
O
BnO
BnO
OMePMBO
OH
152
 
Compound 140 (33.9 g, 46.0 mmol) was dissolved in 1% H2SO4 in MeOH (1 L) and toluene (200 
mL), and stirred at room temperature for 2 h 15 min. The reaction was stopped by stirring with 
Na2CO3 (63 g) until pH > 7 followed by removal of the solvent in vacuo. The residue was dissolved 
in DCM (500 mL), washed with H2O (2 x 100 mL) and the combined aqueous phases were 
extracted with DCM (2 x 100 mL). The combined organic phases were dried (MgSO4), filtered, 
concentrated in vacuo and purified by dry column vacuum chromatography (EtOAc/heptane = 1:9 
→ 3:1) to give 152 (22.3 g, 98%) as a slightly yellow oil. Rf 0.30 (EtOAc/heptane = 1:1). [α]25D 
+20.3 (c 2.2, CHCl3). IR (film): 3475, 3063, 3030, 2925, 1700, 1612, 1586, 1512, 1496, 1456, 
1359,1303, 1251, 1093, 913, 822, 735, 701. 1H NMR (300 MHz, CDCl3): δ 7.41-7.25 (m, 12H), 
6.87 (d, J = 8.3 Hz, 2H), 4.99 (d, J = 10.8 Hz, 1H), 4.89 (d, J = 10.9 Hz, 1H), 4.83 (d, J = 10.9 Hz, 
1H), 4.75 (d, J = 11.8 Hz, 1H), 4.64 (d, J = 11.8 Hz, 1H), 4.60 (d, J = 11.7 Hz, 1H), 4.52 (d, J = 3.5 
Hz, 1H), 4.00 (t, J = 9.2 Hz, 1H), 3.81 (s, 3H), 3.79-3.62 (m, 3H), 3.57-3.46 (m, 2H), 3.37 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ  159.5, 138.9, 138.2, 130.3, 129.9, 128.6, 128.5, 128.2, 128.1, 128.0, 
127.7, 114.0, 98.4, 82.1, 79.7, 77.5, 75.9, 75.2, 73.2, 70.7, 62.0, 55.4, 55.3. HRMS calcd for 
C29H34O7Na [M+Na]+ m/z 517.2197, found m/z 517.2198. 
 
Methyl 3,4-di-O-benzyl-6-deoxy-6-iodo-2-O-p-methoxybenzyl-α-D-glucopyranoside (133) 
O
BnO
BnO
OMePMBO
I
133
 
A mixture of alcohol 152 (21.7 g, 43.9 mmol), PPh3 (18.4 g, 70.1 mmol) and imidazole (6.8 g, 99.9 
mmol) was co-evaporated with toluene (2 x 300 mL) and dissolved in freshly distilled THF (500 
mL). The solution was briefly evacuated and purged with argon 3 times. The solution was then 
heated to reflux and a solution of I2 in freshly distilled THF (0.50 mmol/mL) was added dropwise to 
the reaction mixture until a permanent color change was achieved (113.0 mL, 56.5 mmol). Full 
conversion was confirmed by TLC analysis. The reaction mixture was cooled to room temperature, 
filtered, washed with a little THF and evaporated on Celite. The product was purified by dry 
column vacuum chromatography (EtOAc/heptane = 1:19 → 3:7) to afford 133 (24.7 g, 93%) as a 
Rune Nygaard Monrad – Ph.D. Thesis 
142 
colorless oil, which slowly crystallized upon standing. Rf 0.68 (EtOAc/heptane = 1:1). [α]25D +27.2 
(c 2.1, CHCl3). IR (KBr): 3030, 2916, 2906, 2838, 1613, 1514, 1453, 1358, 1300, 1245,1171, 1112, 
1088, 1073, 1047, 1030, 1012, 735, 695. 1H NMR (300 MHz, CDCl3): δ 7.39-7.25 (m, 12H), 6.86 
(d, J = 8.7 Hz, 2H), 4.99 (d, J = 10.8 Hz, 1H), 4.94 (d, J = 11.0 Hz, 1H), 4.79 (d, J = 10.8 Hz, 1H), 
4.74 (d, J = 11.8 Hz, 1H), 4.68 (d, J = 10.9 Hz, 1H), 4.59 (d, J = 11.8 Hz, 1H), 4.55 (d, J = 3.6 Hz, 
1H), 4.00 (dd, J = 8.8, 9.5 Hz, 1H), 3.81 (s, 3H), 3.54-3.42 (m, 3H), 3.41 (s, 3H), 3.37-3.25 (m, 
2H). 13C NMR (75 MHz, CDCl3): δ 159.4, 138.5, 137.9, 130.0, 129.7, 128.5, 128.4, 127.9, 127.8, 
127.6, 113.8, 98.1, 81.5, 81.4, 79.6, 75.7, 75.3, 73.0, 69.2, 55.5, 55.2, 7.7. HRMS calcd for 
C29H33IO6Na [M+Na]+ m/z 627.1214, found m/z 627.1191. 
 
(3R,4S,5S,6R)-6-[(N-Benzyl)-amino]-3,4-bis(benzyloxy)-5-p-methoxybenzyloxy-nona-1,8-diene 
(134) 
BnO
BnO NHBn
OPMB
134
6
1
 
Freshly distilled THF (100 mL) was added to activated Zn (29.1 g, 0.45 mol) and iodide 133 (26.5 
g, 0.044 mol) divided into five flat-bottomed conical flasks. The atmosphere was exchanged with 
argon and the solutions were sonicated at 40 oC. TMSCl (2.8 mL, 0.022 mol) was added in two 
portions, after 10 min and after 20 min of sonication. When NMR revealed full conversion to the 
aldehyde (2 h), BnNH2 (24.3 mL, 0.22 mol) was added dropwise to the solutions. When NMR 
revealed full conversion of the aldehyde to the imine (1 h), allylbromide (11.6 mL, 0.13 mol) was 
very carefully added dropwise to the solutions. After an additional 4 h of sonication, the solutions 
were cooled to room temperature, combined and diluted with Et2O (1 L). H2O (500 mL) was added 
to precipitate the zinc salts followed by filtration through a plug of Celite. The organic phase was 
washed with brine (2 x 250 mL), which led to formation of a white precipitate which was removed 
by filtration. The combined aqueous phases were extracted with Et2O (2 x 100 mL) and the 
combined organic phases were dried (K2CO3), filtered and evaporated on Celite. Dry column 
vacuum chromatography (EtOAc/heptane 1:4) gave a separable 5.3:1 diastereomeric mixture of 134 
and its C6 epimer (21.5 g, 85%) as a colorless oil.  
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Data for the major isomer 134: Rf 0.42 (EtOAc/heptane = 1:2). 1H NMR (300 MHz, CDCl3): δ 7.38-
7.15 (m, 17H), 6.82 (d, J = 8.6 Hz, 2H), 5.92 (ddd, J = 7.6, 10.4, 17.7 Hz, 1H), 5.69-5.54 (m, 1H), 
5.25 (dd, J = 1.9, 10.4 Hz, 1H), 5.20 (dd, J = 1.4, 16.9 Hz, 1H), 5.06-4.96 (m, 2H), 4.78 (d, J = 10.9 
Hz, 1H), 4.76 (d, J = 11.2 Hz, 1H), 4.66 (d, J = 11.2 Hz, 1H), 4.51 (d, J = 11.9 Hz, 1H), 4.50 (d, J = 
10.8 Hz, 1H), 4.08 (d, J = 11.9 Hz, 1H), 3.93 (dd, J = 3.2, 7.6 Hz, 1H), 3.82 (d, J = 13.1 Hz, 1H), 
3.79-3.75 (m, 2H), 3.78 (s, 3H), 3.69 (dd, J = 3.1, 7.7 Hz, 1H), 3.43 (d, J = 13.0 Hz, 1H), 2.46-2.35 
(m, 2H), 2.32-2.16 (m, 1H). 13C NMR (75 MHz, CDCl3): δ 159.1, 141.1, 138.9, 138.2, 136.5, 
136.4, 131.6, 129.4, 128.7, 128.6, 128.4, 128.3, 128.3, 128.2, 127.7, 127.5, 126.9, 118.4, 116.9, 
113.7, 83.6, 80.6, 79.7, 75.4, 74.5, 70.2, 56.5, 55.4, 50.9, 35.2. HRMS calcd for C38H43NO4Na 
[M+Na]+ m/z 600.3084, found m/z 600.3112. 
 
(3R,4S,5S,6R)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)- 
5-p-methoxybenzyloxy-nona-1,8-diene (153) 
BnO
BnO NBn
PMBO Cbz
153
 
To a solution of amine 134 (19.9 g, 0.034 mol) in DCM/H2O (1:1, 700 mL) at 0 oC was added 
KHCO3 (26.0 g, 0.26 mol), and under vigorous stirring, CbzCl (6.7 mL, 0.048 mol) was added 
dropwise to the solution over a period of 20 min. The reaction mixture was allowed to reach room 
temperature, and after 2 h, the phases were separated and the organic phase was washed with H2O 
(250 mL). The combined aqueous phases were extracted with DCM (150 mL) and the combined 
organic phases were dried (K2CO3), filtered and evaporated on Celite. Dry column vacuum 
chromatography (EtOAc/heptane 1:9) gave 153 (22.5 g, 92%) as a colorless oil. Rf 0.49 
(EtOAc/heptane = 1:2). [α]25D –4.9 (c 2.0, CHCl3). IR (film): 3062, 3031, 2923, 1950, 1879, 1810, 
1696, 1641, 1612, 1585, 1514, 1497, 1453, 1407, 1321, 1300, 1248, 1173, 1078, 924, 915, 823, 
735, 700. 1H NMR (300 MHz, d6- DMSO, 60 oC): δ 7.36-7.16 (m, 20H), 7.12 (d, J = 8.5 Hz, 2H), 
6.87 (d, J = 8.6 Hz, 2H), 5.85 (ddd, J = 7.6, 10.3, 17.5 Hz, 1H), 5.35-5.03 (m, 5H), 4.88-4.75 (m, 
2H), 4.70-4.60 (m, 1H), 4.58-4.02 (m, 9H), 3.93-3.83 (m, 1H), 3.75 (s, 2.7H), 3.73 (s, 0.3H), 3.52-
3.43 (m, 1H), 2.44-2.29 (m, 1H), 2.27-2.13 (m, 1H). 13C NMR (75 MHz, CDCl3): δ 159.1, 157.4, 
138.6, 136.5, 135.9, 135.1, 134.8, 131.0, 129.7, 129.4, 129.2, 128.5, 128.4, 128.3, 128.1, 127.9, 
127.6, 127.5, 126.7, 118.5, 117.5, 113.7, 83.1, 80.8, 79.9, 75.4, 75.2, 70.8, 67.2, 56.5, 55.4, 53.6, 
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35.2. Only the major rotamer reported. HRMS calcd for C46H50NO6 [M+H]+ m/z 712.3633, found 
m/z 712.3614. Anal. calcd for C46H49NO6: C, 77.61; H, 6.94. Found: C, 77.56; H, 7.18.  
 
(3R,4S,5S,6R)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)- 
5-p-methoxybenzyloxy-cycloheptene (154) 
BnO
BnO NBn
PMBO Cbz
154
 
A solution of diene 153 (21.77 g, 30.6 mmol) in freshly distilled DCM (1.2 L) was degassed by 
bubbling nitrogen through the solution for 15 min. Grubbs’ 2nd generation catalyst (1.3 g, 1.5 mmol) 
was added to the solution under a nitrogen atmosphere, and the solution was protected from sunlight 
and left stirring at room temperature for 48 h. The reaction mixture was evaporated on Celite and 
purified by dry column vacuum chromatography (heptane → EtOAc/heptane = 1:3) to give 154 
(20.4 g, 98%) as a colorless syrup, which briefly turned into a white foam under vacuum. Rf 0.45 
(EtOAc/heptane = 1:2). [α]25D –19.1 (c 2.1, CHCl3). IR (film): 3064, 3031, 2921, 1950, 1881, 1813, 
1700, 1612, 1586, 1514, 1496, 1456, 1355, 1246, 1174, 1073, 824, 734, 701. 1H NMR (300 MHz, 
CDCl3): δ 7.42-7.03 (m, 22H), 6.86-6.74 (m, 2H), 5.73-5.54 (m, 2H), 5.25-5.06 (m, 2H), 4.98-4.56 
(m, 6H), 4.42-4.00 (m, 5H), 3.76 (s, 1.2H), 3.73 (s, 1.8H), 3.62-3.52 (m, 1H), 3.31 (t, J = 10.1 Hz, 
0.6H), 2.94-2.78 (m, 0.4H), 2.58 (t, J = 12.9 Hz, 0.4H), 2.02-1.82 (m, 0.6H). 13C NMR (75 MHz, 
CDCl3): δ 159.1, 156.8, 139.0, 138.5, 138.2, 136.7, 132.8, 130.9, 129.7, 129.1, 128.5, 128.3, 128.1, 
127.7, 127.7, 127.5, 127.3, 113.7, 84.7, 83.3, 77.9, 75.3, 75.0, 72.7, 66.9, 61.9, 55.3, 53.8, 30.0. 
Only the major rotamer reported. HRMS calcd for C44H46NO6 [M+H]+ m/z 684.3320, found m/z 
684.3325. 
 
(3R,4R,5S,6R)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)-5-hydroxy-
cycloheptene (135) 
BnO
BnO NBn
OH Cbz
135
 
To a solution of 154 (187 mg, 0.27 mmol) in DCM/H2O (19:1, 15 mL) was added DDQ (165 mg, 
0.73 mmol) followed by stirring at room temperature under an argon atmosphere for 3 h. The 
reaction mixture was diluted with DCM (60 mL) and quenched by washing with sat. aqueous 
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NaHCO3 (30 mL) for 30 min. The aqueous phase was extracted with DCM (2 x 30 mL) and the 
combined organic phases were washed with brine (20 mL). The aqueous phase from the brine 
washing was extracted with DCM (10 mL) and the combined organic phases were dried (Na2SO4), 
filtered and concentrated in vacuo. Purification of the residue by flash column chromatography 
(EtOAc/heptane = 1:4 → 1:3) afforded 135 (136 mg, 88%) as a colorless oil. Rf 0.39 
(EtOAc/heptane = 1:2). [α]25D –13.1 (c 1.1, CHCl3). IR (film): 3545, 3483, 3063, 3031, 2889, 1695, 
1496, 1453, 1416, 1248, 1031, 734, 701. 1H NMR (300 MHz, CDCl3): δ 7.32-7.06 (m, 20H), 5.76-
5.51 (m, 2H), 5.16-4.99 (m, 2H), 4.97-4.22 (m, 5H), 4.14-3.67 (m, 4H), 3.42 (t, J = 7.7 Hz, 1H), 
2.52-2.18 (m, 1H), 2.01-1.80 (m, 1H). 13C NMR (75 MHz, CDCl3): δ  156.4 138.9, 138.2, 136.7, 
132.6, 130.6, 129.5, 128.7, 128.6, 128.5, 128.4, 128.1, 127.9, 127.8, 127.4, 127.2, 84.0, 78.3, 75.3, 
75.0, 72.3, 67.3, 60.0, 50.1, 30.2. Only the major rotamer reported. HRMS calcd for C36H38NO5 
[M+H]+ m/z 564.2744, found m/z 564.2773. 
 
(3R,4S,5S,6R)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)- 
5-(methylsulfanyl)thiocarbonyloxy-cycloheptene (156) 
BnO
BnO NBn
O Cbz
S SMe
156
 
To NaH (267 mg, 50%, 5.56 mmol, prewashed with heptane) was added a solution of imidazole (47 
mg, 0.69 mmol) in CS2 (42 mL, 0.69 mol) under a nitrogen atmosphere. A solution of alcohol 135 
(773 mg, 1.37 mmol) in CS2 (42 mL, 0.69 mol) and freshly distilled THF (35 mL) was added 
dropwise to the reaction mixture under vigorous stirring over a period of 1 h 15 min. After 3 h, MeI 
(432 µL, 3.82 mmol) was added dropwise and the solution was stirred at room temperature 
overnight. The reaction mixture was evaporated on Celite and purified by flash column 
chromatography (EtOAc/heptane = 1:6) to afford 156 (700 mg, 78%) and the byproduct 157 (84 
mg, 13%) as yellow oils. Data for 156: Rf 0.50 (EtOAc/heptane = 1:2). [α]23D –34.7 (c 2.0, CDCl3). 
IR (film): 3087, 3063, 3029, 2923, 2865, 1697, 1496, 1453, 1229, 1202, 1118, 1055, 734, 697. 1H 
NMR (300 MHz, CDCl3): δ 7.28-7.01 (m, 20H), 5.79-5.48 (m, 2H), 5.16-4.98 (m, 2H), 4.70 (q, J = 
11.3 Hz, 1H), 4.57-3.91 (m, 8H), 3.82-3.65 (m, 1H), 2.83-2.52 (m, 1H), 2.38 (s, 1.5H), 2.32 (s, 
1.5H), 2.09-1.84 (m, 1H). 13C NMR (75 MHz, CDCl3): δ 215.0, 156.5, 138.5, 138.4, 138.2, 138.1, 
130.7, 130.2, 128.8, 128.6, 128.5, 128.4, 128.4, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.2, 
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84.6, 79.9, 76.2, 74.2, 72.4, 67.3, 58.9, 54.5, 30.0, 19.2. Only the major rotamer reported. HRMS 
calcd for C38H39NO5S2Na [M+Na]+ m/z 676.2162, found m/z 676.2182. 
 
(Z,3aR,7R,8S,8aS)-3-Benzyl-7,8-bis(benzyloxy)-3a,4,8,8a-tetrahydro- 
3H-cyclohepta[d]oxazol-2(7H)-one (157) 
BnO
BnO NBn
O
O
157
 
Compound 157 was isolated as a byproduct during formation of 156 from 135. Data for 157: Rf 0.27 
(EtOAc/heptane = 1:2). [α]23D –96.4 (c 0.5, CDCl3). IR (film): 3063, 3030, 2924, 2857, 1753, 1496, 
1454, 1416, 1352, 1131, 1086, 1065, 1027, 737, 701. 1H NMR (300 MHz, CDCl3): δ 7.31-7.18 (m, 
13H), 7.05-6.99 (m, 2H), 5.77 (ddt, J = 1.8, 6.1, 12.2 Hz, 1H), 5.67 (dt, J = 4.1, 12.2 Hz, 1H), 4.73 
(d, J = 11.6 Hz, 1H), 4.56 (d, J = 11.6 Hz, 1H), 4.54 (d, J = 15.3 Hz, 1H), 4.41 (d, J = 11.6 Hz, 1H), 
4.27 (d, J = 11.6 Hz, 1H), 4.20-4.13 (m, 3H), 3.92 (dd, J = 2.8, 6.3 Hz, 1H), 3.86 (dd, J = 2.8, 7.0 
Hz, 1H), 2.62-2.51 (m, 1H), 2.05-1.92 (m, 1H). 13C NMR (75 MHz, CDCl3): δ 158.6, 137.9, 135.8, 
129.9, 128.9, 128.6, 128.5, 128.3, 128.1, 128.0, 127.9, 127.8, 127.6, 127.2, 82.7, 82.6, 75.2, 72.9, 
71.0, 52.6, 46.6, 33.4. HRMS calcd for C29H29NO4Na [M+Na]+ m/z 478.1989, found m/z 478.1980. 
 
(3R,4R,6R)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)-cycloheptene 
(136) 
A solution of freshly distilled Bu3SnH (243 µL, 0.92 mmol) in freshly distilled toluene (6 mL) was 
evacuated for 15 min, purged with nitrogen and heated to reflux. To this solution were added 
methyl xanthate 156 (200 mg, 0.31 mmol) and AIBN (10 mg, 0.061 mmol) in freshly distilled 
toluene (4 mL) dropwise under a nitrogen atmosphere over a period of 20 min. Additional toluene 
(1.5 mL) was used to transfer the material. Full conversion was achieved after 50 min and the 
solution was cooled to room temperature and concentrated in vacuo. The residue was purified by 
flash column chromatography (DCM/heptane = 4:1) to give 136 (124 mg, 74%) as a colorless oil. 
Spectroscopic data are given above. 
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(3R,4R,6R)-6-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)-cycloheptene 
(136) 
The (imidazolyl)thiocarbonyl derivative 155 (36 mg, 0.053 mmol) was co-evaporated with freshly 
distilled toluene (2 x 5 mL), evacuated, purged with argon and subsequently dissolved in freshly 
distilled toluene (3 mL). The reaction mixture was heated to reflux, and a solution of AIBN (4 mg, 
0.024 mmol) and Bu3SnH (57 µL, 0.22 mmol) in freshly distilled toluene (1 mL) was then added 
dropwise to the reaction mixture over a period of 30 min. After 3 h, the reaction mixture was 
allowed to reach room temperature and evaporated on Celite. Purification by flash column 
chromatography (EtOAc/heptane 1:9) afforded 136 (8 mg, 27%) as a colorless oil. Spectroscopic 
data are given above.  
 
(2S,3R,5R)-5-[(N-Benzyl)-(N-benzyloxycarbonyl)-amino]-2,3-bis(benzyloxy)-cycloheptanone 
(158) and (3R,4R,6S)-6-[(N-benzyl)-(N-benzyloxycarbonyl)-amino]-3,4-bis(benzyloxy)- 
cycloheptanone (159) 
BnO
BnO NBn
Cbz
O
and
BnO
BnO NBn
Cbz
O
158 159
 
Cycloheptene 136 (600 mg, 1.1 mmol) was dissolved in freshly distilled THF (30 mL) under an 
argon atmosphere and cooled to -40 oC. BH3 • THF (1 M in THF, 2.30 mL, 2.3 mmol) was added 
dropwise to the solution over a period of 20 min. After 3 h at -40 oC, the solution was allowed to 
reach room temperature, and after 4 h 2 M aqueous NaOH (2 mL) and 35% aqueous H2O2 (4 mL) 
were added to the reaction mixture. The solution was stirred at ambient temperature for 1 h, diluted 
with Et2O (70 mL) and washed with H2O (3 x 10 mL) and brine (10 mL). The organic phase was 
dried (K2CO3), filtered and concentrated in vacuo to give an isomeric mixture of alcohols, which 
were used directly in the next step.  
The crude alcohols were dissolved in freshly distilled DCM (19 mL) and added to a solution of 
DMP (929 mg, 2.2 mmol) in freshly distilled DCM (15 mL). The reaction mixture was stirred at 
room temperature for 1 h, after which Et2O (100 mL) was added. The resulting white suspension 
was stirred for 30 min and then gravity filtered. The filtrate was washed with sat. aqueous Na2S2O3 
(2 x 20 mL) and brine (30 mL), and the organic phase was dried (K2CO3), filtered and concentrated 
in vacuo. Flash column chromatography (EtOAc/heptane = 1:9) of the residue gave a separable 2:1 
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mixture of the isomeric cycloheptanones (468 mg, 76% combined yield) as colorless oils; 158 (308 
mg, 50%) and 159 (160 mg, 26%).  
 
Data for the major isomer 158: Rf 0.38 (EtOAc/heptane = 1:2). [α]25D –4.5 (c 1.0, CDCl3). IR (film): 
3088, 3063, 3031, 2930, 2869, 1696, 1496, 1454, 1415, 1357, 1238, 1096, 1072, 1028, 736, 698. 1H 
NMR (300 MHz, CDCl3): δ 7.37-7.00 (m, 20H), 5.21-5.02 (m, 2H), 4.59-4.15 (m, 6H), 4.07-3.38 
(m, 3H), 2.69-2.41 (m, 1H), 2.26-2.12 (m, 1H), 2.01-1.75 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 
209.2, 155.7, 138.6, 138.0, 137.2, 136.4, 128.6, 128.5, 128.4, 128.0, 127.9, 127.8, 127.7, 127.3, 
126.9, 88.7, 79.4, 72.5, 72.2, 67.3, 55.4, 48.3, 37.3, 36.6, 30.5. Only the major rotamer reported. 
HRMS calcd for C36H37NO5Na [M+Na]+ m/z 586.2564, found m/z 586.2549. 
 
Data for the minor isomer 159: Rf 0.31 (EtOAc/heptane = 1:2). [α]25D –9.9 (c 2.0, CDCl3). IR (film): 
3087, 3063, 3030, 2930, 2871, 1695, 1496, 1454, 1415, 1352, 1246, 1095, 1071, 1028, 736, 698. 1H 
NMR (300 MHz, CDCl3): δ 7.30-7.04 (m, 20H), 5.18-5.00 (m, 2H), 4.62-3.95 (m, 7H), 3.57-3.28 
(m, 2H), 2.86-2.31 (m, 4H), 2.14-1.74 (m, 2H). 13C NMR (75 MHz, CDCl3): δ  207.2, 155.8, 138.4, 
138.2, 138.0, 136.5, 128.9, 128.8, 128.7, 128.62, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.7, 
127.3, 81.2, 79.3, 72.3, 72.3, 67.6, 50.6, 48.3, 44.9, 36.9, 29.9. Only the major rotamer reported. 
HRMS calcd for C36H37NO5Na [M+Na]+ m/z 586.2564, found m/z 586.2582. 
 
(-)-Calystegine A3 (117) 
NHHO
OH
HO
117
 
A solution of cycloheptanone 158 (39 mg, 0.069 mmol) in dioxane/H2O (9:1, 3.3 mL) was degassed 
by bubbling nitrogen through the solution for 10 min. Pearlman’s catalyst (8 mg, 7.5 µmol) was 
added to the solution and H2 was bubbled through the solution for 10 min after which the solution 
was stirred at room temperature under 1 atmosphere of H2 for 15 h. TLC analysis revealed 
disappearance of the protected cycloheptanone, and 1 M aqueous HCl (0.7 mL) was added to the 
solution, which was stirred at room temperature under 1 atmosphere of H2 for an additional 32 h. 
The reaction mixture was neutralized by addition of Amberlite IRA-400 OH-, filtered through a 
plug of Celite and thoroughly washed with H2O (15 x 10 mL). The filtrate was co-evaporated with 
EtOH and purified by Sephadex LH-20 column chromatography (EtOAc/EtOH = 4:1) to give 
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(-)-calystegine A3 (117) (9.2 mg, 84%). Rf 0.42 (1-propanol/AcOH/H2O = 4:1:1). [α]25D –13.6 (c 0.3, 
D2O) (lit.289 [α]D –17.3 (c 0.47, H2O)). IR (film): 3382, 2954, 2929, 2857, 1635, 1399, 1387, 1259, 
1088, 1056, 1026, 934. 1H NMR (500 MHz, D2O): δ 3.62 (ddd, J = 6.9, 8.5, 10.5 Hz, 1H), 3.45 (d, 
J = 6.6 Hz, 1H), 3.36 (d, J = 8.4 Hz, 1H), 2.06-1.90 (m, 3H), 1.53-1.43 (m, 3H). 13C NMR (125 
MHz, D2O): δ 93.4, 82.5, 72.7, 54.2, 42.6, 31.8, 29.3. The chemical shift of C1 (93.4 ppm) was 
assigned by HSQC. NMR data are in accordance with literature values.289 HRMS calcd for 
C7H13NO3Na [M+Na]+ m/z 182.0788, found m/z 182.0793. 
 
(-)-Calystegine A3 (117) 
A solution of cycloheptanone 158 (39 mg, 0.069 mmol) in THF/H2O (9:1, 3.3 mL) was degassed by 
bubbling nitrogen through the solution for 10 min. Pearlman’s catalyst (8 mg, 7.5 µmol) was added 
to the solution and H2 was bubbled through the solution for 10 min after which the solution was 
stirred at room temperature under 1 atmosphere of H2 for 15 h. TLC analysis revealed 
disappearance of the protected cycloheptanone, and 1 M aqueous HCl (0.7 mL) was added to the 
solution, which was stirred at room temperature under 1 atmosphere of H2 for an additional 32 h. 
The reaction mixture was neutralized by addition of Amberlite IRA-400 OH-, filtered through a 
plug of Celite and thoroughly washed with H2O (15 x 10 mL). The filtrate was co-evaporated with 
EtOH and purified by Sephadex LH-20 column chromatography (EtOAc/EtOH = 4:1) to give 
(-)-calystegine A3 (117) (8.9 mg, 81%). Spectroscopic data are given above. 
 
Attempted isomerization of calystegine A3 (117) to A6 (166) 
Calystegine A3 (117) (2 mg, 0.013 mmol) was dissolved in pyridine-d5 (0.7 mL, pH = 8-9) or 1 M 
aq. Ca(OH)2 (0.7 mL, pH > 12). The reaction mixtures containing Ca(OH)2 were inhomogeneous 
and stirring was applied. The reactions were performed at 25 or 100 ºC and were followed by TLC 
and 1H NMR. Experiments in pyridine-d5 could be evaporated and the product recovered directly, 
whereas experiments in aq. Ca(OH)2 were acidified with 1 M aq. HCl, neutralized with IRA-400 
OH- ion exchange resin, filtered through a plug of Celite and washed thoroughly with water. The 
filtrate was concentrated in vacuo and the residue was analyzed by TLC and 1H NMR. When 
necessary, the crude product was purified on Sephadex LH-20 eluting with EtOAc/EtOH = 4:1. 
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8.4 Compounds referred to in chapter 5 
 
(3R,4R,5S,6S)-3,4,5,6-Tetrahydroxy-3,4;5,6-di-O-isopropylidene-1-methylcyclohexene (184) 
O
O O
O
184
 
To a solution of diol 183 (100 mg, 0.50 mmol) in 2,2-dimethoxypropane (8 mL, 65 mmol) was 
added camphorsulfonic acid (7.3 mg, 0.31 mmol), and the reaction mixture was stirred at room 
temperature under an argon atmosphere. Full conversion was achieved after 40 min, and the 
reaction was quenched by addition of a few drops of Et3N (pH > 7). The mixture was concentrated 
in vacuo and the residue was purified by flash column chromatography (heptane/EtOAc = 3:1) 
furnishing 184 (88 mg, 73%) as white crystals. Rf 0.45 (EtOAc/heptane = 1:2). 1H NMR (300 MHz, 
CDCl3): δ 5.54-5.49 (m, 1H), 4.53-4.47 (m, 1H), 4.38-4.29 (m, 3H), 1.84-1.81 (m, 3H), 1.45 (s, 
3H), 1.42 (s, 3H), 1.36 (s, 3H), 1.35 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 135.1, 121.1, 110.4, 
110.3, 74.7, 73.1, 72.6, 71.7, 27.2, 27.0, 26.6, 26.5, 20.0. 13C NMR data are in accordance with two 
cis fused isopropylidene acetals.371 
 
(1S,2S,3R,6R)-3-Benzoyloxy-2-hydroxy-4,8,8-trimethyl-7,9-dioxadicyclo[4.3.0]non-4-ene (185) 
O
O
OBz
OH
185
 
A degassed solution of diene 178 (34 mg, 0.10 mmol) and Grubbs’ 2nd generation catalyst (7.4 mg, 
0.0087 mmol) in freshly distilled DCM (24 mL) was protected from sunlight and stirred at reflux 
under an argon atmosphere for 3 days. The reaction mixture was evaporated on Celite and purified 
by flash column chromatography (heptane → heptane/EtOAc = 4:1) to give the target compound 
185 (23 mg, 74%) as a white solid. Rf 0.29 (EtOAc/heptane = 2:1). [α]25D –40.4 (c 1.0, CDCl3). IR 
(film): 3459, 3066, 3036, 2985, 2924, 2855, 1720, 1452, 1380, 1268, 1235, 1110, 1047, 1031, 712. 
1H NMR (300 MHz, CDCl3): δ 8.11-8.06 (m, 2H), 7.59 (tt, J = 2.1, 7.4 Hz, 1H), 7.50-7.42 (m, 2H), 
5.84 (dd, J = 1.0, 8.1 Hz, 1H), 5.57 (dq, J = 1.9, 3.3 Hz, 1H), 4.69-4.64 (m, 1H), 4.56 (ddd, J = 0.7, 
2.9, 5.6 Hz, 1H), 3.97 (dt, J = 2.9, 8.1 Hz, 1H), 2.66 (d, J = 8.1 Hz, OH), 1.78 (dd, J = 1.3, 2.6 Hz, 
3H), 1.43 (s, 3H), 1.40 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 167.2, 134.6, 133.5, 130.0, 129.8, 
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128.6, 124.1, 109.9, 75.9, 74.1, 73.1, 71.8, 27.8, 26.5, 19.2. HRMS calcd for C17H20O5Na [M+Na]+ 
m/z 327.1203, found m/z 327.1212. 
 
(1S,2S,3R,6R)-2,3-Dihydroxy-4,8,8-trimethyl-7,9-dioxabicyclo[4.3.0]non-4-ene (186) 
O
O
OH
OH
186
 
The benzoate 185 (15 mg, 0.049 mmol) was dissolved in 10% NaOMe in anhydrous MeOH (10 
mL) and stirred at room temperature under an argon atmosphere for 3 h. The mixture was 
evaporated on Celite and purified by flash column chromatography (heptane/EtOAc = 1:2) to give 
186 (8.5 mg, 86%) as a colorless oil. Rf 0.04 (EtOAc/heptane = 1:2). 1H NMR (300 MHz, CDCl3): δ 
5.44-5.40 (m, 1H), 4.65-4.58 (m, 1H), 4.50 (dd, J = 2.7, 5.8 Hz, 1H), 4.26 (bd, J = 5.6 Hz, 1H), 
3.68-3.60 (m, 1H), 2.45-2.36 (m, OH), 2.25-2.17 (m, OH), 1.86-1.83 (m, 3H), 1.37 (s, 6H). 
 
(3R,4R,5S,6R)-3,4,5,6-Tetrahydroxy-3,4;5,6-di-O-isopropylidene-1-methylcyclohexene (187) 
O
O O
O
187
 
To a solution of diol 186 (8.5 mg, 0.042 mmol) in 2,2-dimethoxypropane (0.8 mL, 6.5 mmol) was 
added camphorsulfonic acid (0.7 mg, 0.03 mmol), and the reaction mixture was stirred at room 
temperature under an argon atmosphere. After 2 h, the starting material was still present as the 
major spot and additional 2,2-dimethoxypropane (1.0 mL, 8.2 mmol) was added. After stirring for 
an additional 1 h, the reaction was quenched by addition of a few drops of Et3N (pH > 7). The 
mixture was concentrated in vacuo and the residue was purified by flash column chromatography 
(heptane/EtOAc = 3:1 → 1:2) giving 187 (3 mg, 29%) as well as 35% recovered starting material (3 
mg). Rf 0.51 (EtOAc/heptane = 1:2). 1H NMR (300 MHz, CDCl3): δ 5.41-5.33 (m, 1H), 4.74-4.65 
(m, 2H), 4.38 (bd, J = 8.3 Hz, 1H), 3.48 (dd, J = 1.9, 8.8 Hz, 1H), 1.84-1.81 (m, 3H), 1.51 (s, 3H), 
1.46 (s, 3H), 1.42 (s, 3H), 1.38 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 140.3, 120.1, 111.2, 109.9, 
80.2, 75.1, 73.6, 70.7, 29.9, 27.0, 26.7, 24.8, 17.7. 13C NMR data are in accordance with one cis and 
one trans fused isopropylidene acetal.371 
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(1S,2R,3S,6R)-3-Benzoyloxy-2-hydroxy-4,8,8-trimethyl-7,9-dioxabicyclo[4.3.0]non-4-ene (182) 
O
O
OBz
OH
182
 
Following a modified literature procedure,377 a solution of alcohol 181 (1.79 g, 5.9 mmol) in freshly 
distilled DCM (40 mL) under a nitrogen atmosphere was cooled to –20 ºC followed by addition of 
pyridine (2.14 mL, 26.5 mmol) and Tf2O (1.48 mL, 8.8 mmol). The reaction mixture was slowly 
allowed to warm to room temperature and after 1.5 h the reaction was quenched with 2 M HCl (85 
mL). The phases were separated and the aqueous phase was extracted with DCM (2 × 25 mL). The 
combined organic phases were washed with saturated aqueous NaHCO3 (45 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give trifluoromethanesulfonate 189 (2.57 g, 5.9 mmol) as a 
black residue, which was used directly in the next step. The crude trifluoromethanesulfonate 189 
was redissolved in anhydrous DMF under a nitrogen atmosphere, NaNO2 (1.62 g, 23.5 mmol) was 
added and the mixture stirred at room temperature for 5.5 h. The reaction mixture was diluted with 
H2O (120 mL) followed by extraction with Et2O (5 × 50 mL). The combined organic phases were 
dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (EtOAc/heptane = 1:5 → 1:1) to give alcohol 182 (933 mg, 52%) as a slightly 
yellow oil. Rf 0.49 (EtOAc/heptane = 1:1). [α]25D –12.0 (c 2.0, CD3OD). IR (film): 3459, 3064, 3043, 
2985, 2925, 2859, 1719, 1452, 1379, 1316, 1268, 1249, 1216, 1115, 1060, 1026, 979, 907, 710. 1H 
NMR (300 MHz, CDCl3): δ 8.11-8.05 (m, 2H), 7.59 (tt, J = 1.4, 7.4 Hz, 1H), 7.50-7.42 (m, 2H), 
5.76-5.67 (m, 2H), 4.69-4.63 (m, 1H), 4.21 (dd, J = 6.3, 9.0 Hz, 1H), 3.98 (t, J = 8.9 Hz, 1H), 1.77 
(dd, J = 1.3, 2.7 Hz, 3H), 1.55 (s, 3H), 1.41 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 166.7, 139.1, 
133.5, 130.0, 129.6, 128.6, 120.1, 110.6, 77.9, 74.7, 72.7, 72.3, 28.4, 26.1, 18.9. HRMS calcd for 
C17H20O5Na [M+Na]+ m/z 327.1203, found m/z 327.1216. 
 
(1R,2R,3S,6R)-3-Benzoyloxy-4,8,8-trimethyl-2-tetrahydropyranyloxy- 
7,9-dioxabicyclo[4.3.0]non-4-ene (190) 
O
O
OBz
OTHP
190
 
Following a modified literature procedure,378 a solution of alcohol 182 (850 mg, 2.79 mmol) in 
freshly distilled DCM (60 mL) was treated with DHP (0.5 mL, 5.5 mmol) and PPTS (140 mg, 0.56 
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mmol). The mixture was stirred at room temperature under a nitrogen atmosphere overnight. The 
reaction was stopped by addition of saturated aqueous NaHCO3 (100 mL) followed by extraction 
with DCM (3 × 50 mL). The combined organic phases were dried (MgSO4), filtered, concentrated 
in vacuo and purified by flash column chromatography (heptane/EtOAc = 9:1 → 4:1) to give 190 
(925 mg, 85%) as a colorless oil and a mixture of two diastereomers. Rf 0.72 (EtOAc/heptane = 
1:1). IR (film): 3063, 2983, 2938, 2868, 1722, 1452, 1380, 1317, 1265, 1247, 1217, 1162, 1119, 
1062, 1029, 986, 966, 869, 710. 1H NMR (300 MHz, CDCl3): δ 8.12-8.03 (m, 4H), 7.59-7.53 (m, 
2H), 7.48-7.40 (m, 4H), 5.81-5.67 (m, 4H), 5.21 (t, J = 2.6 Hz, 1H), 4.83 (t, J = 3.3 Hz, 1H), 4.68-
4.58 (m, 2H), 4.29 (dt, J = 6.1, 8.3 Hz, 2H), 4.19-4.08 (m, 3H), 3.64-3.54 (m, 1H), 3.46-3.37 (m, 
1H), 3.23-3.14 (m, 1H), 1.78-1.70 (m, 8H), 1.62-1.58 (m, 4H), 1.55 (s, 9H), 1.40 (s, 3H), 1.39 (s, 
6H). 13C NMR (75 MHz, CDCl3): δ 166.4, 166.2, 139.3, 138.1, 133.4, 133.1, 130.2, 129.9, 129.8, 
129.7, 128.7, 128.4, 120.9, 120.1, 110.2, 110.2, 99.0, 97.3, 78.5, 76.1, 75.6, 74.6, 73.0, 72.6, 72.6, 
62.1, 61.3, 30.6, 30.5, 28.3, 28.1, 26.6, 26.5, 25.4, 25.3, 19.1, 19.0, 18.5. HRMS calcd for 
C22H28O6Na [M+Na]+ m/z 411.1778, found m/z 411.1796. 
 
(1R,2R,3S,6R)-3-Hydroxy-4,8,8-trimethyl-2-tetrahydropyranyloxy- 
7,9-dioxabicyclo[4.3.0]non-4-ene (191) 
O
O
OH
OTHP
191
 
Fully protected 190 (595 mg, 1.53 mmol) was dissolved in 10% NaOMe in anhydrous MeOH (60 
mL) and stirred at room temperature for 3 h. The mixture was concentrated in vacuo and purified by 
flash column chromatography (heptane/EtOAc = 4:1) to give alcohol 191 (393 mg, 90%) as a 
colorless oil and a mixture of two diastereomers. Rf 0.51 and 0.63 (EtOAc/heptane = 1:1). IR (film): 
3442, 3037, 2982, 2936, 2860, 1453, 1441, 1372, 1243, 1215, 1135, 1072, 1047, 1022, 1007, 975, 
890. 1H NMR (300 MHz, CDCl3): δ 5.54-5.45 (m, 2H), 4.79 (dd, J = 2.6, 5.5 Hz, 1H), 4.62-4.50 
(m, 2H), 4.40 (d, J = 1.7 Hz, 1H), 4.31 (t, J = 5.8 Hz, 1H), 4.14-4.07 (m, 2H), 4.04-3.91 (m, 3H), 
3.87-3.80 (dd, J = 5.0, 8.5 Hz, 1H), 3.59 (t, J = 8.5 Hz, 1H), 3.56-3.47 (m, 2H), 2.99 (d, J = 8.5 Hz, 
OH), 1.96-1.77 (m, 3H), 1.87-1.85 (m, 3H), 1.84-1.83 (m, 3H), 1.61-1.47 (m, 9H), 1.47 (s, 3H), 
1.43 (s, 3H), 1.36 (s, 3H), 1.34 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 142.1, 138.2, 120.4, 117.3, 
110.0, 109.7, 102.7, 99.4, 84.3, 76.7, 75.9, 75.2, 72.7, 71.1, 70.5, 65.6, 64.0, 31.5, 30.9, 28.5, 28.2, 
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26.6, 26.1, 25.3, 25.1, 21.4, 20.4, 20.3, 19.0. HRMS calcd for C15H24O5Na [M+Na]+ m/z 307.1516, 
found m/z 307.1521. 
 
(1R,2S,6R)-4,8,8-Trimethyl-3-oxo-2-tetrahydropyranyloxy-7,9-dioxabicyclo[4.3.0]non-4-ene 
(192) 
O
O
O
OTHP
192
 
To a solution of alcohol 191 (389 mg, 1.37 mmol) in freshly distilled DCM (65 mL) were added 
Celite (1.8 g) and PDC (1.8 g, 4.78 mmol), and the reaction mixture was stirred at room temperature 
under an argon atmosphere for 26 h. The mixture was filtered through a plug of Celite,  and 
concentrated in vacuo to give a slightly yellow oil, which was purified by flash column 
chromatography (heptane/EtOAc = 3:1) to afford 192 (334 mg, 86%) as a colorless oil and a 
mixture of two diastereomers. Rf 0.62 (EtOAc/heptane = 1:1). IR (film): 2985, 2938, 2886, 1698, 
1453, 1380, 1371, 1240, 1219, 1167, 1125, 1063, 1031, 977, 966, 856. 1H NMR (300 MHz, 
CDCl3): δ 6.54 (dq, J = 1.5, 4.2 Hz, 1H), 6.50-6.46 (m, 1H), 4.98 (t, J = 3.3 Hz, 1H), 4.87 (t, J = 3.2 
Hz, 1H), 4.80-4.74 (m, 2H), 4.54-4.41 (m, 4H), 4.13-4.03 (m, 1H), 3.98-3.89 (m, 1H), 3.52-3.41 
(m, 2H), 1.86 (t, J = 1.4 Hz, 3H), 1.85 (t, J = 1.4 Hz, 3H), 1.80-1.67 (m, 5H), 1.61-1.52 (m, 7H), 
1.52 (s, 3H), 1.47 (s, 3H), 1.43 (s, 3H), 1.40 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 197.2, 196.1, 
137.5, 136.0, 135.8, 111.2, 111.1, 98.6, 97.8, 78.5, 77.7, 76.6, 71.7, 71.6, 62.2, 61.9, 30.4, 30.2, 
28.1, 28.0, 26.7, 25.5, 25.4, 19.0, 18.7, 16.2, 15.9. HRMS calcd for C15H22O5Na [M+Na]+ m/z 
305.1359, found m/z 305.1368. 
 
Gabosine A (171) 
HO
HO
O
OH
171
 
Ketone 192 (52 mg, 0.184 mmol) was dissolved in 80% acetic acid in H2O (3.0 mL) and stirred 
under a nitrogen atmosphere for 9 h at 40 ºC. The reaction mixture was cooled to room temperature 
and co-concentrated with H2O to give a residue, which was purified by flash column 
chromatography (EtOAc) to afford gabosine A (171) (28 mg, 96%) as a white crystalline material. 
Rf 0.16 (EtOAc). [α]25D –125.4 (c 0.8, CD3OD) (lit.348 [α]20D –132 (c 1, MeOH), lit.353 [α]D –131 (c 
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0.27, MeOH). mp 56-60 ºC (MeOH). IR (film): 3354, 2955, 2924, 2862, 1684, 1448, 1236, 1139, 
1092, 1028. 1H NMR (300 MHz, CD3OD): δ 6.75 (dq, J = 1.5, 5.6 Hz, 1H), 4.41-4.36 (m, 1H), 4.32 
(d, J = 10.0 Hz, 1H), 3.73 (dd, J = 4.0, 10.0 Hz, 1H), 1.82 (dd, J = 0.9, 1.3 Hz, 3H). 13C NMR (75 
MHz, CD3OD): δ 200.4, 143.0, 136.9, 75.0, 73.9, 67.4, 15.6. NMR data are in accordance with 
literature values.348,353 HRMS calcd for C7H10O4Na [M+Na]+ m/z 181.0471, found m/z 181.0472. 
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9 Experimental work performed at University of Oxford 
 
9.1 General experimental methods 
All reagents were obtained from commercial sources without further purification. Water (H2O) was 
purified using a Milli-Q purification system. Petrol refers to the fraction of petroleum ether in the 
boiling range of 40-60 ºC. TLC was carried out on aluminum plates precoated with 0.25 mm of 
silica gel 60. The plates were developed by dipping in a solution of (NH4)6Mo7O24 • 4H2O (25 g/L) 
and Ce(SO4)2 (10 g/L) in 10% aqueous H2SO4 followed by heating with a heat gun. Flash column 
chromatography was performed on silica gel 60 (particle size 0.035 – 0.070 mm). NMR spectra 
were recorded on a Bruker AV 400 instrument. Chemical shifts (δ) are given in ppm and residual 
solvents were used as internal references.457 Low resolution mass spectra were recorded on a 
Micromass Platform 1 spectrometer using electron spray ionization with methanol as carrier 
solvent. Optical rotations were recorded on a Perkin-Elmer polarimeter. IR spectra were recorded 
on a Bruker Tensor 27 spectrophotometer and IR absorptions are given in cm-1. Melting points are 
uncorrected. 
 
 
9.2 Protein methods 
 
Protein mass spectrometry 
LC/MS. The protein solutions were analyzed under denaturing conditions by liquid chromatography 
(Waters, Milford, MA) coupled to positive electrospray ionization time of flight mass spectrometry 
(ESI+ TOF MS, Micromass, UK) using a Phenomenex Jupiter 5u C4 300 Å 250 x 4.6 mm column. 
The protein solution was injected and eluted at 1 mL/min using a 35 min linear gradient method 
from solvent A (water/5% acetonitrile/0.1% formic acid) and solvent B (acetonitrile/0.1% formic 
acid), see Table 31. All solvents were degassed by sonication for 15 min prior to use. The output of 
the liquid chromatography was split 1:4 (mass spectrometer/waste) and injected into the mass 
spectrometer with a scan range of 300–1800 m/z, capillary voltage 2500 V, cone voltage of 30 V, 
source temperature of 80 °C, and desolvation temperature of 200 °C. Albumin elutes at 13.5 min 
and is visualized as a charge envelope from 950 to 1750 m/z representing +69 to +41 charges. The 
Rune Nygaard Monrad – Ph.D. Thesis 
158 
spectrum was deconvolved to the uncharged parent mass using MaxEnt 1 (Micromass). Myoglobin 
(horse heart) was used as a calibration standard and to test the sensitivity of the system.  
 
Table 31. Chromatographic conditions for LC/MS. 
Time 
(min) %A %B 
Flowrate 
mL/min 
0.0 95 5 1 
5.0 95 5 1 
20.0 5 95 1 
25.0 5 95 1 
30.0 95 5 1 
35.0 95 5 1 
 
MALDI TOF MS. Analysis of proteins by MALDI TOF ESI+ MS was performed on a MALDI 
micro MX (Micromass, UK). The sample was prepared by loading 2 µL of a solution of protein and 
matrix to the MALDI plate followed by drying under nitrogen. Sinapinic acid or cyano-4-
hydroxycinnamic acid (10 mg/mL in 0.1% TFA in water/acetonitrile = 60:40) were used as 
matrices. The plate was analyzed using positive ionization in linear mode with a 30 kDa – 140 kDa 
scan range using the following parameters: source voltage of 12000 V, pulse voltage 3000 V and 
laser 150. BSA was used as a calibration standard and to test the sensitivity of the system. 
 
Tryptic digestion and MS/MS 
Trypsin (10 µg, 1 mg/mL in 50 mM NH4HCO3) was added to 50 µL of a solution of modified HSA 
(approximately 4 g/L) in NH4HCO3 (50 mM, pH 8.0) and incubated at 37 ºC for 16 h. To the 
resultant solution was added 1% aq. formic acid (5 µL), and the mixture was analyzed by liquid 
chromatography (Agilent) coupled to ESI+ TOF MS (LTQ FT Ultra, Micromass, UK) using a 
Phenomenex Jupiter 5u C18 300 Å 150 x 0.5 mm column. The tryptic peptides were injected and 
eluted at 15 µL/min using a 90 min linear gradient method from solvent A (water/0.1% formic acid) 
and solvent B (acetonitrile/0.1% formic acid), see Table 32. The output of the liquid 
chromatography was injected into the mass spectrometer with a scan range of 100–2800 m/z, 
capillary voltage 3000 V, cone voltage of 35 V, source temperature of 80 °C, and desolvation 
temperature of 200 °C.  
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Table 32. Chromatographic conditions for LC-coupled MS/MS. 
Time 
(min) %A %B 
Flowrate 
µL/min 
0.0 95 5 15 
5.0 95 5 15 
30.0 60 40 15 
60.0 5 95 15 
70.0 95 5 15 
90.0 95 5 15 
 
Size-exclusion chromatography 
Desalting and removal of excess reagents were carried out by PD10 size-exclusion chromatography 
(10 kDa molecular weight cutoff). The PD10 column was washed with buffer or water (25 mL), the 
protein sample (2.5 mL) was loaded and the column was eluted with buffer or water (3.5 mL). 
 
Determination of protein concentration 
Protein concentrations were measured by UV absorbance. The extinction coefficient for unmodified 
HSA at 280 nm (ε280nm = 28730 M-1 cm-1) was calculated from the amino acid sequence410 using the 
following protein concentration calculater: http://www.mrc-
lmb.cam.ac.uk/ms/methods/proteincalculator.html. Determination of protein concentration using 
Bradford assays with BSA as a standard agreed favorably with the concentration obtained by A280. 
The concentrations of modified protein solutions were estimated using Bradford assay. 
 
SDS-PAGE gel electrophoresis 
To microcentrifuge tubes containing protein (15 µL) was added sample loading buffer [3 µL; Tris-
HCl (1.52 g), glycerol (20 mL), SDS (2 g) and bromophenol blue (2 mg) dissolved in H2O (90 mL), 
adjusted to pH 6.8 and made up to 100 mL H2O]. The samples were heated to 100 ºC for 5 min and 
together with protein marker (3 µL) they were loaded to a 10 well Invitrogen NuPAGE® Nowex 4-
12% Bis-Tris gel, which was eluted for 45 min (200 V) with running buffer [20x NuPAGE® MOPS 
(40 mL), H2O (760 mL)]. The gel was incubated in gel stain [Coomassie Brilliant Blue R-250 (2.5 
g), methanol (500 mL), glacial acetic acid (400 mL), H2O (100 mL)] on a rocking table for 30 min. 
The gel stain was then replaced with gel destain [methanol (400 mL), glacial acetic acid (70 mL), 
H2O (530 mL)] and the gel was incubated on a rocking table overnight. 
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Preparative HPLC purification of human serum albumin 
Commercial HSA was purified by preparative high-performance liquid chromatography using a 
Dionex Ultimate 3000 HPLC. 2 mL of a solution of HSA (25 mg/mL) in water was injected into a 
preparative HPLC column (Vydac, C18, 300 Å) at room temperature. A linear gradient method of 
solvent A (water/0.1% formic acid) and solvent B (acetonitrile/0.1% formic acid) was used (Table 
33) and the fractions (Gilson FC204 fraction collector) were collected based on UV absorbance at 
280 nm. The fractions were analyzed by LC/MS. The concentration of the purified protein solution 
was measured by UV absorption at 280 nm. 
 
Table 33. Chromatographic conditions for preparative HPLC. 
Time 
(min) %A %B 
Flowrate 
mL/min 
0.0 95 5 5 
5.0 95 5 5 
10.0 50 50 5 
42.5 25 75 5 
45.0 0 100 5 
50.0 0 100 5 
55.0 95 5 5 
60.0 95 5 5 
 
Purification of human serum albumin419,420 
To commercial HSA (Lee BioSolutions, Inc., 50 mg, 0.75 µmol) and EDTA (1.5 mg, 5 µmol) in aq. 
phosphate buffered saline (5 mL, 20 mM, pH 8.5) were added DTT (10 mg, 65 µmol) in phosphate 
buffered saline (68 µL), and the reaction mixture was stirred at room temperature. The conversion 
was followed by mass spectrometry and after 2 h, full reduction of the Cys34-Cys disulfide was 
achieved. Cysteine and excess reducing agent was removed by PD10 size-exclusion 
chromatography eluting with a solution of EDTA (1 mM) and DTT (0.02 mM) in phosphate buffered 
saline (20 mM, ph 8.0). The solution was left for 48 h at 4 ºC exposed to atmospheric air to refold. 
The protein solution was purified by PD10 size-exclusion chromatography eluting with phosphate 
buffered saline (20 mM, pH 7.4) to give Cys34-Cys reduced HSA in more than 95% yield. The 
protein solution was concentrated using a YM10 Amicon ultrafiltration membrane to a 
concentration of 42 g/L. The protein concentration was determined by UV absorbance. LC/MS: 
found 66437, expected 66438. 
 
Chapter 9 Experimental work performed at University of Oxford 
161 
General protein modification methods 
General procedure A: Modification of HSA with 2-imino-2-methoxyethyl reagents 
Modifying the procedure developed by Stowell and Lee,431 a solution of HSA (clysine = 4-30 mM) in 
phosphate buffered saline (20 mM, pH 9) was added to the IME reagent (223 or 229) (1-25 eq. per 
lysine) as an approximately 1:1 mixture with the corresponding cyanomethyl thioglycopyranoside 
224 or 230. The reaction mixture was stirred very vigorously for 30 sec and was then left under 
gentle stirring overnight at room temperature. After 16 h, the protein solution was cooled to 4 ºC 
and purified by PD10 size-exclusion chromatography eluting with water or phosphate buffered 
saline. The glycoprotein was analyzed by SDS-PAGE gel electrophoresis and/or mass spectrometry 
(MALDI TOF MS). 
 
General procedure B: Modification of HSA with N-hydroxysuccinimide esters 
To an aq. solution of HSA (clysine = 0.8-27 mM) in phosphate buffered saline (20 mM, pH 4-9) was 
added NHS ester 236 or 238 (0.017-250 eq. per lysine) either in crystalline form or dissolved in a 
co-solvent. The reaction mixture was stirred very vigorously for 30 sec and was then left under 
gentle stirring overnight at 25 or 37 ºC. After 16 h, the protein solution was cooled to 4 ºC and 
purified by PD10 size-exclusion chromatography eluting with water or phosphate buffered saline. 
The extent of modification was analyzed by SDS-PAGE gel electrophoresis and/or mass 
spectrometry (LC/MS or MALDI TOF MS). 
 
General procedure C: Incubation of HSA with 1-β-O-acyl glucuronides 
To an aq. solution of HSA (33 g/L) in phosphate buffered saline (20 mM, pH 7.4) were added acyl 
glucuronides 211-216 at a final concentration of 0.5 or 5.0 mM. The reaction mixture was mixed 
very vigorously for 30 sec and then gently shaken at 37 ºC for 16 h. The protein solution was then 
cooled to 4 ºC and purified by PD10 size-exclusion chromatography eluting with water to remove 
salts and excess reagent. The product was analyzed by mass spectrometry (LC/MS). 
 
Incubation of HSA with D-glucuronic acid 
As a control experiment, D-glucuronic acid (0.5 or 5.0 mM) was incubated with HSA (33 g/L) 
according to general procedure C. Workup by size-exclusion chromatography and subsequent 
analysis by mass spectrometry (LC/MS) revealed a completely unmodified spectrum of HSA. 
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Gal-modified HSA (231) 
Following general procedure A, HSA (100 mg, 89 µmol lysines, clysine = 30 mM) was incubated with 
IME reagent 223 (0.4 g, 0.5 mmol) as an approximately 1:2 mixture with cyano compound 224 in 
PBS buffer (3 mL) at pH 9. Workup gave a solution of Gal-modified HSA 231 (42.5 Gal units on 
average, 3.5 mL, approximately 32 mg/mL). MALDI TOF MS: found 76.4 kDa. 
 
Attempted α(2,3)-SiaT-catalyzed sialylation442 of Gal-modified HSA 
To a mixture of sialic acid (5.2 mg, 16.7 µmol) and CTP disodium salt (8.8 mg, 16.7 µmol) was 
added a solution of CMP-sialic acid synthetase (100 µL, 10 mg/mL, 0.04 µmol) in HEPES buffer 
(50 mM aq. HEPES, 10 mM MgCl2, pH 7.8). The resulting solution was diluted with HEPES buffer 
(400 µL), and the reaction mixture was gently shaken in a fermentor at 37 ºC.442 After 1 h, solutions 
of Gal-modified HSA 231 (76.4 kDa, 42.5 Gal units on average, 529 µL, approximately 19 mg/mL, 
approximately 6 µmol galactose) and α(2,3)-SiaT (360 µL, 1 mg/mL in HEPES buffer, 0.009 µmol) 
in HEPES buffer were added to the mixture and the extent of reaction was followed by mass 
spectrometry (MALDI TOF MS). After 8 h, additional solutions of CMP-sialic acid synthetase (100 
µL, 10 mg/mL, 0.04 µmol) and α(2,3)-SiaT (360 µL, 1 mg/mL, 0.009 µmol) in HEPES buffer were 
added to the reaction mixture, but after 24 h still almost no conversion was achieved. Precipitated 
enzymes and reagents were removed by centrifugation and to that solution was added a precipitate-
free solution of α(2,3)-SiaT (0.5 mg, 0.013 µmol) and CMP-sialic acid [made from sialic acid (10.4 
mg, 33.4 µmol), CTP disodium salt (20.0 mg, 37.9 µmol) and CMP-sialic acid synthetase (300 µL, 
10 mg/mL, 0.12 µmol)] in HEPES buffer. After an additional 24 h at 37 ºC approximately 5% 
conversion was achieved. MALDI TOF MS: found 77.0 kDa. 
 
Attempted CstII-catalyzed sialylation of Gal-modified HSA 
To sialic acid (5.2 mg, 16.7 µmol) and CTP disodium salt (8.8 mg, 16.7 µmol) was added CMP-
sialic acid synthetase (100 µL, 10 mg/mL, 0.04 µmol) in HEPES buffer (50 mM aq. HEPES, 10 mM 
MgCl2, pH 7.8). The resulting solution was diluted with HEPES buffer (400 µL) and was gently 
shaken in a fermentor at 37 ºC.442 After 1 h, solutions of Gal-modified HSA 231 (76.4 kDa, 42.5 
Gal units on average, 529 µL, approximately 19 mg/mL, approximately 6 µmol galactose) and CstII 
(360 µL, 2 mg/mL, 0.01 µmol) in HEPES buffer were added and the extent of reaction was 
followed by mass spectrometry (MALDI TOF MS). After 8 h, additional solutions of CMP-sialic 
acid synthetase (100 µL, 10 mg/mL, 0.04 µmol) and CstII (360 µL, 2 mg/mL, 0.01 µmol) in HEPES 
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buffer were added to the reaction mixture, but after 24 h still almost no conversion was achieved. 
Precipitated enzymes and reagents were removed by centrifugation and to that solution was added a 
precipitate-free solution of CstII (1 mg, 0.014 µmol) and CMP-sialic acid [made from sialic acid 
(10.4 mg, 33.4 µmol), CTP disodium salt (20.0 mg, 37.9 µmol) and CMP-sialic acid synthetase 
(300 µL, 10 mg/mL, 0.12 µmol)] in HEPES buffer. After an additional 24 h at 37 ºC approximately 
10% conversion was achieved. MALDI TOF MS: found 77.6 kDa. 
 
Attempted T. cruzi transsialidase-catalyzed sialylation of Gal-modified HSA443,444 
To a solution of Gal-modified HSA 231 (76.4 kDa, 42.5 Gal units on average, 500 µL, 
approximately 19 mg/mL, approximately 5 µmol galactose) and fetuin (100 mg, 16 µmol sialic 
acid) in HEPES buffer (50 mM aq. HEPES, 10 mM MgCl2, pH 7.8) was added a crude batch of 
T. cruzi transsialidase (2.5 mL, approximately 0.05 µmol) in sodium cacodylate buffer (200 mM aq. 
sodium cacodylate, 20 mM MnCl2, pH 7.7), and the reaction mixture was shaken gently in a 
fermentor at 37 ºC. The reaction was followed by mass spectrometry (MALDI TOF MS) and within 
24 h approximately 6% conversion was achieved. MALDI TOF MS: found 77.2 kDa. 
 
GlcNAc-modified HSA (233) 
Following general procedure A, HSA (18 mg, 16 µmol lysines, clysine = 29 mM) was incubated with 
IME reagent 229 (156 mg, 0.25 mmol) as an approximately 1:1 mixture with cyanomethyl 
compound 230 in PBS buffer (550 µL) at pH 9. Workup gave a solution of GlcNAc-modified HSA 
233 (47.5 GlcNAc units on average, 3.5 mL, approximately 6 mg/mL). MALDI TOF MS: found 
79.5 kDa. 
 
β(1,4)-GalT-catalyzed galactosylation445 of GlcNAc-modified HSA 
To a solution of UDP-galactose disodium salt (5.9 mg, 9.7 µmol) in HEPES buffer (100 µL, 50 mM 
aq. HEPES, 10 mM MgCl2, pH 7.8) were added solutions of GlcNAc-modified HSA 233 (79.5 kDa, 
47.5 GlcNAc units on average, 200 µL, approximately 4 mg/mL, 0.5 µmol N-acetyl-glucosamine) 
and β(1,4)-GalT (200 µL, 1 mg/mL, 0.006 µmol) in sodium cacodylate buffer (200 mM aq. sodium 
cacodylate, 20 mM MnCl2, pH 7.4), and the reaction mixture was gently shaken in a fermentor at 37 
ºC. After 24 h, a solution of additional UDP-galactose disodium salt (15.0 mg, 24.6 µmol) and 
β(1,4)-GalT (200 µL, 1 mg/mL, 0.006 µmol) in sodium cacodylate buffer as well as alkaline 
phosphatase (10 mg, 13 U/mg, 130 U) were added, and the reaction mixture was stirred for an 
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additional 24 h. The solution was centrifuged to remove precipitated enzymes and reagents, and the 
solution was analyzed by mass spectrometry (MALDI TOF MS) revealing 16% conversion (7.4 Gal 
units were incorporated on average). MALDI TOF MS: found 80.7 kDa. 
 
 
9.3 Organic synthesis♦ 
 
1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranose (219)431 
O
AcO
AcO
AcO
OAc
OAc
219
 
D-Galactose (1.0 g, 5.6 mmol) was added to dry pyridine (10 mL) and acetic anhydride (10 mL, 106 
mmol) and stirred at room temperature under an argon atmosphere overnight. The liquids were 
removed in vacuo by co-evaporation with toluene to give 219 (2.2 g, 100%) as a semi-crystalline 
syrup. Rf 0.55 (EtOAc/petrol = 1:1); 1H NMR (400 MHz, CDCl3): δ 5.72 (d, J = 8.3 Hz, 1H, H1), 
5.49-5.47 (m, 1H, H4), 5.33-5.31 (m, 1H, H2), 5.10-5.03 (m, 1H, H3), 4.37-4.30 (m, 1H, H5), 4.18-
4.02 (m, 2H, H6,6’), 2.15 (s, 3H), 2.14 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H) (CH3 x 5); 13C 
NMR (100 MHz, CDCl3): δ 170.5, 170.3, 170.0, 169.1 (C=O x 5), 89.8 (C-1), 68.9, 67.5, 67.5, 
66.5, 61.4 (C-2,3,4,5,6), 21.0, 20.9, 20.8, 20.7 (CH3 x 5).  
 
2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide (220)431 
O
AcO
AcO
Br
AcO
OAc
220
 
HBr (153 mL, 33% in acetic acid, 845 mmol) was added to a solution of 219 (30.0 g, 77 mmol) in 
DCM (80 mL) at 0 ºC, and the mixture was stirred at room temperature under an argon atmosphere 
for 4.75 h. The reaction mixture was quenched by addition of H2O (1 L) followed by immediate 
extraction with DCM (3 x 250 mL). The combined organic phases were neutralized by washing 
with sat. aq. NaHCO3 (1 L + 500 mL), dried (Na2SO4), filtered and concentrated in vacuo to give 
220 (31.7 g, 100%) as a brown oil. Rf 0.73 (EtOAc/petrol = 1:1); [α]22D +212 (CHCl3, c 1.0), (lit.478 
                                                 
♦
 A small part of the characterization of the intermediates towards the Gal-IME reagent 223 was performed by Oliver 
Pearce. 
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[α]D +227.4, CHCl3, c 1.7); 1H NMR (400 MHz, CDCl3): δ 6.70 (d, J = 4.0 Hz, 1H, H1), 5.52 (d, J = 
3.0 Hz, 1H, H4), 5.41 (dd, J = 3.3, 10.6 Hz, 1H, H3), 5.05 (dd, J = 3.9, 10.6 Hz, 1H, H2), 4.49 (t, J = 
6.6 Hz, 1H, H5), 4.15 (dd, J = 6.6, 11.4 Hz, 2H, H6,6’), 2.16 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 2.02 
(s, 3H) (CH3 x 4); 13C NMR (100 MHz, CDCl3): δ 170.5, 170.2, 170.0, 169.9 (C=O x 4), 88.2 (C-
1), 71.2, 68.1, 67.9, 67.1, 61.1 (C-2,3,4,5,6), 20.9, 20.8, 20.7 (CH3 x 4).  
 
2-S-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl)-2-thiouronium bromide (221)431 
O
AcO
AcO
AcO
OAc
S NH2
NH2+ Br -
221
 
Bromide 220 (5.73 g, 13.9 mmol) and thiourea (1.59 g, 20.9 mmol) were dissolved in acetone (40 
mL) and heated to reflux. After 3 h, the reaction mixture was cooled to room temperature and the 
product was crystallized by addition of petrol (100 mL). The solution was filtered and the solids 
were dried in vacuo to give 221 (6.62 g, 97%) as a sticky, white solid. Rf 0.03 (EtOAc/petrol = 1:1); 
mp 169 – 171 ºC (acetone/petrol) (lit.479 mp 169.5 ºC); [α]22D +17 (EtOH, c 2.0) (lit.479 [α]22D +16.0, 
EtOH, c 1.6); 1H NMR (400 MHz, d6-DMSO): δ 9.34 (s, 2H), 9.13 (s, 2H) (NH2 x 2), 5.72 (d, J = 
9.9 Hz, 1H, H1), 5.38 (d, J = 3.2 Hz, 1H, H4), 5.23 (dd, J = 3.4, 9.9 Hz, 1H, H3), 5.10 (t, J = 9.9 Hz, 
1H, H2), 4.45 (t, J = 6.2 Hz, 1H, H5), 4.13-4.02 (m, 2H, H6,6’), 2.13 (s, 3H), 2.07 (s, 3H), 2.00 (s, 
3H), 1.94 (s, 3H) (CH3 x 4); 13C NMR (100 MHz, d6-DMSO): δ 169.9, 169.8, 169.7, 169.4 (C=O x 
4), 166.3 (C=NH), 80.1 (C-1), 74.4, 70.4, 67.1, 66.3, 61.2 (C-2,3,4,5,6), 20.5, 20.4, 20,3 (CH3 x 4).  
 
Cyanomethyl 2,3,4,6-tetra-O-acetyl-β-D-thiogalactopyranoside (222)431 
O
AcO
AcO
AcO
OAc
S CN
222
 
Thiouronium bromide 221 (6.56 g, 13.5 mmol), Na2S2O5 (5.2 g, 27.5 mmol) and K2CO3 (2.0 g, 14.8 
mmol) were dissolved in acetone/water (1:1, 80 mL). Chloroacetonitrile (3.4 mL, 54.0 mmol) was 
added to the solution and the reaction mixture was stirred at room temperature for 3 h. The reaction 
mixture was concentrated to give a yellow-white solid, to which ice-cold H2O (200 mL) was added 
to dissolve the salts. The mixture was filtered and washed with water to give 222 (4.00 g) as yellow 
crystals. Additional crystals of the target compound (0.74 g) could be isolated by extraction of the 
combined filtrate and washings with DCM (100 mL). Recrystallization from hot MeOH gave 222 
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(4.74 g, 87%) as white crystals. Rf  0.49 (EtOAc/petrol = 1:1); mp 92 – 94 ºC (MeOH) (lit.422 mp 95 
– 97 ºC); [α]23D -30 (CHCl3, c 0.8) (lit.422 [α]25D -30.0, MeOH, c 5.02); IR (film): 2974, 2937, 2310, 
1745, 1369, 1222; 1H NMR (400 MHz, CDCl3): δ 5.46 (d, J = 3.3 Hz, 1H, H4), 5.25 (t, J = 9.9 Hz, 
1H, H2), 5.09 (dd, J = 3.3, 10.0 Hz, 1H, H3), 4.70 (d, J = 9.9 Hz, 1H, H1), 4.21-4.10 (m, 1H, H6,6’), 
4.01 (t, J = 7.0 Hz, 1H, H5), 3.64 (d, J = 17.0 Hz, 1H, SCHH’), 3.34 (d, J = 17.0 Hz, 1H, SCHH’), 
2.17 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 1.99 (s, 3H) (CH3 x 4); 13C NMR (100 MHz, CDCl3): δ 
170.5, 170.2, 170.0, 169.9 (C=O x 4), 115.9 (CN), 82.4 (C-1), 75.1, 71.6, 67.2, 66.9, 61.5 (C-
2,3,4,5,6), 20.8, 20.7 (CH3 x 4), 14.6 (CH2); m/z (ESI+) C16H21NO9SNa 426 ([M + Na] 94%), 
C32H42N2O18S2Na 829 ([2M + Na] 100%). 
 
2-Imino-2-methoxyethyl β-D-thiogalactopyranoside (223)431 
O
HO
HO
HO
OH
S
NH
OMe
223
 
Cyano compound 222 (2.0 g, 5.0 mmol) was added to a solution of sodium (460 mg, 20.0 mmol) in 
dry MeOH (80 mL). The solution was stirred at room temperature under an argon atmosphere for 
72 h. The pH of the mixture was adjusted to 7-8 by addition of Dowex H+ followed by filtration and 
thorough wash of the filtercake with dry MeOH. Evaporation of the liquids afforded 223 in 57% 
yield (1.26 g, 100% conversion, as a 4:3 mixture with 224) as a slightly orange gum, which turned 
into a fine crystalline product while kept under high vacuum. Rf  0.29 (EtOAc/MeOH = 4:1); mp: 
the crystals decompose at ~45 ºC; [α]23D -43 (MeOH, c 2.0); IR (film): 3357, 2929, 2349, 2164, 
1652, 1593, 1407, 1353, 1086, 1060; 1H NMR (400 MHz, CD3OD): δ 8.54 (s, 1H, NH), 4.54 (d, J = 
9.5 Hz, 1H, H1-CN), 4.31 (d, J = 9.4 Hz, 1H, H1-IME), 4.04-3.38 (m, 6H, H2,3,4,5,6,6’), 3.35 (s, 3H, 
OCH3), 1.90 (s, 2H, SCH2); 13C NMR (100 MHz, CD3OD): δ 170.5 (C=NH), 118.8 (CN), 87.1, 
85.9 (C-1 x 2), 80.9, 80.7 (C-2 x 2), 76.1, 76.0, 71.3, 71.2, 70.5, 70.4, 62.6, 62.5 (C-3,4,5,6 x 2), 
49.2 (OCH3), 24.2 (SCH2); m/z (ESI+) 223: C9H17NO6SNa 290 ([M + Na] 100%), 224: 
C8H13NO5SNa 258 ([M + Na] 74%). 
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2-Acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-D-glucopyranose (225)431 
O
AcO
AcNH
OAc
OAc
AcO
225
 
To N-acetyl-D-glucosamine (10.0 g, 45 mmol) was added dry pyridine (62.5 mL) and acetic 
anhydride (62.5 mL, 661 mmol), and the mixture was stirred at room temperature under an argon 
atmosphere overnight. The liquids were removed in vacuo by co-evaporation with toluene to give a 
13:2 α:β anomeric mixture of 225 (17.6 g, 100%) as a white solid. Rf 0.38 (EtOAc/petrol = 1:1); mp 
121 – 123 ºC (lit.480 mp α-anomer 135 – 136 ºC, β-anomer 185 – 188 ºC (EtOH)); [α]22D +74 
(CHCl3, c 1.0) (lit.480 [α]D α-anomer +89.4, β-anomer +1.2, CHCl3, c 1); 1H NMR (400 MHz, 
CDCl3): δ 6.16-6.12 (m, 1H, NH-α), 5.92 (d, J = 9.3 Hz, 1H, NH-β), 5.70 (d, J = 8.2 Hz, 1H, H1-β), 
5.67 (d, J = 2.6 Hz, 1H, H1-α), 5.26-5.06 (m, 5H), 4.46 (dd, J = 9.1, 10.6 Hz, 1H), 4.31-4.18 (m, 
3H), 4.11-3.93 (m, 2H), 3.80 (dd, J = 2.2, 4.3 Hz, 1H) (α- and β-H2,3,4,5,6,6’), 2.17 (s, 3H), 2.09 (s, 
3H), 2.06 (s, 6H), 2.02 (m, 12H), 1.91 (s, 6H) (CH3 x 10); 13C NMR (100 MHz, CDCl3): δ 171.7, 
171.1, 170.7, 170.2, 170.0, 169.5, 169.3, 169.1, 168.7 (C=O x 10), 92.5 (C-1-β), 90.7 (C-1-α), 72.8, 
72.6, 70.6, 69.7, 67.7, 67.5, 61.6, 61.5, 52.9, 51.0 (α- and β-C-2,3,4,5,6), 23.2, 23.0 (NHCOCH3 x 
2), 21.0, 20.9, 20.7, 20.6, 20.5 (CH3 x 8). 
 
2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-α-D-glucopyranosyl bromide (226)431 
O
AcO
AcNH
OAc
AcO
Br
226
 
HBr (95 mL, 33% in acetic acid, 525 mmol) was added to a solution of 225 (17.5 g, 45 mmol) in 
DCM (50 mL) at 0 ºC, and the reaction mixture was stirred at room temperature under an argon 
atmosphere for 4 h. The reaction mixture was quenched by addition of H2O (500 mL) followed by 
immediate extraction with DCM (3 x 200 mL). The combined organic layers were neutralized by 
washing with sat. aq. NaHCO3 (3 x 250 mL). The combined aq. washings were extracted with DCM 
(100 mL) and the combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo 
to give 226 (8.73 g, 47%) as a yellow oil, which solidified upon standing. Rf 0.58 (EtOAc/petrol = 
1:1); mp 86 – 89 ºC (CH2Cl2) (lit.481 mp 89 – 91 ºC); 1H NMR (400 MHz, CDCl3): δ 6.52 (d, J = 
3.6 Hz, 1H, H1), 6.18 (dd, J = 6.0, 12.6 Hz, 1H, NH), 5.45-5.04 (m, 3H), 4.39-4.04 (m, 3H) 
(H2,3,4,5,6,6’), 2.09 (s, 3H), 2.07 (s, 6H), 2.04 (s, 3H) (CH3 x 4); 13C NMR (100 MHz, CDCl3): δ 
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176.3, 171.5, 170.6, 169.2 (C=O x 4), 91.1 (C-1), 72.6, 70.8, 66.7, 61.0, 53.5 (C-2,3,4,5,6), 23.0 
(NHCOCH3), 20.8, 20.7, 20.6 (CH3 x 3). 
 
2-S-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)-2-thiouronium bromide  
(227)431 
NH2
NH2+ Br -
O
AcO
AcNH
OAc
AcO S
227
 
Bromide 226 (8.28 g, 20.2 mmol), thiourea (2.31 g, 30.3 mmol) and acetone (190 mL) were heated 
to reflux. After 4 h, the reaction mixture was cooled to room temperature and the product was 
crystallized by addition of petrol (650 mL).  The solution was filtered and the solids were dried in 
vacuo to give 227 (8.62 g, 88%) as pale pink crystals. Rf 0.06 (EtOAc/petrol = 1:1); mp 145 – 147 
ºC (acetone/petrol); [α]23D -8.1 (EtOH, c 1.0); IR (film): 3304, 3200, 1745, 1653, 1631, 1375, 1237, 
1045; 1H NMR (400 MHz, d6-DMSO): δ 9.15 (s, 2H), 9.03 (s, 2H) (NH2 x 2), 6.18 (d, J = 3.6 Hz, 
1H, NHAc), 5.56 (d, J = 10.3 Hz, 1H, H1), 5.47-4.71 (m, 3H), 4.21-3.96 (m, 3H) (H2,3,4,5,6,6), 2.01, 
1.98, 1.94, 1.80 (CH3 x 4); 13C NMR (100 MHz, d6-DMSO): δ 170.8, 170.7, 170.4, 170.1 (C=O x 
4), 168.0 (C=NH), 81.5 (C-1), 75.7, 73.4, 68.7, 62.4, 52.1 (C-2,3,4,5,6), 23.4 (NHCOCH3), 21.4, 
21.3, 21.2 (CH3 x 3). 
 
Cyanomethyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-thioglucopyranoside (228) 431 
CN
O
AcO
AcNH
OAc
AcO S
228
 
Thiouronium bromide 227 (8.3 g, 17.1 mmol), Na2S2O5 (6.6 g, 34.7 mmol) and K2CO3 (2.7 g, 19.5 
mmol) were dissolved in acetone/water (1:1, 80 mL). Chloroacetonitrile (4.3 mL, 67.8 mmol) was 
added to the solution and the reaction mixture was stirred at room temperature for 4.5 h. The 
product was precipitated by addition of ice (300 mL), filtered and recrystallized from dry MeOH to 
give 228 (4.86 g, 71%) as a white solid. Rf 0.13 (EtOAc/petrol = 1:1); mp 176 – 178 ºC (MeOH) 
(lit.422 mp 181 – 182 ºC); [α]23D –76 (MeOH, c 0.7) (lit.422 [α]22D –80.8, MeOH, c 5.05); IR (film): 
3331, 2957, 2251, 1739, 1657, 1527, 1401, 1376, 1238, 1048; 1H NMR (400 MHz, CDCl3): δ 5.88 
(d, J = 9.2 Hz, 1H, NH), 5.23-5.09 (m, 2H, H3,4), 4.78 (d, J = 10.4 Hz, 1H, H1), 4.28-4.14 (m, 3H, 
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H2,6,6’), 3.77 (dd, J = 4.7, 9.6 Hz, 1H, H5), 3.67 (d, J = 17.0 Hz, 1H, SCHH’), 3.32 (d, J = 17.0 Hz, 
1H, SCHH’), 2.10 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.97 (s, 3H) (CH3 x 4); 13C NMR (100 MHz, 
CDCl3): δ 171.4, 170.8, 170.6, 169.4 (C=O x 4), 116.3 (CN), 83.2 (C-1), 76.4, 73.4, 68.1, 62.0, 52.9 
(C-2,3,4,5,6), 23.3 (NHCOCH3), 20.9, 20.8, 20.7 (CH3 x 3), 14.8 (CH2); m/z (ESI+) 
C16H22N2O8SNa 425 ([M + Na] 45%), C32H44N4O16S2Na 827 ([2M + Na] 100%). 
 
2-Imino-2-methoxyethyl 2-acetamido-2-deoxy-β-D-thioglucopyranoside (229)431 
O
HO
AcNH
OH
HO S OMe
NH
229
 
Cyano compound 228 (2.0 g, 5.0 mmol) was added to a solution of sodium (460 mg, 20.0 mmol) in 
dry MeOH (80 mL). The solution was stirred at room temperature under an argon atmosphere for 
72 h. The pH of the mixture was adjusted to 7-8 by addition of Dowex H+ followed by filtration and 
thorough wash of the filtercake with dry MeOH. Evaporation of the liquids in vacuo afforded 229 in 
63% yield (1.5 g, 100% conversion, as a 5:3 mixture with 230) as white crystals. When exposed to 
air, the crystals turned into a gum. Rf 0.28 (EtOAc/MeOH = 4:1); mp 136 – 139 ºC (MeOH); [α]23D –
61 (MeOH, c 1.0); IR (film): 3282, 2927, 2250, 1651, 1563, 1446, 1375, 1313, 1063; 1H NMR (400 
MHz, CD3OD): δ 4.66 (d, J = 10.4 Hz, 1H, H1-IME), 4.59 (d, J = 10.4 Hz, 1H, NHCOCH3), 4.47 
(d, J = 10.4 Hz, 1H, H1-CN),  3.94-3.38 (m, 6H, H2,3,4,5,6,6’), 3.35 (s, 3H, OCH3), 1.98 (s, 3H, 
COCH3), 1.90 (s, 2H, SCH2); 13C NMR (100 MHz, CD3OD): δ 173.7 (C=NH), 109.5 (CN), 82.4 
(C-1), 76.9 (C-2), 71.9, 71.8, 62.9, 55.7 (C-3,4,5,6), 49.9 (OCH3), 22.9, 22.8 (SCH2, CH3); m/z 
(ESI+) 229: C11H20N2O6SNa 331 ([M + Na] 100%), 230: C10H16N2O5SNa 299 ([M + Na] 66%). 
 
p-Bromobenzoic acid N-hydroxysuccinimide ester (236)446 
N
O
O
O
O
Br
236
 
A solution of p-bromobenzoic acid (205) (500 mg, 2.5 mmol) and DCC (510 mg, 2.5 mmol) in 
DCM (10 mL) was stirred for 5 min at 0 ºC. N-hydroxysuccinimide (235) (344 g, 3.0 mmol) was 
added to the solution, and after stirring under an argon atmosphere for 10 min, the ice bath was 
removed and the solution was allowed to reach room temperature. After stirring for 3.5 h, the 
solution was filtered through a plug of Celite, the solids were washed with DCM (50 mL) and the 
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combined liquids were concentrated in vacuo followed by purification by flash column 
chromatography (toluene/EtOAc = 9:1) to give 236 (603 mg, 81%) as white crystals. Rf 0.44 
(toluene/EtOAc = 4:1); mp 228 – 230 ºC (acetone) (lit.449 mp 227 – 230 ºC (acetone)); IR (KBr): 
3080, 2988, 1772, 1727, 1589, 1402, 1377, 1234, 1211, 1078, 1066, 992, 847, 741; 1H NMR (400 
MHz, CDCl3): δ 7.99 (d, J = 8.7 Hz, 2H, Ar H x 2), 7.67 (d, J = 8.7 Hz, 2H, Ar H x 2), 2.91 (s, 4H, 
CH2 x 2); 13C NMR (100 MHz, CDCl3): δ 169.2 (CON x 2), 161.4 (COO), 132.5, 132.1 (CH-Ar x 
4), 130.6, 124.2 (C-Ar x 2), 25.8 (CH2 x 2); m/z (ESI-) C7H4O2Br 199 ([M – C4H4O2N] 96%) and 
201 ([M+2 – C4H4O2N] 100%). 
 
p-Bromobenzoic acid N-hydroxysuccinimide ester (236)449 
N-Hydroxysuccinimide (235) (286 mg, 2.5 mmol), p-bromobenzoic acid (205) (500 mg, 2.5 mmol) 
and DCC (501 mg, 2.5 mmol) in dry DMF (8 mL) were stirred at room temperature under an argon 
atmosphere overnight. The reaction mixture was filtered and the solids were washed with EtOAc. 
Concentration of the liquids in vacuo and recrystallization from acetone gave 236 (695 mg, 94%) as 
white crystals. Spectroscopic data are given above. 
 
p-Bromobenzoic acid N-hydroxy-sulfosuccinimide ester sodium salt (238)427,448 
N
O
O
O
O
BrNaO3S
238
 
To N-hydroxy-sulfosuccinimide sodium salt (237) (434 mg, 2.0 mmol), p-bromobenzoic acid (205) 
(402 mg, 2.0 mmol) and DCC (411 mg, 2.2 mmol) was added dry DMF (5 mL), and the reaction 
mixture was stirred at room temperature under an argon atmosphere overnight. The mixture was 
cooled to 4 ºC for 4 h, then filtered and the solids were washed with dry DMF (5 mL). The 
combined filtrate and washings were concentrated in vacuo to give a liquid residue, which was 
crystallized by addition of EtOAc (25 mL). Filtration and drying in vacuo afforded 238 (733 mg, 
92%) as white crystals. Mp > 350 ºC (decomposes slowly); IR (KBr): 3447, 2938, 1778, 1740, 
1652, 1592, 1403, 1372, 1228, 1053, 989, 744; 1H NMR (400 MHz, d6-DMSO): δ 8.03 (d, J = 8.4 
Hz, 2H, Ar H x 2), 7.87 (d, J = 8.5 Hz, 2H, Ar H x 2), 4.12-3.97 (m, 1H, O3SCH), 2.97-2.92 (m, 
2H, CH2); 13C NMR (100 MHz, d6-DMSO): δ 168.8, 165.4 (CON x 2), 161.2 (COO), 132.8, 131.9 
(CH-Ar x 4), 130.0, 123.6 (C-Ar x 2), 56.3 (CH2SO3Na), 31.0 (CH2); m/z (ESI-) C11H7NO7SBr 376 
([M – Na] 86%) and 378 ([M+2 – Na] 100%). 
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10 Appendices 
 
10.1 Appendix I – MS data for cyclodextrin products 
 
MALDI TOF MS data for the crude and peracetylated product mixtures formed by the attempted 
decarbonylation of β-cyclodextrin monoaldehyde (105) following general decarbonylation 
procedure A are shown in  Table 34 and Table 35, respectively. See section 8.2 for further 
experimental details. 
 
Table 34. MALDI TOF MS data of the crude product mixture from the attempted decarbonylation of β-cyclodextrin 
monoaldehyde.  
Observed Mass (Da) Number of glucose 
residues incorporated zero Ac groups one Ac group two Ac groups 
0 1157.6 1199.6 1241.7 
1 1319.7 1361.7 1403.7 
2 1481.8 1523.8 1565.8 
3 1643.9 1685.9 1627.9 
Expected mass of β-cyclodextrin (104): 1157.4 Da.  
 
The data in Table 34 fits well with incorporation of up to three glucose residues (162 Da) and up to 
two acetyl groups (42 Da). 
 
Table 35.  MALDI TOF MS data of the peracetylated product mixture from the attempted decarbonylation of 
β-cyclodextrin monoaldehyde.  
Number of glucose 
residues incorporated Observed Mass (Da) 
0 2040.4 
1 2328.8 
2 2618.2 
3 2906.6 
4 3195.4 
5 3484.1 
6 3772.8 
7 4061.5 
Expected mass of peracetylated β-cyclodextrin: 2040.1 Da.  
 
The data in Table 35 fits well with incorporation of up to seven peracetylated glucose residues (288 
Da). In addition to these major compounds, minor compounds corresponding to incorporation of up 
to 12 peracetylated glucose residues could also be observed. 
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10.2 Appendix II – Solvent accessibilities of HSA 
 
Relative solvent accessibilities were calculated for each individual amino acid residue of HSA using 
the computer program Naccess.455 Solvent accessibilities were calculated for the amino acids 5-582 
in the A strain of dimeric HSA.410 The B strain gave nearly identical values. The relative residue 
accessibility of an amino acid X was calculated as % total side-chain accessibility as compared to 
that residue in the corresponding Ala-X-Ala tripeptide. The solvent accessibility is thereby a 
measure of the accessibility of a given amino acid X relative to the same residue in the tripeptide 
Ala-X-Ala, and accessibilities greater than 100% is not unusual. In that case the amino acid X is 
just more accessible in the protein than in the Ala-X-Ala tripeptide. The calculations were 
performed using different probe sizes (1.0, 1.4 and 2.8 Å, respectively), and as can be seen from the 
reactive accessibility diagrams below, fewer amino acid side-chains become accessible as probe 
size increases. 
 
 
Chapter 10 Appendices 
173 
 
 
 
The relative accessibilities for the lysine residues in HSA are given in Table 36. Based on these 
data, it is anticipated that lysine residues with a higher relative accessibility are more exposed and 
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will therefore be more susceptible to electrophilic attack, however, no direct correlation between 
AG-modification site and calculated accessibility could be observed. For example, the five most 
accessible lysine residues according to Table 36 (lysines 439, 538, 541, 560 and 564) are not found 
to be modified by ibufenac acyl glucuronide 213.  
 
Table 36. Total side-chain accessibilities (%) for lysine residues in HSA relative to the accessibility of the same amino 
acid in the corresponding Ala-X-Ala tripeptide at different probe sizes assessed by the computer program Naccess.455 
Probe size Residue 
1.0 Å 1.4 Å 2.8 Å 
Lys 12 59,10 59,10 66,10 
Lys 20 36,60 31,20 12,10 
Lys 41 47,70 45,80 47,80 
Lys 51 47,70 47,30 48,80 
Lys 64 38,90 31,90 30,50 
Lys 73 25,00 23,00 16,80 
Lys 93 48,90 45,90 42,70 
Lys 106 22,00 9,40 1,00 
Lys 136 38,80 29,10 4,90 
Lys 137 45,10 44,20 41,00 
Lys 159 47,30 44,00 26,90 
Lys 162 41,50 39,00 28,00 
Lys 174 40,80 37,20 37,40 
Lys 181 36,50 32,10 23,30 
Lys 190 50,40 34,60 2,00 
Lys 195 54,50 47,80 12,70 
Lys 199 24,40 15,20 0,00 
Lys 205 66,30 66,20 54,50 
Lys 212 37,40 35,10 22,90 
Lys 225 50,40 49,70 37,20 
Lys 233 40,50 39,30 43,20 
Lys 240 54,60 55,10 56,10 
Lys 262 57,00 57,70 65,50 
Lys 274 32,20 25,00 13,90 
Lys 276 55,70 57,20 70,00 
Lys 281 47,30 47,30 49,20 
Lys 286 21,30 18,50 16,20 
Lys 313 72,40 77,50 97,50 
Lys 317 65,80 69,50 86,70 
Probe size Residue 
1.0 Å 1.4 Å 2.8 Å 
Lys 323 45,30 44,00 48,40 
Lys 351 50,60 51,20 33,70 
Lys 359 71,30 73,30 82,70 
Lys 372 67,40 66,30 71,40 
Lys 378 58,40 59,20 64,70 
Lys 389 58,70 57,00 52,10 
Lys 402 52,80 51,70 49,10 
Lys 413 30,30 23,00 14,00 
Lys 414 16,60 7,10 0,00 
Lys 432 42,40 31,70 3,20 
Lys 436 52,40 48,00 30,40 
Lys 439 82,60 88,70 106,10 
Lys 444 49,20 52,00 40,90 
Lys 466 53,70 46,70 35,20 
Lys 475 56,20 55,40 60,40 
Lys 500 71,40 74,90 90,30 
Lys 519 63,20 60,00 29,30 
Lys 524 52,90 51,50 34,80 
Lys 525 18,60 5,60 1,60 
Lys 534 14,30 10,50 4,40 
Lys 536 40,90 26,90 10,50 
Lys 538 92,40 98,10 100,40 
Lys 541 75,60 80,90 103,20 
Lys 545 59,00 53,40 26,20 
Lys 557 64,40 62,60 65,00 
Lys 560 77,10 82,40 97,90 
Lys 564 78,30 86,30 120,10 
Lys 573 69,80 70,90 64,60 
Lys 574 69,60 73,10 86,80 
 
As mentioned in chapter 6 (section 6.2.5), the following lysine residues were found to be 
glycosylated and/or transacylated by ibufenac acyl glucuronide 213: Lysines 137, 195, 199, 205, 
436, 525 and 534 (Figure 14).  
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Figure 14.  Sequence map of HSA indicating primary amino acid sequence including disulfide bonds (yellow).408,410 
Chemoselective reaction sites for glycosylation with ibufenac AG 213 are coded red; sites for transacylation are coded 
blue, whereas Lys525 exhibiting both glycosylation and transacylation reactivity is coded green. 
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Especially Lys525, which exhibits both glycosylation and transacylation reactivity, has a very low 
accessibility. Also the low accessibility of Lys199 is in contrast to its observed reactivity, however, 
the reactivity of this amino acid can be rationalized by an unusually low pKa of 7.9,482 which may 
be explained by near proximity to His242.408 In general, amino groups with low pKa values are 
more reactive, and furthermore, it seems that glycosylation predominantly occurs at amino groups, 
which are close to other amino groups.417 It has previously been suggested that amino acid residues, 
which are part of Lys-Lys, Lys-His or Lys-His-Lys sequences or which are close to disulfide bonds 
thereby enabling close interaction with a positively charged amino group from another part of the 
protein, are the most reactive sites with respect to non-enzymatic glycosylation.417 Our results are in 
accordance with this assumption, since Lys137, Lys525 and Lys534 are neighbors to either Lys or 
His residues, whereas the amino acids Lys199 and Lys436 are placed next to a disulfide bond 
(Figure 14). The lack of a direct correlation between AG-modification site and accessibility is in 
accordance with a previous report on non-enzymatic glycosylation of HSA concluding that 
accessible surface areas cannot directly be used to predict major glycosylation sites.418 
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10.3 Appendix III – MS data for tryptic peptides 
 
The analytical data for tryptic peptides of HSA modified with p-bromobenzoic acid AG 211, 
ponalrestat AG 212 and p-bromobenzoic acid NHS ester 236 are shown in Table 37, Table 38 and 
Table 39, respectively. The tryptic peptides of HSA modified with acyl glucuronides 211 and 212 
(Table 37 and Table 38) have only been analyzed by mass spectrometry, and no MS/MS analysis 
has been performed. Since these data are not supported by MS/MS analysis, they are not conclusive, 
but they give a good indication of the sites of modification in the case of ponalrestat and p-
bromobenzoic acid AGs.  
 
In general, the observed sites of modification of HSA by ibufenac AG (213) (Table 30), p-
bromobenzoic acid AG (211) (Table 37) and ponalrestat AG (212) (Table 38) as well as p-
bromobenzoic acid NHS ester 236 (Table 39) are in accordance with previously reported sites of 
modification of HSA in vitro483 and in vivo.416,417 
 
 
Table 37. Tryptic peptides of HSA modified with p-bromobenzoic acid AG 211. 
Retention 
time (min) 
m/z 
predicted 
m/z 
observed Residues Sequence 
Modified 
lysine Modification 
22.80 708.6 707.6 137 – 144 K(+)YLYEIAR K-137 Glycosylation 
32.32 822.5 822.2 191 – 195 ASSAK(+) K-195 Glycosylation 
29.23 1106.8 1106.7 191 – 197 ASSAK(+)QR K-195 Glycosylation 
15.59 690.6 690.6 198 – 205 AFK(+)AWAVAR K-212 Glycosylation 
18.58 589.5 589.9 539 – 545 ATK(+)EQLK or ATKEQLK(+) K-541/545 Glycosylation 
Modified protein was hydrolyzed with trypsin and analyzed by LC/MS analysis. The amino acid sequence of 
HSA was derived from the RCSB protein data bank:  DOI 10.2210/pdb1bm0/pdb.411 Residues are numbered 
for this sequence of 585 amino acids. 
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Table 38. Tryptic peptides of HSA modified with ponalrestat AG 212. 
Retention 
time (min) 
m/z 
predicted 
m/z 
observed Residues Sequence 
Modified 
lysine Modification 
30.48 715.6 714.9 137 – 144 K(+)YLYEIAR K-137 Transacylation 
34.47 817.4 817.1 146 – 160  HPYFYAPELLFFAK(+)R K-159 Glycosylation 
28.21 561.4 561.3 191 – 197 ASSAK(+)QR K-195 Transacylation 
21.35 721.1 720.4 198 - 205 LK(+)CASLQK or LKCASLQK(+) K-199/205 Glycosylation 
24.22 633.1 632.9 198 – 205 LK(+)CASLQK or LKCASLQK(+) K-199/205 Transacylation 
25.98 785.6 785.1 210 – 218 AFK(+)AWAVAR K-212 Glycosylation 
29.41 1008.0 1007.4 414 – 428  K(+)VPQVSTPTLVEVSR K-414 Transacylation 
29.35 825.7 826.2 415 – 432 VPQVSTPTLVEVSRNLGK(+) K-432 Glycosylation 
30.42 767.1 767.1 415 – 432 VPQVSTPTLVEVSRNLGK(+) K-432 Transacylation 
28.64 589.0 588.8 429 – 436 NLGK(+)VGSK or NLGKVGSK(+) K-432/436 Transacylation 
26.27 684.5 683.9 539 – 545 ATK(+)EQLK or ATKEQLK(+) K-541/545 Glycosylation 
Modified protein was hydrolyzed with trypsin and analyzed by LC/MS analysis. The amino acid sequence of 
HSA was derived from the RCSB protein data bank:  DOI 10.2210/pdb1bm0/pdb.411 Residues are numbered 
for this sequence of 585 amino acids. 
 
 
 
Table 39. Tryptic peptides of HSA modified with p-bromobenzoic acid NHS ester 236. 
Retention 
time (min) 
m/z 
predicted 
m/z 
observed Residues Sequence 
Modified 
lysine Modification 
29.56 1239.3 1237.8 137 – 144 K(+)YLYEIAR K-137 Transacylation 
30.51 1203.2 1201.8 210 – 218 AFK(+)AWAVAR K-212 Transacylation 
Modified protein was hydrolyzed with trypsin followed by LC-coupled MS/MS analysis. The amino acid 
sequence of HSA was derived from the RCSB protein data bank:  DOI 10.2210/pdb1bm0/pdb.411 Residues are 
numbered for this sequence of 585 amino acids. 
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A catalytic procedure is described for decarbonylation of
unprotected aldoses to afford alditols with one less carbon
atom. The reaction is performed with the rhodium complex
Rh(dppp)2Cl in a refluxing diglyme-DMA solution. A
slightly improved catalyst turnover is observed when a
catalytic amount of pyridine is added. Under these conditions
most hexoses and pentoses undergo decarbonylation into the
corresponding pentitols and tetrols in isolated yields around
70%. The reaction has been applied as the key transformation
in a five-step synthesis of L-threose from D-glucose.
Extending or shortening the carbon chain in unprotected
aldoses has been a subject in carbohydrate chemistry for more
than a century.1 Although many methods are known for chain
elongation of aldoses2 there are only a few procedures for
shortening the carbon chain. The Ruff degradation converts salts
of aldonic acids into one carbon shorter aldoses.3 The reaction
is performed with hydrogen peroxide in the presence of iron-
(III) or copper(II) salts and often occurs in a moderate yield.
Another oxidative degradation reaction converts aldoses into
salts of aldonic acids with loss of one carbon atom.4 This
reaction is carried out with molecular oxygen in an alkaline
solution and gives rise to a good yield in most cases. Moreover,
these procedures for shortening the carbon chain both involve
stoichiometric amounts of inorganic salts.
Aldoses are aldehydes that can undergo a C-H insertion
reaction with a metal followed by decarbonylation. This
transformation converts Cn aldoses into Cn-1 alditols. Andrews
and co-workers exploited this transformation with stoichiometric
amounts of Wilkinson’s catalyst (Rh(PPh3)3Cl).5 The decarbo-
nylation was performed in N-methyl-2-pyrrolidinone (NMP) at
130 °C and afforded alditols in isolated yields ranging from
37% to 87%.5 The high temperature is due to the fact that only
a minute amount of the aldose is present as the free aldehyde
in solution. Ketohexoses underwent decarbonylation under the
same conditions, but in this case the main product was furfuryl
alcohol since ketohexoses are easily dehydrated into 5-hy-
droxymethylfurfural.6 The reactions are stoichiometric since Rh-
(PPh3)3Cl is converted into Rh(CO)(PPh3)2Cl, which will not
perform the decarbonylation unless the temperature is raised to
about 200 °C. However, if additives are added the decarbony-
lation of D-glucose can be achieved with 5-10% of Rh(PPh3)3-
Cl in an NMP solution.7 The additives are either diphenylphos-
phoryl azide,8 sodium azide (both at 50 °C for 24 h), or a 1,ö-
bis(diphenylphosphino)alkane (alkane ) ethane, butane, hexane,
at 130 °C for 24 h). In all cases, the conversion was rather slow
and only a 30-49% HPLC yield of D-arabinitol was obtained
in 24 h.7
Earlier work has shown that catalytic decarbonylations of
aldehydes can be carried out with rhodium catalysts containing
a bidentate phosphine ligand.9 The complex Rh(dppp)2Cl (dppp
) 1,3-bis(diphenylphosphino)propane) has been shown to
decarbonylate simple aldehydes in neat solution.9 Unfortunately,
Rh(dppp)2Cl is not very soluble in organic solvents and has
only found limited use as a decarbonylation catalyst. Recently,
we reinvestigated the application of Rh(dppp)2Cl in this reaction
and found that the decarbonylation of a wide range of aldehydes
could be effectively achieved in refluxing diglyme and that the
active catalyst could be generated in situ from commercially
available RhCl3â3H2O and dppp.10
Herein, we describe the catalytic decarbonylation of unpro-
tected aldoses by the use of Rh(dppp)2Cl. The reaction gives
easy access to a number of chiral polyols which can be used as
building blocks for further synthesis. Furthermore, the decar-
bonylation has been applied as the key step in a concise
synthesis of L-threose from D-glucose.
The initial experiments were performed with D-glucose as
the substrate. It soon became clear that the decarbonylation could
not be achieved with an in situ generated catalyst. When glucose,
RhCl3â3H2O, and dppp were mixed in refluxing diglyme the
reaction immediately turned black due to precipitation of
rhodium metal. Our earlier work has shown that Rh(III) is
reduced to Rh(I) by dppp,10 but glucose is also a reducing agent
and is probably responsible for the further reduction to Rh(0).
It was also attempted to form the active catalyst by mixing
RhCl3â3H2O and dppp in refluxing diglyme and then adding
glucose. However, these experiments mainly led to decomposi-
tion of the carbohydrate. As a result, it was decided to use a
preformed catalyst, Rh(dppp)2Cl, which can be prepared in two
(1) Gyo¨rgydea´k, Z.; Pelyva´s, I. F. Monosaccharide Sugars: Chemical
Synthesis by Chain Elongation, Degradation, and Epimerization; Academic
Press: San Diego, CA, 1998.
(2) For recent examples, see: (a) Palmelund, A.; Madsen, R. J. Org.
Chem. 2005, 70, 8248. (b) Hotchkiss, D.; Soengas, R.; Simone, M. I.; van
Ameijde, J.; Hunter, S.; Cowley, A. R.; Fleet, G. W. J. Tetrahedron Lett.
2004, 45, 9461. (c) Hunter, D. F. A.; Fleet, G. W. J. Tetrahedron: Asymmetry
2003, 14, 3831. (d) Jørgensen, M.; Iversen, E. H.; Madsen, R. J. Org. Chem.
2001, 66, 4625.
(3) (a) Hourdin, G.; Germain, A.; Moreau, C.; Fajula, F. J. Catal. 2002,
209, 217. (b) Jirˇicˇny´, V.; Staneˇk, V. Collect. Czech. Chem. Commun. 1995,
60, 863.
(4) (a) Hendriks, H. E. J.; Kuster, B. F. M.; Marin, G. B. Carbohydr.
Res. 1991, 214, 71. (b) Humphlett, W. J. Carbohydr. Res. 1967, 4, 157.
(5) Andrews, M. A.; Gould, G. L.; Klaeren, S. A. J. Org. Chem. 1989,
54, 5257.
(6) Andrews, M. A. Organometallics 1989, 8, 2703.
(7) Beck, R. H. F.; Elseviers, M.; Lemmens, H. O. J. EP 0716066A1,
1996.
(8) O’Connor, J. M.; Ma, J. J. Org. Chem. 1992, 57, 5075.
(9) Doughty, D. H.; Pignolet, L. H. J. Am. Chem. Soc. 1978, 100, 7083.
(10) Kreis, M.; Palmelund, A.; Bunch, L.; Madsen, R. AdV. Synth. Catal.
2006, 348, 2148.
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steps from RhCl3â3H2O.11 The reaction with this catalyst gave
D-arabinitol as the main product, but the decarbonylation was
still accompanied by significant decomposition due to the poor
solubility of glucose in diglyme. Several cosolvents were
investigated and it was found that smaller amounts of water,
NMP, or N,N-dimethylacetamide (DMA) gave rise to a homo-
geneous reaction mixture. Unfortunately, water forms an azeo-
trope with diglyme with a boiling point of 99 °C, which is much
lower than the boiling point of diglyme (162 °C). The decar-
bonylation requires a rather high temperature in order to proceed
at a reasonable rate and the reactions in diglyme-water mixtures
proceeded too slowly and were highly dependent on the
diglyme-water ratio and the scale. NMP was used in the earlier
decarbonylations with Rh(PPh3)3Cl5-7 and we have shown that
simple aldehydes could be decarbonylated in NMP with a
catalyst generated from RhCl3â3H2O and dppp.10 Glucose also
underwent decarbonylation with Rh(dppp)2Cl in a diglyme-
NMP mixture, but it was difficult to remove the high-boiling
NMP (bp 202 °C) in the workup. DMA (bp 165 °C), on the
other hand, was easier to remove and gave similar results as
NMP. We therefore selected a mixture of diglyme and DMA
for the decarbonylations of monosaccharides. The progress of
the reaction could be monitored by measuring the evolution of
carbon monoxide (Figure 1). The solvents were removed in the
workup by diluting the reaction with water and washing the
mixture with dichloromethane. This afforded D-arabinitol in 71%
isolated yield from D-glucose with 10% of Rh(dppp)2Cl (Table
1, entry 1). The major byproduct was 1,4-anhydro-D-arabinitol,
which was isolated in 20% yield and characterized as the
corresponding triacetate. Only traces were observed of 2,5-
anhydro-D-arabinitol (1,4-anhydro-D-lyxitol) and both anhydro
sugars are probably formed from the parent arabinitol due to
the high reaction temperature. It was not possible to obtain 1,4-
anhydro-D-arabinitol as the major product by increasing the
reaction time since these experiments were accompanied by
significant decomposition.
The decarbonylation still required a rather high catalyst
loading due to the tiny amount of the free aldehyde at
equilibrium.12 A lower catalyst loading gave a lower yield due
to incomplete conversion and decomposition (Table 1, entry 2
and Figure 1). It is known, however, that the mutarotation of
aldoses can be accelerated by acid or base.13 Therefore, several
experiments were performed in the presence of acetic acid or
pyridine (Table 1, entries 3-6). Both additives had a beneficial
effect and made it possible to obtain higher yields with a shorter
reaction time. Pyridine gave the best result and it was therefore
decided to carry out the decarbonylation in the presence of 6%
of pyridine (Figure 1). Under these conditions complete conver-
sion of glucose was achieved with 8% of Rh(dppp)2Cl in 8 h
(Table 1, entry 7).
The reaction was then applied to a number of other monosac-
charides (Table 2). The experiments were performed in the
presence and in the absence of pyridine to illustrate the effect
of the added base. The pentoses generally reacted slightly faster
than the hexoses (Table 2 and Figure 1). Arabinose, ribose,
xylose, mannose, and rhamnose gave similar yields as glucose
(11) (a) van der Ent, A.; Onderdelinden, A. L. Inorg. Synth. 1990, 28,
90. (b) James, B. R.; Mahajan, D. Can. J. Chem. 1979, 57, 180.
(12) Glucose exists as a mixture of the free aldehyde (0.019%), the
hydrated aldehyde (0.022%), two pyranose forms (98.6%), and two furanose
forms (1.29%) in an aqueous solution at 82 °C; see: Maple, R. R.;
Allerhand, A. J. Am. Chem. Soc. 1987, 109, 3168.
(13) Isbell, H. S.; Pigman, W. AdV. Carbohydr. Chem. Biochem. 1969,
24, 13.
FIGURE 1. CO evolution during the course of the decarbonylation
(see the Experimental Section for details).
TABLE 1. Decarbonylation of D-Glucose into D-Arabinitol
entry
amount of
Rh(dppp)2Cl, % additive
reaction
time, h
isolated
yield, %
1 10 none 9 71
2 5 none 11 44
3 5 7% AcOH 9.5 39
4 5 15% AcOH 9 51
5 5 6% pyridine 9.5 55
6 5 13% pyridine 9.5 58
7 8 6% pyridine 8 71
TABLE 2. Decarbonylation of Pentoses and Hexoses
entry aldose methoda
reaction
time, h alditol
isolated
yield, %
1 D-arabinose A 9 erythritol 68
2 D-arabinose B 6.5 erythritol 70
3 D-ribose A 8 erythritol 71
4 D-ribose B 6.5 erythritol 76
5 D-xylose A 8 D-threitol 70
6 D-xylose B 7.5 D-threitol 74
7 D-mannose A 9 D-arabinitol 69
8 D-mannose B 8 D-arabinitol 72
9 L-rhamnose A 11 5-deoxy-
L-arabinitol
66
10 L-rhamnose B 10 5-deoxy-
L-arabinitol
71
11 D-galactose A 9 D-arabinitol 39
12 D-galactose B 8 D-arabinitol 56
13 N-acetyl-
-D-glucosamine
A 16 1-acetylamino-
1-deoxy-
D-arabinitol
42
14 N-acetyl-
-D-glucosamine
B 14.5 1-acetylamino-
1-deoxy-
D-arabinitol
40b
a A: 10% Rh(dppp)2Cl. B: 8% Rh(dppp)2Cl, 6% pyridine. b 15% of
pyridine was used.
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while the yields with galactose and N-acetylglucosamine were
lower. Galactose is less soluble in diglyme-DMA than the other
aldoses while N-acetylglucosamine is known to decarbonylate
slowly due to coordination with the N-acetyl group.5 The long
reaction time and the high temperature did result in some
decomposition of N-acetylglucosamine during the course of the
reaction. In all cases, however, the addition of pyridine gave a
faster transformation and made it possible to use slightly less
of the rhodium catalyst. As in the case of the initial experiments
with glucose, the major byproducts were Cn-1 1,4-anhydroaldi-
tols. For example, 1,4-anhydro-D-arabinitol was isolated in 20%
yield from the experiment in entry 8 while 1,4-anhydro-5-deoxy-
L-arabinitol was obtained in 17% yield from the reaction in
entry 10.
The reaction can also be applied to partially protected
carbohydrate substrates. We envisioned that the tetrose L-threose
could be prepared from D-glucose in a few steps by using the
decarbonylation as the key step. L-Threose is a useful chiral
starting material,14 but is not available from natural sources. It
has previously been prepared by oxidative degradation of other
carbohydrates15 and from L-tartaric acid.16 However, none of
these routes takes advantage of the most abundant carbohydrate,
D-glucose.
The synthesis of L-threose began by converting glucose into
diisopropylidene glucofuranose 117 (Scheme 1). The more labile
5,6-O-isopropylidene acetal was selectively hydrolyzed in
aqueous acetic acid followed by evaporation of the solvent. The
crude triol 2 was then subjected to periodate cleavage to afford
aldehyde 3.18 Previously, periodic acid (H5IO6) in dry ether has
been shown to affect acetal hydrolysis and glycol cleavage in
one step.19 Unfortunately, when we applied this procedure to 1
we only obtained 3 in 40-50% yield, which is much lower
than the 91% yield for the two-step procedure. Aldehyde 3
crystallizes as the dimer, but slowly equilibrates in aqueous
solution to form the monomer. Contrary to the unprotected
aldoses, aldehyde 3 is easy to dissolve in pure diglyme. Again,
it was not possible to conduct the decarbonylation with an in
situ generated catalyst from RhCl3â3H2O and dppp since this
experiment only led to precipitation of rhodium metal. However,
when aldehyde 3 was submitted to 2% of Rh(dppp)2Cl, clean
decarbonylation occurred into 1,2-O-isopropylidene-â-L-threo-
furanose (4). Subsequent removal of the acetal then afforded
L-threose in an overall yield of 71% from D-glucose. L-Threose
is a syrup and exists as an almost equal mixture of the R- and
the â-anomer together with a small amount of the hydrate of
the aldehyde.
In conclusion, we have developed a catalytic procedure for
decarbonylation of unprotected and partially protected carbo-
hydrate aldehydes. This transformation will open new possibili-
ties for using carbohydrates as chiral starting materials in
synthetic chemistry.
Experimental Section
General Procedure for Decarbonylation of Unprotected
Aldoses. To the aldose (400-650 mg, 2.78 mmol) were added Rh-
(dppp)2Cl (214 mg, 0.22 mmol), DMA (3 mL), diglyme (20 mL),
and freshly distilled pyridine (14.5 íL, 0.18 mmol). The mixture
was thoroughly degassed under high vacuum and then stirred at
reflux (162 °C) under a nitrogen atmosphere until TLC (acetone/
BuOH/H2O ) 5:4:1) showed full conversion to the corresponding
alditol (6-16 h). The solution was cooled to room temperature
followed by addition of water (50 mL). The mixture was washed
with CH2Cl2 (4  50 mL) and the combined organic phases were
extracted with water (2  10 mL). The combined aqueous phases
were concentrated and the residue co-concentrated with EtOH. The
resulting residue was further purified by either flash column
chromatography (CH2Cl2/MeOH/H2O ) 4:1:0 to 65:25:4) or reverse
phase column chromatography (H2O). The reaction could also be
monitored by measuring the evolution of carbon monoxide. In this
case, the reaction flask was connected to a burette filled with water.
The bottom of the burette was further connected to a water reservoir
with a large surface area. At rt (25 °C) full conversion of the aldose
corresponds to 68 mL of carbon monoxide.
D-Arabinitol. White crystals. Rf 0.49 (acetone/BuOH/H2O ) 5:4:
1). [R]22D -10.3 (c 0.2, MeOH) (lit.20 [R]19D -12 (c 1, MeOH)).
Mp 98-99 °C (MeOH) (lit.21 mp 101-102 °C (EtOH)). 1H NMR
(300 MHz, D2O) ä 3.86 (ddd, J ) 2.0, 5.3, 7.3 Hz, 1H), 3.77 (dd,
J ) 2.7, 11.5 Hz, 1H), 3.68 (ddd, J ) 2.7, 6.2, 8.8 Hz, 1H), 3.58
(m, 3H), 3.50 (dd, J ) 2.0, 8.3 Hz, 1H). 13C NMR (75 MHz, D2O)
ä 72.3, 71.8, 71.7, 64.5, 64.4. Anal. Calcd for C5H12O5: C, 39.47;
H, 7.95. Found: C, 39.55; H, 7.65.
Erythritol. White crystals. Rf 0.47 (acetone/BuOH/H2O ) 5:4:
1). Mp 116-117 °C (MeOH/heptane) (lit.22 mp 120-121 °C). 1H
NMR (300 MHz, D2O) ä 3.74-3.65 (m, 2H), 3.62-3.49 (m, 4H).
13C NMR (75 MHz, D2O) ä 73.3, 64.0. Anal. Calcd for C4H10O4:
C, 39.34; H, 8.25. Found: C, 39.05; H, 8.00.
D-Threitol. White crystals. Rf 0.52 (acetone/BuOH/H2O ) 5:4:
1). [R]22D -7.5 (c 0.5, MeOH) (lit.23 [R]23D -7.0 (c 0.9, MeOH)).
Mp 89-91 °C (MeOH) (lit.24 mp 90-91 °C (BuOH)). 1H NMR
(14) For recent examples, see: (a) Evans, D. A.; Cee, V. J.; Siska, S. J.
J. Am. Chem. Soc. 2006, 128, 9433. (b) Li, F.; Schwardt, O.; Ja¨ger, V.
Synthesis 2006, 2173. (c) Fu¨rstner, A.; Wuchrer, M. Chem. Eur. J. 2006,
12, 76. (d) Wu, T.; Froeyen, M.; Kempeneers, V.; Pannecouque, C.; Wang,
J.; Busson, R.; De Clercq, E.; Herdewijn, P. J. Am. Chem. Soc. 2005, 127,
5056. (e) Achmatowicz, M.; Hegedus, L. S. J. Org. Chem. 2004, 69, 2229.
(15) (a) Isbell, H. S.; Frush, H. L. Carbohydr. Res. 1979, 72, 301 (from
L-ascorbic acid). (b) Morgenlie, S. Acta Chem. Scand. 1972, 26, 2146 (from
L-sorbose). (c) Perlin, A. S. Methods Carbohydr. Chem. 1962, 1, 68 (from
L-arabinitol).
(16) (a) Chattopadhyay, A.; Dhotare, B. Tetrahedron: Asymmetry 1998,
9, 2715. (b) Nakaminami, G.; Edo, H.; Nakagawa, M. Bull. Chem. Soc.
Jpn. 1973, 46, 266.
(17) Schmidt, O. T. Methods Carbohydr. Chem. 1963, 2, 318.
(18) Gautam, D.; Kumar, D. N.; Rao, B. V. Tetrahedron: Asymmetry
2006, 17, 819.
(19) Wu, W.-L.; Wu, Y.-L. J. Org. Chem. 1993, 58, 3586.
(20) Lewis, D. J. Chem. Soc., Perkin Trans. 2 1991, 197.
(21) Richtmyer, N. K. Carbohydr. Res. 1970, 12, 135.
(22) Trenner, N. R.; Bacher, F. A. J. Am. Chem. Soc. 1949, 71, 2352.
(23) Kitajima, J.; Ishikawa, T.; Tanaka, Y.; Ida, Y. Chem. Pharm. Bull.
1999, 47, 988.
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(300 MHz, D2O) ä 3.69-3.51 (m, 6H). 13C NMR (75 MHz, D2O)
ä 72.9, 63.9. Anal. Calcd for C4H10O4: C, 39.34; H, 8.25. Found:
C, 39.19; H, 8.05.
5-Deoxy-L-arabinitol. Colorless syrup. Rf 0.68 (acetone/BuOH/
H2O ) 5:4:1). [R]22D +11.7 (c 3.8, MeOH). [R]22D +13.1 (c 0.5,
H2O) (reported for the enantiomer25 [R]23D -10.6 (H2O)). 1H NMR
(300 MHz, D2O) ä 3.85-3.74 (m, 2H), 3.64-3.53 (m, 2H), 3.38-
3.28 (m, 1H), 1.17 (d, J ) 6.4 Hz, 3H). 13C NMR (75 MHz, D2O)
ä 74.6, 70.7, 67.1, 63.1, 18.3. Anal. Calcd for C5H12O4: C, 44.11;
H, 8.88. Found: C, 43.85; H, 8.59.
1-Acetylamino-1-deoxy-D-arabinitol. White crystals. Rf 0.49
(acetone/BuOH/H2O ) 5:4:1). [R]22D +23.5 (c 0.5, H2O) (lit.26
[R]22D +23 (H2O)). Mp 142-143 °C (MeOH) (lit.26 mp 146.5-
147.5 °C). 1H NMR (300 MHz, D2O) ä 3.81 (t, J ) 6.7 Hz, 1H),
3.67 (dd, J ) 2.6, 11.4 Hz, 1H), 3.57 (ddd, J ) 4.4, 7.8, 7.7 Hz,
1H), 3.48 (dd, J ) 6.2, 11.5 Hz, 1H), 3.32 (d, J ) 8.5 Hz, 1H),
3.25-3.11 (m, 2H), 1.85 (s, 3H). 13C NMR (75 MHz, D2O) ä 175.4,
71.7, 71.7, 69.1, 63.9, 43.3, 22.8. Anal. Calcd for C7H15NO5: C,
43.52; H, 7.83; N, 7.25. Found: C, 43.67; H, 7.56; N, 7.18.
1,2-O-Isopropylidene-â-L-threofuranose (4). To 1,2-O-isopro-
pylidene-R-D-xylo-pentodialdo-1,4-furanose (3) (500 mg, 2.66
mmol) were added Rh(dppp)2Cl (51 mg, 0.053 mmol) and a
degassed solution of diglyme (10 mL). The mixture was thoroughly
degassed and then stirred at reflux (162 °C) in a preheated oil bath
for 26 h. The solvent was removed under high vacuum at 70 °C to
give a black residue, which was purified by flash column chroma-
tography eluting with ether/pentane ) 2:3 to 4:1 to afford 4 (366
mg, 86%) as white crystals. Rf 0.35 (EtOAc/heptane ) 3:2). [R]22D
+13.1 (c 0.8, acetone) (lit.15b [R]D +13 (c 1, acetone)). Mp 80-
81 °C (ether) (lit.15b,27 mp 84-85 °C (ether/hexane)). 1H NMR (300
MHz, CD3OD) ä 5.78 (d, J ) 3.7 Hz, 1H), 4.35 (d, J ) 3.7 Hz,
1H), 4.04 (d, J ) 2.8 Hz, 1H), 3.92 (dd, J ) 2.9, 9.8 Hz, 1H), 3.68
(dd, J ) 1.0, 9.8 Hz, 1H), 1.32 (s, 3H), 1.19 (s, 3H). 13C NMR (50
MHz, CD3OD) ä 112.7, 106.7, 86.4, 75.9, 73.9, 27.1, 26.4.
Anal. Calcd for C7H12O4: C, 52.49; H, 7.55. Found: C, 52.79; H,
7.47.
L-Threose. 1,2-O-Isopropylidene-â-L-threofuranose (4) (100 mg,
0.62 mmol) was dissolved in 30% aqueous AcOH (10 mL) and
heated to reflux for 4 h. The liquids were removed in vacuo and
the residue was purified by reverse-phase column chromatography
eluting with H2O to give L-threose (74 mg, 99%) as a colorless oil
consisting of a 14:11:5 mixture of the R- and â-furanose forms
and the hydrate. Rf 0.57 (acetone/BuOH/H2O ) 5:4:1). [R]22D +12.3
(c 2.0, H2O) (lit.15b [R]D +12 (c 1, H2O)). 1H NMR (300 MHz,
D2O) ä 5.33 (d, J ) 4.2 Hz), 5.17 (d, J ) 1.1 Hz), 4.94 (d, J ) 6.3
Hz), 4.50-3.36 (m, 4H). 13C NMR (75 MHz, D2O), R-anomer: ä
103.4, 81.9, 76.4, 74.3; â-anomer: ä 97.9, 77.4, 76.1, 71.8;
hydrate: ä 91.0, 74.5, 72.1, 64.2. Anal. Calcd for C4H8O4: C, 40.00;
H, 6.71. Found: C, 40.74; H, 6.72. HRMS calcd for C4H8O4Na
[M + Na]+ m/z 143.0320, found m/z 143.0327. 1H and 13C data
are in accordance with literature values.28
Acknowledgment. Financial support from the Lundbeck
Foundation is gratefully acknowledged. The Center for Sustain-
able and Green Chemistry is sponsored by the Danish National
Research Foundation.
Supporting Information Available: General experimental
methods, characterization of 1,4-anhydro-D-arabinitol and 1,4-
anhydro-5-deoxy-L-arabinitol, synthesis of 2 and 3, and copies of
NMR spectra. This material is available free of charge via the
Internet at http://pubs.acs.org.
JO7017729(24) Birkinshaw, J. H.; Stickings, C. E.; Tessier, P. Biochem. J. 1948,
42, 329.
(25) Bı´lik, L.; Petrusˇ, L.; Zemek, J. Chem. ZVesti 1978, 32, 242.
(26) Jones, J. K. N.; Perry, M. B.; Turner, J. C. Can. J. Chem. 1962, 40,
503.
(27) Francisco, C. G.; Leo´n, E. I.; Martı´n, A.; Moreno, P.; Rodrı´guez,
M. S.; Sua´rez, E. J. Org. Chem. 2001, 66, 6967.
(28) Serianni, A. S.; Barker, R. J. Org. Chem. 1984, 49, 3292.
J. Org. Chem, Vol. 72, No. 25, 2007 9785
184
FULL PAPER
DOI: 10.1002/ejoc.200800983
Synthesis of Gabosine A and N from Ribose by the Use of Ring-Closing
Metathesis
Rune Nygaard Monrad,[a][‡] Mette Fanefjord,[a][‡] Flemming Gundorph Hansen,[a][‡]
N. Michael E. Jensen,[a][‡] and Robert Madsen*[a]
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A concise synthetic route is described for the synthesis of ga-
bosine A and N. The key step uses a zinc-mediated tandem
reaction where methyl 5-deoxy-5-iodo-2,3-O-isopropylid-
ene-β-D-ribofuranoside is fragmented to give an unsaturated
aldehyde which is allylated in the same pot with 3-benzo-
yloxy-2-methylallyl bromide. The functionalized octa-1,7-
diene, thus obtained, is converted into the six-membered ga-
Introduction
The gabosines are a family of secondary metabolites iso-
lated from Streptomyces strains which share a common tri-
hydroxy(methyl)cyclohexenone/-cyclohexanone skeleton.[1]
A total of 14 different gabosines have been identified[2] and
the absolute configuration has been established for gabosine
A–F, I, L, N, and O (Figure 1). None of the 14 compounds
display any significant biological activity, but weak DNA-
binding properties have been shown for several gabosi-
nes.[1a] The biosynthesis of the gabosines occur through a
pentose phosphate pathway in which sedoheptulose 7-phos-
phate cyclizes by an aldol condensation.[3] The chemical
synthesis of the gabosines has been achieved by several stra-
tegies where the carbocyclic ring is either contained in the
starting material [i.e. p-benzoquinone, (–)-quinine, or iodo-
benzene][4] or is created by a Diels–Alder reaction[5] or by
cyclization of a carbohydrate.[6] In the latter case, the car-
bocyclization has been accomplished by an aldol condensa-
tion, a nitrile oxide cycloaddition, a Nozaki–Hiyama–Kishi
reaction, a Horner–Wadsworth–Emmons olefination and
by ring-closing olefin metathesis.
We have described a zinc-mediated tandem reaction for
converting carbohydrates into acyclic dienes that can be cy-
clized by ring-closing metathesis.[7,8] In this reaction, methyl
5-iodopentofuranosides are treated with zinc metal and al-
lylic bromides. First, a reductive fragmentation of the iodo-
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bosine skeleton by ring-closing olefin metathesis. Subse-
quent protective group manipulations and oxidation gives
rise to gabosine N in a total of 8 steps from ribose while the
synthesis of gabosine A employs an additional step for in-
verting a secondary hydroxy group.
(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim,
Germany, 2009)
Figure 1. The gabosine family of secondary metabolites.
furanoside takes place to produce an unsaturated aldehyde
which is subsequently allylated in the same pot by the al-
lylzinc reagent. In this way, the zinc metal serves a dual
purpose by promoting both the reductive fragmentation
and the subsequent allylation reaction.[7] By using this pro-
cedure, we have previously prepared several carbocyclic nat-
ural products from carbohydrates including 7-deoxypancra-
tistatin,[9] cyclophellitol,[10] and calystegine B2, B3 and
B4.[11]
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We envisaged that the tandem reaction would also be an
effective transformation for synthesis of the gabosines as
illustrated with gabosine A and N in Figure 2. This would
require allylic bromide 1 in order to install the methyl group
in the product. Bromide 1 has not been described before,
but the corresponding 3-benzoyloxyallyl bromide has been
developed as an efficient α-hydroxyallylation agent of alde-
hydes in the presence of zinc or indium.[12] We have recently
used 3-benzoyloxyallyl bromide in the tandem reaction with
zinc for synthesis of the conduritols[13] and for chain elong-
ation of aldoses in the presence of indium.[14] On the basis
of these results we expected that the tandem reaction be-
tween 1 and the appropriate iodopentofuranoside could be
achieved to give the desired octa-1,7-diene which upon ring-
closure by metathesis would yield the gabosine skeleton.
Figure 2. Retrosynthesis for gabosine A and N.
Herein, we describe a short synthesis of the two epimeric
gabosines A and N by the use of a zinc-mediated tandem
reaction and ring-closing olefin metathesis.
Results and Discussion
Gabosine A and N have the same stereochemistry at two
hydroxy groups which will both originate from the pentose
in the synthesis. The two natural products differ from each
other at the third hydroxy group which will be installed in
the tandem reaction (Figure 2). -Ribose has the correct
stereochemistry at C-2 and C-3 for both gabosines and the
corresponding methyl furanoside 2a is easy available in two
steps from the parent pentose (Scheme 1).[15] Bromide 1 is
prepared from methacrolein by haloacylation with benzoyl
bromide. The synthesis is carried out in the same way as
the preparation of 3-benzoyloxyallyl bromide from acro-
lein.[16] The kinetic product is initially formed by 1,2-ad-
dition to the aldehyde, but slowly equilibrates to the
thermodynamic 1,4-addition product. The addition is
rather slow, but the reaction can be accelerated by adding
zinc(II) bromide as catalyst. Thus, treatment of methacro-
lein with benzoyl bromide and zinc(II) bromide gave the
desired product in 76% yield after 2 h as a 4:3 mixture of
the E and Z isomer which could not be separated by silica
gel chromatography. When the reaction was performed in
the absence of zinc(II) bromide the time for complete con-
version increased significantly, but the yield was still accept-
able and in this case only the E isomer was formed. Because
this isomer is crystalline and completely stable at 5 °C we
favored the latter synthesis of bromide 1. Furthermore, the
synthesis could be performed on a large scale and the rea-
gent isolated without the use of flash chromatography.
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Scheme 1. Reagents and conditions: (a) CH2Cl2, room temp. (b)
Zn, THF, H2O, 40 °C, sonication.
The tandem reaction between 1 and 2a was carried out
in a THF/H2O mixture under sonication at 40 °C. Treat-
ment of furanoside 2a with zinc for 2 h followed by addition
of bromide 1 gave 85% yield of a 2:1 mixture of dienes 3
and 4 which could be separated by silica gel chromatog-
raphy (Scheme 1). Notably, the stereochemistry at the hy-
droxy group is the same in 3 and 4 which make both com-
pounds suitable for the synthesis of gabosine N. The struc-
ture of 3 and 4 was elucidated after ring-closing metathesis
by 1H NMR and by isopropylidene formation from the cor-
responding diol. The stereochemical outcome is in accord-
ance with our earlier observations[13] and can be rational-
ized by the Felkin–Anh model.[17] The same mixture of 3
and 4 was obtained when the E:Z mixture of 1 was em-
ployed in the tandem reaction.
Because 3 and 4 both have the correct stereochemistry
for gabosine N several experiments were carried out to in-
vert the stereochemical outcome of the allylation in order
to prepare gabosine A by the same reaction. We have shown
earlier that the stereochemistry in the tandem reaction can
be changed by using the unprotected ribofuranoside 2b[18]
or by using indium metal[10,18] where the latter is known to
react by chelation control. However, treatment of 2b with
zinc in the presence of bromide 1 did not furnish the desired
diene 5. Instead, a complex mixture was obtained resulting
from degradation of 2b and self-coupling of 1. When the
same reaction was attempted with indium metal, self-coup-
ling of 1 was the main product and very little fragmentation
of 2b occurred. It was therefore decided to carry out the
fragmentation with zinc and isolate the intermediate alde-
hyde and then perform the subsequent allylation with in-
dium. Only aldehydes that are prepared by fragmentation
of protected ribofuranosides are sufficiently stable to be iso-
lated. Hence, ribofuranosides 2a and 2c were fragmented
with zinc followed by treatment of the corresponding alde-
hydes with 1 and indium. The allylations were carried out
in the presence and in the absence of a Lewis acid[10] and
in different solvent mixtures. Unfortunately, all attempts to
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obtain a decent yield of diene 5 failed. In most cases, bro-
mide 1 only underwent self-coupling and it appears that
this reaction is faster than the allylation of the aldehydes.
In other cases, small amounts of dienes were obtained as
diastereomeric mixtures, but the major isomers had the
same stereochemistry as in 3 and 4. As a result, we decided
to abandon the tandem reaction for synthesis of diene 5
and instead chose to invert the stereochemistry at the hy-
droxy group in 3 (vide infra).
The next step involved ring-closing olefin metathesis and
was carried out with Grubbs’ 2nd generation catalyst[19] in
refluxing dichloromethane. Under these conditions the
major diastereomer 3 cyclized cleanly to give cyclohexene 6
in 97% yield (Scheme 2). However, the minor isomer 4 re-
acted more sluggishly and afforded the corresponding cy-
clohexene 7 in 74% yield. The yield of 7 did not improve
by using Grubbs’ 1st generation catalyst, Hoveyda–Grubbs’
2nd generation catalyst or by changing the solvent to re-
fluxing toluene.
Scheme 2. Reagents and conditions: (a) 10% (PCy3)(C3H4N2Mes2)-
Cl2Ru=CHPh, CH2Cl2, 40 °C. (b) K2CO3, MeOH, room temp. (c)
DHP, PPTS, CH2Cl2, room temp. (d) NaOMe, MeOH, room temp.
(e) PDC, CH2Cl2, room temp. (f) AcOH, H2O, room
temp.40 °C.
To complete the synthesis of gabosine N the allylic posi-
tion had to be oxidized to the ketone. These experiments
were only performed with the major diastereomer 6, but
similar reactions can be envisioned from the minor isomer
7. First, diol 8 was prepared by deprotection of 6 and it
was attempted to carry out a selective allylic oxidation in
the presence of PDC, MnO2 or DDQ. However, these ex-
periments only gave the desired ketone 9 in very low yield
due to incomplete conversion or over-oxidation and it was
therefore decided to protect the homoallylic hydroxy group
in 6 prior to the oxidation. The THP group was chosen
for this purpose since it can be removed under the same
conditions as the isopropylidene acetal. Treatment of
alcohol 6 with dihydropyran gave fully protected 10 in good
yield which was followed by removal of the benzoate to give
allylic alcohol 11. The oxidation of 11 could now be ac-
www.eurjoc.org © 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 2009, 396–402398
complished in a satisfying yield with PDC to furnish pro-
tected gabosine 12. Finally, deprotection under acidic con-
ditions afforded gabosine N with spectral and physical data
in excellent accordance with those reported for the natural
product.[1a,4b]
The synthesis of gabosine A could be achieved by a sim-
ilar sequence after inverting the hydroxy group in cyclohex-
ene 6. The inversion was carried out by initial conversion
into the triflate followed by displacement with sodium ni-
trite in DMF to give alcohol 13 in 52% yield (Scheme 3).
Attempts to improve the yield by using potassium nitrite in
DMF or tetrabutylammonium nitrite in toluene[20] were not
successful. Alcohol 13 was converted into gabosine A by
using the same four steps as employed for gabosine N. THP
protection gave acetal 14 and removal of the benzoate af-
forded alcohol 15 which was oxidized to the corresponding
ketone 16 in 66% overall yield from 13. Hydrolysis of the
acetal protecting groups then furnished gabosine A with
spectral and physical data in agreement with those reported
for the natural product.[1b,4d]
Scheme 3. Reagents and conditions: (a) Tf2O, pyridine, CH2Cl2,
–20 °C room temp., then NaNO2, DMF, room temp. (b) DHP,
PPTS, CH2Cl2, room temp. (c) NaOMe, MeOH, room temp. (d)
PDC, CH2Cl2, room temp. (e) AcOH, H2O, 40 °C.
Conclusions
In summary, we have developed an 8-step synthesis of
gabosine N and a 9-step synthesis of gabosine A. In both
cases, -ribose serves as the starting material and the cyclo-
hexene skeleton is created by a zinc-mediated tandem reac-
tion followed by ring-closing olefin metathesis. The results
emphasize the utility of these two reactions in the prepara-
tion of polyhydroxylated carbocyclic natural products from
carbohydrates.
Experimental Section
General: CH2Cl2 was dried by distillation from CaH2 while MeOH
and DMF were dried with 4-Å molecular sieves. Zinc dust ( 10
micron) was activated immediately before use: zinc (5 g) in 1  HCl
(50 mL) was stirred at room temperature for 20 min and then fil-
tered, rinsed with water and Et2O and finally dried at high vacuum
with a heat gun. Zinc(II) bromide was dried at high vacuum with
a heat gun. All other reagents were obtained from commercial
sources and used without further purification. Reactions were
monitored by TLC using aluminium plates precoated with silica
gel 60. Compounds were visualized by dipping in a solution of
(NH4)6Mo7O24·4H2O (25 g/L) and Ce(SO4)2 (10 g/L) in 10% aque-
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ous H2SO4 followed by heating. Melting points are uncorrected.
Flash column chromatography was performed with E. Merck silica
gel 60 (particle size 0.040–0.063 mm). Optical rotations were mea-
sured with a Perkin–Elmer 241 polarimeter while IR spectra were
recorded with a Bruker Alpha FT-IR spectrometer. NMR spectra
were recorded with a Varian Mercury 300 instrument. Residual sol-
vent peaks were used as internal reference in 1H NMR (δCHCl3 =
7.26 ppm and δCD2HOD = 3.31 ppm) while CDCl3 (δ = 77.16 ppm)
and CD3OD (δ = 49.0 ppm) served as the internal standards in 13C
NMR spectroscopy. High-resolution mass spectra were recorded at
the Department of Physics and Chemistry, University of Southern
Denmark.
(E)-3-Bromo-2-methylprop-1-enyl Benzoate (1). Procedure with
ZnBr2: Benzoyl bromide (1.3 mL, 11.0 mmol) was added to a solu-
tion of freshly distilled methacrolein (770 mg, 11.0 mmol) in anhy-
drous CH2Cl2 and Et2O (1:1, 18 mL) under nitrogen. The mixture
was cooled to –20 °C followed by addition of anhydrous ZnBr2
(25 mg, 0.11 mmol). The reaction was stirred at 0 °C for 2 h and
then quenched by addition of saturated aqueous NaHCO3 (15 mL).
The aqueous solution was extracted with CH2Cl2 (310 mL) and
the combined organic layers were dried (Na2SO4), filtered, and con-
centrated in vacuo. The residue was purified by flash column
chromatography (EtOAc/hexane, 1:20) to give 2.12 g (76%) of the
desired compound as a white crystalline mass (4:3 mixture of the
E and Z isomer).
Procedure without ZnBr2: Freshly distilled methacrolein (15.0 mL,
181.7 mmol) was dissolved in anhydrous CH2Cl2 (200 mL) under
nitrogen. Benzoyl bromide (22.0 mL, 183.5 mmol) was added at
0 °C and the solution was stirred at room temperature for 10 d.
The mixture was concentrated in vacuo and the residue dissolved
in pentane. Cooling to –20 °C gave white crystals which were iso-
lated and recrystallized from pentane to afford 1 (27.8 g, 60%). Rf
= 0.19 (EtOAc/heptane, 1:10). M.p. 61–62 °C. IR (KBr): ν˜ = 3096,
2844, 2913, 1727, 1451, 1382, 1287, 1162, 1122, 704 cm–1. 1H NMR
(300 MHz, CDCl3): δ = 8.14–8.08 (m, 2 H), 7.66–7.57 (m, 2 H),
7.52–7.45 (m, 2 H), 4.07 (s, 2 H), 1.98 (d, J = 1.4 Hz, 3 H) ppm.
13C NMR (75 MHz, CDCl3): δ = 163.2, 134.0, 133.9, 130.1, 128.9,
128.8, 119.2, 36.5, 13.2 ppm. HRMS: calcd. for C11H11BrO2Na [M
+ Na]+ 276.9835; found 276.9848.
3-Benzoyl-1,2,7,8-tetradeoxy-5,6-O-isopropylidene-2-C-methyl-D-
allo- and -D-altro-octa-1,7-dienitol (3 and 4): Activated Zn (1.21 g,
18.5 mmol) was added to a degassed solution of ribofuranoside
2a[15] (1.07 g, 3.4 mmol) in THF/H2O (4:1, 30 mL). The mixture
was sonicated at 40 °C under nitrogen until TLC revealed full con-
version to the aldehyde (2 h). A deoxygenated solution of bromide
1 (1.28 g, 5.1 mmol) in THF (8.0 mL) was then added in two por-
tions; one after 2 h and one after 3.5 h of sonication. After sonicat-
ing for an additional 2 h 45 min at 40 °C, the reaction mixture was
filtered through a plug of Celite and the filter cake was rinsed thor-
oughly with CH2Cl2. The filtrate was washed with saturated aque-
ous NaHCO3 (30 mL) and H2O (230 mL). The combined aque-
ous phases were extracted with CH2Cl2 (230 mL) and the com-
bined organic phases were dried (MgSO4), filtered, and concen-
trated in vacuo. Purification by flash column chromatography
(EtOAc/heptane, 1:5) gave dienes 3 and 4 (0.95 g, 85%) as a separa-
ble 2:1 mixture.
3: Rf = 0.33 (EtOAc/heptane, 1:2). [α]D30 = –5.0 (c = 1.0, CHCl3).
IR (film): ν˜ = 3499, 3074, 2986 2925, 2855, 1720, 1650, 1611, 1452,
1373, 1318, 1270, 1218, 1110, 1070, 1027, 874, 712 cm–1. 1H NMR
(300 MHz, CDCl3): δ = 8.10–8.05 (m, 2 H), 7.58 (tt, J = 1.4, 7.4 Hz,
1 H), 7.49–7.41 (m, 2 H), 6.05 (ddd, J = 7.2, 10.4, 17.4 Hz, 1 H),
5.68 (d, J = 3.1 Hz, 1 H), 5.43 (ddd, J = 1.2, 1.7, 17.2 Hz, 1 H),
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5.30 (ddd, J = 1.1, 1.7, 10.4 Hz, 1 H), 5.20–5.18 (m, 1 H), 5.15 (p,
J = 1.5 Hz, 1 H), 4.71–4.65 (m, 1 H), 4.09–4.05 (m, 2 H), 2.01 (d,
J = 4.2 Hz, OH), 1.94 (s, 3 H), 1.49 (s, 3 H), 1.34 (s, 3 H) ppm.
13C NMR (75 MHz, CDCl3): δ = 165.5, 140.6, 134.3, 133.3, 130.3
129.8, 128.6, 118.5, 116.1, 109.3, 79.1, 77.8, 77.5, 70.9, 28.0, 25.5,
20.3 ppm. HRMS: calcd. for C19H24O5Na [M + Na]+ 355.1516;
found 355.1530.
4: Rf = 0.27 (EtOAc/heptane, 1:2). [α]D29 = –2.8 (c = 1.5, CHCl3).
IR (film): ν˜ = 3490, 3091, 3071, 2987, 2937, 1725, 1654, 1602, 1452,
1379, 1316, 1270, 1218, 1116, 1070, 1027, 918, 875, 712 cm–1. 1H
NMR (300 MHz, CDCl3): δ = 8.14–8.08 (m, 2 H), 7.58 (tt, J = 1.4,
7.4 Hz, 1 H), 7.50–7.42 (m, 2 H), 6.07 (ddd, J = 6.7, 10.4, 17.1 Hz,
1 H), 5.61 (s, 1 H), 5.46 (d, J = 17.1 Hz, 1 H), 5.32 (d, J = 10.8 Hz,
1 H), 5.07–5.02 (m, 2 H), 4.73 (t, J = 6.4 Hz, 1 H), 4.20 (dd, J =
6.1, 9.2 Hz, 1 H), 3.85 (ddd, J = 1.9, 4.7, 9.2 Hz, 1 H), 1.99 (d, J
= 4.8 Hz, OH), 1.88 (s, 3 H), 1.48 (s, 3 H), 1.28 (s, 3 H) ppm. 13C
NMR (75 MHz, CDCl3): δ = 165.3, 141.1, 133.7, 133.3, 130.1,
129.8, 128.6, 118.2, 112.9, 109.0, 78.7, 77.1, 76.2, 69.0, 28.1, 25.5,
20.1 ppm. HRMS: calcd. for C19H24O5Na [M + Na]+ 355.1516;
found 355.1521.
(1S,2S,3S,6R)-3-Benzoyloxy-2-hydroxy-4,8,8-trimethyl-7,9-dioxabi-
cyclo[4.3.0]non-4-ene (6): Grubbs’ 2nd generation catalyst (151 mg,
0.18 mmol) was added to a degassed solution of diene 3 (578 mg,
1.7 mmol) in anhydrous CH2Cl2 (54 mL) under nitrogen. The solu-
tion was protected from sunlight and stirred at reflux under nitro-
gen for 4 d. The reaction was stopped by addition of charcoal
(5.52 g) and the mixture was filtered through a plug of Celite. The
filtrate was concentrated in vacuo and purified by flash column
chromatography (heptane/Et2O, 3:1) to afford the target compound
(511.5 mg, 97%) as a white solid. Rf = 0.52 (EtOAc/heptane, 1:1).
[α]D29 = +65.0 (c = 1.1, CHCl3). IR (film): ν˜ = 3408, 3072, 2987,
2933, 2866, 1711, 1454, 1371, 1348, 1277, 1223, 1108, 1036, 1014,
712 cm–1. 1H NMR (300 MHz, CDCl3): δ = 8.14–8.09 (m, 2 H),
7.59 (tt, J = 2.1, 7.4 Hz, 1 H), 7.49–7.42 (m, 2 H), 5.79–5.74 (m, 1
H), 5.70 (bd, J = 3.8 Hz, 1 H), 4.67–4.61 (m, 1 H), 4.45 (dd, J =
3.2, 6.5 Hz, 1 H), 4.12 (dt, J = 3.5, 6.9 Hz, 1 H), 2.47 (d, J =
6.9 Hz, OH), 1.83 (d, J = 0.8 Hz, 3 H), 1.56 (s, 3 H), 1.43 (s, 3 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 166.8, 134.4, 133.5, 130.0,
129.8, 128.6 123.1, 110.6, 74.0, 72.0, 71.4, 67.3, 27.3, 25.9,
20.2 ppm. HRMS: calcd. for C17H20O5Na [M + Na]+ 327.1203;
found 327.1212.
(1S,2S,3R,6R)-3-Benzyloxy-2-hydroxy-4,8,8-trimethyl-7,9-dioxadi-
cyclo[4.3.0]non-4-ene (7): A degassed solution of diene 4 (34 mg,
0.10 mmol) and Grubbs ’ 2n d generation catalyst (7.4 mg,
0.0087 mmol) in freshly distilled CH2Cl2 (24 mL) was protected
from sunlight and stirred at reflux under argon for 3 d. The reac-
tion mixture was evaporated on Celite and purified by flash column
chromatography (heptaneheptane/EtOAc, 4:1) to give the de-
sired compound (23 mg, 74%) as a white solid. Rf = 0.29 (EtOAc/
heptane, 2:1). [α]D25 = –40.4 (c = 1.0, CDCl3). IR (film): ν˜ = 3459,
3066, 3036, 2985, 2924, 2855, 1720, 1452, 1380, 1268, 1235, 1110,
1047, 1031, 712 cm–1. 1H NMR (300 MHz, CDCl3): δ = 8.11–8.06
(m, 2 H), 7.59 (tt, J = 2.1, 7.4 Hz, 1 H), 7.50–7.42 (m, 2 H), 5.84
(dd, J = 1.0, 8.1 Hz, 1 H), 5.57 (dq, J = 1.9, 3.3 Hz, 1 H), 4.69–
4.64 (m, 1 H), 4.56 (ddd, J = 0.7, 2.9, 5.6 Hz, 1 H), 3.97 (dt, J =
2.9, 8.1 Hz, 1 H), 2.66 (d, J = 8.1 Hz, OH), 1.78 (dd, J = 1.3,
2.6 Hz, 3 H), 1.43 (s, 3 H), 1.40 (s, 3 H) ppm. 13C NMR (75 MHz,
CDCl3): δ = 167.2, 134.6, 133.5, 130.0, 129.8, 128.6, 124.1, 109.9,
75.9, 74.1, 73.1, 71.8, 27.8, 26.5, 19.2 ppm. HRMS: calcd. for
C17H20O5Na [M + Na]+ 327.1203; found 327.1212. Deprotection
with NaOMe in MeOH gave the corresponding diol as described
below for 8. No reaction occurred when the diol was treated with
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2,2-dimethoxypropane and camphorsulfonic acid at room tempera-
ture for 1 h.
(1S,2S,3S,6R)-2,3-Dihydroxy-4,8,8-trimethyl-7,9-dioxabicyclo[4.3.0]-
non-4-ene (8): K2CO3 (49 mg, 0.36 mmol) was added to a solution
of benzoate 6 (0.107 g, 0.38 mmol) in anhydrous MeOH (10 mL)
and the mixture was stirred at room temperature under nitrogen
for 3 h. The reaction was quenched with 1  HCl until neutral pH,
followed by extraction with CH2Cl2 (315 mL). The combined or-
ganic phases were dried (MgSO4), filtered, and concentrated in
vacuo. Purification by flash column chromatography (EtOAc/hep-
tane, 1:1) gave diol 8 (50 mg, 72%) as white crystals. Rf = 0.13
(EtOAc/heptane, 1:1). [α]D25 = +69.9 (c = 1.0, CHCl3). IR (film): ν˜
= 3447, 3002, 2931, 2858, 1370, 1231, 1177, 1083, 1038, 975 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.40 (dq, J = 1.4, 2.8 Hz, 1 H),
4.55–4.50 (m, 1 H), 4.48–4.44 (m, 1 H), 3.84 (dd, J = 4.1, 11.4 Hz,
1 H), 3.77–3.69 (m, 1 H), 3.34 (d, J = 9.3 Hz, OH), 2.74 (d, J =
11.5 Hz, OH), 1.84 (t, J = 1.5 Hz, 3 H), 1.38 (s, 3 H), 1.31 (s, 3 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 137.0, 122.2, 110.3, 76.7,
73.6, 70.5, 67.5, 28.2, 26.4, 21.0 ppm. HRMS: calcd. for
C10H16O4Na [M + Na]+ 223.0941; found 223.0931. Reaction with
2,2-dimethoxypropane and camphorsulfonic acid at room tempera-
ture for 40 min gave 73% yield of the corresponding bis(isopropyl-
idene) compound.
(1R,2S,3S,6R)-3-Benzoyloxy-4,8,8-trimethyl-2-tetrahydropyranyl-
oxy-7,9-dioxabicyclo[4.3.0]non-4-ene (10): DHP (0.4 mL, 4.4 mmol)
and PPTS (14 mg, 0.056 mmol) were added to a solution of alcohol
6 (657.7 mg, 2.16 mmol) in anhydrous CH2Cl2 (20 mL). The solu-
tion was stirred at room temperature under argon overnight. The
reaction was stopped by addition of saturated aqueous NaHCO3
until neutral pH. The phases were separated and the organic phase
was dried (MgSO4), filtered, and concentrated in vacuo. The resi-
due was purified by flash column chromatography (heptane/
EtOAc, 5:1) to give 10 (627.0 mg, 75%) as a colorless oil and a
mixture of two diastereomers. Rf = 0.44 (EtOAc/heptane, 1:1). IR
(film): ν˜ = 3070, 2981, 2939, 2873, 1715, 1452, 1369, 1270, 1232,
1109, 1069, 1054, 1016, 963, 919, 709 cm–1. 1H NMR (300 MHz,
CDCl3): δ = 8.13–8.06 (m, 4 H), 7.52 (tt, J = 1.4, 7.4 Hz, 2 H),
7.44–7.36 (m, 4 H), 5.82–5.78 (m, 2 H), 5.62–5.58 (m, 2 H), 4.95–
4.89 (m, 2 H), 4.66–4.58 (m, 2 H), 4.56–4.50 (m, 2 H), 4.15 (dt, J
= 2.6, 4.7 Hz, 2 H), 4.00–3.84 (m, 2 H), 3.55–3.44 (m, 2 H), 1.78
(t, J = 1.3 Hz, 3 H), 1.76 (t, J = 1.4 Hz, 3 H), 1.70–1.59 (m, 8 H),
1.57 (s, 3 H), 1.55 (s, 3 H), 1.53–1.43 (m, 4 H), 1.41 (s, 3 H), 1.40
(s, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 167.0, 166.9, 133.0,
132.8, 132.8, 131.5, 130.6, 130.3, 130.0, 128.4, 128.3, 126.4, 125.2,
111.0, 110.8, 97.2, 96.3, 74.5, 73.9, 73.6, 72.0, 69.8, 69.4, 69.3, 66.4,
63.0, 61.8, 30.1, 30.1, 28.3, 28.0, 26.8, 26.6, 25.5, 25.4, 20.8, 20.5,
19.5, 18.3 ppm. HRMS: calcd. for C22H28O6Na [M + Na]+
411.1778; found 411.1774.
(1R,2S,3S,6R)-3-Hydroxy-4,8,8-trimethyl-2-tetrahydropyranyloxy-
7,9-dioxabicyclo[4.3.0]non-4-ene (11): Fully protected 10 (150 mg,
0.386 mmol) was dissolved in 10% NaOMe in anhydrous MeOH
(10 mL) and stirred at room temperature for 3 h. The mixture was
evaporated in vacuo and purified by flash column chromatography
(heptane/EtOAc, 3:1) to give 11 (91 mg, 83%) as a colorless oil and
a mixture of two diastereomers. Rf = 0.28 and 0.33 (EtOAc/hep-
tane, 1:1). IR (film): ν˜ = 3529, 2983, 2937, 2874, 1440, 1371, 1227,
1133, 1120, 1075, 1051, 1029, 1012, 985, 970, 814 cm–1. 1H NMR
(300 MHz, CDCl3): δ = 5.41–5.37 (m, 1 H), 5.34 (dq, J = 1.4,
2.8 Hz, 1 H), 4.92 (dd, J = 3.1, 4.3 Hz, 1 H), 4.77 (dd, J = 3.2,
4.5 Hz, 1 H), 4.58–4.50 (m, 2 H), 4.48–4.43 (m, 2 H), 4.02–3.92 (m,
4 H), 3.88 (dd, J = 1.9, 4.2 Hz, 1 H), 3.82 (dd, J = 2.4, 3.9 Hz, 1
H), 3.55–3.44 (m, 2 H), 1.96–185 (m, 2 H), 1.83 (s, 3 H), 1.82 (s, 3
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H), 1.80–1.66 (m, 4 H), 1.57–1.46 (m, 6 H), 1.41 (s, 3 H), 1.39 (s,
3 H), 1.33 (s, 3 H), 1.32 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3):
δ = 138.6, 136.9, 121.9, 120.5, 110.8, 110.5, 99.2, 95.9, 76.4, 74.3,
74.3, 73.6, 73.6, 70.2, 69.9, 67.1, 63.1, 62.9, 30.7, 30.5, 28.2, 27.8,
26.8, 26.4, 25.4, 25.3, 21.2, 20.7, 19.7, 19.6 ppm. HRMS: calcd. for
C15H24O5Na [M + Na]+ 307.1516; found 307.1529.
(1R,2R,6R)-4,8,8-Trimethyl-3-oxo-2-tetrahydropyranyloxy-7,9-dioxa-
bicyclo[4.3.0]non-4-ene (12): PDC (0.235 g, 0.63 mmol) was added
to a solution of alcohol 11 (51 mg, 0.18 mmol) in anhydrous
CH2Cl2 (15 mL) and the mixture was stirred at room temperature
under nitrogen for 20 h. The solution was concentrated in vacuo
and purified by flash column chromatography (heptane/EtOAc,
2:1) to give 12 (36 mg, 71%) as a colorless oil and a mixture of two
diastereomers. Rf = 0.33 (EtOAc/heptane, 1:1). IR (film): ν˜ = 2984,
2937, 2871, 1699, 1453, 1379, 1351, 1229, 1145, 1120, 1074, 1024,
971, 889 cm–1. 1H NMR (300 MHz, CDCl3): δ = 6.32–6.28 (m, 1
H), 4.93–4.89 (m, 1 H), 4.82–4.76 (m, 2 H), 4.56 (d, J = 2.6 Hz, 1
H), 3.92–3.84 (m, 1 H), 3.55–3.46 (m, 1 H), 1.96–1.84 (m, 3 H),
1.81 (t, J = 1.4 Hz, 3 H), 1.62–1.50 (m, 3 H), 1.37 (s, 3 H), 1.32 (s,
3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 196.0, 139.2, 134.5,
111.7, 99.5, 78.5, 74.9, 73.2, 63.1, 30.3, 28.0, 27.2, 25.6, 19.5,
15.6 ppm. Only NMR spectroscopic data for the major dia-
stereomer are reported. HRMS: calcd. for C15H22O5Na [M +
Na]+ 305.1359; found 305.1346.
Gabosine N: Ketone 12 (36 mg, 0.13 mmol) was dissolved in 80%
acetic acid in H2O (2.0 mL) and stirred under nitrogen for 23 h at
room temperature followed by 16 h at 40 °C. The reaction mixture
was cooled to room temperature and concentrated in vacuo to give
a residue that was purified by flash column chromatography
(EtOAc/MeOH, 99:1) to afford gabosine N (17.7 mg, 88%) as white
crystals. Rf = 0.12 (EtOAc). [α]D25 = –150.5 (c = 0.3, CD3OD) [lit.[1a]
[α]D20 = –152.0 (c = 0.89, H2O), lit.[4b] [α]D = –142 (c = 0.16,
MeOH)]. M.p. 174–176 °C (MeOH) [lit.[4b] 174–175 °C (MeOH),
lit.[1a] 182.5–183.3 °C]. IR (film): ν˜ = 3427, 3308, 3244, 2943, 2925,
2851, 1680, 1408, 1343, 1197, 1132, 1044, 1022, 937, 854 cm–1. 1H
NMR (300 MHz, CD3OD): δ = 6.48 (dq, J = 1.5, 2.2 Hz, 1 H),
4.58–4.54 (m, 1 H), 4.34 (dt, J = 2.5, 3.4 Hz, 1 H), 4.23 (d, J =
2.5 Hz, 1 H), 1.81 (dd, J = 1.5, 2.2 Hz, 3 H) ppm. 13C NMR
(75 MHz, CD3OD): δ = 200.2, 145.9, 134.5, 77.7, 76.6, 69.2,
15.3 ppm. NMR spectroscopic data are in accordance with litera-
ture values.[1a,4b] HRMS: calcd. for C7H10O4Na [M + Na]+
181.0471; found 181.0475.
(1S,2R,3S,6R)-3-Benzoyloxy-2-hydroxy-4,8,8-trimethyl-7,9-dioxabi-
cyclo[4.3.0]non-4-ene (13): A solution of alcohol 6 (1.79 g,
5.9 mmol) in freshly distilled CH2Cl2 (40 mL) under nitrogen was
cooled to –20 °C followed by addition of pyridine (2.14 mL,
26.5 mmol) and Tf2O (1.48 mL, 8.8 mmol). The reaction mixture
was slowly warmed to room temperature and after 1.5 h the reac-
tion was quenched with 2  HCl (85 mL). The phases were sepa-
rated and the aqueous phase was extracted with CH2Cl2
(225 mL). The combined organic phases were washed with satu-
rated aqueous NaHCO3 (45 mL), dried (MgSO4), filtered, and con-
centrated in vacuo to give the crude trifluoromethanesulfonate
(2.57 g, 5.9 mmol) as a black residue, which was used directly in
the next step. The crude trifluoromethanesulfonate was redissolved
in anhydrous DMF under nitrogen, NaNO2 (1.62 g, 23.5 mmol)
was added and the mixture stirred at room temperature for 5.5 h.
The reaction mixture was diluted with H2O (120 mL) followed by
extraction with Et2O (550 mL). The combined organic phases
were dried (MgSO4), filtered, and concentrated in vacuo. The resi-
due was purified by flash column chromatography (EtOAc/heptane,
1:51:1) to give alcohol 13 (933 mg, 52%) as a slightly yellow oil.
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Rf = 0.49 (EtOAc/heptane, 1:1). [α]D25 = –12.0 (c = 2.0, CD3OD).
IR (film): ν˜ = 3459, 3064, 3043, 2985, 2925, 2859, 1719, 1452, 1379,
1316, 1268, 1249, 1216, 1115, 1060, 1026, 979, 907, 710 cm–1. 1H
NMR (300 MHz, CDCl3): δ = 8.11–8.05 (m, 2 H), 7.59 (tt, J = 1.4,
7.4 Hz, 1 H), 7.50–7.42 (m, 2 H), 5.76–5.67 (m, 2 H), 4.69–4.63 (m,
1 H), 4.21 (dd, J = 6.3, 9.0 Hz, 1 H), 3.98 (t, J = 8.9 Hz, 1 H), 1.77
(dd, J = 1.3, 2.7 Hz, 3 H), 1.55 (s, 3 H), 1.41 (s, 3 H) ppm. 13C
NMR (75 MHz, CDCl3): δ = 166.7, 139.1, 133.5, 130.0, 129.6,
128.6, 120.1, 110.6, 77.9, 74.7, 72.7, 72.3, 28.4, 26.1, 18.9 ppm.
HRMS: calcd. for C17H20O5Na [M + Na]+ 327.1203; found
327.1216.
(1R,2R,3S,6R)-3-Benzoyloxy-4,8,8-trimethyl-2-tetrahydropyranyl-
oxy-7,9-dioxabicyclo[4.3.0]non-4-ene (14): DHP (0.5 mL, 5.5 mmol)
and PPTS (140 mg, 0.56 mmol) were added to a solution of alcohol
13 (850 mg, 2.79 mmol) in freshly distilled CH2Cl2 (60 mL). The
mixture was stirred at room temperature under nitrogen overnight.
The reaction was stopped by addition of saturated aqueous
NaHCO 3 (100 mL) fol lowed by extract ion with CH 2Cl2
(350 mL). The combined organic phases were dried (MgSO4),
filtered, concentrated in vacuo and purified by flash column
chromatography (heptane/EtOAc, 9:14:1) to give 14 (925 mg,
85%) as a colorless oil and a mixture of two diastereomers. Rf =
0.72 (EtOAc/heptane, 1:1). IR (film): ν˜ = 3063, 2983, 2938, 2868,
1722, 1452, 1380, 1317, 1265, 1247, 1217, 1162, 1119, 1062, 1029,
986, 966, 869, 710 cm–1. 1H NMR (300 MHz, CDCl3): δ = 8.12–
8.03 (m, 4 H), 7.59–7.53 (m, 2 H), 7.48–7.40 (m, 4 H), 5.81–5.67
(m, 4 H), 5.21 (t, J = 2.6 Hz, 1 H), 4.83 (t, J = 3.3 Hz, 1 H), 4.68–
4.58 (m, 2 H), 4.29 (dt, J = 6.1, 8.3 Hz, 2 H), 4.19–4.08 (m, 3 H),
3.64–3.54 (m, 1 H), 3.46–3.37 (m, 1 H), 3.23–3.14 (m, 1 H), 1.78–
1.70 (m, 8 H), 1.62–1.58 (m, 4 H), 1.55 (s, 9 H), 1.40 (s, 3 H), 1.39
(s, 6 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 166.4, 166.2, 139.3,
138.1, 133.4, 133.1, 130.2, 129.9, 129.8, 129.7, 128.7, 128.4, 120.9,
120.1, 110.2, 110.2, 99.0, 97.3, 78.5, 76.1, 75.6, 74.6, 73.0, 72.6,
72.6, 62.1, 61.3, 30.6, 30.5, 28.3, 28.1, 26.6, 26.5, 25.4, 25.3, 19.1,
19.0, 18.5 ppm. HRMS: calcd. for C22H28O6Na [M + Na]+
411.1778; found 411.1796.
(1R,2R,3S,6R)-3-Hydroxy-4,8,8-trimethyl-2-tetrahydropyranyloxy-
7,9-dioxabicyclo[4.3.0]non-4-ene (15): Fully protected 14 (595 mg,
1.53 mmol) was dissolved in 10% NaOMe in anhydrous MeOH
(60 mL) and stirred at room temperature for 3 h. The mixture was
concentrated in vacuo and purified by flash column chromatog-
raphy (heptane/EtOAc, 4:1) to give alcohol 15 (393 mg, 90%) as a
colorless oil and a mixture of two diastereomers. Rf = 0.51 and
0.63 (EtOAc/heptane, 1:1). IR (film): ν˜ = 3442, 3037, 2982, 2936,
2860, 1453, 1441, 1372, 1243, 1215, 1135, 1072, 1047, 1022, 1007,
975, 890 cm–1. 1H NMR (300 MHz, CDCl3): δ = 5.54–5.45 (m, 2
H), 4.79 (dd, J = 2.6, 5.5 Hz, 1 H), 4.62–4.50 (m, 2 H), 4.40 (d, J
= 1.7 Hz, 1 H), 4.31 (t, J = 5.8 Hz, 1 H), 4.14–4.07 (m, 2 H), 4.04–
3.91 (m, 3 H), 3.87–3.80 (dd, J = 5.0, 8.5 Hz, 1 H), 3.59 (t, J =
8.5 Hz, 1 H), 3.56–3.47 (m, 2 H), 2.99 (d, J = 8.5 Hz, OH), 1.96–
1.77 (m, 3 H), 1.87–1.85 (m, 3 H), 1.84–1.83 (m, 3 H), 1.61–1.47
(m, 9 H), 1.47 (s, 3 H), 1.43 (s, 3 H), 1.36 (s, 3 H), 1.34 (s, 3 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 142.1, 138.2, 120.4, 117.3,
110.0, 109.7, 102.7, 99.4, 84.3, 76.7, 75.9, 75.2, 72.7, 71.1, 70.5,
65.6, 64.0, 31.5, 30.9, 28.5, 28.2, 26.6, 26.1, 25.3, 25.1, 21.4, 20.4,
20.3, 19.0 ppm. HRMS: calcd. for C15H24O5Na [M + Na]+
307.1516; found 307.1521.
(1R,2S,6R)-4,8,8-Trimethyl-3-oxo-2-tetrahydropyranyloxy-7,9-dioxa-
bicyclo[4.3.0]non-4-ene (16): Celite (1.8 g) and PDC (1.8 g,
4.78 mmol) were added to a solution of alcohol 15 (389 mg,
1.37 mmol) in freshly distilled CH2Cl2 (65 mL) and the reaction
mixture was stirred at room temperature under argon for 26 h. The
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mixture was filtered through a plug of Celite, and concentrated in
vacuo to give a slightly yellow oil, which was purified by flash col-
umn chromatography (heptane/EtOAc, 3:1) to afford 16 (334 mg,
86%) as a colorless oil and a mixture of two diastereomers. Rf =
0.62 (EtOAc/heptane, 1:1). IR (film): ν˜ = 2985, 2938, 2886, 1698,
1453, 1380, 1371, 1240, 1219, 1167, 1125, 1063, 1031, 977, 966, 856
cm–1. 1H NMR (300 MHz, CDCl3): δ = 6.54 (dq, J = 1.5, 4.2 Hz,
1 H), 6.50–6.46 (m, 1 H), 4.98 (t, J = 3.3 Hz, 1 H), 4.87 (t, J =
3.2 Hz, 1 H), 4.80–4.74 (m, 2 H), 4.54–4.41 (m, 4 H), 4.13–4.03 (m,
1 H), 3.98–3.89 (m, 1 H), 3.52–3.41 (m, 2 H), 1.86 (t, J = 1.4 Hz,
3 H), 1.85 (t, J = 1.4 Hz, 3 H), 1.80–1.67 (m, 5 H), 1.61–1.52 (m,
7 H), 1.52 (s, 3 H), 1.47 (s, 3 H), 1.43 (s, 3 H), 1.40 (s, 3 H) ppm.
13C NMR (75 MHz, CDCl3): δ = 197.2, 196.1, 137.5, 136.0, 135.8,
111.2, 111.1, 98.6, 97.8, 78.5, 77.7, 76.6, 71.7, 71.6, 62.2, 61.9, 30.4,
30.2, 28.1, 28.0, 26.7, 25.5, 25.4, 19.0, 18.7, 16.2, 15.9 ppm. HRMS:
calcd. for C15H22O5Na [M + Na]+ 305.1359; found 305.1368.
Gabosine A: Ketone 16 (52 mg, 0.184 mmol) was dissolved in 80%
acetic acid in H2O (3.0 mL) and stirred under nitrogen for 9 h at
40 °C. The reaction mixture was cooled to room temperature, con-
centrated and co-concentrated with H2O to give a residue that was
purified by flash column chromatography (EtOAc) to afford gabos-
ine A (28 mg, 96%) as a white crystalline material. Rf = 0.16
(EtOAc). [α]D25 = –125.4 (c = 0.8, CD3OD) lit.[1b] [α]D20 = –132 (c =
1, MeOH), lit.[4d] [α]D = –131 (c = 0.27, MeOH). M.p. 56–60 °C
(MeOH). IR (film): ν˜ = 3354, 2955, 2924, 2862, 1684, 1448, 1236,
1139, 1092, 1028 cm–1. 1H NMR (300 MHz, CD3OD): δ = 6.75
(dq, J = 1.5, 5.6 Hz, 1 H), 4.41–4.36 (m, 1 H), 4.32 (d, J = 10.0 Hz,
1 H), 3.73 (dd, J = 4.0, 10.0 Hz, 1 H), 1.82 (dd, J = 0.9, 1.3 Hz, 3
H) ppm. 13C NMR (75 MHz, CD3OD): δ = 200.4, 143.0, 136.9,
75.0, 73.9, 67.4, 15.6 ppm. NMR spectroscopic data are in accord-
ance with literature values.[1b,4d] HRMS: calcd. for C7H10O4Na [M
+ Na]+ 181.0471; found 181.0472.
Supporting Information (see also the footnote on the first page of
this article): 1H and 13C NMR spectra for compounds 1, 3, 4, 6–
8, 10–16, gabosine A and N.
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Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely 
used drugs on the market. Whilst they are considered safe, several NSAIDs 
have been withdrawn from the market as a result of adverse drug 
reactions.1 NSAIDs are extensively metabolised to their 1--O-acyl 
glucuronides (AGs),2 and the risk of NSAID AGs covalently modifying 
biomacromolecules such as proteins or DNA, leading to immune 
responses and cellular dysfunction constitutes a major concern in drug 
discovery and development.3-6 The assessment of the degree of protein 
modification and potential toxicity of individual NSAID AGs is therefore of 
importance in both drug monitoring and development. Herein, we report 
the covalent attachment of 1--O-acyl glucuronides of ibuprofen and 
several NSAID analogues to human serum albumin (HSA) protein in vitro 
under conditions encountered in therapy. Previously unobserved 
transacylation and glycosylation adducts are formed; the observed protein 
product ratios can be rationalised by the degree of -substitution in the 
acyl group. Structure-based protein reactivity correlations of AGs, such as 
these, may prove a useful tool in distinguishing between carboxylic acid-
containing drugs of similar structure that ultimately prove beneficial (e.g., 
Ibuprofen) from those that prove toxic (Ibufenac).7 
  
Carboxylic acid containing drugs, most notably the NSAIDs are primarily 
metabolised to their 1--O-acyl glucuronides in the liver.2 The glucuronidation of 
various drugs, which takes place during Phase II metabolism, is typically a 
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detoxification process that also increases water solubility thereby enabling 
excretion; the resulting products are typically deemed to be pharmacologically 
inactive.6 However, in contrast to the unreactive glucuronides of alcohol and 
phenolic drugs, some of the resulting glucuronides of carboxylate drugs (acyl 
glucuronides, AGs) are highly reactive metabolites;8 as a consequence AGs 
have very recently been deemed to be toxic by regulatory authorities.6  Although, 
the increased reactivity of AGs compared with their parent drugs has almost 
exclusively been attributed to transacylation reactions with biological 
nucleophiles4,9 (Figure 1b, e.g., formation of an amide bond with the amine group 
found at the terminus of the side-chain of lysine), alternative reaction pathways 
are potentially accessible to AGs (Figure 1c)4 that might lead to alternative 
protein modification products. Surprisingly, these modification products have not 
been previously identified. Here we use AGs of the NSAIDs (Figure 2a) to show 
that not only do both pathways (Figure 1b and 1c) have the potential to 
covalently modify endogenous human proteins, but that the predominant 
pathway varies according to drug metabolite identity. 
Once formed enzymatically during Phase II metabolism (Figure 1b) AGs 
may react via several competing pathways. Hydrolysis to reform the parent drug 
and transacylation by direct displacement by attack of nucleophiles (following 
Figure 1b) competes with acyl migration to produce 2-, 3- or 4-O-AGs followed by 
N-glycosylation and possibly also the Amadori rearrangement10 (following Figure 
1c). 1--O-Acyl glucuronides are stable in acid, but under basic or neutral 
conditions migration occurs to produce 2-, 3- or 4-O-AGs.11,12 After migration, the 
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acyl group is less prone to hydrolysis or direct displacement by transacylation, 
and stable 2-, 3- or 4-O-AGs can be isolated.13 Both the transacylation and the 
glycosylation pathways are theoretically capable of covalently modifying hepatic 
and plasma proteins in vivo however, the resulting modified proteins have not 
been fully characterised.4  
Around 25% of all drugs that are withdrawn due to severe toxicity contain 
carboxylic acid groups and acyl glucuronide activity has been implicated as a 
possible mechanism.1,14,15 Yet, the underlying chemical reactivity that might allow 
prediction of which drugs will show excellent efficacy leading to widespread use 
(e.g. 1b/c Ibuprofen) or toxicity in man leading to withdrawal (e.g. 1a, 
Ibufenac)7,16 is not well understood; the similarity in structures such as 1b/c and 
1a suggest that this is a subtle effect. It has been suggested, but not 
demonstrated, that one of the potential mechanisms underlying this observed 
idiosyncracy of toxicity of NSAIDs is AG-derived covalent modification of 
endogenous proteins.3 Evidence for such an AG-induced toxicity mechanism is 
still lacking,2,4,5,17 but, by way of circumstantial support, it has been shown that 
reversible binding of other compounds (like diazepam and warfarin) to plasma 
proteins, such as human serum albumin (HSA), is severely altered when plasma 
protein is modified by AGs.18  
To investigate the nature and extent of AG binding to plasma proteins, a 
series of ibuprofen based 1--O-acyl glucuronides; ibufenac 1a, (R)- and (S)-
ibuprofen 1b-c and a dimethyl analogue 1d, as well as AGs of p-bromobenzoic 
acid 2, as a model NSAID, and the aldose reductase inhibitor ponalrestat19 3 
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were incubated with HSA. AGs were synthesised via a 3-step protection-
acylation-deprotection strategy (Figure 2b) via allyl, benzyl or para-
methoxybenzyl glucuronate esters.20,21 
To obtain a representative single protein species suitable for precise 
reaction monitoring, abundant human serum protein HSA was reduced and re-
purified. Commercially available and isolated HSA contains several post-
translational modifications of which the disulfide oxidation of Cys34 by coupling 
to a single cysteine amino acid residue is the most abundant.22 HSA was treated 
with 13 mM DTT at pH 8 to reduce the Cys34-Cys disulfide bond, followed by 
removal of cysteine and excess DTT by size-exclusion chromatography. The 
protein was then refolded in 0.02 mM DTT under exposure to atmospheric air to 
reform the internal disulfide bridges. Protein refoldng to a different secondary 
structure than native HSA is not believed to be occur.22 This novel protein 
purification strategy allowed ready access to pure HSA suitable for precise AG 
protein reactivity assessment. 
AGs 1-3 were incubated with pure HSA at physiological levels (33 g/L).23 
AGs are generally thought to be rapidly excreted, but substantial plasma 
concentrations, sometimes exceeding their parent drug, are often found.24,25  In 
order to mimic conditions encountered in therapy, an AG concentration of 
0.5 mM in phosphate buffered saline (20 mM, pH 7.4) at 37 ºC, corresponding to 
the peak plasma concentration of drug achieved in chronic cystic fibrosis patients 
treated with ibuprofen was used.26 In addition, high-concentration experiments 
using 5.0 mM AG were also performed. In all cases, identical conditions and 
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incubation times were used for direct comparison of the reactivity of different 
AGs; this allows direct extrapolation of the levels of reactivity from the amount of 
reaction product. The extent of coupling to HSA was analysed by LC-coupled 
TOF MS (ES+) (Table 1 and Figure 3). 
 
Table 1. Selectivity and conversion after incubation of HSA with AGs 
Entry AG 
Conc. 
mM 
Selectivity 
TA : Glyc 
Conversion 
% 
1 2 0.5 <5 : 95 58 
2 2 5.0 <5 : 95 59 
3 3 0.5 55 : 45 4 
4 3 5.0 72 : 28 24 
5 1a 0.5 60 : 40 16 
6 1a 5.0 61 : 39 44 
7 1b 0.5 64 : 36 5 
8 1b 5.0 63 : 37 23 
9 1c 0.5 44 : 56 9 
10 1c 5.0 55 : 45 24 
11 1d 0.5 - 0 
12 1d 5.0 34 : 66 8 
Incubation of 33 g/L HSA with AGs for 16 h at 37 °C and pH 7.4. Selectivities between the 
transacylation (TA) and glycosylation (Glyc) products and conversions (% modified HSA) 
were calculated based on peak heights in respective deconvoluted mass spectra.  
 
At concentrations of both 0.5 and 5.0 mM of p-bromobenzoic acid AG 2 (entries 1 
and 2) glycosylation adducts (Figure 1c) were observed following incubation for 
16 h at a conversion of 58 and 59%, respectively. This is the first time a stable 
glycosylation adduct have been isolated in vitro under conditions encountered in 
therapy. Previously, such N-glycosylation (imine) adducts of proteins have only 
been found by trapping the adducts with a reducing agent like sodium 
cyanoborohydride12,18,27 or at extreme high AG concentrations as compared to 
HSA.12,27,28 Furthermore, in most cases full characterisation of the formed 
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adducts was not performed.12,18,28 Surprisingly, stable glycosylation adducts are 
formed without addition of a reducing agent, however this high conversion even 
at 0.5 mM of 2 clearly indicates that irreversible glycosylation of endogenous 
proteins can occur during treatment with drugs that are metabolised to AGs.  
p-Bromobenzoic acid AG 2 reacts exclusively via the glycosylation 
pathway, and no transacylation product could be observed (Figure 1b). However, 
more subtle and intriguing results were observed following incubation with the 
AGs of ponalrestat 3 and the profens 1a-d (entries 3-12, Table 1); both 
transacylation and glycosylation were unambiguously observed. These AGs were 
not as reactive as 2 with respect to protein modification. In most cases only trace 
modification occurred at 0.5 mM of AG, and significant amounts of coupling 
products could only be observed at relatively high AG concentrations (5.0 mM). 
In the case of ponalrestat AG 3 the transacylation and glycosylation adducts 
were formed in a 72:28 ratio at a combined yield of 24% at 5.0 mM 3 (entry 4). 
The ibuprofen analogues (entries 5-12) also gave a mixture of transacylation and 
glycosylation adducts, and the degree of modification can be visualised in the 
combined mass spectrum of 1a-d (Figure 3). Ibufenac (1a), (R)- (1b) and (S)- 
(1c) Ibuprofen AGs showed clear reactivity with combined yields of 44, 23 and 
24% respectively, whereas the ,-disubstituted dimethyl analogue 1d was 
significantly less reactive (entries 11,12, Table 1) showing no more than 8% 
reaction even at the higher concentrations and showing only trace products 
above background at lower concentrations. Interestingly, in addition to individual 
transacylation and glycosylation adducts, small amounts of dual adducts 
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resulting from concomitant transacylation and glycosylation were also seen for 
1a-c.  
These dual adducts highlighted that more than one reaction site was 
present on HSA. To map these sites and to confirm the identities of the 
glycosylation and transacylation products modified proteins were characterized 
through ‘peptide mapping’ using tryptic digest followed by MS/MS sequencing 
analysis. The products of reaction of Ibufenac-AG 1a with HSA map to 7 different 
lysine residues and revealed that different sites were selectively modified by 
different reaction processes (Table 2 and Figure 4); these sites only correlate in 
part with accessibility (see SI) and only Lys525 is reactive in both pathways.29 
Table 2. Peptide Mapping of Reaction Sites in HSA when Modified with Ibufenac AG 1a 
Retention 
time 
(min) 
m/z 
predicted 
m/z 
observed 
Peptide 
Residues 
Peptide 
Sequence 
Modified 
Amino 
Acid 
Modification 
33.49 704.1 704.1 137 – 144 K(+)YLYEIAR K137 Glycosylation 
24.36 921.8 921.4 191 – 197 ASSAK(+)QR K195 Transacylation 
27.80 621.6 621.6 198 – 205 LK(+)CASLQK K199 Glycosylation 
27.80 621.6 621.6 198 – 205 LKCASLQK(+) K205 Glycosylation 
24.16 450.5 451.2 433 – 439 VGSK(+)CCK K436 Transacylation 
22.07 652.7 651.4 525 – 534 K(+)QTALVELVK K525 Transacylation 
18.86 740.7 741.1 525 – 534 K(+)QTALVELVK K525 Glycosylation 
22.07 652.7 651.4 525 – 534 KQTALVELVK(+) K534 Transacylation 
Modified protein was hydrolyzed with trypsin followed by LC-coupled MS/MS analysis. The amino 
acid sequence of HSA was derived from the RCSB protein data bank:  DOI 
10.2210/pdb1bm0/pdb.
30
 Residues are numbered for this sequence of 585 amino acids. 
 
As might be expected from the reactivity of -unsubstituted ponalrestat AG 3, 
both transacylation (lysines 195, 436, 525 and 534) as well as glycosylation 
(lysines 137, 199, 205 and 525) adducts could be observed for -unsubstituted 
ibufenac AG 1a (Table 2); in all cases the mapping results correlated strongly 
with the observed ratios determined by direct MS (Figure 3 and Table 1).  
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Alkyl AGs displayed (Table 1) lower reactivities than aryl AGs; with 
p-bromobenzoic acid AG 2 a majority of HSA was modified even at 0.5 mM. 
Furthermore, both the nature and extent of protein modification with alkyl AGs 
was highly dependant on the degree of -substitution; variation of -substitution 
from unsubstituted (1a, 3) to monosubstituted (1b-c) to disubstituted (1d) AGs, 
moves reaction preference from transacylation to a preference for glycosylation. 
This is a logical observation consistent with BAc2 nucleophilic substitution at the 
carbonyl group of an AG; a higher degree of -substitution constitutes an 
increased steric hindrance disfavouring addition during such a transacylation 
pathway. In contrast, acyl migration is not affected to the same extent by 
increased -substitution,4 and glycosylation adducts are therefore predominantly 
formed for highly -substituted AGs as with the dimethyl analogue 1d. In addition 
to different selectivity (transacylation versus glycosylation), alkyl AGs with no -
substitution are more reactive than mono- and disubstituted alkyl AGs, and AGs 
of drugs without -substitution are therefore more likely to modify endogenous 
proteins in vivo than AGs of -substituted drugs. The increased reactivity of 
ibufenac AG (1a) compared to (R)- (1b) and (S)-ibuprofen AG (1c) due to the 
lacking -methyl substituent is striking considering that ibufenac was withdrawn 
from the U.K. market in 1968 as a result of hepatotoxicity,7,31 whereas (R/S)-
ibuprofen is still extensively used. 
The observed reactivity of alkyl AGs with respect to -substitution is also 
reflected in their half-lives. Unsubstituted alkyl AGs have been found to have 
half-lives of less than 1 h (zomepirac 0.45 h, diclofenac 0.51 h), while 
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monosubstituted ((S)-naproxen 1.8 h, (S)-ibuprofen 3.3 h) and disubstituted 
(clofibric acid 7.3 h, gemfibrozil 44 h) alkyl AGs have half-lives around 1 to 4 h 
and from 7 to more than 40 h, respectively.4 As indicated by short half-lives 
(probenecid 0.40 h, diflunisal 0.67 h)4 and supported by the reactivity of 2, 
aromatic AGs are highly reactive with respect to protein modification, but they 
seem to be too hindered for transacylation to occur, thus glycosylation adducts 
are formed exclusively. 
In summary, we have shown for the first time that multiple modes of 
reactivity exist for 1--O-acyl glucuronides of widely-used pharmaceuticals with 
an abundant human protein under concentrations representative of those found 
in vivo. Importantly, we reveal here the first direct observations of stable AG-
glycosylation adducts, which is highlighted by contrasting human protein reaction 
selectivities determined by both site and drug-AG identity; these range from near 
exclusive glycosylation (>95%) to majority acylation (>70%). These demonstrate 
that althoughglucuronic acid alone cannot glycosylate human protein, unlike 
glucose,29 AGs are sufficiently activated to cause extensive glycosylation. In this 
way we have established a rationalisation of AG reactivity based on structure, 
which we believe provide a useful tool in the informed development of new 
carboxylic acid containing drugs as well as in the monitoring, interpretation and 
assessment of the potential toxicity of existing drugs.6 This work strongly 
indicates that AG-induced modification of plasma proteins during treatment with 
carboxylic acid containing drugs can take place in a number of ways that lead to 
different, and in some cases previously unidentified covalent adducts. This 
202
Monrad et al  page 11 
 
 
seems of particular current relevance given recent decisions of certain drug 
development organizations to exclude all carboxylic acids, and in the light of 
regulatory opinions on AGs.6 We are currently evaluating both the antigenic and 
immunogenic response of these unnatural protein motif structures as putative 
haptens, which may exist at high concentrations in patients chronically treated 
with e.g., NSAIDs.  
 
 
Methods 
Purification of human serum albumin. Commercial HSA (Lee BioSolutions, 
Inc., 50 mg, 0.75 µmol) and EDTA (1.5 mg, 5 µmol) in aq. phosphate buffered 
saline (5 mL, 20 mM, pH 8.5) were added dithiothreitol (10 mg, 65 µmol) in 
phosphate buffered saline (68 µL) and the reaction mixture was stirred at room 
temperature. The conversion was followed by mass spectrometry and after 2 h, 
full reduction of the Cys34-Cys disulfide was achieved. Cysteine and excess 
reducing agent was removed by PD10 size-exclusion chromatography eluting 
with a solution of EDTA (1 mM) and dithiothreitol (0.02 mM) in phosphate 
buffered saline (20 mM, pH 8.0). The solution was left for 48 h at 4 ºC exposed to 
atmospheric air to refold. The protein solution was purified by PD10 size-
exclusion chromatography eluting with phosphate buffered saline (20 mM, 
pH 7.4) to give Cys34-Cys reduced HSA in more than 95% yield. The protein 
solution was concentrated using a YM10 Amicon ultrafiltration membrane to a 
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concentration of 42 g/L. The protein concentration was determined from 280nm = 
28730 M-1 cm-1. ESI+ TOF MS: found: 66437, expected 66438. 
 
General incubation of acyl glucuronides with HSA. To an aq. solution of HSA 
(33 g/L) in phosphate buffered saline (20 mM, pH 7.4) were added acyl 
glucuronides 1a-d, 2 or 3 at a final concentration of 0.5 or 5.0 mM. The reaction 
mixture was mixed very vigorously for 30 sec and then gently shaken at 37 ºC for 
16 h. The protein solution was then cooled to 4 ºC and purified by PD10 size-
exclusion chromatography eluting with water to remove salts and excess 
reagent. The product was analysed by mass spectrometry (ESI+ TOF MS). 
 
Supplementary information available: Additional discussion, experimental 
methods, raw and processed protein mass spectra as well as mass spectra of 
tryptic peptides. 
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Figure Legends 
Figure 1: The Reactions and Putative Products of Phase II Drug Metabolism. (a) 
Typical glucuronidation of nucleophilic groups (Nu) in drugs during Phase II 
metabolism forms highly stable glucuronide glycosidic bonds and produces 
pharmacologically inactive metabolites (b) glucuronidation of carboxylic acid 
containing drugs forms acyl glucuronides (AGs) that can react with proteins through 
transacylation or (c) intramolecular acyl migration and subsequent reaction with 
proteins to form glycation and glycosylation products. 
70 words 
 
Figure 2: AGs of NSAIDs and Analogues. (a) Six representative, validated Phase II 
metabolites were used to study protein reactivity. These incorporated systematic 
variations in structure to probe variations in reactivity and reaction pathways (b) AGs 
were chemically synthesized through a novel partial protection strategy and made 
use of mild deprotection strategies that uniquely allowed access to these highly labile 
AG products (1-3); harsher conditions employed in other syntheses were 
incompatible. 
71 words 
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Figure 3.  Reaction of AGs with HSA. Mass spectra of 33 g/L HSA incubated with 
ibuprofen analogues 1a-d at 5.0 mM for 16 h at 37 ºC and pH 7.4. 1a: transacylation 
(blue), found: 66610; expected: 66612; glycosylation (red), found: 66787; expected: 
66788; dual addition (both transacylation and glycosylation, green), found: 66957; 
expected: 66962. 1b: transacylation, found: 66627; expected: 66626; glycosylation, 
found: 66802; expected: 66802. 1c: transacylation, found: 66625; expected: 66626; 
glycosylation, found: 66801; expected: 66802. 1d: transacylation, found: 66635; 
expected: 66640; glycosylation, found: 66813; expected: 66816. Unmodified HSA is 
the major peak in all cases (found: 66440, 66442, 66439 and 66439 Da; expected: 
66438 Da). 
95 words  
 
Figure 4: Mapping the Sites and Types of Reactivity of Metabolites with Human 
Serum Protein. Sequence map of HSA indicating primary amino acid sequence 
including disulfide bonds (yellow). Chemoselective reaction sites for glycosylation are 
coded red; sites for transacylation are coded blue, whereas Lys525 exhibiting both 
glycosylation and transacylation reactivity is coded green (see Table 2 for reactivity 
details). 
59 words  
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Figure 1 (width 89mm or 183mm or 120mm)
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Figure 2 (width 89mm or 183mm or 120mm)
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Figure 4 (width 89mm or 183mm or 120mm)
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